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Abstract 
This thesis is concerned with economic evaluation in the primary prevention of cardiovascular 
disease. Policymakers are increasingly focussed on reducing the health and economic 
burden of CVD and to reduce health inequalities. However, the approach to primary 
prevention suffers from fundamental weaknesses that this research intends to help address.  
 
There is general lack of effectiveness and cost effectiveness evidence underpinning current 
primary prevention interventions. First, there is a policy impetus towards mass screening 
strategies to target individuals at high risk of developing CVD when more focussed 
approaches may be more cost effective. Second, clinicians prioritise individuals on the basis 
of 10-year risk scores, which are strongly driven by age, and not the potential benefits (or 
costs) from treatment. Third, targeted and population interventions are often still treated as 
competing approaches, whereas the key issue is how they might best combine.  
 
The key premise of this thesis is that the aims of primary prevention are the avoidance of 
premature morbidity, mortality and to close health inequalities - subject to a budget constraint. 
A CVD Policy Model was created using the same nine risk factors as used in the ASSIGN 10-
year risk score, currently used in clinical practice in Scotland, to estimate life expectancy, 
quality adjusted life expectancy and lifetime hospital costs. This model can be employed to 
estimate the cost effectiveness of interventions and the impact on health inequalities. The 
model performed well in a comprehensive validation process in terms of face validity, internal 
validity, and external validity. Life expectancy predictions were re-calibrated to contemporary 
lifetables. This generic modelling approach (i.e. using a wide range of inputs and producing a 
wide range of outputs) is intended to avoid the need to build bespoke models for different 
interventions aimed at particular risk factors or to produce particular outputs.  
 
In application, the CVD Policy Model is intended to assist clinicians and policymakers to 
develop a more coherent approach to primary prevention, namely: to design more efficient 
screening strategies; prioritise individuals for intervention on the basis of potential benefit 
(rather than risk); and to assess the impact of both individually targeted and population 
interventions on a consistent basis. Using the model in these ways may enable primary 
prevention approaches to be more consistent with guidelines from health sector 
reimbursement agencies, which may result in a more efficient use of scarce resources. 
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Chapter 1 Introduction 
Purpose 
This thesis is concerned with the development and application of the Scottish Cardiovascular 
Policy Model. The intention is to assist policymakers by developing a single comprehensive 
model that can be used in the development and evaluation of primary prevention 
interventions, including those targeted on individuals deemed to be at high risk of a CVD 
event, and also interventions that impact on the entire population.  
 
The introduction chapter provides a relatively detailed overview of the key issues with respect 
to the primary prevention of cardiovascular disease (CVD). In summarising the clinical and 
economic burden of CVD, the chapter then discusses the policy approaches to primary 
prevention and the extent of the current evidence. The overall aim to identify key research 
gaps that the thesis is then intended to help address. 
 
The burden of cardiovascular disease  
Cardiovascular disease (CVD) is associated with substantial burden of disease(1), is a 
leading cause of inequality(2) and results in substantial economic costs(3). CVD is a global 
issue and it is a particular issue in Scotland, where it is the leading Western European 
country in terms of coronary heart disease (CHD) mortality(4). In line with other countries, 
premature mortality due to CVD has been falling, with the incidence becoming more 
concentrated in more socially deprived communities(5). 
 
CVD also results in substantial morbidity and economic costs. Estimates are not published for 
Scotland, however for the UK as a whole the estimate of the health service and wider 
economic costs is in excess of £31billion per annum(6). Yet, between 80% and 90% of 
premature CVD is preventable(7).  
 
The aims and approaches of primary prevention 
The causes of CVD are well researched. Known risk factors can be divided into modifiable 
and non-modifiable categories(8). The former include variables such as age and family 
history, while the latter include cholesterol and smoking. In effect, the entire population is at 
risk, and most people could benefit from changes to modifiable risk factors. Efficacy evidence 
suggests that the potential impact of interventions could be hugely significant(9).  
18 
 
 
There is a vast array of interventions that may influence CVD, including ‘downstream’ 
interventions delivered to individuals (e.g. pharmaceuticals, lifestyle advice), to ‘upstream’ 
interventions that influence health directly (e.g. legislation) or health behaviours by changing 
the social determinants of health (e.g. employment, housing)(10).   
 
Policymakers are embarking on major primary prevention initiatives in an attempt to avoid the 
premature incidence of CVD, reduce health inequalities and avoid the downstream financial 
consequences(11-12). There are two main strands to primary prevention. First, there is the 
targeted approach where a pre-defined population are screened and then individuals deemed 
to be at high risk are referred onto a range of interventions. Second, there is the population 
approach where interventions are intended to impact on everyone in a defined population 
without the need for screening to assess baseline risk (13-14).  
 
A targeted approach is based on clinical guidelines which recommend individuals aged 40-74 
year olds who are asymptomatic are screened for known CVD risk factors using a 10-year 
risk score(8). High risk individuals are identified as those with a ≥ 20% risk of a CVD event 
over the following 10 years, and prioritised for a series of intensive interventions. Clinical 
guidelines list a menu of possible interventions, including pharmaceutical and lifestyle 
interventions. There are various risk tools in use across the developed world such as the 
Framingham score(15) which is used in the United States and England, and SCORE which is 
used in many European countries(16).  
 
In Scotland, the SIGN clinical guidelines(9) recommend that clinicians use the ASSIGN 10-
year score which was developed in 2007 to be used specifically in Scotland. This was 
intended to replace the Framingham score which was previously used (17). In particular, the 
ASSIGN score includes a measure of socioeconomic deprivation as an independent risk 
factor that detects the underlying social gradient in CVD, particularly prevalent in Scotland. 
The Framingham score does not include deprivation as a risk factor, and consequently may 
actually increase inequalities if socioeconomic gradient in CVD risk is not considered when 
calculating risk and prioritising individuals for intervention(17). 
 
In 2007 Scotland launched Keep Well, a targeted primary prevention programme focussed on 
the most deprived communities, and those aged 45-64 years(12). This is in contrast to clinical 
guidelines that recommend screening all individuals aged 40-74 years every 5 years. To date, 
19 
 
there has not been a rigorous economic evaluation of the impact of the Keep Well 
programme. In 2009 England launched a primary prevention programme following clinical 
guidelines, in contrast to Scotland. Similarly, an economic evaluation is not planned. The 
mass screening approach underway in England is now under consideration in Scotland. 
 
The second approach to primary prevention is a population approach. The intention is to 
impact on the whole population, rather than only affecting individuals at high risk over 10-
years.  Interventions most commonly refer to changes to legalisation and regulation, such as 
a reduction in saturated fat in processing food, a ban on smoking in enclosed public spaces, 
and mass media campaigns. Further, while a targeted approach focuses on those aged 40 
years and above, it is also the case that the onset of risk behaviours and incidence of inflated 
risk factors can occur in young adults, including teenagers, and especially in deprived 
areas(18). For instance, policymakers are increasingly concerned regarding a possible 
obesity epidemic and prevalence of sedentary lifestyles from an early age(19-21).  
 
Evidence gaps and uncertainties regarding the approaches to 
primary prevention  
Overall, there are serious (and often similar) concerns raised by the clinical, public health and 
economic communities regarding primary prevention.  These are outlined before detailing 
how these concerns represent an excellent opportunity for health economists to fully engage 
with the primary prevention effort, and perhaps have an influence over both the development 
and evaluation of interventions.  
 
There are four broad concerns. First, it is unknown what the most (cost) effective screening 
approaches are to identifying high risk individuals. While Scotland has a screening 
programme currently focussed on deprived communities; there is however a policy impetus to 
screen the entire population. This is in recognition of the seriousness of the CVD issue and 
perhaps in response to England’s national programme. However, a feasibility study regarding 
whether primary care is able to take on a large influx of patients does not appear to have 
been conducted. It may be the case that identifying individuals through routine primary care 
databases could avoid the need for mass screening(22). Further, there are concerns that a 
mass screening approach places equality of access over equality of outcomes and that such 
a policy may actually increase health inequalities(23). Programmes which require individual 
voluntary uptake tend to engage less well with deprived communities, and the “inverse care 
law” has demonstrated that deprived practices are also less well equipped(24).  
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Second, the rationale behind using 10-year risk scores to discriminate between and prioritise 
individuals for intervention is increasingly questioned(25-26). Risk is not a measure of the 
potential benefit from treatment, as risk is influenced by both modifiable and non-modifiable 
factors. For instance, everyone is at high risk over a certain age given inevitable mortality. 
Yet, younger individuals with inflated modifiable risk factors can actually be excluded from 
interventions. However, it is younger people who may have the most to gain from early 
intervention, in terms of avoiding premature events.  
 
Further, while CVD is the leading cause of death, there are other competing causes of death 
(e.g. cancers). There are concerns whether interventions prevent CVD only for individuals to 
die of other causes(27). Consequently, there is a need to focus on modifiable risk, think more 
clearly regarding competing causes of death and make explicit the potential benefits of 
interventions. Most individuals, clinicians and policymakers would agree that the aims of 
prevention are the avoidance of premature mortality and morbidity(15). Given these aims 
discrimination and prioritisation of individuals may best be made explicitly on the basis of 
benefit, not risk. This is not to suggest that clinicians do not have potential benefits in mind 
when treating individuals, but rather the process is not as explicit or formalised as it could be. 
 
Third, there is considerable doubts regarding whether the targeted approach taken together 
(screening, prioritisation interventions) is likely to be value for money(28). There is robust 
evidence regarding the impact of single interventions, especially pharmaceutical (29-30) and 
certain lifestyle interventions, in particular smoking cessation interventions(31). However, 
there is little evidence with regards to the efficacy, effectiveness and cost effectiveness of the 
multi-factorial interventions being rolled-out in Scotland and elsewhere. Particular concerns, 
relate to the long run compliance behaviour of individuals from both pharmaceutical and 
lifestyle interventions. The complex issues of implementation and context may also be 
important in attempting to transferring learning between locations(32). Economic evaluation 
has been relatively poor at conditioning estimates on such contextual issues(33). 
 
Fourth, the targeted and population approaches to primary prevention have traditionally been 
seen as a competing, with advocates running the risk of polarising the debate(13-14). 
Perhaps, part of the reason for polarisation is that it can be (implicitly) assumed that the 
targeted approach favours pharmaceutical interventions(13) and the population approach 
favours lifestyle interventions. However, this is needn’t be case. Mass administration of drugs 
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has been recommended in the literature(34) and lifestyle interventions can be targeted on 
individuals. As will be argued in the thesis, a targeted and population approach can be quite 
compatible, and indeed be used strategically to reinforce impacts. Modelling exercises have 
indicated the huge potential impact that could result from legislative changes on reducing 
CVD and extending life expectancy(35); although the actual evidence supporting these 
exercises is still lacking. 
 
Overall, policymakers are intent on responding comprehensively to mitigate the incidence and 
burden of CVD; however, there is a lack an equally comprehensive evaluation effort to 
influence the choice of approaches and interventions. The objectives of primary prevention 
are clear, but there are major question marks regarding whether current initiatives can best 
meet these objectives, given limited resources. Policymakers are using a dual approach of 
targeted and population wide interventions, but not necessarily in an explicit or coordinated 
manner. The recent emphasis has been on funding and implementing targeted approaches: 
to screen, identify and prioritise individuals for a wide mix of multi-factorial interventions.  
 
Informing primary prevention approaches: the role of modelling 
Economic evaluation is intended to build upon clinical evidence to consider both the benefits 
and resource costs from interventions. Consideration of available budget is essential given 
scarce public resources, and the inherent opportunity costs in decision making. The aim of 
economic evaluation is to help policymakers choose the best buys and make the most of 
scarce budgets. 
 
The key feature of economic evidence is the development of a common outcome measure to 
enable different types of interventions to be compared directly and consistently. There are 
different forms of economic evidence however(36), such as cost benefit analysis, cost utility 
analysis and cost effectiveness analysis. The first is the traditional approach of economics 
and, in taking a societal perspective, attempts to value all outcomes that result from an 
intervention. The latter two, as applied in health economics, are a particular forms of 
economic evaluation developed for the health sector. A health perspective is taken where 
evidence is tailored to what decision makers (are assumed) to consider when allocating 
sector budgets. The outcomes considered are restricted to health (and personal social 
services)(37). This thesis takes a health perspective, and consequently the intention is to 
compare targeted and population intervention on health outcomes and health service costs.  
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Economic information can be part of a pragmatic trial design to help ensure relevant 
information is collected, such as an appropriate measure of health benefits, to generate 
quality adjusted life expectancy (QALE), and estimate the impact on health service costs, net 
of intervention costs(38). However, trials and evaluation studies are subject to a wide range 
of limitations. Key amongst such limitations is that studies in general can only detect short run 
impacts whereas the impacts on health may only be fully realised over the long term. This is 
particularly the case for prevention and when interventions are extended from the elderly to 
younger adults. Therefore, there is an important role of economic modelling to project long 
term impacts of ‘within-trial’ evaluations, that are often necessarily conducted over the short 
term(38), and especially to sensitise assumptions regarding compliance over the longer term. 
Further, many interventions can be evaluated against a ‘do-nothing’ scenario(31). However, 
what is clear in that the policy direction in the prevention of CVD is to ‘do something’. 
Therefore, there is also an important role for modelling to simulate head-to-head 
comparisons, given interventions essentially compete for scarce public budget.    
 
Limitations of current economic models 
From first principles, it would be ideal if a single economic model was wide enough in scope 
to evaluate the range of targeted and population interventions and had the ability to produce 
outcomes commensurate with the aims of primary prevention. This generic approach to 
modelling is in a sense an extension of the rationale for a generic approach to economic 
evaluation. That is, there could be a consistent modelling approach, in addition to a 
consistent outcome measure. Such consistency may help to foster additional confidence by 
policymakers in comparing evidence from different interventions. 
 
A major application of an economic model is to inform the targeted approach to prevention, 
where perhaps the greatest uncertainties are with respect to economic evidence. It is 
desirable that an economic model is congruent with the clinical risk scoring models that are 
used to prioritise individuals for interventions in the first place. Building a model using the 
same wide range of variables employed in 10-year risk scores would enable greater 
congruence between how individuals are prioritised and how interventions are evaluated. 
Consequently, this approach may help align economic models with clinical models, and 
perhaps further encourage the acceptance of economic models and model outputs in clinical 
and policy circles.  
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Further, it is also important to develop a model that can help assess the impact of population 
interventions also to provide consistency in comparing both targeted and population 
interventions. 
 
In considering existing policy models, the phrase: “[a]ll models are wrong but some are 
useful” is a helpful starting point(39). Experts have developed best practice guidance which is 
periodically updated(40-44). It is evident that certain modelling approaches and features can 
help enhance the credibility of models. Models should be as simple as possible, fully reported 
and validated, including: (i) face validity, that the model represents a medical issue properly; 
(ii) internal validity, which is a check on whether the model can estimate the outcomes from 
the dataset(s) from which it was constructed; and (iii) external validity, which tests whether 
the model can predict outcomes in a dataset not used in the construction of the model. 
Further, it is important that models are calibrated to the population of interest. This is 
particularly important if the model has been built using historical data and /or is intended for 
use in a different context (e.g. a different country). Overall, following best practice guidance is 
important so that both analysts and peers have confidence in using models, and decision 
makers trust the outcomes produced. 
 
There are a range policy models in existence which will be reviewed in the thesis. All have 
considerable merits, and several have been used persuasively to estimate the impact of 
mainly population wide interventions. However, no model is ideally suited to estimate the 
impacts of both targeted (especially, multi-factorial programmes) and population wide 
interventions. Three models use the same variables used in 10-year risk scores, but only 
estimate the impacts of interventions on reducing CVD events (and consequent life years 
saved) over 10 years. No models estimate the full lifetime impact of interventions on CVD or 
all cause mortality taking into account the fact that same risk factors also drive other 
conditions such as cancers and respiratory diseases. Also, no model estimates the full impact 
of interventions on health service costs from interventions that may extend life expectancy. 
The later is important as interventions essentially postpone events or change the cause of 
eventual death(27), and meanwhile individuals incur greater co-morbidities as life expectancy 
increases(45-47). Further, few models quality adjust outcomes to take into account the 
morbidity impacts of avoiding non-fatal events. Sensitivity analysis can also be limited and 
validation is usually restricted to tests of internal validity. Finally, of key importance for 
Scotland, is that no model uses the same variables in the ASSIGN score. This is notable 
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given Scotland suffers from a pronounced social gradient in CVD. Overall, no current policy 
model is ideally placed for use in Scotland.  
 
Purpose of thesis I: to build the Scottish CVD Policy model 
The overall purpose of the thesis was to develop the Scottish CVD Policy Model to build upon 
the strengths and limitations of current exiting policy models in an attempt to help address the 
perceived weakness of current approaches to primary prevention.   
 
A generic model was developed using the same set of nine variables employed in the 
ASSIGN risk score and used to estimate the impact of changes to modifiable risk factors on 
quality adjusted life expectancy (QALE), lifetime costs and health inequalities. In this sense, 
the model is intended to be a ‘natural extension’ to 10-year risk scores and have the capacity 
to inform the development and evaluation of the targeted approaches to primary prevention. 
In addition, the model is developed using data sources and statistical methods that are 
intended to be generalisable to the Scottish general population. Following best practice 
guidance, the model building process and resultant outputs are intended to be transparent 
and validated on the Scottish population. In application, the model is intended to be used by 
policymakers to help inform and evaluate both targeted and population interventions. 
 
Purpose of thesis II: applying the model to address key research 
questions 
Overall, the intention was to develop a new and comprehensive Scottish CVD Policy Model to 
help inform primary prevention and address certain key uncertainties as discussed, which are 
formulated into the following specific research questions:  
 
(i) If the current approach to prioritising individuals for intervention is to use 10-year risk 
scores, can the model be used to identify optimal screening approaches to identify high-risk 
individuals? 
 
(ii) Given the weaknesses in 10-year risk scores, can a new approach to prioritising 
individuals be developed based upon individuals’ potential to benefit rather than risk?  
 
(iii) Can the model be used consistently to assess the cost effectiveness of both targeted and 
population interventions?   
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In addressing these issues pragmatically, an important observation is that policymakers are 
intent on forging ahead with primary prevention interventions, despite a relatively weak 
evidence base. Consequently, the immediate decision context for policy makers is which 
interventions to choose; rather than a willingness to delay decisions before further research is 
available. As a consequence, the focus of the thesis was to demonstrate the application of 
the model to evaluate interventions by generating mean estimates, and focus on 
heterogeneity; rather than also provide a full uncertainty analyses. In other words, given the 
policy context, at present, there is an “irrelevance of inference”(48).  Nonetheless, it is 
important to note that the model is capable of conducting a full uncertainty analysis which will 
also be discussed, including probabilistic sensitivity analysis and value of information analysis 
in order to inform decisions regarding funding further research(49).  
 
Structure of thesis and chapter outline  
The thesis is divided into three parts, building upon one another. Each part begins with an 
overview section to help orientate the reader, and is composed of particular chapters.   
 
Part 1 - Part 1 aims to provide the background for the thesis. Chapter 2 illustrates the health 
and economic burden resulting from CVD, before describing the targeted and population 
approaches to primary prevention. In summarising the existing literature, there appears to be 
a general lack of evidence underpinning the practice of primary prevention, particularly 
regarding the impact of the targeted multi-factorial programmes which is the key policy focus 
in Scotland.  
 
The aim of Chapter 3 is intended to make the case for the Scottish CVD Policy Model to help 
inform clinicians and policymakers regarding the development and evaluation of 
interventions. The chapter introduces the rationale for economic modelling, to be used in 
tandem with evidence from clinical trials, to produce cost effectiveness evidence. The chapter 
collates best practice guidance regarding how to build an economic model, and uses this to 
appraise current policy models, which are identified through a systematic review.  The key 
strengths and weaknesses of existing models are discussed, before further developing the 
rationale for building the Scottish CVD Policy Model to help address the research questions. 
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Part 2 - Part 2 forms the main empirical element of the thesis and describes how the model 
was developed. Chapter 4 details the approach to creating and populating the model drawing 
upon the best practice guidance.  Importantly, access was granted to the Scottish Heart 
Health Extended Cohort (SHHEC) and consisted of approximately 16,000 individuals who 
were free of CVD. In linking this dataset to Scottish Morbidity Records (SMR) all 
hospitalisations incurred by individuals could be tracked. This was the dataset employed in 
the development of the ASSIGN 10-year risk score used in clinical practice within Scotland, 
thus providing an opportunity for the policy model to be developed using the same variables 
that serve as risk factors. This approach is intended to provide consistency between the 
clinical model used to screen and prioritise individuals, and the policy model that may then be 
used to evaluate the impact of interventions intended to modify risk factors.  The policy model 
was comprehensively validated, in terms of face validity, internal validity and externally 
validity; and life expectancy predictions were also re-calibrated to the latest Scottish 
lifetables, at the time of writing.  
 
Chapter 5 then builds upon the statistical modelling to generate and populate the model with 
economic information. This allows the model to generate QALE and lifetime hospitalisation 
costs.  Quality adjustment consisted of background morbidity (population norms) and the 
negative impact of experiencing CVD events (utility decrements), including first and 
subsequent events. Estimates of lifetime costs include all hospitalised events, CVD and non-
CVD. A key feature is that all estimates are generated directly (rather than using secondary 
sources) and using Scottish data sources. This is intended to enhance the applicability of 
outputs to Scottish decision makers, the (immediate) intended users of the model.  The 
chapter ends with a brief demonstration of how the model could be used in evaluation to 
assess the impact of changes to risk factors on (quality adjusted) life expectancy and lifetime 
health service costs. 
 
Part 3 - Part 3 of the thesis demonstrates how the model can be used to help address the 
research questions, identified above.  Four short chapters follow to show how the model can 
be used to improve the approach to primary prevention. Chapter 7 uses the model to help 
identify optimal screening strategies by simulating the potential cost effectiveness of different 
approaches to detect the high risk in the general Scottish population. Chapter 8 uses the 
model to develop a new approach to prioritising individuals for intervention on the basis of the 
potential lifetime benefit from modifying risk factors. This approach could in principle replace 
current clinical practice which uses a 10-year risk score that is driven by age, which is non-
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modifiable. The chapter simulates the potential impact that a switch from 10-year risk to 
potential benefit may have in the Scottish general population in terms of the reprioritisation of 
individuals, potential gains in population health, and the impact on health inequalities. 
Chapter 9 then illustrates how the model could be used to estimate the cost effectiveness of 
Keep Well. The Scottish Government has no immediate plans to undertake an economic 
evaluation. The expectation of policymakers is that, given the burden of CVD and the 
existence of robust efficacy evidence, the programme will be a good use of public resources. 
The policy model is used to challenge such assumptions and illustrate the huge uncertainty 
regarding whether the programme is cost effective, and the consequent need for a rigorous 
economic evaluation. Finally, chapter 10 simulates the potential impacts of a variety of 
population interventions concentrating on changes to regulation in smoking, and the reduction 
of the salt and saturated fat content in food. The final demonstration shows how the model 
can be used to inform the optimal mix between targeted and population interventions. The 
model demonstrates that utilising both approaches may make strategic sense to both 
increase population health and reduce health inequalities.  
 
The concluding chapter completes the thesis and summarises the aims, approach and 
applications of the Scottish CVD Policy Model. The model is intended to be fit-for-purpose 
and ready for use. However, no model should ever be considered complete(43-44, 50-52) 
and there are also several limitations that a future research agenda could help address. The 
chapter ends by discussing a range of potential innovations that could be made to improve 
the current model, broaden its scope from CVD (e.g. to other chronic diseases), extend it 
focus (e.g. to younger adults and children) and consequently widen its potential policy 
applications.   Overall, the hope is that the aims of the thesis have been fulfilled and that a 
fruitful agenda has been identified for future research. 
28 
 
Part 1: The burden of cardiovascular disease and the 
role of economic modelling  
Overview 
The first part of the thesis is intended to set the overall context regarding the burden of 
cardiovascular (CVD) disease in Scotland and the need for a Scottish CVD policy model to 
help inform both the clinical and policy approaches to primary prevention.  
 
Two chapters follow. Chapter 2 provides a detailed discussion of the health and economic 
burden of CVD, the risk factors that drive CVD in the population and the current approaches 
to prevention that seeks to reduce modifiable risk. Primary prevention approaches can be 
classified into targeted approaches that focus on individuals identified as being at high risk of 
a CVD event, and population wide approaches that impact on the entire population. Notably, 
there is a general lack of economic evidence underpinning these approaches and, in 
particular, the targeted approach. The chapter identifies four key areas of uncertainty 
regarding current approaches to primary prevention, which are reformulated into associated 
research questions for the thesis to address. 
 
Chapter 3 discusses the role of economic modelling to help generate the kind of cost 
effectiveness evidence that national reimbursement agencies, such as the Scottish Medicine 
Consortium (SMC) and the National Institute for Health and Care Excellence (NICE) require 
to approve new interventions. Economic modelling can be used to compliment trial evidence 
by, for instance projecting short term clinical outcomes such as changes in risk factors to 
generate outcomes such as quality adjusted life expectancy. However, modelling can be a 
complicated process, and may involve the use of complex data sources, assumptions and 
statistical techniques. Therefore, while economic models are necessary, a common criticism 
is that models can become “black boxes”(53). To enhance the rigor, credibility and trust by 
decision makers in model outputs, experts in economic modelling have developed best 
practice guidance. The chapter conducts a systematic review of existing policy models that 
can be used to inform primary prevention, and appraises identified models using these best 
practice guidelines. The chapter then makes the case that a new Scottish CVD Policy Model 
is needed for use in Scotland to address the four research questions identified in Chapter 2.  
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Chapter 2: The burden of cardiovascular disease and 
approaches to primary prevention 
 
2.1 Introduction 
Cardiovascular disease (CVD) is a major cause of mortality and is a leading cause of health 
inequalities across the world(1-2). In recent years, the primary prevention of CVD has 
become a key national policy priority in order to avoid the first instance of the disease and the 
downstream consequences in terms of premature mortality and the economic impact on the 
health service and the wider economy. The purpose of the chapter is to review the burden of 
CVD in Scotland and the policy approaches to primary prevention. 
 
The chapter is structured as follows: Section 2.2 reviews the clinical burden of CVD, 
highlighting the socioeconomic inequalities in mortality and morbidity of CVD. Section 2.3 
estimates the economic burden of CVD in Scotland on the health service, informal care and 
the wider economy. Section 2.4 then reviews the risk factors that are known to drive the 
incidence of CVD and describes how these are distributed across the general population in 
Scotland. Having illustrated the causes and consequences of CVD, the chapter reviews 
current approaches to primary prevention and the associated evidence with respect to 
modifying risk factors. Section 2.5 provides an overview of prevention strategies in general, 
before sections 2.6 to 2.9 discuss the targeted and population approaches to primary 
prevention in detail and the associated evidence base. Section 2.10 summaries the 
limitations in the evidence base, before section 2.11 develops four associated research 
questions. Section 2.12 concludes by emphasising that there is a need for (more) economic 
evidence to inform decision making in primary prevention and help ensure that funded 
interventions are actually value money. 
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2.2 The clinical burden of cardiovascular disease 
 
2.2.1 Defining cardiovascular disease 
Coronary heart disease (CHD) and cerebrovascular disease (CBVD) are the two main forms 
of cardiovascular disease (CVD).  CHD is a disease of the heart and coronary arteries 
caused by the build-up of fatty materials in the blood vessels that supply the heart with 
oxygen. This can result in a range of events, the most common being: angina, irregular 
heartbeat (arthymia) heart attack (myocardial infarction) or heart failure. CBVD is where the 
blockage restricts blood to the either the brain resulting in a stroke, or in the extremities of the 
body resulting in peripheral arterial disease (intermittent claudication)(54).  
 
The international classification of disease (ICD) is the accepted standard regarding the 
coding and grouping of events by disease area and particular events. The versions of ICD 
referred to in the thesis are ICD-9 and ICD-10, with the relevant codes with respect to CVD 
shown in Table 2-1. ICD-9 codes refer to the pre-2000 period, and ICD-10 codes refer to the 
post-2010 period. Events are grouped into the broad categories of non-fatal CHD, non-fatal 
CBVD, and CVD death, from CHD or CBVD. These groupings will be used when building the 
structure of the Scottish CVD Policy Model, in part 2 of the thesis. 
 
Table 2-1: Defining cardiovascular disease 
Event ICD codes
CHD ICD9 410-414; ICD10 I20-I25
CVBD ICD9 430-438; ICD10 G45, I60-I69
CVD death ICD9 390-459; ICD10 I00-I99
 
Source: World Health Organisation(55) 
 
2.2.3 The mortality burden of cardiovascular disease  
Cardiovascular disease (CVD) is a major cause of death worldwide and in 2010 resulted in 
30% of all deaths before the age of 75 years(56).  There can be wide variations across the 
world in terms of CVD mortality. For instance, in the United States in 2009 CVD accounted for 
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29.9% of all deaths before the age of 75 years, and equivalent figures in the European Union 
in 2010 ranged from 37% in Central and Eastern European Countries to 17% in France(1).  
 
Within the European Union there is a clear North East-South West gradient in mortality rates, 
with Southern and Mediterranean countries having amongst the lowest rates. For instance, 
the  age standardised mortality rates (SMR) for CHD was 89 for Portugal, Italy and Spain, 
whereas the SMR was UK, Ireland and Finland was 218(1).  
 
Mortality rates have actually been falling rapidly in recent decades in most developed 
countries. In Western European countries, the annual percentage fall in CVD mortality was 
1.8% in men and 2.1% in woman from 1970 to 2000 for those between 45 and 74 years(57).   
 
Regarding Scotland, the main source for mortality statistics is the Information Service 
Directorate (ISD). In Scotland, CVD accounted for 30% of all deaths in 2011, with the other 
major causes of mortality being cancers and respiratory diseases, as figure 2-1 illustrates.  
 
Figure 2-1 CVD as share of all deaths before the age of 75 years in 2011 
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Source: Generated using ISD data(5) 
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Mortality reductions relative to Government targets 
Figures 2-2 and 2-3 illustrate the fall in SMR per 100,000 for under-75 year olds between 
2001 and 2010. The year 2001 to 2010 was chosen as this provides the longest time period 
over which ISD provides data consistently at both the general population level, and lower 
levels of aggregation, such as age group and socioeconomic deprivation status (discussed 
shortly). Further, trends are shown relative to the Scottish Government targets(58) for which 
ISD have generated annual trend targets.  
 
Figure 2-2 is concerned with CHD mortality and illustrates a 40% reduction in CHD mortality 
for men relative to a target of 42% over this period. For exposition, this target was shown as a 
linear gradient to facilitate comparison with actual falls. The equivalent reduction for women 
was 46% relative to a target of 42%. Overall, in considering men and women together the 
combined target reduction of 42% was met. In comparing the levels of CHD mortality 
between men and women, the SMR rate was 2.7 times greater in men than women in 2001 
and this rose to 2.9 in 2010.  
 
Figure 2-2 Reductions in CHD mortality relative to Government targets 
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Source: Generated using ISD data(5) 
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Figure 2-3 illustrates equivalent reductions in CBVD mortality. The target reduction was 34% 
for both men and women and this was surpassed with the reduction in mortality rate for males 
of 41% and 48% respectively, with a combined reduction of 44%.  
 
Figure 2-3 Reductions in CBVD mortality relative to Government targets 
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Source: Generated using ISD data(5) 
 
Variation by age group 
The reduction in CHD death varied across age groups (figures 2-4 and 2-5). These are the 
age groups that ISD report. For men, the reduction in CHD was 35% for 44-64 year olds and 
43% those aged between 64-74 years between 2001 and 2010. There were similar variations 
across age groups for women and the reduction in mortality was also greatest in the 65-74 
year olds, falling by 45%. The (age-sex) SMR was higher for men than women across all age 
groups, and this ratio was fairly constant between 2001 and 2010.  In 2010, the SMR rate for 
men was 3.3 times higher than women for 44-64 year olds and 2.1 times higher for 64-74 
year olds. 
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Figure 2-4 CHD – Changes in CHD mortality - men  
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Source: Generated using ISD data(5) 
 
Figure 2-5 CHD – Changes in CHD mortality - women  
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Source: Generated using ISD data(5) 
 
There were similar variations in SMR across age groups for CBVD as found for CHD, and for 
both men and women. The reduction in mortality was also greatest in the 65-74 year olds, 
falling by 44% and 45% for men and women respectively. The SMR was also higher for 
males than females across all age groups but the ratio increased slightly between 2001 and 
2010.  In 2010 males SMR rate was 1.3 times higher than women for 44-64 year olds and 1.5 
times higher for 64-74 year olds. 
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Figure 2-6 Changes in CBVD mortality - men  
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Source: Generated using ISD data(5) 
 
Figure 2-7 Changes in CBVD mortality - women  
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Source: Generated using ISD data(5) 
 
Variation by deprivation  
Figure 2-8 illustrates (age/sex) SMR CHD mortality by fifths of socioeconomic deprivation. 
The Scottish Government uses a measure of socioeconomic deprivation called the Scottish 
Index of Multiple Deprivation (SIMD). The SIMD score is an aggregated measure of material 
deprivation derived from 37 indicators in seven domains (income, employment, health, 
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education, access to services, housing and crime) and is determined at the data zone level 
(geographical areas with a median population of 769)(59). Equivalent statistics are not 
produced for CBVD mortality by SIMD. 
 
Figure 2-8 Changes in CHD mortality by fifths of socioeconomic deprivation (SIMD) 
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Source: Generated using ISD data(5) 
 
Notably, inequalities in CHD mortality have been falling.  While mortality rates across all fifths 
of SIMD fell markedly between 2001 and 2010, the reduction (34.1%) in the age-sex 
standardised CHD mortality rate among the most deprived fifth has been almost double the 
reduction observed in the least deprived category (18.1%). The most deprived fifth had a 
mortality rate which was 66% higher than the least deprived fifth in 2010 – almost half the 
gradient in 2001 (108%).  
 
Variation by age and deprivation 
Figure 2-9 illustrates the (age) SMR rate for CHD in men and split by those below and above 
65 years in 2009 and across fifths of SIMD. Further, the bars represent average rates 
between 2004 and 2009. Equivalent statistics were not available for women.  
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Figure 2-9 Five year average of CHD Mortality: 2004-2009  
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Source: Generated using ISD data(5) 
 
The incidence of CHD mortality for those under 65 years is greater in the most deprived 
communities. Further, mortality rates are progressively higher for increasing fifths of 
socioeconomic deprivation. Mortality in SIMD 5 in the under 65s was over 3 times higher than 
in SIMD 1 (ISD, 2011) – compared to 50% higher for all age groups taken together. A similar 
relationship is also found for CBVD, although the SMR are on the whole slightly lower with 
the exception of SIMD 1. 
 
 
 
 
 
 
 
 
 
 
 
38 
 
Figure 2-10 Five year average of CBVD Mortality: 2004-2009 
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Source: Generated using ISD data(5) 
 
Survival from CVD events 
It is also important to estimate survival from events, as a means to help understand the 
morbidity and resource cost burden of CVD. Morbidity is discussed in detail in the next 
section. Figure 2-11 and 2-12 illustrates survival for those conditions that ISD report statistics 
for. In general, 30-day survival from acute myocardial infarction and unstable angina is high, 
around 98%; similar for both men and women and has been fairly flat since 2001. In contrast, 
30 day survival post-stroke is lower than acute myocardial infarction, but has been rising 
steadily over the past 10 years. The survival rate for both sexes combined rose from 79% in 
2001 to 83% in 2010. Males have a higher survival rate than women rising from 82% in 2001 
to 86% in 2010. 
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Figure 2-11 Trends in 30 day survival post-acute myocardial infarction and unstable angina  
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Source: Generated using ISD data(5) 
 
Figure 2-12 Trends in 30 day survival post-stroke 
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Source: Generated using ISD data(5) 
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2.2.4 Morbidity burden of cardiovascular disease 
Figure 2-13 illustrates the prevalence of those living with CVD in Scotland, split by males and 
females.  The source of this information is the Scottish Health Survey (SHeS). Individuals 
self-report having experienced events, including angina, heart attack, stroke, heart murmur, 
abnormal heart rhythm, or ‘other heart trouble. The survey began in 1995, however the years 
2003 to 2011 are shown as these are the earliest and most recent survey that contain 
prevalence rates.  
 
The y-axis is truncated in an effort to illustrate variation between years. A wider range in the 
y-axis would have resulted in the trend appearing relatively flat. In 2003, 14.9% of men and 
14.5% of women were living with CVD. By 2011, this proportion had risen to 15.6% for men 
and fell to 13.8% for women.  However, these changes are within 1 percentage point, and the 
SHeS does not report expected sampling error.  
 
Figure 2-13 Percentage of the population above 16 year living with CVD 
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Source: Generated from the Scottish Health Surveys(60-63) 
 
Morbidity by age  
Figure 2-14 and 2-15 shows the percentage of those living with CVD by age group and sex.  
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Figure 2-14 Percentage living with CVD by age group - men 
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Source: Generated from the Scottish Health Surveys(62, 64) 
CVD events are: angina, heart attack, stroke, heart murmur, abnormal heart rhythm, or ‘other heart trouble 
 
Figure 2-15 Percentage living with CVD by age group - women 
4 5
7
12
18
31
37
5
7 8
15 15
28
33
0
10
20
30
40
50
60
16-24 25-34 35-44 45-54 54-64 65-74 75+
P
er
ce
n
ta
g
e
Age group
2003 2010
 
Source: Generated from the Scottish Health Survey(62, 64)  
CVD events are: angina, heart attack, stroke, heart murmur, abnormal heart rhythm, or ‘other heart trouble 
 
As expected, prevalence increases with age. Most notably, however, CVD appears to be a 
significant problem across all ages, including the under-40 year olds. Also, while prevalence 
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rates have been falling in older age groups, it is rising in younger age groups and especially 
in men.   
 
CVD is also responsible for substantial morbidity in the form of pain, disability and poorer 
quality of life(65-66). Economists attempt to measure the impact of living with a condition on 
reducing health related quality of life. Current estimates in Scotland are not available. This is 
a major gap in the evidence base however, and the discussion will be revisited in detail later 
in the thesis, in Chapter 3 and Chapter 5.  
 
2.3 The economic burden of cardiovascular disease 
It is important to estimate the economic impacts of CVD in addition to the health burden. 
There are no official statistics that estimate the economic costs of CVD to Scotland. The 
following analysis builds upon previous estimates made for the UK(6).  
 
Table 2-2 illustrates the cost of CVD to the UK economy in 2011, which was estimated to be 
£35 billion. The estimates update previous research which had reported costs in 2006 prices, 
where the cost was estimated to be £31 billion(6). These were inflated 2011 prices by using 
 
Table 2-2 Health service costs, UK 2011 
  £ million % of total £ million % of total £ million % of total
Health care costs 16,453 46.9% 3,718 36.1% 3,631 38.2%
Productivity losses due due to mortality 5,056 14.4% 2,809 27.3% 883 9.3%
Productivity losses due due to morbidity 4,395 12.5% 1,652 16.0% 1,652 17.4%
Informal care 9,205 26.2% 2,120 20.6% 3,329 35.1%
Total 35,108 100.0% 10,300 100.0% 9,496 100.0%
Cost per capita £574 £169 £155
CVD CHD Stroke
 
Source: Adapted from  Luengo-Fernandez, R.(6) 
 
the Consumer Price Index (CPI)(67) with the exception of health care costs which was 
inflated using the Health Service Cost Index (HSCI)(68). 
 
Health care incurs the single most important expenditure representing 47% of the total cost, 
followed by productivity losses of 27% that are split by mortality (14.4%) and morbidity 
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(12.5%) and informal care 26%. The estimates are also disaggregated for CHD and stroke, 
with the former accounting for the greatest costs, with the exception of health service costs. 
Overall, it is estimated that CVD results in a per capita cost of £574. 
 
An estimate of Scottish costs were made based upon Scotland’s percentage share of those in 
UK living with CVD and those dying due to CVD causes. These percentage shares, or 
weights, are estimated before applying them to the UK cost estimate of Table 2-3.  
 
To estimate Scotland’s share of those living in the UK with CVD, it was necessary to first 
estimate the actual numbers of people in Scotland and the UK with CVD. To do this national 
statistics were accessed for each home nation (England, Scotland, Wales and Northern 
Ireland), providing estimates of the number of people alive and who are aged 16 and 
over(69). Then, using health surveys which are particular to each home nation the 
percentage of 16 years and over living with CVD was estimated. By applying the percentages 
of those living with CVD to the numbers in the population, an estimate of the actual numbers 
living with CVD across all four home nations was generated.  
 
Second, by summing across the four nations, an estimate of the total number in the UK living 
with CVD was made. This was estimated to be 6.5 million people. Scotland’s share of this 
total was estimated to be 9.8% by dividing the number living with CVD in Scotland by the UK 
total. This is a disproportionate share, given that Scotland’s population is 8.7% of the UK as a 
whole. 
 
Table 2-3 Estimating Scotland share of the UK’s CVD morbidity, 2011 
Population %  share of UK total
(16+ years) Number % of population
Scotland 4,361,484          639,955 14.7% 9.8%
England 41,805,100        5,285,377 12.6% 81.0%
Wales 2,507,100          383,473 15.3% 5.9%
N. Ireland 1,423,234          220,001 15.5% 3.4%
United Kingdom 50,096,918        6,528,807 13.0% 100.0%
Prevalence
 
Sources:  Office for National Statistics(69), Scottish Health Survey(62), Health Survey for England(70), Welsh 
Health Survey(71), Health and Well-being Survey, Northern Ireland(71)  
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Next, Scotland’s share of UK mortality from CVD was made for 2011. The number of CVD 
fatalities for each of four country’s was taken directly from the ONS(72). The number of 
events for CBVD was not available, and the sub-category of stroke is shown instead. Table 2-
4 provides the resultant estimates with Scotland representing 9.4% of total UK mortality from 
CVD. 
 
Table 2-4 Estimating Scotland’s share of the UK’s CVD mortality, 2011 
Total % CHD % CBVD %
Scotland 13,539 10.4% 8,941 11.0% 4,598 9.4%
England and Wales 113,559 87.2% 70,196 86.6% 43,363 88.4%
Northern Ireland 3,060 2.4% 1,966 2.4% 1,094 2.2%
United Kingdom 130,158 100.0% 81,103 100.0% 49,055 100.0%
 
Sources: Office for National Statistics(73) 
 
With Scotland’s share of UK morbidity and mortality estimated, these were applied as weights 
applied to Table 2-5 an estimate of Scotland’s share of the UK cost burden. First, Scotland’s 
share of UK health service costs was estimated. Morbidity and mortality shares were 
averaged [(9.8% + 9.4%)/2] to obtain 9.6% and then applied generate an estimate of £1.6 
billion. Second, to estimate, productivity costs the weights of mortality and morbidity were 
applied respectively, generating estimates of £495 million to mortality, and £413 billion due to 
morbidity. Finally, to estimate informal care costs, Scotland’s morbidity share was applied to 
the UK total which resulted in an estimate of £865 million. Overall, the economic burden of 
CVD in Scotland was estimated to be £3.4 billion in 2011, at a per capita cost of £769 - 
compared to a UK per capita cost of £574.  
 
Given the total spend by NHS Scotland was £11.7 billion(74) in 2011, spending on CVD 
accounts for approximately 30%, which is equivalent to the percentage share of all deaths 
due to  CVD (Figure 2-1).   
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Table 2-5 Estimating Scotland’s share of economic costs due to CVD  
£ million % total £ million % total £ million % total
Health care costs 1,579 47.1% 357 35.9% 349 38.6%
Productivity losses due to mortality 495 14.8% 284 28.5% 87 9.6%
Productivity losses due to morbidity 413 12.3% 155 15.6% 155 17.2%
Informal care 865 25.8% 199 20.0% 313 34.6%
Total 3,353 100.0% 996 100.0% 903 100.0%
Cost per capita 769 228 207
CVD CHD Stroke
 
Source: Estimated using Tables 2- 4 
 
In terms of health care costs, it is also possible to have a further disaggregation to 
understand how the NHS spends its resources regarding CVD. This is illustrated in Figures 2-
16 to 2-18. These figures are for the UK, as equivalent figures for Scotland are not available. 
For CVD as a whole, most spend by the health service is on inpatient care (72%) and 
medication (20%). In contrast, primary care accounts for just 6%. In considering stroke in 
isolation approximately 92% is on inpatient care, with just 2% on medications. 
 
Figure 2-16 Health care costs of CVD 
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Source: Luengo-Fernandez, R.(6) 
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Figure 2-17 Health care costs of CHD 
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Source: Luengo-Fernandez, R.(6) 
Figure 2-18 Health care costs of stroke 
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Source: Luengo-Fernandez, R.(6) 
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2.4 Risk factors for cardiovascular disease 
 
2.4.1 Identifying risk factors 
The incidence of CVD is determined by a complex interaction of risk factors acting over the 
lifecourse(75). A large number of international and UK epidemiological studies have identified 
multiple risk factors that are important to explain CVD incidence(76-78). Risk factors can be 
classified into demographic, biomarkers, lifestyle, social and genetic factors. Demographic 
factors include age and sex; biomarkers include variables such as cholesterol; lifestyle 
variables include smoking and diet; and social variables include measures of deprivation, 
which in turn is driven by such factors as income, employment, housing and education(59). 
To date, while work is on-going to identify genetic risk factors, there have not been a 
breakthrough in identifying risk factors that provide clinically meaningful additions to more 
traditional risk factors(8).   
 
It is important to identify risk variables as either modifiable or non-modifiable. Identifying 
which risk factors are modifiable can then focus decision makers on interventions that may 
influence the risk of CVD. Modifiable risk factors include those amenable to change by 
interventions. Biomarkers, lifestyle behaviours, and social variables that ultimately driven 
behaviour are modifiable(8).  Demographic and genetic risk factors are not modifiable, though 
research in the latter is on-going.  
 
A large international study, of high and low income countries, found that nine risk factors 
(biomarkers and lifestyle variables) may explain up to 94% of the CHD risk within 
populations(76). These risk factors included: smoking, history of hypertension or diabetes, 
waist hip ratio, dietary pattern, physical activity, alcohol consumption, blood apolipoproteins 
and psychosocial factors were identified as the key risk factors. The effect of these risk 
factors was consistent in men and women across different geographic regions and by ethnic 
group. Other studies have focussed on a narrow set of risk factors.  A UK study found that 
three risk factors accounted for at least 80% of the attributable risk of CHD in men(79). A 
WHO report found that  declines in total cholesterol may have accounted for more than 50% 
of all reductions in CHD events(80). Considered differently, there may be diminishing 
marginal returns to the inclusion of additional risk factors when attempting to infer the risk of 
CVD events(81).  
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Risk factors tend to be continuously distributed in the population(82) following a bell shaped 
distribution. Most of the population have low levels of risk factors, but some individuals have 
particularly inflated factors (in the right tail) putting them at a high risk of events. The chapter 
will shortly describe approaches to the primary prevention of CVD to reduce risk factors. A 
targeted approach focuses on the right hand tail of the bell shaped curve, whereas a 
population wide approach attempts to shift risk in the entire population. 
 
High risk individuals tend to cluster and are not evenly spread across the general population. 
For instance, the elderly are at high risk due to age and are at risk of all major causes of 
mortality.  However, age itself is not modifiable by intervention. Of particular policy interest is 
that biomarkers, social context and poor health behaviours that can lead to inflated risk 
factors also cluster in certain groups(83) and are in principle modifiable by intervention, 
 
Importantly, health behaviours do not develop in a vacuum but are influenced over the 
lifecourse by the environment that individuals develop within, which determine opportunity 
(e.g. access to healthy lifestyle) and define cultural norms (e.g. the behaviours that are 
exhibited)(75). There is a significant research effort with regard to the wider determinants of 
health, investigating the influences for instance of income, employment, housing, education, 
and the physical environment. These influences may have direct impacts on psychological 
well-being and also shape the opportunities and norms that individuals and communities 
face(84-85). 
 
The chapter now turns to describing in more detail how risk factors are distributed in the 
Scottish population, before detailing how risk factors have been embedded into scores to 
predict future CVD events, and identify individuals who may be most at risk. 
 
2.4.2 The prevalence of risk factors in Scottish general population 
Table 2-6 describes how the prevalence of modifiable risk factors has changed over time 
within the Scottish general population aged 16 years and above.  The data was collated by 
accessing the full range of the Scottish Health Surveys (SHeS) which date from 1995, and 
were repeated intermittently with the most recently available pertaining to 2010 (at the time of 
thesis submission). The information in the SHeS is self-reported by survey respondents and 
the table concentrates on those risk factors where there are sufficient information to generate 
a time trend of two points or more. The focus of the table is on behavioural risk factors or 
BMI. The SHeS has had a lack of good response rates from survey respondents giving 
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permission for bloods to be taken, to estimate cholesterol, or even for blood pressure 
readings to be taken. In particular, missing data can be as high as 80% for such biomarkers.  
 
Overall, the prevalence of risk factors has generally fallen which is consistent with falls in 
CVD mortality rates seen earlier. In particular, smoking prevalence has decreased the most 
with a drop of 8 percentage points, followed by hazardous alcohol consumption with a drop of 
6 percentage points. In stark contrast, however, the percentage of the population considered 
overweight or obese was estimated to be 63 percent in 2010, an increase of 11 percentage 
points since 1995.  
 
Table 2-6 Change in risk factors over time 
Smokers
All 35 35 31 29 28 -7
Male 34 36 32 29 29 -5
Female 36 33 31 28 28 -8
Low physical activity 
<30 mins per week
All - - - 32 31 -1
Male - - - 28 29 1
Female - - - 33 33 0
All - - 79 78 78 -1
Male - - 80 80 80 0
Female - - 79 78 78 -1
Alcohol
Hazardous
All - - 28 25 22 -6
Male - - 33 30 27 -6
Female - - 23 20 18 -5
BMI 25 +
Overweight/ Obese
All 52 57 61 63 63 11
Male 56 61 64 66 66 10
Female 47 52 57 60 60 13
% point change
Fruit & vegetables     < 
5 a day
20102008200319981995
 
Source: Scottish Health Surveys. Note there was insufficient detail in the early release version of 2011 to include 
it. 
 
Figure 2-19 illustrates the percentage of the total Scottish population with one of more of the 
risk factors identified in table 6. This is shown for both men and women. The distribution of 
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the risk factor count approximates a normal distribution. Just 2% have no risk factors, with 
nearly 60% having 3 risk factors or above. 
 
Figure 2-19 Distribution of risk factors in the Scottish general population 
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Source: Adapted from Scottish Health Survey 2010 
 
Figure 2-20 illustrates the distribution of those living with multiple risk factors using the 2010 
SHeS. Multiple risk factors are defined for exposition as having three risk factors or more.  
The distribution of modifiable risk factors is high across all age groups and increases with 
age. 
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Figure 2-20 Prevalence of three risk factors or above by age group 
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Source: Adapted from Scottish Health Survey 2010 
 
Notably, the prevalence of risk factors in young people aged between 16-24 years appears to 
be relatively high, with 46% having 3 or more inflated risk factors. It was not possible to 
generate a time series for the Scottish population. It has been noted elsewhere that there is a 
dearth of survey information for younger adults 16-25 regarding risk behaviours(86). 
 
There is a growing body of evidence that many risk behaviours in youths tend to cluster 
together, particularly in young people from the most deprived backgrounds. There is also 
evidence that early initiation of a particular behaviour, such as smoking or alcohol use for 
example, is associated with other risk-taking behaviours in later adolescence and early 
adulthood, including sexual risk taking, binge drinking, teenage pregnancy and delinquency. 
For instance, the Scottish Schools Adolescent Lifestyle and Substance Use Survey 
(SALSUS) found that in 2008 alcohol was consumed in the week prior to the survey by 11% 
of 13-year-olds and 31% of 15-year-olds, with no differences between genders(87). Among 
those who reported drinking in the previous week, 15-year-olds boys consumed on average 
17 units and girls consumed an average of 12 units. Further, 14% of girls and 16% of boys 
aged 15 are regular smokers, with the rates for both genders having decreased since 1998; 
and among 15-year-olds, 21% of boys and 12% of girls reported illicit drug use in the past 
month. 
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Risk factors are also associated with a deprivation gradient, consistent with observed event 
rates – figure 2-21. An analysis of the Scottish Health Survey 2010 revealed that smoking 
prevalence in SIMD 5 is 45% compared to 14% in SIMD 1(78). Such differences in behaviour 
are key reasons behind the deprivation gradient in prevalence of CVD mortality and 
morbidity. 
 
Figure 2-21 illustrates that the prevalence of individuals with three inflated risk factors or 
above increases steadily as deprivation status worsens. For instance, 50% of those in the 
least deprived fifth have multiple risk factors, which increased to 67% in the most deprived 
fifth. 
 
Figure 2-21 Prevalence of three risk factors or above by deprivation status 
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Source: Adapted from Scottish Health Survey 2010 
 
Survey data on the interaction of age group and deprivation status is lacking; however, it is 
broadly known that the deprivation gradient in risk behaviours begins at an early stage in the 
lifecourse(86). The Scottish Collaboration for Public Health Research and Policy(88) 
commissioned the Medical Research Council’s Social and Public Health Science Unit  to 
analyse health behaviours in young adults aged 18/19 years old within the West of Scotland, 
a region known to have amongst the highest deprivation rates in Scotland(89). Using the 20-
07 study(90), the risk behaviours of young adults aged 18/19 years were analysed over 
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time(86).  For males and females, rates of current smoking changed very little between 1990 
and 2003 whereas rates of heavy smoking (defined as 70+ cigarettes per week) dropped by 
over a third. Among males, rates of drinking more than the government recommended 
maximum units of alcohol in the previous week increased only slightly between 1990 and 
2003, while the rates of ever having used illicit drugs increased by about 50% between 1990 
and 2003. The most striking increase in risk behaviours were among females, where at age 
18–19: drinking more than the weekly recommended maximum units of alcohol more than 
doubled between 1990 and 2003; binge drinking doubled between 1990 and 2003; 
experience of illicit drugs more than doubled between 1990 and 2003; and sex at age <16 
years more than trebled between 1990 and 2003. In terms of earlier adolescent risk 
behaviour, rates of smoking initiation at age <14 years was similar in both cohorts for both 
genders, whilst rates of monthly drinking at age 15 more than doubled in males between 
1990 and 2003, and increased by more than four times among girls between 1990 and 2003.  
 
2.5 The prevention of cardiovascular disease: overview 
In taking stock of the chapter so far, CVD has been falling in the Scottish general population; 
however, it remains the number one cause of death, results in large numbers of people living 
with CVD, and has considerable resource costs on the health service and wider economy. 
Also, while known modifiable risk factors have in general come down, the clustering of 
multiple risks remains high across the whole population, but especially in more deprived 
groups where it was seen that mortality in the under-65s was particularly high (Figures 2-9 
and 2-10). Further, there is concern regarding the onset of risky behaviours and risk factors in 
younger adults and the increasing problem of obesity in society in general.  Consequently, 
policymakers are increasingly intent on responding to the tackling the causes of CVD to 
prevent a potential rise in the incidence and prevalence of CVD. 
 
2.5.1 Four levels of prevention 
The different approaches of prevention are well developed conceptually, and there are 
essentially four levels: primordial prevention, primary prevention, secondary prevention and 
tertiary prevention.  
 
Primordial prevention is focussed on preventing the emergence of the risk factors themselves 
by encouraging healthier lifestyles, behaviours and environments. This approach tends to 
focus on children and young adults, to encourage healthy lifestyles. This can manifest itself in 
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a number of different types of interventions, from general health promotion interventions in 
schools directly focussed on children(91), to interventions in adults with risky behaviours (e.g. 
smoking) that may lead to indirect influences on children, such as adults that quit smoking 
may influence children not to take up smoking(92). Given the manifestation of risky 
behaviours at early age groups, as discussed previously, Scotland is increasingly looking 
more systematically at developing interventions that can be described as primordial 
prevention(93). 
 
Primary prevention is where interventions seek to control exposure to risk factors. The 
intention is to prevent or postpone the first instance of an event in individuals who are 
asymptomatic, but considered at risk.  Interventions may include regular screening for risk 
factors, and lifestyle and pharmaceutical interventions, as will be described in detail when 
considering evidence for each type of intervention.  
  
In contrast, secondary prevention is designed to prevent or postpone subsequent CVD 
events following a first event. Interventions may include surgery, and lifestyle and 
pharmaceutical interventions. Individuals may be regularly screened for signs of elevated risk 
factors as a means to gauge the intensity of prescribed interventions(94). 
 
Tertiary prevention is the application of measures to reduce or eliminate long-term 
impairments and disabilities, minimising suffering caused by existing departures from good 
health and to promote the patient’s adjustments to his/her condition. Interventions are 
typically palliative in nature(95).  
 
2.5.2 Strategies for primary prevention: targeted and population 
approaches  
Strategies for primary prevention include an individual-centred ‘high-risk’ strategy, termed 
here a targeted approach; and a population ‘average-risk’ strategy, termed here a population 
approach – see table 2.7. These approaches have been in existence for some considerable 
time, and each is associated with certain well-defined pros and cons. The following section 
describes these two approaches in general terms, without specific mention of CVD. The 
reason is that such approaches are common in most areas of primary prevention irrespective 
of the disease focus(96-98).  The subsequent discussion in the chapter details the 
approaches as applied to CVD. 
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The targeted approach to prevention generally consists of screening a population to identify 
individuals at high risk of a disease and to then offer a range of interventions tailored to the 
individual in an effort to reduce risk. This is most commonly associated with the clinical 
approach to prevention focussed on individuals. The generic advantages include: that 
interventions are more likely to be appropriate; individuals who realise they are high risk are 
more likely to change behaviour; have agreement from clinicians who are trained to focus on 
individuals who are seen as current cases, and high risk individuals may gain more from 
interventions than low risk individuals. However, there are also disadvantages. These include 
the likely expense of identifying the high risk; the dangers of developing crude cut-off points 
between high and moderate risk, where the latter may still be a significant clinical risk; that 
most events in a population actually occur in the non-high risk; and that the underlying 
aetiology of the disease may not be addressed (e.g. offering pharmaceutical may reinforce 
unhealthy behaviours); and that individuals may not be sufficiently incentivised to reduce risky 
behaviours if the consequence is being on the outside of local social networks. 
 
An alternative approach to primary prevention is a population approach, which is most 
commonly attributed to Geoffery Rose as formalising the approach(99-100). He first observed 
that risk is distributed across the entire population, approximating a normal distribution; and 
that the high risk are essentially a small proportion of the population represented by the tail-
end of the normal distribution. Further, it was argued that most event rates occurred in those 
at moderate risk as they constitute the largest group in the population. The inference is that a 
small shift in the mean risk of the entire population could lead to a greater reduction in the 
burden of disease compared to a high risk approach to prevention, which concentrates on an 
extreme tail of the distribution.  Consequently, it is argued that “the only strategy with the 
potential to greatly increase the proportion of the population at low-risk status is the 
population-wide approach to primary prevention”(101).  
 
Interventions may include legislative changes, mass media campaigns and offering lifestyle 
advice to all groups. Further, even mass administration of pharmaceuticals has been 
proposed as a possible intervention(34). The population approach is argued to be more 
comprehensive, encompassing those at any risk and can extend to primordial prevention by 
preventing the onset of risky behaviours. However, such approaches are not without possible 
disadvantages, including that the benefits of interventions may be outweighed by risks for 
certain individuals, and this may especially be the case for mass administration of 
pharmaceuticals. The approach may be an inefficient use of resources, given that most 
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Table 2-7 Comparison of targeted and population approaches 
  Individual-centred ‘high-risk’ strategy Population ‘average-risk’ strategy 
Advantages  Intervention is appropriate to the 
individual. 
 People who learn that they are at 
high risk may be more likely to 
change behaviour  
 Physicians feel justified in reducing 
risk factors in high-risk patients. 
 High-risk individuals are likely to 
gain more benefit than lower-risk 
individuals. 
 Intervention aimed at roots of 
problem reduces illness in the 
whole population, including those 
at low or average risk. 
 Tackles condition in its early 
stages when interventions may be 
more effective.  
 A small change in the level of a risk 
factor in a population can improve 
the health of a large number of 
people  
 
Disadvantages  Difficulties and costs of identifying 
high risk groups and individuals.  
 Dividing line between average and 
high-risk is often arbitrary, and 
many ‘average-risk’ people can still 
be at significant risk. 
 Little impact on the disease burden 
in society. Most cases of disease 
occur in people at low or moderate 
risk. 
 Palliative and temporary—the 
determinants are not addressed. 
 A change of behaviour sufficient to 
reduce risk may put the individual 
outside the norms of the particular 
social circle. 
 Small benefit to most individuals 
may be outweighed by the risk of 
the intervention.  
 Potentially inefficient: demands 
change by a large number of 
people who would not have 
developed the disease at all. 
 Little motivation for low-risk 
individuals to change behaviour.  
 Danger of increasing inequity in 
health.  Unless specifically 
designed strategies are used,  
 Intervening in apparently healthy 
people is ethically more sensitive 
that intervening in people with 
problems.   
 
 
 
people may not have developed the disease and, depending on the intervention proposed, 
there may be limited incentives for low-risk people to change behaviour.  
 
A key distinction needs to be made regarding population health interventions that are offered 
to the whole population where individuals are free to engage or not; and those interventions 
that are essentially paternal where individuals are passive recipients. The former would 
include screening programmes and media campaigns, and the latter would include legal and 
regulatory changes. It has been shown that where the impacts of interventions require 
individual engagement and compliance health inequalities can widened(23). Further, when 
interventions are offered to everyone irrespective of the underlying risk profiles then 
inequalities can also widen, given it is also known that more socially disadvantaged 
individuals have greater prevalence of risk factors. 
 
Source: Adapted from Rose(102) 
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This parallels what Tudor Hart described as the “Inverse Care Law”: that the availability of 
good medical care tends to vary inversely with the need for it in the population served(102). 
Thus, the people in the poorest health gain the lowest net health benefit from the 
interventions. Disadvantage can occur at every stage in the process, from the person's beliefs 
about health and disease, and actual health behaviour, to presentation, screening, risk 
assessment, negotiation, participation, programme persistence, and treatment adherence. 
This effect has been usefully described this cumulative inequality as the “staircase 
effect”(103). Finally, from a libertarian perspective, it may be ethically less tolerable to 
intervene in people who do not have health problems, if this restricts or coerces 
behaviour(104-105). 
 
The next two sections detail the targeted and population approach as it is applied to the 
primary prevention of cardiovascular disease, at present.  
 
2.6 The targeted approach to primary prevention of 
cardiovascular disease 
 
2.6.1 General approach  
There is an increasing focus on primary prevention with the aims to reduce the premature 
incidence of CVD and the associated health and economic burdens. To date, the clinical and 
policy focus has been on the adult population. However, it is recognised that the scope of 
preventative interventions should include children and younger adults, as discussed earlier. In 
particular, the widening focus of prevention is due to concerns regarding a potential obesity 
epidemic, with increasingly sedentary lifestyles and the rise of unhealthy lifestyles(19-21, 
106-109).  The next two sections describe both the targeted and population approach to the 
primary prevention CVD, and the associated evidence base.  
 
The targeted approach to the primary prevention of CVD requires identifying and treating 
relevant risk factors. The clinical understanding of how best to measure and respond to the 
risk of CVD has evolved over a number of years(8). Historically, clinical guidelines 
recommended that individual risk factors, such as systolic blood pressure and cholesterol 
were measured and managed in isolation(8).  Threshold levels of risk factors were identified 
which defined the cut-off point regarding normal levels. If an individual exceeded a threshold 
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level they were then referred onto particular treatments with the aim to reduce the risk factor 
to below the threshold level.  
 
There is now a wealth of supporting evidence that major CVD risk factors like blood pressure 
or blood lipid levels are not only individually poor predictors of a patient’s CVD risk but also of 
a patient’s potential to benefit from treatment(25).  
 
Clinical guidelines now recommend screening all individuals from 40 -74 years old every 5 
years using a risk tool to assess multi-factorial risk over 10-years(15-16), Figure 2-22 
illustrates the process. Such ‘global’ risk scores use both non-modifiable risk factors (such as 
age and sex),  
 
Figure 2-22 Overview of a high risk approach: screening and tailored interventions 
 
No intervention
Intensive drug 
& behavioural advice
Clinical screening, every 5 years
Medium risk 10-19%
Lifestyle advice
Low risk 0-10% High risk ≥ 20%
Target population 
40 - 74 years
 10-year risk scores
 
 
Source: Inferred from Clinical Guidelines(9) 
 
and modifiable risk factors (such as smoking status and blood pressure). Risk calculators are 
now routinely embedded into administrative software packages and readily available in 
general practice(8).  High risk individuals are identified as those with a risk score of ≥ 20% 
0-9  
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and are referred onto a range of intensive drug therapies (such as statins and anti-
hypertensives) and behavioural advice (such as smoking and diet advice). Individuals with 
any symptomatic manifestation of CVD, including diabetes, are assumed to be at high risk of 
cardiovascular events and do not require formal risk estimation.  
 
Those with a risk score of between 10-19% are classified as medium risk and are offered the 
behavioural advice only. Low risk patients are those with a risk score of 0-9% are not offered 
specific interventions. In this respect, a high risk approach embeds primary prevention in 
general practice, as the ‘gatekeepers’ to onward intervention. 
 
2.6.2 The targeted approach in Scotland 
Scotland introduced a primary prevention programme called Keep Well in 2007(12). While 
clinical guidelines recommended screening the entire population aged 40-74 years, Keep 
Well is focused on 45-64 year olds living in the 15% most deprived areas as identified by the 
Scottish Index of Socioeconomic Deprivation (SIMD). The explicit policy aim of the 
programme is to reduce health inequalities.  
 
The Keep Well programme consists of the standard process as outlined in Figure 2-22. 
Individuals are invited to attend clinical screening and general practices are recommended to 
follow the SIGN Guidelines to then screen individuals using the ASSIGN score. The ASSIGN 
score, and other risk scores, will be described in detail shortly. The score was developed for 
specific use in Scotland and uses SIMD as a risk variable which accounts for the social 
gradient in CVD. Individuals who are identified as high risk are then referred onwards to an 
intensive set of pharmaceutical and lifestyle interventions.  
 
The Keep Well programme began as a pilot in Glasgow and has been rolled-out gradually to 
other deprived areas in Scotland, achieving national coverage in 2011. The Keep Well 
programme will be revisited in Part 3 where the pilot will be evaluated.  
 
2.6.3 Developing risk tools: an overview of modelling approaches  
Before reviewing the main risk scores that are in use in clinical practice, this short section 
provides an intuitive overview regarding how risk scoring tools are created, and tested for 
accuracy. 
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The approach of survival analysis 
The key defining characteristic of risk scores is that they predict the risk of event over a 
period of time. Survival analysis is defined as a term used to describe a set of methods 
designed specifically for analysing a longitudinal dataset where time to event is an explicit 
marker for individuals who are followed over time. The output of the survival analysis is to 
estimate both a survival function and a hazard function. The survival function, St, gives, for 
every time period, the probability of surviving (or not experiencing the event) up to that time.  
 
S(t) = Pr(T>t) 
 
The hazard function, h(t), gives the instantaneous probability that the event will occur, per 
time unit, given that an individual has survived up to the specified time.  
 
λ (t) = f(t) /S(t) 
 
The role of censoring  
In developing regression models for survival analysis to estimate survival and hazards the 
straightforward application of multiple regression techniques is inappropriate for two main 
reasons. First, normality cannot typically be assumed as empirical observation will usually 
show that survival times are not normally distributed. Second, there is the issue of censoring. 
Observations are censored when the information about their survival time is incomplete(110). 
 
Censoring can manifest in three forms: Left censoring, interval censoring and right censoring. 
Left censoring is when an individual experiences the event of interest before the beginning of 
the study period. Interval censoring is when an individual is lost to follow-up for a period of 
time and then returns to the dataset. The most commonly encountered form is right 
censoring. This occurs when the individual does not experience the event with the study 
period; when an individual is lost to follow-up permanently within the period of observation; 
when an individual experiences the event of interest after the study period; and finally multiple 
censoring when the individual experiences the event multiple times after the observation 
period.  
 
Intuitively, censoring represents a particular type of missing data, which standard multiple 
regression techniques cannot address. Survival analysis seeks to incorporate information 
from both censored and uncensored observations in estimating model parameters. Censoring 
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that is random and non informative is usually required in order to avoid bias in a survival 
analysis. Conveniently, this is most often assumed to be the case. 
 
There are three main approaches to survival analysis: non-parametric, semi-parametric and 
parametric approach. Each is outlined described in turn.  
 
Non-parametric approaches  
This approach relies solely on the observed data to estimate survival relative to an exposure 
of interest. No distributional assumptions are imposed on the data. The objectives are to 
compare relative survival times between different groups (e.g. male and female).  
 
Lifetable or actuarial approach: This used in situations where it is known that for a group of 
interest, a number of events occurred over a long observation period, but it is unknown when 
an event occurred. A lifetable or actuarial approach estimates the time to event in a relatively 
crude fashion by first dividing the observation period into a series of equally spaced intervals 
and assumes that the number of events are spaced equally across all periods. The result is 
that the probability of event is the same in each period. However, this approach isn’t 
appropriate in developing risk scores given that it is known that risk is not uniform in time, and 
for instance increases with age. More refined methods are available. 
 
Kaplan-Meier (KM) approach: A KM approach is the most popular non-parametric approach 
and is sometimes referred to as a product limit estimator. It can be used when it known when 
the event of interest occurred. The application of a KM approach is when time is not 
continuous, but rather the distribution is discrete with the incidence of events defining 
consecutive time periods. Again, the assumption of independent censoring is made such that 
remaining survivors over time are representative for all subjects.  
 
Let di be the number of deaths at t(i), and let ni be the number alive just before t(i). The hazard 
is:  
 
λ (t) = (ni – di) / ni 
 
However, this approach is also not appropriate in the estimation of risk scores, where the 
objective is to estimate the relationship between risk factors (measured continuously or 
categorical) and the hazard of events. Therefore, a regression approach is necessary. 
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Semi-parametric approach  
The most popular regression model for the estimation of risk scores is the Cox proportional 
hazards regression model. The Cox regression model is a semi-parametric model, which 
makes no assumptions about the shape of the baseline hazard function, but assumes that the 
hazard ratio comparing any two observations is constant over time in the setting where the 
predictor variables do not vary over time. This is the proportional hazards assumption. This 
shown in log for expositions, as it defaults to a linear equation: 
 
Inλ(t) = Inλ(t) * (b1 X1 + b2X2 + ... + bnXn)  
 
Parametric approach  
These models assume that the underlying distribution of survival over time follows a certain 
probability distribution. The risk of event(s) is composed of two-parts. First, by a linear 
predictor, the sum of the products of covariates and the estimated coefficients; and secondly 
the use of an ancillary parameter resulting in event risks changing in time.  
 
There are several distributions that are commonly used. The exponential distribution 
assumes that the hazard is a function of the linear predictor and does not vary with time. This 
is shown in logs for consistency with other possible model choices: 
  
Inλ (t) = Inλ 
 
The Weibull distribution is described by a scale parameter λ and shape parameter p. 
 
If p is less than 1 then the instantaneous hazard monotonically decreases with time; if p 
equals 1 instantaneous hazard is constant over time (equivalent to the exponential 
distribution); and if p is greater than 1 instantaneous hazard increases with time.  
 
Inλ (t) = In(λ p pt p -1 ) 
 
The Gompertz distribution is given by 
 
Inλ (t) = In(xb)In(γt) 
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Where xb is the linear predictor from the regression and γ is the ancillary parameter 
estimated from the data. The Gompertz distribution is commonly used when predicting 
mortality, predicting rates consistently well(110). 
 
Validation of risk score predictions: discrimination and calibration 
It is important to test how good a risk score is to enhance its credibility to be used in clinical 
practice(111-112). There are two main tests commonly used to assess risk scores: 
discrimination and calibration(113). Discrimination is the ability of the risk score to 
differentiate between patients who do and do not experience an event during the study 
period. The most widely reported measure of model discrimination for CVD risk prediction 
models is the C-statistic. The C-statistic is a function of both the sensitivity and specificity of 
the model across all of its values, and it represents the ability of the score to discriminate 
(future) cases from non-cases(114). The sensitivity of a test is the probability of a positive test 
result, or for a value above a threshold, among those with disease (cases). The specificity is 
the probability of a negative test result, or a value below a threshold, among those without 
disease (non-cases). The Receiver Operator Curve (ROC) is a plot of sensitivity versus 1-
specificity (often called the false-positive rate) that offers a summary of sensitivity and 
specificity across a range of cut points for a continuous predictor.  
 
The C-statistic is quantified by calculating the area under the ROC; a value of 0.5 represents 
chance and 1 represents perfect discrimination. A C-statistic of between 0.70 and 0.80 is 
considered adequate and between 0.80 and 0.90 is considered offering excellent 
discriminatory ability(114).   In short, the C-Statistic is a simple measure to test whether a 
model can rank order individuals: that the probability that the measure or predicted risk is 
higher for a case than for a non-case.  
 
Strengths of the C-Statistic are in its simplicity to combine sensitivity and specificity in a single 
measure, and the ability to discriminate between higher and lower risk cases. However, this is 
also its weakness. That is, it is a measure of relative ranking, not the probability that 
individuals are classified correctly or that a person with a high test score will eventually 
become a case. This is a key weakness for using the C-Statistic to judge 10-year risk scores, 
which are prognostic models with the intention to predict absolute risk. Cook(115) provides an 
illustration that in a prospective cohort that is considered generally low risk (such as many 
population-based cohorts) there may be a small proportion of individuals who are at high risk, 
with most at low or very low risk. The C-statistic does not take this distribution into account. 
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For instance, differences between two individuals who are at very low risk (e.g. 1.0% versus 
1.1%) have the same impact on the C-statistic as two individuals who are at moderate versus 
high risk (e.g. 5% versus 20%) if their differences in rank are the same. For prognostic risk 
tools this would appear to be a major issue as the prioritisation of individuals and treatment 
decisions are based on classifications of absolute risk. Therefore, while discrimination is 
important it is a weakness if models are assessed solely using the C-Statistic(114). 
 
The C-statistic is also limited when a risk tool considers whether to add additional risk 
variables. It has been shown that the addition of key risk factors, such as cholesterol can 
makes a substantive difference to absolute risk, but can make very little difference to the C-
Statistic if the risk model already included certain other variables, including age and blood 
pressure. In short, the C-statistic is useful, but is not ideal - on its own at least - to assess the 
performance of risk models(115).  
 
Calibration, on the other hand, directly assesses the ability of a risk prediction model to 
predict accurately the absolute level of events that are subsequently observed. When the 
average predicted risk within defined subgroups of a prospective cohort matches the 
proportion that develops the event of interest the model is described as well-calibrated(115). 
Calibration can be assessed by dividing the population at risk into deciles of predicted risk 
and plotting the predicted risk versus the observed event rate.  The statistical metric often 
used to test for the calibration of a risk model is the Hosmer-Lemeshow test(116). A p-value 
of ≥ 0.05 indicates that  
 
the null hypothesis (that there is a lack of fit) can be rejected in favour of the alternative that 
there is good agreement between observed and predicted results for such a test.  
 
When good model fit is not achieved in the original estimation of the model it can be 
recalibrated to the population of interest. Recalibration can be a simple and pragmatic 
exercise, and for risk models this may simply involve inserting an intercept, adjusting the 
slope coefficient, or adjusting the ancillary parameter is a parametric model is used 
(discussed shortly). Overall, recalibration is likely to be important in prognostic models that 
are generated using historical data, and where the relationship between risk factors and 
outcomes may have changed over time; or when attempting to use a model developed in one 
setting in another setting.  
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To reiterate, in current clinical practice, the performance of CVD risk scores is judged (at 
times only) using the C-Statistic(115). This is illustrated in the next section when we review 
the major risk prediction scores in use in the developed world. 
 
2.6.4 Common risk scores used in clinical practice  
This section reviews the most commonly used risk scores in clinical practice in the developed 
world. It is not intended to be a systematic review of all risk scores within the literature, but 
rather the key scores used in United States, Europe, England and Scotland (Table 2-8). 
 
Framingham score – US Version 
Population  
The Framingham score was the first risk score in use and was developed in the United 
States. This was based on the Framingham Cohort, which began in 1948. The original cohort 
consisted of 5,209 individuals aged between 30-62 years old, who were predominately white 
Caucasians. Participants are rescreened every two years for a detailed medical history, 
physical examination, and laboratory tests(117).  
 
Since the original cohort there have been five additional cohorts, including: (i) a second 
generation study (Framingham Offspring Study) in 1971. This consisted of the adult children 
of the original cohort and their spouses in 1971; (ii) a third generation study in 2002, the  
grandchildren of the original cohort; (iii) a study of the spouses of the second generation; (iv) 
a particular ethnic cohort in an attempt to diversify the cohort to be reflective of the changing 
ethnic mix of US, and finally; (v) there was also the addition of the first generation of this 
ethnic cohort.  
 
Consequently, the Framingham cohort continues to be an evolving study with continued 
follow-up, though no new cohorts have been preannounced to date. Further, as the cohort 
has been updated, new variants of the score have been produced periodically, which vary 
accordingly to sample size, age range, risk factors, clinical end-points and time frame (e.g. 
10-years and above, which is discussed at the end of the chapter).   
   
The first CVD score was developed in 1991(118) and was focused on CHD event. The latest 
score developed for the US was published in 2008(119) widens the focus to CVD. This was 
based on a sample size of 8,491 individuals who were followed for an average 12 years. The 
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baseline (observation years) used in this particular study are staggered over several years, 
beginning in 1971 and combining observations from the original cohort and the second 
generation study. 
 
Risk factors / clinical end-points 
Sex-specific multivariable risk functions were derived that incorporated age, total and high-
density lipoprotein cholesterol, systolic blood pressure, treatment for hypertension, smoking, 
and diabetes status. Other variables such as diastolic blood pressure, body mass index, and 
triglycerides also were considered, but they were not statistically significant. The clinical end-
points included coronary heart disease, stroke, peripheral artery disease, or heart failure. 
 
Modelling approach 
A Cox-proportional hazards model is used, with different versions for men and women. 
 
Validation: Discrimination and calibration 
Tests of discrimination and calibration were conducted. The score demonstrated good 
discrimination with C-statistics of 0.763 for men and 0.793 for women. Further, the model 
showed reasonable calibration. Of those identified as being at high risk (top quintile of 
predicted risk) 49% of men and 60% of women had a CVD event.  The model also 
demonstrated good specificity. Of those identified not at high risk 85% and 84%, of men and 
women respectively did not have an event. 
 
Application 
The score has been developed for use in the United States. 
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  Table 2-8 Summary of dominant risks used in clinical screening  
Population (baseline screening) Risk Factors / intervention threshold End-points Modelling  approach Validation / calibration Application
Framingham United States Age, total and high-density lipoprotein cholesterol, Coronary heart disease, stroke, peripheral Cox proportional hazards model C-Statistic:0.763 men, 0.793 women. US
1971 - systolic blood pressure, treatment for hypertension, artery disease, or heart failure
Mean follow-up 12 years smoking, and diabetes status. No calibration
8,491
30-74 years Separate equations for men and women
20% + denotes high risk
Framingham United States Age, sex, smoking status, systolic blood Fatal and non-fatal myocardial infarction, new angina Cox proportional hazards model Re-calibrated to the UK population. England
1971 - pressure, and the ratio of total cholesterol to fatal and non-fatal stroke, cerebral haemorrhage Factor of 1.3 for family history
Mean follow-up 12 years HDL cholesterol and transient cerebralischaemia Factor of 1.4 for Asian ethnicity
8,491
30-74 years 20% + denotes high risk
SCORE Europe - 12 countries Age, sex, total-HDL cholesterol ratio, CVD mortality Weibull proportional hazards model C-Statistic: ranged from 0.71 - 0.84, Europe-wide
1972 - 1987 smoking, systolic blood pressure across risk straum
Mean follow-up 13 years Separate models for CHD death
205,178 5% + denotes high risk and stroke death No calibration
19 to 80 years
ASSIGN Scotland Age, SBP, total cholesterol, HDL Deaths from cardiovascular causes Cox proportional hazards model C-Statistic: 0.727 men, 0.765 women. Scotland
1984 - 1995 cholesterol, diabetes, family history, coronary  heart disease
Mean follow-up 18 years socioeconomic deprivation, cigarettes per day cerebrovascular disease No calibration
16,000 coronary artery interventions
30-74 years Separate equations for men and women
20% + denotes high risk
QRISK2 England and Wales Age, sex, SBP, ratio total cholesterol/HDL Myocardial infarction, angina, coronary heart Cox proportional hazards model C-Statistic: 0.792 men, 0.765 women. England 
1994 - 2008 cholesterol, diabetes, family history, disease, stroke, and transient ischaemic attack.
Mean follow-up 12 years socioeconomic deprivation, smoking status, Calibration: from 0.92 -0.95 across deciles
Over 2 million ethnic status, BMI, treated hypertension, 
30-74 years rheumatoid arthritis, chronic renal disease, 
atrial fibrilllation
20% + denotes high risk
68 
 
Framingham score – UK Version  
 
Population  
The Second Joint British Societies (JBS2) clinical guidelines recommend using a modified 
version of the score that uses the risk factors in the original 1991 study(15, 120). The 
population dated from 1971 and was comprised of 8,491 individuals. 
 
Risk factors / end-points 
The score uses the risk factors of age, sex, smoking status, systolic blood pressure, total 
cholesterol and HDL cholesterol.  The CHD end-points used were fatal and non-fatal 
myocardial infarction and new angina, and the CBVD end-point includes fatal and non-fatal 
stroke, cerebral haemorrhage and transient cerebralischaemia. Some primary cardiovascular 
events, such as aortic aneurysm or lower limb ischaemia, are not included. However, on their 
own these represent a small proportion of all CVD events.  
 
JBS2 recommends that the risk score is adjusted for Asian individuals and those with a family 
history of premature CVD, defined as < 55 for men and <65 for woman. The score for Asian 
individuals is multiplied by a factor of 1.4, and for those with family history the multiplicative 
factor is 1.3. For those who are Asian and have a family history these factors are applied 
simultaneously. 
 
Modelling approach  
A Cox-proportion hazard model was used.  
 
Validation: Discrimination and calibration 
A specific validation and calibration exercise of the score in the UK was not conducted as part 
of JBS2 guidelines. However, a large systematic review of cardiovascular risk assessment in 
primary prevention has shown that the performance of Framingham risk scores varies 
considerably between populations, and that accuracy relates to the background risk of the 
population to which it has been applied(28). There is a general agreement that Framingham 
over predicts absolute risk in populations with low observed CVD mortality and under predicts 
in populations with high CVD mortality(121). The adjustments described above for Asian 
communities and those with family history attempts to calibrate the score accordingly. 
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Application 
In England, the Framingham score is still the recommended by Department of Health(122). 
JBS2 recommends the use of risk charts, to communicate how risk factors translate into 10-
year scores, as an aid to comprehension for both clinicians and individuals(15, 120). Figure 
2-23 provides an illustration for non- diabetic men. Separate charts are shown for 10-year 
age bands, and smoking status.  
 
Figure 2-23 JBS2 10-year risk charts 
 
 
Source: JBS2 Guidelines 
 
Profiles towards the top right corner denote the highest systolic blood pressure and total to 
HDL cholesterol values, resulting in the highest risk. A key driver of risk is age. For equivalent 
risk profiles, the risk of CVD increases with age, and by aged 60 almost all profiles is denoted 
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at high risk. The presence of this age gradient is revisited in later in the discussion, in the 
context. 
 
The National Institute for Health and Care Excellence (NICE) has withdrawn its 
recommendation that general practioners (GPs) should use Framingham exclusively. Rather, 
GPs have the liberty to use Framingham or QRISK2, which is discussed shortly.  
 
Systematic COronary Risk Evaluation (SCORE) 
Population  
SCORE(123) was developed by the European Society for Cardiology (ESC) and 
recommended for use in ESC Clinical Guidelines(16). The datasets used in creating the 
score originated from 12 countries, over a staggered baseline period of 1972- 1987 and there 
as with an average follow-up of 13 years. In total, 205,178 individuals were included in the 
study aged between 18 and 80 years old. 
 
Risk factors / end-points 
The risk factors of age, sex, ratio of total to HDL cholesterol, smoking status and systolic 
blood pressure were used. The end point is CHD death and stroke death. The score adds 
these two together to have an overall risk of CVD.  
 
Modelling approach  
A Weibull proportional hazards model was used. Separate equations are estimated for CHD 
death and stoke death. The total CVD death risk is calculated by simply adding the risk of 
CHD death and stroke death together.   
 
Validation: Discrimination and calibration 
Internal validation was conducted using the age range of 45-64 years, and separately for 
certain high and low risk countries. The former included Russia, Scotland, Sweden and the 
UK. The latter included France and Germany.  Validation was conducted for the risk 
thresholds of 3%, 5%, 7%, and 10%. The C-statistic ranged from 0.71 to 0.84 demonstrating 
good discrimination. However, the variability in sensitivity was marked, ranging from 20% to 
87%; and specificity 19% to 95%. This wide range reflects the fact that the tests were done 
for 4 thresholds, with event predictions for the higher thresholds performing better. There 
were no tests of calibration. 
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Application 
SCORE is used across European countries where it was derived, with the exception of 
Scotland and England.  England uses Framingham mainly, and Scotland has being using the 
ASSIGN score, discussed next.  
 
ASsessing cardiovascular risk using SIGN guidelines (ASSIGN) 
Population  
A Scottish specific risk score was developed in 2007 to replace the Framingham score which 
had previously been widely used. It was found that the Framingham score overestimated the 
observed CHD risk in the cohort as a whole, and it seriously underestimated the large 
gradient in risk by socioeconomic status(17). Therefore, application of the Framingham score 
as a basis for preventive treatment may have resulted in relative under-treatment of the most 
socially deprived. 
 
The ASSIGN score (ASsessing cardiovascular risk using SIGN guidelines to ASSIGN 
preventive treatment) was developed to include social deprivation as a risk factor(124). 
ASSIGN score is based on the Scottish Heart Health Extended Cohort, a series of population 
studies from the 1980s and 1990s followed up until the end of 2005. The Scottish Heart 
Health study recruited men and women across 25 districts of Scotland in 1984-87 and the 
Scottish MONICA Project recruited in Edinburgh and Glasgow in 1986 and in Glasgow alone 
in 1989, 1992 and 1995. In total, this involved collecting baseline data from 6,419 men and 
6,618 women  
 
Risk factors / clinical end points 
The ASSIGN score estimates sex specific equations using the variables age, family history, 
diabetes, socioeconomic deprivation, systolic blood pressure, total cholesterol, HDL 
cholesterol, and the number of cigarettes smoked per day. Risk factors were measured 
continuously where possible (with dichotomous variables for sex, family history, diabetes). 
 
Socioeconomic deprivation was measured by the Scottish Index of Multiple Deprivation 
(SIMD), as introduced previously. Family history of cardiovascular disease is defined as 
coronary disease or stroke in parents or siblings below age 60 or in several close relatives.  
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Modelling approach  
A Cox-proportion hazard model was used. Separate models were generated for males and 
women, following significant interactions between sex and SIMD, which persisted following 
adjustment for other covariates. 
 
Validation: Discrimination and calibration 
The ASSIGN score and Framingham score (the version reviewed under Framingham 
England) were tested together using the SHHEC dataset(121). The results were similar when 
taking the population as a whole, slightly favouring ASSIGN. The predicted high risk was 
14.4% for ASSIGN and 16.0% for Framingham, where the observed incidence was 11.7%. 
The C-statistics for ASSIGN was 0.727 versus Framingham 0.716 for men and 0.765 versus 
0.741 for women – both in favour of ASSIGN. In averaging across sex, the sensitivity of the 
scores was 46.3% for ASSIGN and 45.6% for Framingham. Specificity was 82.5 and 82.6% 
for ASSIGN and Framingham respectively.   These results might be expected given that the 
dataset used to conduct the tests was the same used to construct the ASSIGN score. The 
real added value of ASSIGN over Framingham is the ability to detect the underlying social 
gradient in the incidence of events. However, there were no calibration tests. 
 
Application 
The SIGN97 Guidelines recommended using ASSIGN as the risk score of choice in Scotland, 
given it was developed for specific use in Scotland and detected the underlying social 
gradient in the incidence of CVD.  SIGN recommends that all adults aged 40 years to 74 
years are screened every five years. In addition, SIGN recommends that screening is 
widened to individuals at any age with a first-degree relative who has premature 
atherosclerotic CVD or familial dyslipidaemia. In practice, however, this is not done routinely. 
The important of family history in detecting high risk individuals will be revisited in Part 3. 
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QRISK2 
Population  
QRISK2(125) was developed in East Anglia in the UK, and is a rapid update of the preceding 
QRISK(126-127). The 10-year risk score was developed in East Anglia, with a patient group 
of over two million patients aged 30 to 84 years from 1994 to 2008.  
 
Risk factors / end-points 
A very wide range of risk factors are used including age, systolic blood pressure, the ratio of 
total to HDL Cholesterol, diabetes, family  history, socioeconomic deprivation, smoking status 
(five levels, including former smoker), BMI, treated hypertension, rheumatoid arthritis, chronic 
renal disease, and atrial fibrillation. Socioeconomic deprivation was measured by the 
Townsend score, which is similar to the SIMD score (used in ASSIGN). Family history is 
slightly more restrictive than ASSIGN defined as coronary heart disease in a first degree 
relative.  Notably, up to 80% of risk factor information is missing in the baseline screened 
dataset, and extensive multiple imputation was undertaken. The end-points in the score 
include myocardial infarction, angina, coronary heart disease, stroke, and transient ischaemic 
attack. 
 
Modelling approach  
A Cox-proportional hazards model was used to estimate the 10 year event risk. 
 
Validation: Discrimination and calibration 
The performance of the QRISK2 model was compared with the original Framingham 
score(125) using the QResearch database. QRISK2 performs well in terms of discrimination 
with C-statistic is 0.792 for men versus 0.779 for Framingham. The model is also well 
calibrated to the population. Individuals were scored, divided into tenths of predicted risk and 
then the ratio of observed risk to predicted risk was estimated. This was called the calibration 
slope and ranged from 0.92-0.95. QRISK2 did not find any socioeconomic deprivation 
gradient in the incidence of CVD unlike ASSIGN. 
 
Application 
The score is not specifically recommended by any Guidelines at present, but general 
practioners are at liberty to use QRISK2 if felt appropriate. 
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Overall, there a variety of different risk scores in use across the developed world. Most 
notably, Scotland has developed a particular risk score, called ASSIGN which in particular 
includes a measure of socioeconomic deprivation: the more deprived an individual is the 
deemed to be the great the risk of event. In application this score detects an underlying social 
gradient in the risk of events that accord with the gradient in event rates.  
 
An additional issue of note is the range of risk factors that can be included. For instance, 
SCORE has six, ASSIGN has nine, and QRISK has 11. However, when comparing the 
performance of risk score directly, it makes very little difference to the overall proportion of 
the population found to be at high risk.  This is consistent with the finding of law of diminishing 
marginal returns to risk factor inclusion(81) . These observations raise three issues. First, in 
choosing a risk score the main concern should be whether a particular risk factor aids 
discrimination between individuals – this is the necessity of using ASSIGN in Scotland.  
Second, in considering whether to add or replace risk factors key issue are not only whether it 
adds to predictive capacity and discrimination but also whether information on risk factors is 
available. QRISK2 includes more than double the risk factors of the Framingham score it is 
seeking to replace in England. However, it is difficult to see the added value, and this adds to 
the burden of the collection of risk factor information and potential for missing data. Third, 
from an economic perspective it is also important to assess the cost effectiveness of including 
additional risk factors, rather than saturating models with additional biomarkers, behaviours, 
genetic factors, and social variables. There is lack of research regarding the latter(8).  
 
Notably, no risk tool includes physical activity as an independent risk factor despite inactivity 
being a known independent risk factor(128). Regarding ASSIGN the reason is that physical 
activity was not reported within the baseline screening survey. It is unclear as to the reason 
for its exclusion, is perhaps related to measurement issues. We return to the issue of physical 
activity later, and the potential challenges this poses in evaluating intervention effects. 
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2.7 Targeted approach: review of the evidence  
 
2.7.1 Categories of evidence  
The previous sections outlined the approaches to screening and identifying individuals 
deemed to be at high risk of a CVD event, and who are then subsequently referred onto a 
range of interventions. Section 2.7 as a whole is concerned with reviewing the evidence 
underpinning this approach. This particular sub-section defines the different types of evidence 
used in the chapter.  There are three main categories of evidence: efficacy, effectiveness and 
cost effectiveness, as Table 2-9 outlines.   
 
Table 2-9 Types of evidence 
 
Type of evidence 
 
 
Working definition  
 
Efficacy 
 
 
The maximum impact of an intervention detected under 
clinical conditions.  
 
Effectiveness 
 
The impact of an intervention in a real world setting. 
 
 
Economic evidence 
 
 
The value for money of an intervention.  
 
 
Efficacy evidence  
Efficacy refers to the maximum capacity of an intervention to result in changes in clinical 
outcomes. Clinical epidemiology had developed a hierarchy of evidence which essentially 
ranks the rigour of alternative study designs.  
 
One of the difficulties in using efficacy evidence, as will be illustrated when reviewing the 
evidence for CVD interventions, is that the nature of outcome chosen can be particular to a 
study. For instance, efficacy evidence can relate to changes to a risk factor, events, disease 
mortality or all cause mortality. Further, studies can vary widely regarding the time period 
over which evidence is measured. From a particular study perspective, this is perfectly 
rational when the aim is to test efficacy on a particular medical outcome. However, from a 
policy or decision maker perspective that may need to collate a range of evidence and 
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choose between interventions, such an array of outcomes can inhibit comparability across 
interventions. This issue will be revisited shortly under the approach to economic evaluation. 
 
Effectiveness evidence 
Effectiveness evidence refers to the impact of the intervention under real world settings 
where, for instance, individuals’ uptake and compliance behaviour with the intervention may 
vary between settings. Further, such effectiveness studies should report possible side effects 
and intolerance from medications where relevant.  
 
The approach of economic evaluation 
The basic premise of economic evaluation is that resources are scarce, and decision makers 
need to prioritise resources to achieve a set of explicit aims. Economic evidence essentially 
builds upon efficacy and effectiveness estimates, to look at both the benefits of an 
intervention and also the resource impacts, including the costs of an intervention and knock-
on cost impacts from events saved, or incurred. Drummond defines economic evaluation as 
the ‘comparative analysis of alternative courses of action in terms of both their costs and 
consequences”(p9)(129). 
 
Economic evaluation is intended to produce the evidence that can allow decision makers to 
prioritise resources according to economic first principles. There are two important first 
principle concepts that determine the kind of information economic evaluation is required to 
produce(130). The first is ‘opportunity cost’: when investing resources in one area, the most 
relevant cost for the decision maker to consider is the opportunity for benefit that is forgone 
because those resources are not invested elsewhere. The second is that of the ‘margin’: 
when changing the resource mix, the most relevant costs and benefits for the decision maker 
to consider are the marginal costs and benefits resulting from the proposed change in the 
resource mix, rather than the average or total costs and benefits of all the historical resources 
used.   
 
There are three main approaches to economic evaluation used in health economic 
evaluation: cost effectiveness analysis, cost utility analysis and cost benefit analysis(129, 
131-132).   The first two approaches are the most common. Each is outlined in turn, and with 
respect to how resources can be prioritised using the information generated.  
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According to McGuire (p76), a cost effectiveness analysis is employed when ‘…there is a 
fixed benefit or health effect to be achieved, and the objective is to seek the most technically 
efficient—i.e. least cost—way(131). For instance, if drug B is seeking to replace drug A, and 
both have the same health effect yet drug B is cheaper, then choosing drug B is the most 
technically efficient option.  Further scenarios encountered in cost effectiveness analysis are 
where a new intervention is seeking to replace an existing intervention, and both costs and 
the level of health effect are different(37). The decision to adopt (reject) the new intervention 
is straightforward if the new intervention both costs less (more) and the effects are more 
(less). Here the new intervention is said to ‘dominate’ the existing intervention. In cases 
where the new intervention cost more (less) and the benefits are higher (lower) then the 
adoption decision is less straightforward. Here an incremental cost effectiveness ratio (ICER) 
is calculated which is the ratio of the additional costs to the additional outcomes generated. 
The ICER essentially generates a cost per unit of outcome. The decision to adopt the new 
intervention is conditional upon whether the ICER is below the maximum amount that the 
health sector is willing to pay (WTP) for an additional gain in health effect. This maximum 
WTP is termed the threshold value, and is driven (among other things) by the health sector 
budget. Where there are multiple independent interventions competing with one another for 
adoption then a cost effectiveness table can be constructed to rank order interventions, using 
the methods of ‘dominance’ and ‘extended dominance’(37). Using this approach to prioritise 
resources between alternatives to achieve a common outcome can lead to what is termed 
‘productive efficiency’; defined in a health care context as ‘...the maximisation of health 
outcome for a given cost, or minimisation of cost for a given health outcome(133).  
 
Cost utility analysis is a second form of economic evaluation that requires benefits to be 
comparable across interventions and patient groups(134). ’Utility’ is a term used to  define a 
measure of health outcome using the preferences of individuals or society(129). To create 
utility a two-stage process is conducted. First, a condition-specific(134-136) or more 
commonly a generic health related quality of life (HRQoL) questionnaire is administered, such 
as Short Form 12 (SF-12)(137), EuroQol-5D (EQ-5D)(138) or Health Utilities Index 
(HUI)(139).  Responses are then weighted by preferences regarding the desirability of 
different health states. This then generates preference-weighted HRQoL scores which are 
essentially a linear index of possible utility scores. The range of the index can vary depending 
on the initial HRQoL questionnaire used. The SF-12 can be converted to utilities using the 
SF-6D algorithm, producing a score than can range from 0.29 to 1. The EQ-5D can be 
converted to utilities producing a score that can range from -0.54 to 1, where negative values 
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indicate states worse than death. The utility score can be used itself as the measure of health 
effect, and it is common for the utility scores to be used to weight expectations of length of life 
generating a more comprehensive generic outcome measure called Quality Adjusted Life 
Years (QALYs).  These approaches to generate utilities will be described in much more detail 
later in the thesis. Alternative metrics to QALYs, but based on a similar approach, include 
Disability Adjusted Life years (DALYs)(140), and Healthy Years Equivalent (HYE)(141). To 
estimate whether a new intervention represents value for money a similar process as 
described under cost effectiveness analysis is undertaken to then improve the productive 
efficiency of the health service(37).   
 
The third approach of economic evaluation is cost benefit analysis (CBA). The standard 
approach in CBA is to value all outcomes (including health and non-health outcomes) in 
financial terms by asking recipients of the intervention (or the general public) their willingness 
to pay for outcomes. The underlying premise is that the social value of an intervention can be 
measured legitimately in financial terms.  Given outcomes and costs are in enumerated in 
financial terms, a CBA is intended to estimate the net social impact of an intervention(s) i.e. 
outcomes in financial terms minus costs in financial terms. Positive net values represent an 
improvement in social welfare, negative values represent a net reduction in social welfare and 
a zero value is neutral. 
 
The approach of CBA takes what is termed a ‘societal perspective’, by attempting to 
incorporate all costs and benefits resulting from an intervention. In contrast, the approach of 
cost effectiveness analysis and cost utility analysis take a narrower ‘health perspective’ by 
restricting the scope of the evaluation to collect information on the costs and benefits (health 
only) to the health sector, and in the UK this extends to personal social services(37). The 
approach of CBA develops the widest generic outcome measure that is intended to represent 
social welfare (including heath and non-health outcomes). The rationale is to help decision 
makers to allocate resources between alternative uses to improve social welfare and improve 
the allocative efficiency of resource use.  Allocative efficiency is achieved when resources are 
allocated so as to maximise the welfare of the community(133).  
 
CBA is the traditional approach of welfare economics, whereas the practice of cost 
effectiveness analysis and cost utility analysis is the dominant approach of economic 
evaluation in the health sector. The general argument made for using cost effectiveness/cost 
utility analysis is that the health sector budget has been apportioned to deliver health 
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outcomes, and decision makers may be only interested in the health benefits and costs that 
accrue to the sector. Arguments that can be made for CBA is that health sector decision 
makers may be interested in more than utility or QALYs(142) and perhaps the role of 
economic evaluation is also to challenge decision makers and influence the health sector 
budget itself, rather than begin from an assumption that policy makers adopt the heath 
perspective(143).  
 
Approach of economic evaluation in the United Kingdom 
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) has 
guidance recommending the approach of cost utility (or cost effectiveness) analysis when 
undertaking economic evaluation(37, 144).  The resource costs considered are those that fall 
on the health sector and also personal social services. An evaluation should ideally account 
for both the intervention costs and further impacts on health sector costs, such as events 
avoided or delayed. HRQoL impacts should be measured by surveying patients (or carers). 
To generate utilities, the valuation of HRQoL should reflect the preferences of the general 
population, and the recommendation is that the EQ-5D should be used to promote 
standardisation of preference elicitation across economic evaluations. Further, a key feature 
of cost effectiveness analysis is that outcomes and costs should be discounted at 3.5% to 
reflect the lower value placed on distant outcomes. Also, an equity judgement is taken that 
the value of an additional QALY is equal regardless of the recipient. NICE recommends that 
an intervention is cost effective is the cost per QALY is below £20-30,000(37, 144). In 
Scotland, while health policy is devolved, NICE’s methodology is generally accepted by both 
the Scottish Medicine Consortium (SMC) and NHS Scotland.  
 
It is important to note, however, that guidance is evolving over time.  An important issue is the 
price that the NHS pays for pharmaceuticals. The current approach is that prices are 
negotiated through the Pharmaceutical Price Regulation Scheme (PPRS) which is a voluntary 
agreement between the Department of Health (DH) and the pharmaceutical industry. The 
PPRS determines profit rates from drug sales to the National Health Service (NHS) every 5 
years utilising price and profit controls(145). Therefore, the current NICE guidance on 
economic evaluation treats prices as exogenous inputs to the economic evaluation and then 
generates a cost per health gain (e.g. cost per QALY), with the adoption decision made 
relative to the willingness to pay threshold of £20-30,000. However, the PPRS scheme 
expires in January 2014, and the Department of Health announced that NICE will thereafter 
play a key role in price setting; where the price set is intended to reflect the social value that 
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the pharmaceutical is expected to produce. The pricing system is called ‘Value Based Pricing’ 
and the general concept is that prices should reflect the value created, and should include 
considerations of the burden of illness, unmet need, future innovation, and wider social 
benefits. This system has been introduced in Sweden, for instance(146). The implications for 
the role of NICE and the approach to economic evaluation going forward will be important to 
observe. The intention of this section is not to rehearse differing views but to make the point 
that approach to economic evaluation is subject to on-going innovation.  
 
Further, NICE’s recent Public Health guidance(147) recommends that economic evaluation 
takes a broader perspective by considering non-health outcomes alongside health outcomes. 
It is recommended that where appropriate a societal perspective is adopted to consider all 
major costs and outcomes. It is suggested that a cost consequence analysis (CCA) be 
conducted, which is essentially a social accountancy exercise, listing all major outcomes in 
natural units.  To then value outcomes in economic terms, it is recommended that health 
outcomes are valued as Quality Adjusted Life Years (QALYs) to permit direct comparability of 
public health interventions with other interventions. Similar to the previous guidance, a QALY 
is valued equally regardless of the recipient. 
 
It is also recommended that evaluators consider undertaking a cost benefit analysis (CBA), 
when evaluating public health interventions. In practice, this would entail valuing all outcomes 
in the CCA in economic terms (health and non-health) to estimate the overall social value of 
an intervention, where health is one component. The guidance also recommends that the 
discount rate for costs and benefits should be 1.5%. This is in contrast with guidance for the 
economic evaluation of health technology which recommends a discount rate of 3.5% for both 
cost and benefits. A potentially interesting issue is whether within the CBA the WTP survey 
includes valuing QALYs. This may then allow for the social valuation of a QALY to vary 
dependent on the recipient and, if so, this would contrast with guidance in for the economic 
evaluation of health technology. Again, the purpose of this discussion is descriptive rather 
than evaluative as to the merits of one approach over another. Overall, the key point is that 
the first principles of economic evaluation are clear; however, the particular approach 
adopted may be tailored to the decision problem at hand, and methods are evolving over 
time. 
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Quality of evidence 
Understanding the risk factors of CVD, and which interventions may impact on modifiable risk 
requires scientific attribution. For health researchers, it is standard practice to refer to a 
hierarchy of evidence, as illustrated in Table 2-10 where there are 6 ‘levels’.  
 
In short, the randomised control trial is considered as the most rigorous study design to 
compare the impact of a treatment on an intervention group relative to control group, where 
the act of randomisation is intended to evenly distribute all known covariates, leaving the 
difference between groups as the intervention itself.  These studies designs can vary, for 
instance with respect to the extent blinding such as study participants (single blinded), 
physicians (double blinded) and study administrators (triple blinded). Systematic reviews of 
RCTs, where the conclusions are aligned, provide the most robust evidence (Level 1), 
followed by a single or multiple RCTs without conducting a formal systematic review (Level 
2). 
 
Table 2-10 Hierarchies of evidence 
One Systematic review(s) of well designed randomised control trials
Two Evidence from at least one well designed randomised controlled trial
Three Evidence from well designed observation studies, such as matched-control cohort studies
Four Evidence from well conducted natural experiments
Five Expert opinion elicited under scientific conditions
Six View of peers
Level Description
 
Source: adapted from Evidence Based Nursing Practice(148) 
 
Non-RCTs designs are essentially different forms of either observational studies (level 3), 
such as matched controlled studies which may require statistical adjustment for known 
confounders to infer treatment estimates. Natural experiments (Level 4) are where it may be 
possible to develop attributable evidence of a policy change that proceeded in the absence of 
explicit experiment. For instance, econometric techniques such as interrupted time series or 
where changes in the outcome of interest may be traced back to the introduction of 
legislation. 
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Level 5 is where expert opinion is collated by convening an expert/stakeholders group to elicit 
opinions systematically through tools such as Delphi Panels. Level 6 is simply the view of 
peers, and while not evidence may be important when considering the need to conduct trials 
or studies.  
 
Additional challenges in generating and generalising from evidence  
In general terms, it is more straightforward to generate evidence for drugs rather than lifestyle 
interventions. The use of RCTs is relatively straightforward when assessing the impacts of 
drugs. However, there can be additional challenges in both generating and generalising from 
service based interventions. This is particularly the case when interventions are 
programmatic and need to be implemented through a delivery system. This can lead to 
interventions being termed ‘complicated’ and ‘complex’.  
 
Interventions are complex where there are multiple components and where causal chains are 
long term. These features make it difficult to identify active ingredients and to distinguish 
between a good intervention and poor implementation(72, 73).    
 
Further, interventions may also be ‘complex’ in the sense that they can interact with local 
context (e.g. past and present interventions). In effect, context is an effect-modifier(149). For 
instance, perhaps ‘upstream’ interventions that focus on improving the living conditions of 
communities live (e.g. housing, regeneration) are prerequisites for sustained ‘downstream’ 
interventions that attempt to change health behaviours directly(36).  
 
These common features can cause difficulties in establishing both causality (e.g. the 
opportunity for randomised trials is limited) and the generalisability of evidence, given that 
context can vary substantially between settings. Evidence synthesis is a particular 
challenge(150). The interaction of economic evidence with context provides an opportunity for 
interdisciplinary research in the future in order to improve both the generation and 
generalisability of evidence(51-52, 151). 
 
The practical consequence of this is that even if evidence is found that lifestyle interventions 
have made significant impacts and are cost effective, it can be more difficult to assess how to 
transfer the intervention between settings. It has been suggested that rather than preserve 
the absolute fidelity of an intervention, the steps of the intervention are maintained but how it 
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is delivered is adopted for local context in order to suit local resource ability and cultural 
practice(152).  
 
The role of modelling  
Of particular concern in this thesis is the role of modelling to help generate economic 
evidence. As will be discussed in detailed throughout the thesis, preventative interventions 
may have the greatest impact over the long term. Experimental studies, often conducted over 
relatively short time periods, can detect short term or intermediate outcomes, such as 
changes in risk factors or events. However, as discussed previously economic evaluation is 
concerned with ‘final outcomes’ such as (quality adjusted) life expectancy and impacts on 
health service costs.  In generating economic evidence, modelling is undertaken. Chapter 3 
discusses the rationale for modelling in detail.   
 
In addition, modelling studies may be undertaken in the absence of any evidence. First, such 
exercises can be done to either analyse historical data for the purpose of investigating the 
associations between events and interventions that occurred. Second, modelling exercises 
can be used to predict future events and the potential for (further) event reductions. Third, 
modelling can also be undertaken to highlight uncertainties in the evidence base and need for 
economic evaluation.  
 
Modelling is now undertaken routinely to evaluate health interventions. However, given its 
widespread use and application there is a need for good modelling practices to ensure the 
best opportunity for achieving robust and transparent result open to peer review.  Chapter 3 
discusses the latest guidance on how to build and disseminate economic models. For the 
time being, this chapter will simply summarise the evidence available. 
 
2.7.2 Approach taken to identify studies 
There is a significant on-going effort by researchers to undertaken new studies and perform 
periodic systematic reviews. Rather than undertake a new systematic review this section is 
essentially a summary and interpretation of key studies. It is not intended to be exhaustive, 
but rather to provide a valid interpretation of the overall body of evidence. Further, only 
interventions directly focussed on particular risk factors were considered, and those delivered 
by the health sector. Therefore, interventions excluded include those where CVD is not the 
main aim, but may nonetheless have knock-on effects on relevant behaviours, such as 
mental health interventions that seek to enhance an individuals’ general sense of self-efficacy 
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that may then lead to healthier lifestyle choices. Also excluded are the wider determinants of 
health that may influence lifestyle choices indirectly, such as housing and regeneration.   
Further, interventions designed to ‘nudge’ behaviour are also not considered(153). 
  
Efficacy, effectiveness and cost effectiveness evidence is reviewed. In reviewing the clinical 
evidence, clinical guidelines were drawn upon.  Specifically, the Scottish Intercollegiate 
Guidelines Network (SIGN) developed the SIGN 97 guidelines for the primary prevention of 
cardiovascular disease(9). Within this document there was the collation of numerous 
systematic reviews of both pharmaceutical and lifestyle interventions, and was published in 
2007. Further, the National Institute for Health and Care Excellence(NICE) Programme 
Development Group (PDG) for the primary prevention of CVD undertook an extensive review 
of the literature which related to population health interventions, and mainly included lifestyle 
interventions, rather than a focus on pharmaceuticals(154-156). This review was published in 
2009.   In an effort to update these evidence reviews, a literature search for more recent 
systematic reviews was also conducted by reviewing Cochrane Libraries and also a general 
search of the literature using PUBMED dated from 2008 to the end of 2012. 
 
A similar approach was adopted to search for effectiveness and cost effectiveness evidence. 
The research by the NICE PDG is heavily drawn upon. Further, PUBMED was searched for 
more recent evidence relating to singled drugs and multi-factorial interventions that combine 
drugs and perhaps also with lifestyle interventions.  
 
2.7.3 Targeted prevention: efficacy evidence /modelling studies 
In reviewing relevant studies a distinction is made between evidence derived from 
evaluations and estimates derived from modelling studies.  
 
Pharmaceuticals 
As discussed, cholesterol is a key risk factor; though more specifically it is low density 
lipoprotein (LDL) which is the harmful component which comprises 60-70% of total 
cholesterol. Guidelines recommend that high risk individuals (whether raised cholesterol or 
not) be given a 40 mg dose of a statin drugs daily. There is also a log-linear relationship 
between the statin dosage and reductions in LDL, with each doubling of the dose being 
associated with a fall in LDL of 6%.  A meta-analysis found that a reduction LDL of 1.6 mmol/l 
halves the CHD event risk after 2 years(9).There are a variety of different types of statins. 
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Guidelines recommend a dosage of 40 mg per day and trials have found this reduces LDL by 
between 29% (pravastatin) to 53% (rousuvastatin).  
    
Further, there is also evidence that statins increase high density lipoprotein, which then 
improves health outcomes. The West of Scotland Coronary Prevention Trial (WOSCOPS) 
found that pravastatin increased HDL Cholesterol(157). Table 2-11 summarises mean 
estimates, providing a range where possible. 
 
A Cochrane systematic review of fourteen RCTs in 2011 found no evidence of significant 
harm(158-159).  At present, statins are not recommended for those at CVD risk below 
20%(29-30). However, there is on-going debate. A recent systematic review of 27 RCTs 
found that statins could be safety prescribed to those at lower risk(160). However, previous 
studies have concluded that statins should not be prescribed to individuals below a 1% 
annual all-cause mortality risk or an annual CVD event rate of below 2%(159). This is aligned 
with treating individuals with a risk score of 20% or greater 10-year risk of developing CVD. 
 
Table 2-11 Evidence of efficacy - pharmaceuticals 
 
 
Benefits 
 
Risks 
Statins 
 
-  LDL of 29-53% 
+ HDL of 5% 
Controversy: possible + risk 
stroke 
Anti-hypertensives 
 
 - CHD by 15-25% 
 - Stroke by 30-40% 
None reported 
Aspirin 
 
- MI 15-25% + risk bleeding 70% 
+ stroke 40% 
“+” denotes increase; “–“ denotes decrease; “M” denotes myocardial infarction 
 
Anti-hypertensives are prescribed to reduce blood pressure. There are five main types of anti-
hypertensives, namely: thiazides, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin receptor-II antagonists, calcium channel blockers and beta-blockers. All have 
approximately equivalent impacts and when combined appear to have additive impacts. The 
SIGN97 clinical guidelines also report that anti-hypertensives can reduce the risk of CHD by 
15-25% and stroke by 30-40%. There is an approximate linear relationship between dosage 
of anti-hypertensive and CVD risk between the values of 115/70 and 170/100 mm Hg, with 
the numerator denoting systolic blood pressure and the denominator diastolic blood pressure. 
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Clinical guidelines recommend that individuals are treated where systolic blood pressure 
(SBP) is ≥ 140 mmHg and diastolic blood pressure is  ≥ 90mmHg; or where the risk of CVD 
calculated by the ASSIGN score is ≥ 20% over 10 years. The relationship between lowering 
blood pressure and CVD outcomes is approximately linear: the higher the baseline risk: the 
greater the reduction(9). The target level for SBP is 100-115 mm Hg, however there is no 
evidence that lowering below this has harmful effects. 
 
SIGN Guidelines also recommend that asymptomatic individuals at high risk be given a daily 
dose of aspirin of 75mg as anti-platelet therapy. Pooled RCT results estimate a reduction in 
the risk of myocardial infarction of 30%. However, there can be serious side-effects with the 
relative risk of stoke increasing by risk of 40% gastrointestinal bleeding by 70%. There was 
no impact on all cause mortality.  Guidelines recommend not extending aspirin to those not at 
high risk. However, there is a renewed debate regarding the safety of prescribing aspirin to 
any individuals eligible under primary prevention. The most recent paper found that the risk of 
bleeding outweighed any benefits(161-162).  
 
There is also on-going interest in combining medications into a single polypill. In a modelling 
study(34), it was estimated that the incidence of coronary heart disease could be reduced by 
80% if all men and women over the age of 55 took a “polypill” of six low dose drugs.  The 
assumption being that this is an age threshold most individuals would benefit. However, the 
study also assumed compliance of 100%. There is also no trial evidence as yet in a Cauasian 
population, although several studies are on-going(163). Positive impacts were found in a trial 
conducted on an Indian population(164). 
 
In summary, there is relatively robust evidence of the benefits of certain pharmaceuticals. 
While there can be a risk of side effects, clinical guidance recommends offering statins, anti-
hypertensives and aspirin to patients found to be at high risk of a CVD event. There remains 
controversy that non-high risk patients should be offered similar treatment. Further, a key 
observation is that the outcome measures reported are not consistent, consisting of risk 
factors or events. This is a recurring theme in the evidence base, and can make it difficult to 
directly compare the effects of different interventions; and inhibits an assessment of the 
impact of interventions against the ultimate objectives of prevention which is to avoid 
premature mortality. 
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Lifestyle interventions  
The following summarises the evidence of dietary, physical activity and smoking 
interventions, as these are the main focal points for primary prevention. A variety of dietary 
interventions have been reviewed, in the literature both in terms of additions and abstinence 
from certain food stuffs.  A systematic review of 27 studies found that reductions in dietary fat 
intake reduced CVD events by 16%, but had a small insignificant impact on total 
mortality(165). SIGN Guidelines recommend diets low in saturated fats. Table 2-12 provides 
mean estimates with ranges from different studies for illustration, where possible. 
 
It is also recommended that individuals with hypertension should reduce salt intake as much 
as possible. A Cochrane meta analysis of 28 studies found that for individuals with SBP of ≥ 
160 a daily reduction of salt intake of 6mg resulted in a reduction in SBP of 7.11/3.88 
mmHg(166). 
 
Table 2-12 Evidence of efficacy – lifestyle changes 
 Risk factor 
Saturated fat reduction 
 
 - 15-35% CVD events 
Salt reduction 
(6mg reduction) 
 
- 7.11 mm Hg (SBP)  
- 3.88 mm Hg (DBP) 
Fruit and vegetables 
(400 g per day) 
 
- 14-23% CHD events 
Physical activity 
(sedentary to moderate) 
 
- SBP 3.8 mmHg 
- DBP 2.8 mmHg. 
- MI 26-30% 
Smoking cessation 
 
- RRR death x3  
MI = myocardial infarction; RRR = relative risk reduction 
 
Further, it is also recommended by SIGN97 that all individuals should consume 400g of fruit 
and vegetables each day. Such diets are also associated with low fat intake. Two systematic 
reviews of cohort studies found that the reduction in CHD events was between14% to 23%. 
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There is strong evidence that physical inactivity has been shown to be independent risk 
factor, after adjusting for other known risk factors; however, it is argued that it remains 
unclear to what extent increasing activity levels reduces CVD risk(128).  
 
Nonetheless, there are a wide range of studies estimating the impact of physical activity on 
other known CVD risk factors that do point to positive impact. A meta-analysis of 54 RCTs 
found that previously sedentary adults who undertook moderate aerobic exercise of 30 
minutes and three times a week could decrease SBP 3.8 mmHg and DBP by 2.8 
mmHg(167). No dose response was reported. 
 
The impact of exercise on lipids levels was inconsistent. Of 51 trials, 24 showed that HDL 
increased, which is protective of CVD events. However, the range across the 51 trials 
showed that the HDL varied from -5.8% to +24%(167). The Interheart study found that HDL 
levels increased by 5% (76).  No dose response was reported. In terms of event risk, the 
Interheart study found that moderate exercise compared to sedentary reduce the risk of 
myocardial infarction by 14% (26% – 30%, CI 95%).  
 
Importantly, it can be difficult to draw general inferences regarding the particular type of 
interventions that may work best. The impact of interventions can differ widely by type of 
activity, frequency, duration and intensity; and also report different outcomes. It appears that 
energy expenditure and frequency of activity are the key drivers of risk rather than type or 
duration of activity(168).  
 
The evidence regarding smoking is relatively unequivocal. SIGN97 reports that there is a 
strong and dose response relationship between smoking and all CVD events and overall 
mortality. For instance, male smokers are three times more likely to die between 45-64 years, 
and twice as likely to die aged between 65-84 years, than non-smokers. Risks increase with 
the number of cigarettes smoked per day, with the risk of a myocardial infarction 10 times 
higher for those who smoke 40 per day.  
 
Overall, there is relatively strong evidence that adopting healthy lifestyles can have significant 
impacts on risk factors and the incidence of CVD events. The major areas of uncertainty 
relates to multi-factorial programmes, either in terms of a polypill or combination of drugs and 
lifestyle changes. In particular, there is a lack of knowledge regarding the compliance rates 
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and how the impacts of interventions interact in terms of the combined reduction in risk 
factors and events. 
 
2.7.4 Targeted approach: effectiveness evidence /modelling studies 
The key difference between efficacy and effectiveness is compliance behaviour. That is, 
whether individuals, under real world settings, take the appropriate medicines and in the 
appropriate doses. Further, when considering effectiveness of lifestyle interventions it is 
important to recognise that interventions can vary enormously in the intervention design (e.g. 
staff specialities), delivery (e.g. setting), target group (e.g. age, socioeconomic background), 
and evaluation methods (e.g. outcomes, time, information collected). This makes 
synthesising extremely difficult(51).  
 
Pharmaceutical interventions 
There are few studies that have assessed the real world effectiveness of pharmaceuticals 
over the long term. In general terms, it appears that compliance behaviour for asymptomatic 
patients is relatively low for any medications. For instance, studies find that compliance rarely 
will exceed 50%(13).  This suggests that the efficacy estimates previously reviewed should 
be at least halved when estimate effectiveness over the long term.  
 
With regards to a polypill there is also uncertainty about how the benefits that where identified 
for single intervention (e.g. stains) might combine when collated into a single pill. Even opti-
mistically assuming a hypothetical combined risk reduction of 40% (that is, 15%+25%), over 
half the cardiovascular risk will remain. If compliance was say 50% on average in the 
population, then the risk reduction would be halved. Nonetheless, clinical guidelines infer that 
these impacts are sufficient to maintain that screening and prescribing should continue for 
high risk individuals.  
 
Lifestyle interventions 
The evidence base regarding the effectiveness of interventions to promote healthy lifestyle is 
mixed. Clinical guidance recommends that such interventions are not rolled-out routinely 
without an accompanying study, and ideally to assess long term compliance. Counselling to 
stop smoking is an exception. There are a wide number of studies assessing the 
effectiveness of smoking initiatives. Smoking interventions are varied, and can include one or 
a combination of medications (including patches), one-to-one counselling, and group therapy, 
combined with general lifestyle advice.  As such, it can be difficult to draw general inferences. 
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Despite, high relapse rates, with long term compliance falling to as low as 5%(169), decision 
makers have deemed this sufficient to continue funding such programmes. The cost 
effectiveness evidence will be summarised shortly.  
 
The major areas of uncertainty in the evidence base relates to multi-factorial programmes 
that combine pharmaceutical and lifestyle interventions. Table 2-13 details key studies 
gathered from the NICE PDG which extended to 2008, which was then combined with a more 
recent search of the literature. There were two studies that reviewed the effectiveness of 
multifactorial interventions that were targeted on high risk individuals – following a screening 
of the whole population. The interventions were Seeze District Control which began in 1983 
and had a 10-13 year follow-up and Oxcheck in 1995 which had a 4 year follow-up. There 
were significant changes in key risk markers, such as BMI and dietary behaviours. However, 
it is difficult to interpret the clinical significance of changes to certain risk factors and event 
rates are often not reported. A more recent study published in 2012 was of the 
EUROACTION intervention. This was a clustered RCT of 6 practices from across Europe and 
for the asymptomatic population there were positive changes in blood pressure and 
cholesterol, after a 1-year follow-up. 
 
More recently, a Cochrane Review in 2011 focused on counselling and educational 
interventions included 55 trials aimed at modifying one or more cardiovascular risk factors in 
the adult general population(170). The review concluded that there is no evidence that such 
interventions to change behaviour reduce total or coronary heart disease mortality or clinical 
events in general populations. The review found that effects were only found when individuals 
had pre-existing disease such as hypertension or diabetes.  
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Table 2-13 Efficacy/effectiveness evidence - multi-factorial interventions 
Programme Interventions Study design Outcomes / results
The Sezze District Control Population screening programme Controlled before and after study  BMI - 10% (women), blood fasting glucose -15% (men)
Italy assessing 10-year risk Matched intervention and control area
1983 High risk offer intensive lifestyle Baseline screening in 1983 and follow-up screening
20-69 years old and behavioural interventions in 1993-1996
10 - 13 year follow-up
OXCHECK Screening for CVD risk factors, 11,090 invited for randomisation RCT TC - 0.19 mmol/l, SBP - 2.5 mm/Hg, diastolic - 1.1 mm/Hg 
Luton and Dunstable Individuals with high risk factors invited to nurse appointment Control attended health check in 4th year BMI - 0.38 kg/m2, physically active +3.3%, consumption of
England in 1st year (1989-90) and attendees invited to further check in Four year follow-up full cream -7.5%, consumption of butter -8.7 %
1995 4th year (1992-93)
35-64 years old
Comparison of screening strategies to find those at high risk
6 risk factor identified: (i) SBP > 140 mmHg (ii) smoking 
(iii) BMI > 28 (iv) fat intake 110g/day (v) family history CVD
first degree relative <60 years (vi) TC > 7.5mmol/l
Comparing mass screening on population for all risk factors  
against different targetted approaches that first screen for one
risk factor initially and then for the high risk screening for other 
risk factors
EUROACTION Screening and treatment of high risk patients with individualised Clustered RCT: 6 pairs of general practices in Hypertensive patients(> 140 SBP/90 DBP); - 17%;
Mistry H et al lifestyle counselling and medications. Europe-wide. 6 countries  total cholesterol -13%
2012 1019 intervention patients; 1005 control patient
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2.7.5 Targeted approach: cost effectiveness evidence / modelling 
studies 
From an economics perspective, the important issue is whether the observed changes in risk 
factors and events are enough to justify the cost the interventions themselves. This is the 
rationale for taking a cost effectiveness approach, as described earlier. 
 
Pharmaceutical interventions 
The evidence regarding the cost effectiveness of single pharmaceutical interventions appears 
to be robust for individuals defined as high using 10-year risk scores. There is strong 
evidence that medications including statins(NICE)(171), anti-hypertensives (NICE)(172) and 
aspirin (NICE)(173) are cost effective, with the incremental cost effectiveness ratio below  
£20-30,000 recommended by NICE and followed by SMC – table 2-14. The uncertainty is not 
whether to prescribe a drug but rather which should the first line intervention, as the extent of 
benefits and costs of different drugs may differ(172).  
 
Table 2-14 Cost effectiveness evidence - pharmaceuticals 
 
Type 
 
 
Cost per outcome 
 
Statins 
 
Cost saving and has same or greater effectiveness; to £2,500 per QALY 
 
 
Anti-hypertensives 
 
Cost saving and has same or greater effectiveness; to £1,976 per QALY 
 
Aspirin 
Cost saving and has same or greater effectiveness; to £22,000 per QALY 
 
 
Overall, NICE recommends that such medications should be used in the primary prevention 
of CVD, but only when individuals are found to be at high risk. This is consistent with clinical 
guidelines.  
 
A recent systematic review of the cost effectiveness of statins found that the key driver was 
cost, and as cost falls so statins become cost effective even for low risk groups(171). This 
closely matches the clinical literature with regards to the efficacy and effectiveness of 
medications of the low risk. Prices have tended to come under downward pressure as drugs 
have come off-patent and generic versions have entered the market. However, treating the 
low risk remains a source of controversy. It has been argued that medicalising low risk 
93 
 
individuals may create perverse incentives if healthy behaviours become unhealthy as a 
result(174). Further, it is unclear whether potential side-effects had been accounted for in 
most studies. 
 
Notably, however, there are no cost effectiveness studies of polypill to date. However, a 
recent modelling study also showed that a combination of different interventions may be cost 
effective(175). 
 
Lifestyle interventions 
The cost effectiveness evidence for certain lifestyle interventions is also strong(31), In 
particular, the evidence for smoking is unequivocal. This is even the case when compliance 
rates (abstinence from smoking) falls as low as 5% as found by a recent modelling study that 
extrapolated trial results to the longer term(169). Importantly, individual studies that make up 
these guidance documents have relied on the use on important assumptions, with respect to 
the long run compliance with healthier lifestyles. However, even following scenario analysis 
where assumptions around compliance are sensitised the inferences can remain robust; that 
such interventions appear to be cost effective.   
 
In terms of the international evidence base, a recent modelling study(175-176) which drew 
upon the ACE-Prevention study, a large scale review of the literature of effectiveness 
estimates to then estimate cost effectiveness, found that certain physical activity intervention 
scan be cost effective. Notably, the exception was for multi-factorial programmes referred 
through general practioners. A study from the Netherlands also suggested that the particular 
form of the interventions and local context are key factors driving whether interventions are 
cost effective(177). 
 
There are few cost effectiveness studies assessing of multi-factorial interventions, combing 
pharmaceutical and lifestyle interventions. The Oxcheck study, British Family Heart Studies, 
and EUROACTION interventions, previously summarised, found positive changes in certain 
CVD risk factors.  Following these studies, economic modelling was conducted to infer 
whether these programmes are also cost effective – table 2-15. This required modelling to be 
undertaken to extrapolate trial results. It is inferred that the Oxcheck and the British Family 
Heart Studies could be cost effective if changes in risk factors found in trial were sustained for 
at least five years and tend year respectively(178). On the other hand, the inference was that  
EUROACTION was likely to be cost effectiveness over 10 years(179).   
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The Department for Health for England, created an economic model to project the impacts of 
the Vascular Screening Checks programme that began to roll-out nationwide from 2009(122), 
as discussed earlier. It was reported that the modelling found that the programme is likely to 
be very cost effective, with estimates of £7,000 per quality adjusted life year gained, below 
the cost effectiveness threshold of £20-30,000(180). However, it is difficult to assess how 
robust these estimates are. The model itself is not available for external review, and certain 
modelling assumptions that were reported appear to be very optimistic. For instance, within 
the detail of the report, the most notable assumption was regarding long term compliance. 
Regarding statins for instance, it was assumed that asymptomatic individuals would be 70% 
compliant over the long term. However, previous research suggests compliance would be 
unlikely to exceed 50%(13). It is reasonable to expect that this compliance assumption would 
have had a major impact on the cost effectiveness results reported. However, no sensitivity 
on compliance rates was conducted.  
 
In reflecting on the models used to estimate cost effectiveness, two main issues are 
apparent. First, bespoke models appear to be built for (almost) every new intervention 
encountered. This seems inefficient. A single model that estimates the risk of CVD using a 
wide range of risk factors could in principle be used repeatedly.  This could enhance the 
direct comparability of the cost effectiveness of different interventions. The second issue that 
the economic models are not always well-reported to permit third parties to review. The next 
chapter reports on a systematic review of models that have adopted a generic approach in an 
attempt to model the impact of a range of different interventions.  
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Table 2-15 Cost effectiveness evidence – multi-factorial interventions  
 
Programme Interventions Study design Outcomes / results
Field et al Modelling study, using study finding after 4 years and All strategies cost effective with mass screening least.
1995 See table 2-11 projecting over lifetime ICER ranged from £97 to £503 measured in £/Lifeyears
Long term projections of OXCHECK
Mistry et al See Table 2-11 Modelling study, using study finding after 1 year and Not cost effective - most costly; fewer QALEs compared
2012 projecting over 11 years using Framingham equations. to usual care
Cost effectiveness of EUROACTION
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Overall, the evidence base for the targeted approach to primary prevention is inconsistent. 
There is strong efficacy evidence that single interventions can have positive net impacts on 
risk impacts, but there is a lack of robust efficiency, effectiveness and cost effectiveness 
evidence for multi-factorial interventions. The challenge for researchers is to conduct rigorous 
and longer trials, combined with transparent modelling approaches to estimate the lifetime 
impacts of interventions. 
 
Turning to Scotland specifically, it is now clear that there is no prior evidence that the targeted 
prevention programme called Keep Well, that is being rolled out nationwide, will have major 
impact and be cost effective. Further, the programme is being rolled out without a rigorous 
economic evaluation. Consequently, it would appear that while policymakers are justifiably 
concerned regarding the incidence of CVD and health inequalities, policy is being rolled out 
mainly on aspiration rather than expectation.  
 
2.8 A population approach to the primary prevention of 
cardiovascular disease and evidence base 
Population approaches are intended to impact on everyone in the population of concern, in 
contrast to a targeted approach on the high risk, as discussed earlier. This general approach 
has gained traction in policy circles regarding the primary prevention of CVD. It is argued that 
population approaches need to be at the centre of a comprehensive approach to combat the 
underlying aetiology of the disease, and that “all other strategies will, at best, only restrain the 
epidemics; they will not prevent them”(181). A population approach is endorsed by numerous 
bodies, including the European Heart Network(182), for instance.  
 
Population interventions include a varied set of interventions, from mass media campaigns 
and lifestyle advice to legal and regulatory changes. The following now summarise the 
effectiveness and cost effectiveness of population wide interventions. 
 
2.8.1 Population approach: effectiveness evidence/modelling 
studies 
The landmark study was in North Karelia which was 5-year community intervention study in 
Finland, beginning in 1972 with the aim to reduce CHD risk factors(183).  A combination of 
interventions were delivered simultaneously: including mass and local media campaigns; 
training of health service staff, engaging with volunteers and community leaders for health 
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promotion; environmental changes, such as smoking restrictions; and food processing and 
supply restrictions to use low-fat dairy and meat products.  There were major falls in key risk 
factors, including smoking prevalence, cholesterol and blood pressure.  Following a 25-year 
period (1972-1997) it was reported that CHD mortality declined in North Karelia by 73%, and 
compared to 65% in Finland as a whole over the same time period(184).  
Table 2-16 details 19 major studies since North Karelia that was reviewed by the NICE NPD. 
Most studies tend to be observational matched-control studies, with interventions delivered to 
entire localities (e.g. state level) with a neighbouring location used as a control. In general, 
studies do not have the benefit of such a long follow up as in North Karelia and varied widely 
according to time period, setting (different countries), and the intervention(s) (e.g. mass 
media, screening). It can be observed that 15 studies report significant changes in one of 
more risk factors, and 4 studies had no significant changes.  
 
It is difficult to assess to what extent the changes in risk factors would result in clinically 
meaningful outcomes regarding future events. In general the evidence base is promising, but 
far from comprehensive or convincing that a particular type of intervention is likely to lead to 
substantial reductions in primary events. Overall, the impacts seen in North Karelia, that 
inspired many such interventions around the world has not been replicated elsewhere.
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Table 2-16 Effectiveness evidence of population interventions 
Programme Interventions Study design Outcomes / results
The Norsjo Project Mix of lifestyle interventions, consisting of information Matched controlled before and after study TC - 0.8 mmol/l,
Whole community of Norsjo provision from existing providers regarding education, Control was region of Northern Sweden, 
Sweden diet,exercise.  Surveys: 1,893 individuals
5500 individuals Risk factor screening offered to 30 to 60 year olds 7 year follow-up
1985 with individual counselling.
The North Karelia Project Comprehensive education programme integrated Matched controlled before and after study Smoking prevalence - 28% (men), TC -3% (men), SBP -3% (men), 
Rural county within existing health and social services, including: Control was Kuopio similar size and socioeconomic indicators  -5% (women), DBP 3% (men), - 4% (women)
Whole community Mass media, training of staff in CVD prevention, information 3 surveys over 15 years of follow-up
180,000 individuals services, provision of healthy foods, smoking restrictions
1972
The Pawtucket Heart Health Program Behaviour change  promoted via local statutory, church Matched controlled before and after study BMI -0.62 kg/m2
Rhode Island and community organisations; then combined with mass media Matched community,
United States from TV adverts to newspaper ads and billbards Surveys, 1,255 individuals
71,204 individuals 10 year follow-up
The Stanford Five City Project Two cities with interventions Matched controlled before and after study SBP -3.8mmol/l,
Five cities City wide mass media education campaigns: TV, radio, Three cities as controls. BMI -0.83 in intervention group
1980  newspapers , combined with community level education Surveys : 1,148 intervention individuals, 743 control individuals
Two cities with intervention campaigns distribution of media products (eg. Leaflets) 6 year follow-up
245,000 individuals
The South Carolina Cardivascular Mass media education campaigns (TV, radio, newspapers) Matched controlled before and after study  % with TC > 5 mmol/L -3.7% (women), BMI >25 kg/m2 -2.9%
Prevention (Heart to Heart Project) Community levels cooking demonstrations, restaurant labelleing. Survey: 1,130-1,259 individuals Consumption of animal fats -4.9%, consumption of fruit & veg +
Florence 4 year follow-up consumption up 5.2%
46,227 individuals
1987
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Table 2-16 continued 
Programme Interventions Study design Outcomes / results
Action Heart Mix of lifestyle interventions, including: Matched controlled before and after study, with one control area Smoking prevalence -by 3.5% pts,  semi-skimmed
2 towns in England Schools based activities such as health eating, anti-smoking, similar in socioeconomic indicators milk consumption + 7% pts 
(Swinton and Wath) trained teachers to discuss heart health topics 18-64 year olds Execise in children (≥3 times per week) + with
13,000 households Whole community activities to delivery leaflets to all households 4 year follow-up odd ratio of 1.76 versus control
1993 to drink semi-skimmed milk Wholemeal bread consumption + Odds ratio of 1.3
Coeur en Sante St Henri Mix of lifestyle interventions, including: Matched controlled before and after study No significant difference in any outcomes 
Canada anti-smoking, diet (e.g. Health menu in restaurants), Intervention participants 849 individuals, control 825 individuals
25,000 people exercise (e.g. walking clubs), healthy living videos from a chosen matched control area.
1995 18-64 year olds
Five year follow-up
The Dutch Heart Health Mix of lifestyle interventions, including: Matched controlled before and after study SBP -7.8 mmHg (men), -5.5 mmHg(women) 
Community Intervention anti-smoking campaigns, exercise (e.g. nutrition tours 2,414 in intervention group, 758 in control group BMI -0.36 kg/m (men), -0.25 kg/m (women)
Maastricht & four surrounding areas of supermarkets), exercise (walking and cycling clubs) 3 year follow-up Blood glucose -0.33mmol/l (women)
180,000 people
1988
Health and inequality in Finnmark Mix of lifestyle interventions, including: Matched controlled before and after study DBP -2.1 mmHg, SBP -2.1 mmHg (men), 
Batsfjord (Arctic village) Confining smoking to designated areas of buildings, Intervention village (2,500 individuals), and three matched -2.5 mmHg (women)
Norway Exercise (wide range of activities e.g. aerobics, control villages in coastal areas Physical active + 8% (men), 
Whole village - 2,500 people skiiing, dances), diet (prepared healthy meals for fishermen 3 year follow-up Low fat milk consumption +7.9% (women)
1988 for sea, healthy menus circulated), other (e.g, cholesterol 
screening in supermarkets
Health and inequality in Finnmark Aim to reduce MI risk score by 25% Matched controlled before and after study TC - 0.1 mol/l, BMI - 0.9 kg/m2,
North Cape (Arctic village) Individual counselling on smoking, diet, exercise, 4,000 in intervention group , 5,000 in control group MI risk score -0.5 pts (women)
Norway 6 year follow-up Smoking -4.6% (women)
Whole village - 4,000 people
1988
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Table 2-16 continued 
Programme Interventions Study design Outcomes / results
Heartbeat Wales Mix of lifestyle interventions, including: No significant reductions
9 district health authorities Mass media (regular adverts, news coverage), Diet (approval Survey, 13,045 interventions, 4,534 control.
1982 for certain catering establishment to have Heartbeat wales brand, 5 year follow-up
Encourage farmers to produce low fat breeds), Exercise (sponsored
programmes in communities, awards for exercise friendly employers,
GPs( further training in prevention)
The Kilkenny Health Project Mass media to promote important of CHD as morbidity/mortality Matched controlled before and after study % with BMI > 25 kg/m2 - 13% (women)
Community health promotion Health promotion activities in schools,counselling service for Survey: 792 in intervention, 604 in control
programme diet advice, annual anti-smoking 10k run 5 year follow-up
73,186 people
1985
The National Research Programm 1A Mix of lifestyle interventions, but integrated into local health Matched controlled before and after study No significant reductions
on Primary Prevention of CVD in service provision, using mix of conselling for healthy behaviours Health checks undertaken for risk factors
Switzerland 3 year follow-up
Community wide - two town
combined population of 28,000
1977
The Otsego-Schoharie Heart Health Mix of lifestyle interventions, including: Matched controlled before and after study Smoking prevalence -9.6%, 
Program Diet (promotion of healthy foods), mass media campaigns regarding Survey: 424 intervention and 424 for control
Rural villages, combined population healthy lifestyles, opportunity for risk factor screening, 5 year follow-up
158,000 20-69 year olds
1990
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Table 2-16 continued 
Programme Interventions Study design Outcomes / results
The Bootheel Project Mix of lifestyle interventions, including: Matched controlled before and after study Smoking down 24%, low fat milk consumption 
England smoking cessation, exercise (e.g. walking clubs), 6 control counties up 42%, exercise up 76%, 
Schools programme diet (e.g. cooking demos), and media campaigns. Not randomised wholemeal bread consumption up 33%.
6 counties Delivered by new programmes Survey: 1,501 individuals
Began 1994 18-64 year olds
Five year follow-up
The British Family Heart Study Screening for CVD risk factors Matched controlled before and after study CVD risk score (Dundee score) - 16.1% (men), 15.7 (women)
England Counselling and follow-up sessions, with number of  General Practices were randomised to the Smoking prevalence -4.1% (men), 3.5% (women)
15 towns session tailored to five particular risk strata  intervention TC - 0.12 mmol/l (men), SBP -7.5 mmHG (men), -7.7 mmHg(women)
Whole community (no exclusion) Matched control group on socioeconomic status % DBP < 100 mmHg -4.6% (men), 2.2 (women)
Rescreening: 10,283 individuals BMI - 1.8% (men), 2.2 (women)
40-59 year olds
One year follow-up
The Danish Municipality Project Mix of lifestyle interventions, including: smoking cessation, Matched controlled before and after study No significant outcomes
Slangerup (rural town) exercise ( weekly classes), diet (healthy eating with rural town of simiar socioeconomic status
8,000 people demonstrations) Survey: 567 intervention individuals; 629 control
1993 individuals
20-65 year olds
One year follow-up
The German Cardiovascular Project Mix of lifestyle interventions, including: smoking cessation, Matched controlled before and after study Falls in smokers 7%pts, systolic blood
Six regions in former West Germany exercise, diet. Control was three independent samples of the West German pressure 2%, cholesterol 2%.
Whole population Increased access to existing service providers population
1984 Surveys: 1,900 intervention individuals, 5,000 control individuals
25-69 year olds
Seven year follow-up
The Minnesota Heart Health Programme Mix of lifestyle interventions, led by community leaders Matched controlled before and after study Smoking prevalence - 1.4% (women)
Three communities with interventions Mass media campaigns, risk factor screening, 3 matched communities
Whole population adults education programmes, schools based programmes Surveys: 7,079 individuals in whole population, with 300-500
1986  individuals (ages 30-74) included in rescreening of risk factors
5 year follow-up
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A number of modelling studies have examined the causes of the substantial reductions in 
mortality observed over the last few decades. For example, in Scotland it has been estimated 
that changes in the three main risk factors (smoking, cholesterol and blood pressure) 
accounted for about 50% of the mortality reductions observed between 1975 and 1994, 10% 
was attributed to other risk factors, and 40% to clinical treatments(185-186). This is 
consistent with similar studies in England and Wales(187-191), and international studies(192-
195).  
 
2.8.2 Population approach: cost effectiveness evidence/modelling 
studies 
Nine studies are summarised in Table 2-17. Notably, certain studies included a modelling 
component which was used to extrapolate trial results to then estimate economic outcomes. 
Most studies compared the impact of an intervention against no comparator.  Overall, there is 
a wide range of estimates from cost saving to $240,000 per disability adjusted life year 
(DALYs).  
 
Several important observations can be made with respect to how the economic evidence was 
developed. First, there were a variety of approach to reporting results, including the annual 
risk of events, event rates avoided, life years, or disability adjusted life years. This makes 
direct comparisons of the cost effectiveness of different interventions difficult. Given the 
rationale for economic evaluation is to have a generic measure of outcome (to improve upon 
the variety of ways efficacy evidence can be report), it is not ideal that there is such a wide 
distribution of outcomes used. Second, the discount rate used is not consistent across 
studies. This is understandable as different jurisdictions may have particular guidance. Third, 
not all studies used modelling, with some preferring to adopt ‘within-trial’ evaluations, where 
follow-up across studies was a maximum of 5 years(196). Fourth, when modelling is used to 
project evaluation findings the methods used are not always well reported. Overall, a lack of 
consistency in modelling approaches, time horizons, and final outcomes reported mean that a 
general conclusion regarding cost effectiveness is impeded. 
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Table 2-17 Cost effectiveness evidence – population interventions 
 
Programme Interventions Study design / Modelling approach Outcomes / results
Baxter et al Mix of lifestyle interventions, including: smoking cessation Matched controlled before and after study £31 per life year gained
UK Rotherham (18-64 years) clinics for blood pressure screening, weight control, Control without intervention
Community coronary heart disease programme leaflets.
1997
Assman and Schulte Potential impact of implementing Use of Framingham risk equations Cost per life year
1990 Helsinki Heart Study Lifetime horizon (age and risk factors adjusted in time) Men < 60 yrs: 30k DM 
Primary prevention programme Coronary Discount rate - 4% for benefits and costs Men 60-64 yrs: 40k DM
Heart disease, West Germany Population divided into 5 groups with different in Women < 60 yrs: 86k DM 
interventions received: Grp 1 - no therapy; Women 60-64 yrs: 110k DM
Grp 2 - nutritional advice; Grp 3 - stringent diet; 
Grp 4 - nutritional advice + fibrate/nicotinic acid;
Grp 5 - stingent diet + ion exchange resin / HMG CoA 
reductase inhibitor for group V
Langham et al See Table 2-14 Within trial evaluation (4 years) Attending 4th year screening: ICER £1.22/1% reduction 
1996 Discounting: Benefits 0%, cost 6% in CHD; (ii) Non-attenders 4th year screening: ICER £2.25/ 
Cost effectiveness of OxCheck Authors say risk reductions reported by OxCheck in CHD;
United Kingdom resulted in drop in CHD risk by 20% of those attended
check in 4th year and 13% of those not attending
Lasater et al 10 week late weight programme, including: goal setting, No control ICER
1991 record keeping. 10 week horizon $1.30 per pound loss
United States, Rhode Island
Community based programme to reduce obesity
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Table 2-17 continued 
 
  
Programme Interventions Study design / Modelling approach Outcomes / results
Tosteson et al Interventions estimated were those from 25 year time horizon Stanford Five-City Project: ICER $3,200/lifeyear
1997  Stanford Five-City Project, and North Discounting: Benefits 5%, cost 5% North Karelia Project: ICER $6,100
United States Karelia project. The Coronary Heart Disease Policy Model Range of ICERs from cost saving to $400k/lifeyears
The cost effectiveness of populationwide educational
approaches to reduce TC 
Wonderling et al see table X Time horizon unclear ICER worse case: $38k/lifeyear
1996 Discounting: Benefits 0%, costs 6%
United Kingdom
Cost effectiveness of the british family heart study
Lindholm Wide range of interventions from mass media, keep fit 15 year follow-up, ICER: £1,200 / life year
1996 classes, food labelling, screening and further advice for all Estimated mortality from Framingham equation Worst case £14,000 / life year
Cost effectiveness of community CVD programme
Lowensteyn et al Comparion of supervised and unsupervised aerobic exercise Cohort of 1,000 Unsupervised programme ICER: $11k/life year
2000 classes of 30 mins 35-74 years Supervised programme ICER: ranged from $9k/life year
Canada Time horizon 67 years $87k/life year
Cost effectiveness of aerobic exercise Use of Cardiovascular Disease Life Expectancy Model
Murray et al Comparison of: (i) mass media, (ii) mass Lifetime horizon, (i) vs do nothing: $160 / DALY; (ii) vs (i) $250 / DALY
2003 media + legislation to reduce salt in processed foods Discounting: Benefits 3%, cost 3%
United Kingdom
Population health impacts of interventions to 
reduce SBP and TC
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In addition, to these studies a recent review of NICE public health guidance was 
consulted(31). It appears that interventions to promote physical activity(197-198), mass 
media to promote healthy eating(199), and smoking(200-202) are very cost effective – table 
2-18. Many smoking interventions are already implemented, and several new interventions 
were actually ‘dominated’ (cheaper and more effective) than existing services. Therefore, 
despite an apparent scepticism from the clinical community(9), lifestyle interventions do 
appear to be value for money. Perhaps the apparent difference of opinion is due the fact that 
seemingly small average changes in behaviour at the individual level may appear clinical 
insignificant; but when summed across the population results in a large population impacts. 
Given these interventions are typically cheap to implement they are also very cost effective. 
 
Table 2-18 Cost effectiveness evidence – lifestyle interventions 
 
Type  
 
Cost per outcome 
 
 
Physical activity 
 
 £84  to  £900 per QALY 
 
Mass media/health 
eating 
 
£87 per QALY 
Smoking 
 
£50 to  £6,000 per QALY 
 
Further, a modelling study by the NICE PDG estimated the potential impact in the English 
population from implementing several legislative changes(35). The distribution of risk factors 
in the population was estimated using cross-sectional surveys. It was assumed that reduction 
in salt and trans-fats in processed foods could realistically result in reductions in SBP by 5% 
and TC by 5% respectively.  
 
Looking internationally, similar kinds of modelling studies have found that the potential for 
public health interventions can be greatly in reducing CVD event costs effectively, including 
smoking, physical activity, diet, and regulation(203-210).  
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2.9 Combining targeted and population approaches  
As discussed previously, the targeted and population approach to primary prevention each 
confers potential advantages and disadvantages. It remains commonplace for the different 
approaches to primary prevention to be pitted against one another, as if these were 
competing approaches(13-14).  The, at times, polarised nature of such discussions can be 
predicated on false premises. For instance, a potential danger is equating a targeted 
approach with pharmaceutical interventions and a population approach with more lifestyle 
interventions. For instance, those concerned about medicalising the population(13) can 
ignore that a targeted approaches also includes lifestyle advice. Equally, advocates of a 
population approach can ignore that mass administration of pharmaceutical is also an option. 
Indeed Wald and Law have advocated medicalising everyone over the age of 55 years to 
receive a polypill. The key point here is that it is erroneous to make sweeping judgements 
regarding the relatively desirability of one strategy over another; rather the ‘devil is in the 
detail’ regarding what intervention is proposed. 
 
Encouragingly, there is increasing recognition that the approaches can be 
complementary(211-212) The CHD and Stroke Strategy for Scotland recommends that local 
primary prevention strategies incorporate both approaches(58, 213). Further, the 2012 
European Guidelines on prevention emphasises the importance of both population and 
individual strategies for reducing CVD(214). High risk patients provide clinicians with 
‘caseness’ and an imperative to offer interventions. However, a high-risk strategy alone will 
not have a significant impact on the population. As Rose argues, this requires a shift in the 
distribution of risk in the population as a whole(215). However, if extending interventions to 
the entire population requires active engagement of individuals then this may result in 
widening inequalities, as more deprived groups tend to both engage less and health services 
tend to be less well resourced. A population strategy that can puts addition investment in 
areas of greatest need may offset such risks. 
 
 The key point is that both population and targeted approaches appear to be necessary to 
decrease the population burden of CVD and reduce health inequalities in particular groups 
where modifiable risk factors cluster. It is therefore rational for policy to consider tackling the 
societal factors that promote the development of unhealthy behaviours; and also to focus 
resources on those at greatest risk and where interventions may offer immediate benefits. In 
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this sense the approaches can be viewed as complimentary, as has been argued 
elsewhere(216). 
 
In reviewing the evidence base regarding the effectiveness and cost effectiveness of 
interventions (Table 2-19) the search of the literature was similar as discussed previously. 
That is, the search began with the 2008 NICE Programme Development Group systematic 
reviews, and a new search was conducted using PubMed dating from 2008. The search 
looked for studies that compared the relative performance of targeted versus population 
approaches, in addition to studies that looked at the impact of combining approaches.  
 
Four studies were found in the NICE PDG review: one effectiveness study and three cost 
effectiveness studies. In all cases, a population approach was more cost effective that a 
targeted approach. One study compared the cost effectiveness of a combination of 
population and targeted approaches against a targeted approached. The combination was 
more cost effective.  
 
More recently, a modelling study estimated the contribution in the reduction of CHD mortality 
and morbidity in a Dutch population over a period of 40 years attributable to targeted and 
population interventions(216). The study found that population interventions such as legal 
changes (e.g. tobacco control) were responsible for the majority of observed declines in 
events. 
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Table 2-19 Effectiveness and cost effectiveness evidence – combining targeted and population approaches 
Programme Interventions Study design / Modelling approach Outcomes / results
The Stanford Three Communities Study Mass media campaigns on CVD risk factors. Matched controlled before and after study For town that combined mass media and one to one
Three towns, combined population of CVD risk scoring and intenstive one-to-one counselling with Two towns were interventions, one was control counselling cholesterol fell from 20% (men) to 40% (women)
42,000  high risk individuals One intervention town received media only, the other
1,972 town received media and counselling for HR
Hall et al  (i) Whole population - mass media campaigns on health lifestyle Modelling, using literature for potential impacts (i) vs do nothing cost saving
1998 (ii) High risk:  screening and long term counselling for those from interventions on risk factors (ii)  vs (i) ICER $28k, 
Cost effectiveness of different prevention strategies  in 15% distribution of overweight,  smoking, SBP, TC, 5-year time horison (iii) vs (ii) ICER $13k
Australia (iii) combined approach of i and ii Discount rate 6% benefits and costs
Kinlay et al (i) Screening and referral following CHD Guidelines Modelling, using risk profiles from Hunter, Australia (i) vs do nothing $44,667 per CHD case averted
1994 (ii) Mass media dietary advice using literature for potential impacts of interventions (ii) vs (i) $260,000 for high risk approach
Cost effectiveness of two screening/treatment Discount rate 5% benefits and costs
strategies
New South Wales, Australia
Kristiansen et al (i) Whole population approach: Mass media, tax incentives Modelling study (i) vs do nothing: ICER £12/life years
1991 (ii) Screening for high TC, with dietary advice (iii) lipid (ii) vs (i): ICER £101k/QALY 
Cost effectiveness of three cholesterol lowering lowering drugs and diet advice for those known to (iii) vd (ii) ICER £126/QALYs
strategies  > 8.0 mmol/l
Norway
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2.10 Summary and limitations of the evidence 
It appears that population approaches have the opportunity to be most effective and cost 
effective. In particular, a recent modelling study(35) suggests that substantial outcomes could 
be achieved by legislative changes, rather than population approaches to changing lifestyles.   
However, few studies have directly assessed the impact of interventions on reducing 
inequalities in the population.   
 
The evidence for individually targeted multi-factorial programmes has not been well-
researched. However, there is strong evidence that particular interventions are cost effective. 
A major source of concern is whether extending screening to an entire population is cost 
effective and may result in widening inequalities. 
 
Overall, the efficacy evidence base is inconsistent, particularly as different studies report 
different outcomes (risk factors, events, disease mortality, and all cause mortality). This can 
make it difficult to compare the impacts of different interventions. However, the economic 
modelling also appears to suffer from a similar criticism in that outcomes can include risk 
factors, events, life years, QALYs, DALYs. Further, there can be ambiguity regarding the 
modelling approaches taken to estimate such outcomes.  
 
Generalising from the evidence regarding targeted and population approaches can be 
difficult. This is particularly the case for interventions aimed at lifestyle changes. These 
interventions are service-led, and there is not only variability in the actual results of the 
interventions, but also heterogeneity regarding the nature of the populations receiving 
interventions, delivery mechanisms and the outcomes reported. Further, much of the 
evidence was outwith a UK context. Returning to the previous discussion regarding 
generalisability, both how an intervention is delivered and the wider social and policy context 
may be vital in generating effect sizes. Therefore, an evidence synthesis and meta-analysis 
of studies was not feasible, as expected given the variation of interventions and context(51, 
150). 
 
Overall, while economic evidence is essential; it is assumed here that policy makers would 
ideally like an evidence base that is consistent in terms of outcomes produced in order to 
allow direct comparison of different interventions. Further, it is also inferred that outcome 
measures used should ideally be commensurate with the aims of primary preventions: 
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avoidance of premature mortality and morbidity, avoidance of associated health service 
costs, and the reduction in inequalities.  This would then allow policymakers to compare 
interventions directly, and choose between interventions consistently. At present, such 
evidence and the approach to generating evidence in a consistent manner is quite limited. 
 
2.11 Discussion: developing three research questions for 
the thesis to address  
The chapter, so far, has been essentially reviewing and reporting. The purpose of this 
penultimate section is to interpret the findings of the chapter, and to assess gaps in the 
evidence base, especially with regard to the ultimate aims of prevention, as a means to 
develop research questions for the thesis. 
  
The key premise of the thesis is that the aims of primary prevention are the avoidance of 
premature CVD and to improve life expectancy, quality adjusted life expectancy, and to 
reduce health inequalities. However, it is unclear whether the current approaches are aligned 
with these aims, especially given the reality of scarce resources and need to make efficient 
choices. Rather, the rationale and evidence base underpinning certain clinical and policy 
decisions is lacking, and may be misaligned with the aims of prevention. Three research 
questions are developed below. As a means to justify why these questions are considered 
key, relevant themes from the chapter are drawn together. 
 
2.11.1 Question 1: Is it cost effective to screen the entire population 
or take a more focussed approach?   
Clinical guidelines recommend screening everyone in the population from 40-74 years to 
detect high risk individuals. For instance, England since 2009 began to roll-out a national 
screening programme. In contrast, Scotland has decided to screen only the most deprived 
individuals and those aged between 45-64 years. It is not clear what evidence these 
decisions are based upon. Further, both England and Scotland claim that the respective 
screening programmes will lead to the closing of health inequalities. 
 
It is important that there is a better understanding regarding optimal screening approaches.  
Population wide screening may have the best opportunity in detecting everyone at high risk, 
but the efficiency of such an approach is questionable as high risk individuals actually 
compose a small proportion of the population; and there is the potential for a negative impact 
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on health inequalities as more affluent groups are known to engage more with statutory 
services, as discussed. On the other hand, while Scotland has initially adopted a more 
focused approach, perhaps the screening criteria could be widened from the most deprived 
groups and have an opportunity to capture all (most) of the high risk in the general 
population, without having to screen everyone. Overall, it is important to investigate the 
coverage, cost effectiveness and impact on health inequalities of alternative screening 
approaches.  
 
2.11.2 Question 2: How best to prioritise individuals for 
intervention?   
Weaknesses of 10-year risk scores 
(i) Age drives 10-risk: A major problem in the application of 10-year scores is that risk is 
driven mainly by age. For instance, the risk charts show previously illustrates that younger 
individuals with inflated risk factors may not be classified as high risk, purely because of age 
and yet may stand the most to benefit in terms of early prevention and potential lifetime 
benefits. In contrast, as age increases individuals can be automatically be classed as high 
risk even with individual risk factors are at normal levels according to clinical guidelines.  
 
This issue is increasing recognised(25-26, 114).  Further, it is important to note that this 
problem arises not primarily due to the risk score itself, but rather with the application of a 
universal threshold to denote high risk, which has been described as arbitrary and without 
evidence in terms of treatment benefits or cost effectiveness(25).  
 
(ii) CVD risk score ignore competing risks: An important issue is that CVD risk scores do not 
consider the competing risk of non-CVD events, and death. For instance, treating the elderly 
for CVD risk may simply change the cause, not timing, of death(27).  
 
Existing alternatives to 10-year risk scores 
In recent years the literature has developed a range of responses to the perceived 
weaknesses of 10-year risk scores, with some responses more comprehensive than others. 
 
(i) 30-year scores: In an effort to capture the long term risk of CVD the time frame over which 
risk is estimated has been increased by certain authors. For instance, the Framingham score 
now has a version that can estimate the 30-year risk of events(117). This is intended to be 
more relevant for younger patients to capture that while short term risk may be low, long term 
112 
 
risk is likely to be much higher. The idea is that by focusing on cumulative risk younger 
individuals would be seen as higher priority. This approach however does not address the 
fundamental issue that risk is driven by age, rather than modifiable factors. The score has not 
been used in practice, at present. 
 
(ii) Lifetime scores: Researchers on the QResearch database have now developed lifetime 
CVD scores(217). This work is also in response to the age gradient inherent in 10-year 
scores. A practical challenge that has been identified is how to discriminate between 
individuals, given everyone is at high risk of CVD over a lifetime, and what an appropriate 
threshold would be to prioritise interventions(26). A further issue is that CVD is the sole focus, 
ignoring the competing causes that are also affected by risk factors. This approach may lead 
to  counter-intuitive results. For instance, non-smokers live longer on average than smokers, 
given the competing risks of cancers; which results inhigher cumulative risks of CVD than 
smokers, and would be given priority(26).  
 
The practical utility of lifetime scores has been questioned, with preference given to 
conducting 10-year risk scoring regularly rather than focusing of lifetime risk(26). The 
advantage of using shorter term risk scores may be to define caseness; that is, where patient 
of high risk may require intensive pharmaceutical interventions, as opposed to those with low 
short term risk who could be referred to lifestyle interventions to reduce longer term risk. This 
argument holds sway given that the reversal of the damage caused by risk factors is greater 
in younger individuals. However, this does not address the issue that risk is partially driven by 
non-modifiable risk factors. Given competing risks, concern remains that interventions may 
simply change the cause of death especially in the elderly(27).  
 
(iii) Age defined risk scores: Norwegian Clinical Guidelines have attempted to respond to the 
problem of the age gradient which is inherent in the application of a universal threshold level 
of risk determining intervention. Specific thresholds have been developed for different 10-year 
age bands from 40 to 70 years(218). Underlying the choice of risk threshold is the expected 
cost effectiveness of treating an individual at that or above that risk level. The assessment of 
cost effectiveness is informed by literature reviews and expert clinical opinion.  We discuss 
the nature of cost effectiveness, and the associated evidence, shortly.  
 
However, the estimation of benefits is restricted to the avoidance of CVD death. There is no 
consideration of the wider benefits on avoiding CVD morbidity, or the avoidance of competing 
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events, that are driven by the same risk factors, including cancers and respiratory diseases. 
Further, if treatment guidelines were to be based on benefit rather than risk then it begs the 
question why the benefits are not made explicit, rather than returning to risk thresholds. 
 
Need for a new approach: prioritising on the basis of potential benefit rather than risk?  
Prioritising individuals on the basis of CVD risk scores is unlikely to result in the greatest 
treatment benefits. The fundamental problem is that risk scores are comprised of a mixture of 
modifiable and non-modifiable factors. This is true for 10-year, 30-year or lifetime risk. Risk is 
not a measure of the potential benefit from interventions.  
 
If primary prevention has the objective to improve life expectancy and quality of life then 
perhaps it is more rational to prioritise individuals on this basis. It has also been argued that 
focusing on net benefits is more clinically interpretable than risk(219). In estimating potential 
benefits it is necessary to account for competing risks. SCORE has recently developed a tool 
that seeks to estimate the impacts of interventions on extending life expectancy by 
accounting for the impact of risk of CVD death and the competing cause of non-CVD 
death(220). The tool has just been developed and is undergoing validation tests before 
looking at the feasibility of using this in clinical practice. A switch to a potential benefit 
approach does begs the question what an appropriate benefit threshold should be, and 
whether this should be based solely on clinical benefit or (also) cost effectiveness. Note, that 
the tool does not produce estimates of the latter. 
 
An ambiguity in the new SCORE approach is how the competing risk analysis was 
undertaken and the estimation of cause specific hazards for the end-point of CVD, CVD 
death and non-CVD death. Further, the datasets are not ideal. Rather than longitudinal 
cohorts of individuals, it appears that a variety of different country datasets are used rather 
than having a single cohort of individuals followed-up. Importantly, no account is made of 
socioeconomic deprivation, known to be an independent risk factor in Scotland, as discussed. 
Nonetheless, the use of a competing risk approach this is an important development in the 
evolution of CVD prevention. 
 
Overall, it appears necessary to develop a new comprehensive tool that can estimate the 
potential benefit from changes to modifiable risk factors, as a means to prioritise individuals 
for intervention. 
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2.11.3 Question 3: How best to combine targeted and population 
approaches?  
Traditionally, the literature has been polarised between a targeted and population approach. 
Nonetheless, there is recognition that the two approaches are not necessary mutually 
exclusive and perhaps a combination of approaches might be better to address the aims of 
prevention(221-222). Targeted and population-wide approaches may not only complement 
one another as independent strategies, but they can interact with each other to either 
enhance or inhibit the effectiveness and cost effectiveness of each other(10, 150). 
 
From an economic viewpoint, it is contended that the extent to which one strategy is 
emphasised over another should depend on the evidence of impact: effectiveness, cost-
effectiveness and overall budgetary considerations. Cost effectiveness evidence should also 
be used to develop complimentary strategies. It is contended that the extent to which one 
strategy is emphasised over the other should depend on the evidence of impact: 
effectiveness, cost-effectiveness and overall budgetary considerations. However, it is 
precisely this kind of evidence which is lacking, in general.  
 
2.12 Summary  
To summarise, cardiovascular disease is the number one cause of premature mortality and is 
a major cause of morbidity, health service costs and wider economic costs. Further, CVD is a 
leading cause of health inequalities and particularly in Scotland. In response, there is a 
significant clinical and policy response in the form of primary prevention initiatives in an effort 
to avoid or postpone the first incidence of CVD, and the consequent clinical and economic 
burden. There are two main approaches to primary prevention: a targeted approach on high 
risk individuals and a population wide approach. Both have advantages and disadvantages, 
and it seems sensible to consider how these approaches might best combine to address the 
aims of primary prevention. 
 
However, there are important uncertainties regarding the impacts of current primary 
prevention initiatives, and policies appear to be predicted on aspiration rather than 
expectation. In particular, there is a lack of evidence regarding targeted multi-factorial 
interventions which is the main focus of primary prevention in the Scotland, and elsewhere. 
Overall, there are three main strategic weaknesses at present, which serve as research 
questions. First, there is uncertainty regarding appropriate screening approaches to detect 
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high risk individuals. Second, there is concern that prioritising individuals for intervention on 
the basis of risk will not lead to the greatest benefits, given 10–year scores are driven by age. 
Third, while targeted and population approaches can often be pitched as rival approaches, 
they are not mutually exclusive. A key uncertainty is how they might best combine.   
 
The approach of cost effectiveness analysis offers the potential for a unified method for 
evaluating interventions and guiding decisions, at both the clinical and policy level. This would 
enable congruence with reimbursement agencies such as the National Institute for Health 
and Care Excellence (NICE). Cost effectiveness analysis essentially combines information 
regarding the clinical and resource impact of an intervention, offering a generic measuring 
stick whereby all intervention can be assessed consistently.  
 
However, gaps in the evidence base cannot be resolved using trial information alone. For 
instance, it is infeasible for trial to be conducted over a lifetime. To help generate appropriate 
economic evidence there is an important role of modelling to project trial results on economic 
outcomes such as quality adjusted life expectancy and health service costs. The next chapter 
discusses the role of modelling and makes the case that a Scottish specific CVD model is 
required to help address the limitations in the evidence base.  
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Chapter 3: The need for a Scottish CVD Policy Model 
3.1. Introduction 
 The previous chapter detailed the health and economic burden resulting from cardiovascular 
disease and current primary prevention approaches to avoid the premature onset of CVD. 
Notably, there is a lack of economic evidence concerning both the targeted and population 
approaches to primary prevention.  
 
This chapter develops the rationale for the development of a Scottish CVD Policy Model 
which can help generate economic evidence of interventions and inform the approaches to 
primary prevention. The chapter is structured as follows: Section 3.2 and 3.3 introduces the 
rationale for and application of economic modelling. Section 3.4 then outlines the common 
criticisms that can be directed at economic models in general, before section 5 discusses 
best practice guidance that modellers can usefully follow to help ensure models that are fit-
for-purpose and minimise potential criticisms. Section 3.6 then undertakes a systematic 
review of existing policy models and uses best practice guidelines to help critique the models. 
Section 3.7 collates and summarise the key strengths and weaknesses of the models that 
were reviewed, before Section 3.8 discusses the need for a Scottish Policy Model. Section 
3.9 concludes. 
 
3.2 The rationale for modelling I: generating economic 
evidence  
As discussed in Chapter 2, the aim of economic evidence is to inform resource allocation 
decisions from across the health sector. The ultimate aim of economic analysis is to develop 
a consistent body of evidence to enable decision makers to fund interventions offering the 
best value for money.  
There is an important role for modelling to both generate new economic evidence and 
synthesis existing evidence for the purpose of making decisions, which the following two 
sections discuss respectively.  
 
It is important to provide a general definition of what a model is. A model is simplified 
representation of reality: "a logical mathematical framework that permits the integration of 
facts and values to produce outcomes of interest [to clinicians and] decision makers"(43).   
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For the purpose of generating economic evidence, modelling can be used in tandem with 
clinical trials to overcome the perceived shortcomings of trials. There are six main reasons 
where an economic analyst may wish to employ modelling(38, 40, 223-225).  
 
First, as illustrated in Chapter 2, trials measure clinical efficacy where outcomes are 
necessarily short term studies often report short terms outcomes such as risk factor changes 
(e.g. blood pressure), or intermediate endpoints (e.g. myocardial infarctions). However, 
individuals, clinicians, policymakers and health economists may be interested in longer term 
impacts (e.g. mortality). Modelling can be used to extrapolate short term efficacy findings 
such as changes in blood pressure or events onto (quality adjusted) life expectancy. 
 
Second, models can assist in estimating the generalisabiliy of trial results to other settings. 
Trial evidence is concerned with internal validity; however, economic evidence is ultimately 
concerned with external validity and generalisability - to provide advice to policymakers 
regarding the expected value for money in the intervention was to be delivered in the future 
and perhaps in different settings.  The cost effectiveness of an intervention may be 
dependent on the nature of delivery, such as the skill set of those delivering the intervention, 
intensity and frequency. Modelling may be important to estimate the impact of changing 
resource costs and clinical effectiveness between settings. 
 
Third, modelling can be used to estimate “head-to-head” comparisons of alternative 
competing interventions in the absence of trial evidence comparing two interventions of 
interest. Most trials compare an intervention against usual care. However, usual care may 
differ between settings. In this case, modelling can be used to synthesis evidence from 
different trials and infer what the head-to-head results are most likely to be.  
 
Fourth, modelling can be used to incorporate information which may not be collected in trials, 
such as the quality of life impacts of non-fatal events, or resources costs.  This information 
may either be generated from other primary studies or, more commonly, taken from 
secondary sources.  
 
Fifth, models can be used to produce relevant information in the absence of hard data. For 
instance, it can be very difficult to conduct population wide experiments. This was illustrated 
in Chapter 2 regarding the variety of modelling studies that have been undertaken to estimate 
the potential impact of population interventions, for example legislative changes.  
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Six, modelling can be useful in order to explore uncertainty and undertake sensitivity analysis 
with respect to estimates of clinical and economic outcomes. In short, clinical evidence will 
also be subject to uncertainty in the estimates produced. Further, to produce economic 
evidence several sources of information will often be combined, the process of which may 
introduce uncertainty and may involve assumptions in the absence of data (e.g. long term 
compliance with medication).  It is important that uncertainty can be fully articulated and that 
estimates, of for example effect sizes, are subject to a sensitivity analysis to explore the 
consequences on the economic outcomes produced. These issues will be more fully explored 
under the detailed discussion regarding best practice guidance. 
 
Overall, there is a complimentary role for economic modelling to be used alongside trial 
evidence. Further, it is now commonly suggested that economists can usefully be involved in 
trial design themselves, to influence sample sizes, data collection and perhaps the length of 
trial themselves. These so-called ‘pragmatic trials’(38) can then mitigate against some of the 
drawbacks of more orthodox clinical trials. Nonetheless, there is a limit to the length of trials 
(e.g. lifetime trials are infeasible), and there is a practical limit to the amount of information a 
trial can include. Consequently, it is likely that there will always be a role to be compliment 
trials and produce economic outcomes. 
 
3.3 The rationale for modelling II: to help make decisions 
The ultimate purpose of modelling is to act as a normative decision-making aid that can 
structure evidence on clinical and economic outcomes in a form that helps decision makers 
choose from among competing courses of action and the allocation of scarce resources(40).  
 
The nature of the modelling should be conditional on the decision context at hand. Decision 
making in health care involves two sets of related decisions: those concerning appropriate 
service provision on the basis of existing information; and those concerned with whether to 
fund additional research to reduce the uncertainty relating to the decision(226). 
 
If the decision maker needs to choose between interventions using existing information, then 
the decision should be based solely on a comparison of the expected or mean estimates of 
impacts. An assessment of uncertainty is irrelevant(48). However, where decision makers 
have flexibility to accept, reject or a delay a decision then modelling can be usefully employed 
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to generate both mean estimates of impacts, and whether decisions should be delayed in 
order to conduct further research.  
 
Therefore, modelling can be an invaluable tool to help decision makers both structure the 
decision problem at hand, and inform the optimal decision given the information available. In 
general, modelling is recommended as both a ‘tool of first and last resort’ for economic 
evaluation(38, 225). In effect, there are three main stages where a model can be used(227). 
The first stage is to conduct pre-trial modelling. This is where an economic model can be 
used to help inform whether a trial is needed in the first place. That is, by using a model to 
synthesise all the available evidence a model can estimate whether the intervention under 
consideration is likely to be value for money.  
 
The second stage is to use the model in the full scale evaluation of the intervention, to 
estimate cost effectiveness and provide a full assessment of uncertainty in the estimates 
made. If uncertainty is so great that there are doubts regarding the cost effectiveness of an 
intervention, then the model can also help pin-point where the most important areas are in 
terms the parameters that most impact on cost effectiveness estimates. This exercise then 
informs not only whether a trial should be conducted but also which areas of uncertainty the 
trial should focus upon.  This exercise is termed value of information analysis(228), and will 
be discussed further in the chapter. 
 
The third stage, is to then use the evaluation evidence from the trial, combine this with the 
pre-trial modelling exercise, and then recommend both the optimal decision option given 
existing information, and also reassess whether further trial evidence are required in the 
event decision can be delayed(48). 
 
Regarding terminology, models that are built with the explicit purpose of generating evidence 
to inform a decision(s) are often termed decision analytic models(227). 
 
3.4 Policy Models  
Most often decision analytic models are constructed afresh to meet a specific decision 
problem, which is generally to assess the cost effectiveness of a single intervention such as a 
new statin drug. This practice is described in this thesis as a “bespoke approach” to 
modelling. In contrast, “generic approach” to modelling is where there is an attempt to 
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widening the scope of the model, with the intention to offer the opportunity to use a single 
model to inform a wider range of decisions. For instance, in the area of CVD it may be useful 
to have a single comprehensive model that could assess the cost effectiveness of a range of 
single and multi-factorial interventions, such as anti-hypertensive and statins drugs, and 
lifestyle interventions such as smoking and diet. Models that adopt such a generic approach 
are termed policy models in this thesis.  
 
There are potential advantages of building policy models: they can be efficient if it avoids the 
need to build bespoke models for particular interventions aimed at certain risk factor(s); 
provide a consistent approach to assess the cost effectiveness of interventions that may be 
competing with one another for scarce resource; and conditional on a credible and 
transparent model, a policy model may enhance the opportunity for decision makers to gain 
familiarity and trust in using a model. 
 
3.4 Common criticisms of models 
While modelling is undertaken routinely there are common criticisms that the modelling 
process itself can introduce biases and lead to erroneous conclusions regarding cost 
effectiveness and decisions made(53). 
 
First, decision analytic models are open to potential manipulation with respect to the data 
used to elicit a favourable result. This can extend to a choice of comparator, selection of 
evidence, and generation of effect estimates, for instance(229). 
 
Second, there can be concerns regarding the potential for using inappropriate data. It has 
been expressed that insufficient attention can be paid to the quality of the clinical data used 
and that only when there are several well-powered trials reinforcing findings can there be 
confidence in the effect sizes used in models.  
 
Third, there are general concerns regarding the extrapolation of clinical or intermediate 
outcomes. It has often been argued that extrapolations using only data collected in the short 
term, may omit potential longer term negative consequences. A key issue is to validate model 
predictions to test, for instance, whether intermediate outcomes are good predictors of final 
outcomes.  
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Fourth, there are more specific concerns when observational data is used to extrapolate 
findings. This may result in bias given the relative limitations in drawing causal inferences 
compared to trial evidence. Further, the observational data may be incomplete. As discussed 
shortly, it can be common for models in cardiovascular disease to estimate the life years 
saved and the resource impacts by simply estimating the impact on CVD events. However, 
by ignoring competing causes this may bias the estimates produced, both in terms of life 
expectancy and the overall impact on health services, beyond the avoidance (or 
postponement of a CVD event).  
 
Fifth, in building a model there is the potential for intended and unintended biases, from 
inappropriate model pathways, syntax errors and failure to link variables. This raises the need 
for further validation regarding the integrity of the model structure and estimation of final 
outcomes. 
 
It is important to recognise that many of these criticisms can also be applied to trials; such as 
choosing inappropriate comparators, or drawing erroneous inferences from short term results. 
However, the potential for manipulation and error is greater in modelling.  The fundamental 
issue underlying most of these criticisms is a potential lack of transparency. Models can often 
be perceived as “black boxes” where third parties may find it difficult to follow a models 
causal structure, to evaluate decisions regarding the data sources used, and to evaluate the 
potential accuracy of model outputs. 
 
Despite these potential pitfalls, modelling is unavoidable when decisions need to be made but 
there is lack of hard evidence and/or the decision is too complex to simply rely on human 
judgement. Models can never be a substitute for evidence and there is an important role for 
extended pragmatic trials to test an interventions’ effectiveness and cost effectiveness over 
time. However, lifetime trials are infeasible and there is a practical limit to the amount of 
information trials can incorporate. Consequently, there is a role for both trials and modelling. 
 
Overall, "all models are wrong but some are useful"(39). In recognising the potential pitfalls 
and limitations of models, the next section discusses best practice guidelines for modelling 
regarding how to construct, use and disseminate models to help ensure that models can be 
as useful as possible to decision makers. 
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3.5 Consensus guidelines for building economic models 
The importance of developing best practice guidelines to enhance the credibility and 
practicality of models has been recognised for some time by prominent authors(38, 44). Most 
notably there have been several guidelines developed through expert consensus from ISPOR 
in 2003(43), through the UK’s Health Technology Assessment (HTA) Programme in 2004(42) 
and 2006(41), to guidelines from Canadian researchers in 2010 (230) and most recently 
ISPOR 2012(231).  These guidelines have progressively built upon one another as new 
insights and consensus evolves. 
 
The purpose of guidelines is to clarify the key generic stages within the modelling process, to 
guide modellers regarding appropriate choices within each modelling stage, and in general 
encourage greater clarity in the reporting of the model and model outputs. However, given 
that modelling problems may differ considerably, a rigid and prescriptive set of one-size-fits-
all rules are inappropriate(41-42). Rather the emphasis on guidelines is on encouraging the 
use of criteria to make transparent modelling choices so that models and their outputs can be 
appraised, and ideally replicated, by third parties. 
 
The following draws heavily upon the latest ISPOR 2012 Guidelines on best practice(231-
236), which itself references, and may be regarded as building upon, previous guidance 
documents. Discussion is presented in the form of a checklist reminiscent of the format that 
Philips et al used in previous guidance developed 2004(42). The purpose of a checklist is to 
serve as an aid for the transparent appraising of existing models.  
 
Five key modelling stages are identified and within each stage the best practice guidance is 
described. This is summarised in Table 3-1 and presented as if the development of a model 
is a “linear process” where a modeller completes one stage before moving to the next. This is 
a simplification for exposition purposes; in practice, there may be several iterations within and 
between the stages.  
 
Further, models have value not only as prediction tools but also as explanatory and 
communication tools. That is, the value of a model lies not only in the results it generates, but 
also in its ability to reveal the logical connection between inputs (i.e. data and assumptions) 
and outputs in the form of valued consequences and costs(43). For this reason, a model 
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should not be a “black box” for the end-user but be as transparent as possible, so that the 
logic behind its results can be grasped at an intuitive level(43).  
 
The following is a synthesis of expert guidance produced in recent years. These are 
referenced above, with the intention to repeatedly reference the same sources throughout 
this section.  
 
3.5.1 Modelling stage 1: Conceptualising the problem 
(i) Policy context:  The policy context of a model is that it should be clearly stated, and this 
should include the strategic policy question at hand, the policy audience, whether the model 
has been developed bespoke for a single problem, or is intended to have multiple and/or on-
going uses. It is also important to report how the model has been funded, as the model may 
be tailored to a particular decision maker’s priorities and values. Sponsorship bias may exist 
with respect to how models may be constructed and information presented. On the one hand, 
models funded by manufacturers run the risk of being skewed to represent a particular 
intervention in a favourable light. On the other hand, models funded by public sector decision 
makers may be skewed towards interventions that offer cost containment. Overall, the policy 
and funding context may influence the entire model building process. 
 
(ii) Consultation of experts and stakeholders: To inform the understanding of the modelling 
problem and consequent model construction, it is important to consult relevant experts. For 
instance, clinicians and epidemiologists may be important in helping to define the clinical 
problem and its consequent representation in a model structure. Stakeholders such as 
patients and policymakers can inform the decision process behind which outcomes a model 
produces. Such consultation, if undertaken, should ideally be preceded by a review of 
relevant literature (including other relevant models) and then formally by convening an 
expert/stakeholders group to elicit opinions systematically through tools such as Delphi 
Panels.  
 
(iii) Statement of the decision problem: The decision problem that the model is intended to 
address should be clearly stated. This may be an iterative process, such that an explicit 
statement offers that opportunity for focused discussion between the modeler, medical 
experts and policymakers. Once specified, the problem then determines how the modelling 
problem is considered and the subsequent construction of the model. 
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(iv) Statement of the model perspective: The model perspective determines which information 
inputs should go into a model, including which costs and outcomes. Alternative perspectives 
used in health economics include a health care decision maker perspective and a societal 
perspective, as discussed in Chapter 2.  
 
In the UK, a health care decision maker approach is the standard approach that health 
economists have used and embedded in NICE guidance(144). This recommends in the 
‘reference case’ for economic evaluation that costs and outcomes should be from the 
perspective of the National Health Service and personal social services. The rationale is that 
these sectors are mandated to improve population health and so, from a practical viewpoint, 
cost effectiveness (utility) analysis may be best at tailoring economic evidence to budget 
holder objectives.  
 
However, guidance evolves. For instance, as discussed in Chapter 2, NICE’s  recent Public 
Health guidance recommends that the perspective of economic evaluation takes a broader 
societal perspective (beyond the health and personal social services)(147). It is 
recommended that an economic evaluation should consider all major costs and outcomes. It 
is suggested that a cost consequence analysis (CCA) be conducted, which is essentially a 
social accountancy exercise, listing all major outcomes in natural units.  To then value 
outcomes in economic terms, it is recommended that health outcomes are values as Quality 
Adjusted Life Years (QALYs). This allows comparability of public health interventions with 
other interventions.  
 
In addition, it is recommended that evaluators consider undertaking a cost benefit analysis 
(CBA), which would in practice mean using the CCA, and then values all outcomes, health 
and non-health and estimate the overall social value of an intervention, where health is one 
component.  
 
 (v) Statement of the model scope: Following decisions regarding the previous steps above, 
the requirements with respect to the models scope should be readily apparent. That is, the 
model should then be developed such that its inputs and outputs are relevant to the policy 
context, the modelling problem and the perspective taken of the economic evaluation.  
 
(vi) Defining the target population: It is important to make clear the intended recipient 
population of the intervention(s). This should include both the intended geographical 
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coverage and also recipient medical characteristics. The former may extend to international 
or national uses (or lower forms of aggregation e.g. urban or rural). The latter may include the 
disease history of the individuals of interest (e.g. asymptomatic, comorbidity). Further, it 
should be clear whether the model is focused on individuals or cohorts, and if the latter what 
particular subgroups are of interest. 
 
(vii) Health outcomes: The rationale for choosing to model outcomes should be justified.  The 
focus of economic evaluation is on whether an intervention may have substantive impacts on 
final outcomes of interest, such as quality adjusted life expectancy. A model structure, 
discussed below, will typically link intermediate outcomes (e.g. risk factors) to final outcomes. 
The choice of these intermediate outcomes should be justified (e.g. only certain CVD event 
states).  
 
(viii) Intervention strategies/comparators: The model problem will determine which 
intervention strategies and comparators should be compared. This should be made explicit. 
The problem that a model is intended to address may be specific to a particular intervention 
or may be more generic in the sense that the model may wish to consider multiple different 
interventions.  
 
(viiii) Time horizon: The time horizon of the model should be long enough to reflect important 
differences between the long-run consequences and costs of alternative options and 
strategies.  Lifetime horizons are appropriate for many models and are almost always 
required for models in which the options have different time varying survival rates. Shorter 
horizons may be justified if survival and morbidity does not differ among intervention options. 
Importantly, a lack of long-term follow-up data should not be used as a rationale for failing to 
extend the time horizon as long as is relevant to the decision under analysis. 
 
(x) Cycle length: The cycle length of the model should be short enough so that multiple 
changes in pathology, symptoms, treatment decisions, or costs within a single cycle are 
unlikely. On this basis the choice of cycle length should be justified.  
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Table 3-1 Best practice guidance for building an economic model 
Modelling stages Elements with each stage Best practice / transparent reporting of 
Policy context The sponsor / funder of model
Consultation of experts and stakeholders Comprehension of clinical and policy problem
Statement of decision problem Clinical and/or policy problem
Statement of model scope Spectrum of conditions considered
Statement of model  perspective Societal,  decision maker, individual
Target population Geography, individual characteristics
Health outcomes Events, QALYs, DALYs, other
Intervention strategies/comparators Nature of, frequency, intensity, duration
Time horizon Sufficient duration to reflect important difference in treatment options
Cycle length Consistent with natural history of the disease
Converting the model problem into a model structure Explicit process (e.g. written record, conceptual mapping)
Choosing a model type Key criteria: (i) individual vs cohort; (ii) static vs interactions; (iii) short vs long term horizons
          Tabular model Spreadsheet, (hidden) cell formulas
           Decision tree Cohort, static, short time horizons
           State transition Cohort, health states/discrete time, static, long time horizons
           Discrete event simulation Individual, continuous time, interactions, short or long time horizon
           Dynamic transmission model Individual or cohort, continuous time, non-linear interactions, short or long time horizon
           Hybrid or novel models Combines features, new features
Stage 2: Conceptualising the model
Stage 1:Conceptualising the problem
 
 
 
 
 
127 
 
Table 3-1 Best practice guidance for building an economic model - continued 
Modelling stages Elements with each stage Best practice / transparent reporting of 
Data identification Transparency of methods used to identify, and justification, for choices of data sources
Data modelling Statistical and epidemiological techniques should be justified
Baseline data Either based on natural history of disease from epidemiological/observational study, or from control group of experimental study
Costs Consistent with perspective and in accordance with relevant guidance
Quality of life weights (utilities) Appropriate for disease states and decision problem
Treatment effects Systematic reviews/meta analysis to infer treatment impact and uptake/compliance assumptions
Incremental cost effectiveness ratio Difference in costs / difference in benefits 
Discounting Consistent with guidelines (e.g. NICE/SMC recommends 3.5% for all outcomes)
Stochastic (first-order) uncertainty Undertake either deterministic or preferably probabilistic sensistivity analysis 
Parameter (second order) uncertainty Report means and standard errors; undertake either deterministic or preferably probabilistic sensistivity analysis 
Heterogeniety Test model's ability to discrimate between unit of analysis
Structural uncertainty Consider structural sensitivity analysis reformulating model (modelling assumptions / model structure) 
Face validity Seek agreement by experts regarding consistency of model structure with current science
Internal validity Test model ability togenerate outcomes from the source data used in model development
External validity Test models ability to generate outcomes from a study not used in model development
Cross validity Test the consistency of outputs between different models
Predictive validity Test models ability to make forecasts
Reporting and dissemination Dissemination of model documentation to enable third party to assess and replicate model
Stage 3: Data identification and incorporation
Stage 4: Uncertainty analysis
Stage 5: Validation and reporting
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3.5.2 Modelling stage 2: Conceptualising the model 
(i) Converting the model problem into a model structure: It is recommended that the process 
of converting the model problem to the development of a model structure is made explicit. 
Various methods have been suggested, including expert consultation, influence diagrams and 
concept mapping. The use of model schematics to represent the model structure, functioning 
(e.g. disease process/interventions) and simplifying assumptions can then provide a focal 
point for interested parties to develop the model. 
 
(ii) Choosing a model type: There are no prescriptive rules: almost any problem can be 
represented by any type of model.  The general rule of thumb is that a model should be 
parsimonious: a simple as the modelling problem permits. 
 
Three key specific considerations are identified: The first issue refers to the unit of 
representation; and whether the model problem is primarily concerned with individuals or 
cohorts. For instance, modelling the relationship between continuous variables and outcomes 
is more conducive to providing outputs specific to individual profiles defined by the variables 
used in the modelling. This would then enhance the discriminatory ability of the model. In 
contrast,   the categorisation of variables means that individuals are assigned to a subgroup 
and treated as homogenous. The latter limits the ability of a model to explore heterogeneity. 
  
The second key consideration is whether interactions between agents in the model are 
required. Interactions may be a feature of units of analysis (individuals or cohorts) co-
evolving; or between the treatment and the unit of analysis. The former may be the result of 
constrained resources and the manifestation of queuing for instance. The latter may result 
from a treatment impact on how disease spreads in populations. Models without interactions 
are static in nature and can be consequently simpler. 
 
The third key consideration is time: both the overall time horizon that the model runs for and 
the cycle length that a model needs to consider given the problem at hand. The longer the 
time horizon and smaller the unit of time the more complex a model can become.  
 
The most popular model types are now described, and broadly ordered from the simplest to 
the most complicated. The discussion reflects how particular model types are most often 
associated with certain features (e.g. individual rather than cohort).  However, it is important 
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to recognise that such demarcation is largely for exposition purposes.  The models types 
discussed are stylised categories and there is room for continual innovation. For instance, the 
possibility of hybrid models that may draw upon features common to different stylised model 
types is also discussed. Indeed, the Scottish CVD Policy Model that is developed in this 
thesis may best be described as a hybrid model, combining particular features of different 
stylised model types. 
 
(ii-a) Tabular models: The term tabular model is used to refer to a class of models that 
represent the decision problem as a series of cells within a spreadsheet. The relationship 
between variables and outcomes are embedded in cell formula. There is no time element 
represented to assess the consequences of changing variables on outcomes of interest over 
time. Rather, a tabular model is often chosen when the relationship between initial inputs and 
final outcomes is the key focus. This model type may be suitable when the decision problem 
is simple, cohorts are modelled and there are limited steps in the modelling process. As the 
modelling problem becomes more complex and the representation of transitions is important, 
then tabular models can lack transparency. 
 
(ii-b) Decision trees: The decision tree visibly represents the transition of a cohort over time 
where there are no interactions. The model begins with a “root node” and the subject is faced 
with a series of branches each representing possible pathway (or scenario). Each branch 
may split into a sequential pathways defined by specific intermediate events towards a final 
end-node (e.g. death). Each end-node denotes the final pay-off (e.g. life expectancy) that an 
agent (e.g. individual) can expect if following a particular pathway (or scenario).  The 
completion of each pathway is associated with a particular probability. It is often the case that 
from the starting node to the end-node there are a number of intermediate chance nodes 
where agents move in one direction or other. Therefore, often the probability associated with 
an end node is the product of a series of conditional probabilities.  Importantly, the sum of 
probabilities associated with each possible pathway or scenario must equal 1; as the 
pathways are intended to be exhaustive of all model scenarios. Therefore, to solve the model, 
and estimate the ‘expected’ outcome, the model simply sums across the product of the 
probabilities of following a particular pathway and the pay-off associated the particular end-
node.   
 
Decision trees are a simple and transparent method of representing a decision problem.  In 
principle, any decision problem can be represented by a decision tress, if the assumption of 
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independence between units of analysis is maintained. However, in practice there is a limit to 
the manageable size of a decision tree and so this model type is best suited to limited 
number of branches and short time horizons in each branch.   
 
(iii-c) State transition: State-transition models are the most common form of modelling in 
health economics. The term is commonly used interchangeably with Markov models. They 
can be most often used to represent cohorts but can in principle be used to model individuals. 
No interactions between units of analysis are permitted. The emphasis of the model is in 
defining specific event states and time is modeled discretely, such that subjects transit 
between states at specific time points defined by the cycle length (e.g. 1 year increments).  
 
The model functions such that as the time increases, the proportion of the cohort remaining in 
the starting state tends to zero and a higher proportion of the group filters through the model 
states to eventually reach the final state(s). This process is typically termed the “Markov 
chain” and movement through the model is termed the “Markov trace”. An important limitation 
of a Markov model is that is assumes that during a single cycle, each patient undergoes no 
more than one state transition. In reality, transitions occur continuously throughout each 
cycle. Therefore, counting the membership only at the beginning or at the end of the cycle will 
lead to errors. This error will be larger the longer the cycle length. To more accurately reflect 
the continuous nature of state transitions, a common assumption is that the transition occurs 
at the mid-point of the cycle. This adjustment is called a ‘half-cycle’ correction and is 
calculated as the average of survival at the beginning and end of a cycle(237).  
 
This model type is often used when the disease process can be represented by a 
manageable number of states and over long time horizons where the use of decision trees 
may become unmanageable. A further key limitation of state transition models is that the 
probability of moving from one state to the next state is not conditional upon history, such as 
time in state or prior states. This “memoryless feature” is commonly known as the “Markov 
assumption”. This can become a particular problem when the need to model recurrent events 
is necessary and event history is important for determining future events. This loss of history 
can be resolved by developing extra (tunnel) states to represent history; however this can 
easily result in a model structure which becomes large and unmanageable.   Overall, Markov 
models are typically simple to implement, and computations are typically straightforward; 
however, awareness of the limitations are necessary.  
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(ii-d) Discrete event simulations (DES): These models focus on the individual agent, 
interactions are permitted, and time to event is modelled continuously. The rationale is that 
the modelling may more accurately reflects the reality of the problem under consideration. 
Further, two forms of interactions are permitted both direct and indirect. Direct interaction 
most commonly refers to infectious disease transmission where individual agents’ infect each 
other. Indirect interaction most commonly is the result of constrained resources where the 
consequence is that individuals compete for resources, which may then result in queuing for 
instance. In contrast, decision trees and state transition models do not model resource 
constraints endogenously within the model. 
 
The result of these modelling features is that individuals can build-up complex histories which 
then determine future conditional probabilities. The overriding aim of DES is to attempt to 
more accurately reflect the underlying disease, event and policymaking process. The 
potential downsides are that the models can become very complex and are information 
intensive, which may require extensive assumptions in the absence of hard data. The key 
issue whether to choose a DES over a simpler model is whether the downsides are 
outweighed by more accurate predictions and better decision making.   
 
(ii-e) Dynamic transition models: The structure of dynamic transition models can be very 
flexible. The description of these models in the latest ISPOR guidelines provides a very wide 
definition. These models can be used to model individuals, cohorts, populations or indeed 
health care systems as a whole. Time is most often modelled continuously and the models 
are often implemented with long time horizons.  To model the risk of transmission, the use of 
differential equations are most often used to represent the interactions, and equations can 
either be static or stochastic.  
 
These models can become very complex. Similar to DES the purpose of adopting such 
models rather than a simpler structure should be clear. Representing complex relationships 
may not necessarily aid explanation of the disease processes, and the key issue is whether 
the impact of an intervention is more accurately represented in changing outcomes of 
interest. 
 
(ii-f) Hybrid models: This summary of the most common model types is stylised in the sense 
that particular modelling features (e.g. modelling time to event) may not be exclusive to 
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particular model types (e.g. DES). There may be an opportunity for continual model 
innovation, and there may be opportunities to combine features resulting in hybrid models.  
 
When undertaking such an exercise and considering how to use the resultant information, the 
guiding principle is that a model should be parsimonious: as simple as possible, but no 
simpler. That is, it may not be necessary to model the full complexity of a disease, it relevant 
outcomes can be generated robustly by a more aggregated structure.  If such structural 
simplifications are made, then these should be justified on grounds that they would be 
unlikely to materially affect the results of the analysis. Model choice itself is a judgment call by 
a consensus of stakeholders including clinicians, statisticians, and modelers. The issue of 
validating the model structure will be revisited under modelling stage five.  
 
Overall, it is recommended that modellers should not choose a particular model type at the 
outset, but rather first define the model problem, and have awareness of the desirable 
features that a model could usefully contain. At the beginning of a modelling project there 
may be an opportunity to think afresh regarding whether innovations can be made, which 
may involve combining features normally associated with different models. In choosing or 
developing a model a key issue is how complex the model needs to be. This should be a 
product of the decision problem of concern. In decision analytical modelling in health 
economics the main purpose of the model is to produce accurate final outcomes (e.g. life 
expectancy) - not necessarily the details of causal processes - that allow an overall 
judgement whether an intervention is value for money.  To inform the judgement whether a 
simple or complex model is more able to produce accurate outcomes, models should be 
subject to rigorous validation tests. The rationale and process of validation is further 
discussed shortly, under Modelling stage 4. 
 
3.5.3 Modelling stage 3: Data identification and incorporation 
(i) Data identification: Models require considerable data input and data sources need to be 
recent and credible. However, the availability of comprehensive high quality data remains a 
problem. The data may come from a variety of sources including clinical trials, meta-
analyses, surveys, databases, medical records, audits, Delphi panels (expert opinion) and 
official tariff lists for health care resource use. 
 
If secondary data sources are being used to create the model (structure and statistical 
estimation) then systematic reviews of the literature should ideally be conducted on key 
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model inputs. Evidence that such reviews have been done, or a justification for failing to do 
so based on the adequacy and generalisability of readily obtained data, should accompany 
the model(52). 
 
If known data sources are excluded from consideration in estimating parameters the 
exclusion should be justified. Data sources and results should not be rejected solely because 
of a lack of comprehensiveness (e.g. not from a clinical trial). Further, in the absence of any 
or adequate data, expert opinion is a legitimate method for generating or assessing 
parameter estimates.  If expert opinion is elicited, and the results are sensitive to the 
elicitations, then the process of elicitation should be disclosed in detail. Expert estimates 
derived from formal methods such as Delphi or Nominal Group techniques are preferred. 
 
A model should not be faulted because existing data falls short of ideal standards of scientific 
rigor. Decisions will be made, with or without the model. The value of a model is that it can 
synthesis existing evidence, point to uncertainties and also make the case for postponing 
decisions until better evidence is found. 
 
(ii) Data modelling: This refers to the statistical and/or mathematical steps that are taken to 
transform empirical observations into a form that is useful for modelling. The aim is to define 
how units of analysis (e.g. individuals or cohorts) transit through a model structure towards 
events of interest (e.g. CVD, death). For instance, the approach of survival analysis is used is 
when it is important to estimate time to event and appropriate longitudinal data is available. 
This approach was discussed in Chapter 2 when introducing CVD risk scores. Further, 
modelling may also be required to generate appropriate costs and the health related quality of 
life of units as the model cycles, as outlined below. Cross-sectional data sources can be used 
for this and the application of regression techniques such as ordinary least squares may be 
applicable. The model structure then harnesses this information to estimate how units of 
analysis transit through the model, incur events and accumulative costs and (quality adjusted) 
life expectancy,  
 
(iii) Baseline data: This refers to the data used to initially populate the model to develop  
baseline results, in the absence of intervention. This information may come from the control  
group of a study, or from an observational dataset.  
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(iv) Costs: For the purpose of evaluation it is important that a model can estimate the cost of 
the intervention, events costs and wider cost implications. If a health perspective is taken 
then wider impacts are limited to health service costs. If a societal perspective is adopted 
then all substantive impacts are accounted for, such as intersectoral outcomes, productivity 
implications and so forth.  
 
In practice, most evaluations are limited to assessing the intervention costs and event costs. 
For instance, the review of economic evidence for CVD interventions in Chapter 2 found that 
no study assessed the interventions impact on wider health service (e.g. from longer life 
expectancies, or the wider economic costs). In general terms, this could pose a serious 
limitation to such evaluations. For instance, if an intervention leads to increase life 
expectancy then the additional costs from the accumulation of comorbidities may outweigh 
any particular events cost avoided, or delayed. This may lead to erroneous conclusions that 
an interventions are cost saving, whereas in actual fact they may lead to increased costs from 
an older population. 
 
(v) Health related quality of life: Conditional upon the modelling problem, such as modelling 
the impact of a particular disease event it is normally important to estimate health related 
quality of life in addition to length of life, if the event was non-fatal.  
 
Health related quality of life (HRQoL) can be measured through the application of generic 
questionnaires where respondents self-assess their health status. Chapter 5 will discusses 
HRQoL in detail. There are a variety of possible questionnaires available.  The most 
commonly used in the UK is EuroQol EQ-5D index(138) and the Short Form 12 or 6 (SF-12 
or 36)(137, 238), which divides questions in physical and mental health. The “EQ-5D-3L” 
refers to there being three levels (3L) per question. This is the most commonly used version. 
The other version is called the EQ-5D-5L, where there are 5 levels (5L) of possible 
responses.  SF-12 consists of 12 questions and SF-36 has 36 questions.  
 
These questionnaires can generate a wide variety of different health states given the range of 
potentially different combination of responses. To measure overall HRQoL a single summary 
score is generated by applying weights to different question responses. These weights are 
derived from general population preferences regarding the desirability of different health 
states. This generates preference-weighted HRQoL which economists call utilities. Modelling 
can be used to then estimate the impact of experiencing an event on reducing utility. These 
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estimates are called utility decrements. This process of estimating utilities and utility 
decrements can then be used to weight length of life to generate quality adjusted life 
expectancy (QALE). 
 
NICE recommends using the ED-5D; however, this doesn’t necessarily preclude using 
alternative instruments. Previous studies have shown close correlation overall between 
measures in general(239). However, in healthy or sick individuals the scores can differ in 
terms of which tool is most sensitive. This will be discussed in chapter 5 when considering 
how to measure quality of life in the context of primary prevention of CVD where populations 
are asymptomatic. Further, NICE recommends that the valuation of outcomes should be 
equal regardless of who in the population is affected by the intervention. 
 
(vi) Treatment effects: With the previous steps in place, the model can estimate the impact of 
interventions. For instance, interventions may slow the transition from one state to another 
(e.g. free of CVD to a CVD event). This will then change patient history and have impacts on 
(quality adjusted) life expectancy and costs.  
 
In the context of policy models there may be challenges in modelling treatment effects when 
multi-factorial interventions are considered, that include a mix of pharmaceutical and/or 
lifestyle interventions that impact on different risk factors. The key issue is how these 
interventions interact to then lead to reductions in risk factors (or CVD outcomes directly). For 
instance, statins and dietary changes both impact on cholesterol.  There nature of the 
challenge would depend on whether the model is used in trials or to conduct a purely ‘what-if’ 
analysis. If the model was used to extrapolate known trial results then it may not be 
necessary to understand the underlying interactions, and the combined impact on risk factors 
and/or event rates would be known. However, as discussed in the previous chapter while 
there is fairly substantial evidence of the impact of single interventions on reducing one (or 
more) risk factors, there is a lack of secondary literature on the combined impact of multiple 
interventions.  This is despite the fact current CVD clinical guidelines recommend such multi-
factorial intervention programs, which policymakers are following.  
 
To model the impact of such multi-factorial programmes important assumptions would be 
required regarding how interventions interact. Possibilities include applying an additive 
relationship as discussed by Capewell(13), however this does not seem to make intuitive 
sense. As new interventions are included in a package of interventions, eventually adding 
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relative risk reductions would result in negative risk and implying immortality in the limit. This 
is clearly incorrect. An alternative approach may be to apply a simple multiplicative 
relationship where as new interventions are added to a package of interventions, the products 
of the relative risk reductions of individual interventions are taken.   
 
A further potential challenge is modelling the impact of physical activity interventions. As 
discussed in chapter 2, physical inactivity is an independent risk factor in predicting CVD 
events, after adjusting for other known risk factors. This may present a challenge if a model 
estimates the impact of intervention through risk factors changes using the same variables 
employed in risk tools. A potential solution is to use trial evidence on the evidence of physical 
activity (in isolation or as part of multi-factorial package of interventions) and then adjust the 
risk factors to match the observe event rates. Nonetheless, this would represent a practical 
fix, rather than an elegant solution.  
 
An additional challenge for modelling long term impacts is the sustainability of changes to risk 
factors / event rates over time. Sustainability is likely to be a function of lag effects between 
intervention and risk factors, and also patient compliance with particular interventions (e.g. 
statin use) over time. This is a challenge for both extrapolating trial results and for purely 
‘what-if’ modelling exercises. 
 
(vii) Generate incremental cost effectiveness ratio (ICER): Once the model has been created, 
populated and the interventions have been defined, it is then important to enable the model to 
generate cost effectiveness evidence. This is done through generating an ICER, where the 
numerator is the difference in the additional costs between ‘new’ intervention (to a 
‘comparator’); and where denominator is the difference in the effect between the intervention 
‘new’ intervention (to a ‘comparator’). 
 
(viii) Discounting: Further, it is important that outputs are discounted to account for societal 
time preference, to reflect that outcomes realised in the future are valued less in present day 
terms.  The guidance from NICE is that benefits and costs should be discounted at 
3.5%(144). However, the Public Health guidance  recommends that the discount rates are 
1.5%(147). Discounting then results in an ICER represented in net present value terms, and 
congruent with economic theory. Note that while the Scottish Medicines Consortium (SMC) 
makes adoption decision regarding new interventions, the methods used to undertake 
economic evaluation follow NICE guidelines.  
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3.5.4 Modelling stage 4: Uncertainty analysis 
At all stages in the evaluation and modelling process uncertainty is prevalent(227). There is 
uncertainty in the: (i) sample data used (to assess efficacy or effectiveness); (ii) model 
structure (used to represent the modelling problem); (iii) analytical methods employed (e.g. 
the instruments used to estimate utilities); and (iv) generalisability of results to different 
settings. The consequence of the different forms of uncertainty is the assessment as to 
whether an intervention is value for money is also subject to uncertainty.  
 
The systematic examination and responsible reporting of uncertainty are hallmarks of good 
modelling practice(43). There are two separate, but interrelated decisions: (i) whether to fund 
a particular intervention; (ii) whether to invest in further research to reduce uncertainty.  
However, the role and urgency of sensitivity analysis is, in part, conditional upon the 
modelling problem. If the model has been built to assist a decision maker and they must 
make a decision regarding resource allocation now, have no role in commissioning further 
research and a decision cannot be reviewed in the future then uncertainty analysis has a 
limited role and the decision should be based on the mean estimates.   
 
There are four main types of uncertainty in estimates produced(49). The first type of 
uncertainty is stochastic uncertainty which refers to the random variability in the estimates 
produced. This is random variability not attributable to features of individuals, and is 
sometimes described as first order uncertainty. The second type of uncertainty is parameter 
uncertainty. This is represented by the error term in the beta coefficients of the estimates. 
This is sometimes called second order uncertainty.  The third type of uncertainty is 
heterogeneity and the difference in estimates that can be attributable to characteristics of 
individuals. This can be represented by difference in the beta coefficients of the estimates.  
To explore parameter uncertainty, the reporting of estimates should include means and 
confidence intervals. It is also important to explore heterogeneity in model results to separate 
out natural variation explained by individual characteristics, from statistical uncertainty in the 
modelling results.  This can be undertaken by conducting sub-group analysis consistent with 
the modelling problem under investigation.  The fourth type of uncertainty is structural 
uncertainty and relates to the uncertainty surrounding the modelling assumptions, including 
the structure of the model (e.g. model type) and analytical methods employed, such as the 
choice of discount rates or estimation of inputs such as health utilities (e.g. whether EQ-5D or 
SF-6D is used). Structural uncertainty may be at least as important as parameter uncertainty. 
Therefore, where possible it is best practice to sensitise the model structure. This can be 
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done by reformulating the model, choosing different distributional assumptions in parameter 
estimations, and varying key exogenous inputs to the model such as the utility estimates, 
discount rates, and so forth. 
 
Further, it is important that modelling undertakes sensitivity analysis to “stress test” the extent 
to which model outputs change due to change in key inputs, such parameter values or 
structural assumptions. This then allows the model to estimate not only mean impacts but 
also to present the uncertainty surrounding such estimates. Standard methods of sensitivity 
analysis in health economic models can be broadly divided into two categories: deterministic 
sensitivity analysis and probability sensitivity analysis (240). Deterministic sensitivity analysis 
is where parameters in the models are changed manually. This can be undertaken in four 
ways: (i) If one parameter is changed at a time while all others retain their base-case 
specifications, it is called “one-way sensitivity analysis”; (ii) if more than one parameter is 
changed at the same time then it is called “multi-way sensitivity analysis”; (iii) “Threshold 
analysis” is concerned with identifying the critical value of parameters above or below which 
the conclusion of a study will change; (iv) An “analysis of extremes” involves incorporating the 
best and worst estimates of inputs, and then generating extreme scenarios.  
 
Probabilistic sensitivity analysis is an automated process where all parameters are varied 
simultaneously. This is undertaken by specifying a priori probability distributions (e.g. normal, 
log-normal, beta), which should be justified by the evidence based. It may be that parameters 
are not (or expected to be) independent. Where data permits, the covariance relationship 
between parameters should be estimated and used to inform the PSA, for instance through 
the development of a using a Cholesky decomposition matrix. If data is not available, 
independence need not be a default position but rather the process of choosing distributions 
need to be justified (e.g. secondary data, Bayesian synthesis, subject judgment)(228). This 
method involves exploring the parameters, but in running these multiple times and averaging 
across estimates this is intended to take into account stochastic variations. Monte Carlo 
simulation analysis is a convenient way to automate this process(241).  
 
To represent uncertainty graphically, the standard approaches are to plot the estimates on a 
cost effectiveness plane and/or generate cost effectiveness acceptability curves 
(CEACs)(242). The former approach can show the range of ICER estimates and relative to a 
decision threshold which is represented as a line maximum willingness to pay for a unit of 
effect. However, when we don’t know the threshold then the approach of CEAC is a method 
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of illustrating the probability of cost effectiveness as the threshold value changes. Separate 
CEACs can be produced for different sub-groups if treatment decisions can be considered 
independent. Further, when considering multiple treatment options that are mutually exclusive 
the approach of using a cost effectiveness acceptability frontier (CEAF) is a convenient way 
of representing the optimal choice based on net benefit(227-228).  
  
Decisions based on existing information will be uncertain, and there will always be a chance 
that the ‘wrong’ decision will be made.  As discussed in section 3.3 if an adoption decision is 
required then decisions should be taken on the basis of mean expectations of outcome; the 
uncertainty surrounding mean estimates is irrelevant. However, although we make the correct 
decision now based on our current estimate of expected net benefit, there is a chance that 
another alternative would have had higher net benefit once our current uncertainties are 
resolved.  If our decision based on current information turns out to be ‘wrong’, there will be 
costs in terms of health benefit and resources forgone.  Where there is the opportunity to 
delay an adoption decision in order to undertake further research then the approach of value 
of information analysis can assess whether conducting further research is value for 
money(243). That is, the extent to which to invest in further research to reduce the possibility 
of making a wrong decision given the economic impacts. With estimates of the probability of 
error and the opportunity costs of error we can calculate the expected cost of uncertainty or 
the expected opportunity loss surrounding the decisions.  The expected costs of uncertainty 
can be interpreted as the expected value of perfect information (EVPI), since perfect 
information can eliminate the possibility of making the wrong decision(227). Total EVPI is 
commonly expressed in net monetary benefits. The higher the EVPI the greater the 
opportunity cost of an incorrect decision, and consequently the rationale for delaying a 
decision to undertake further research increases.  This provides an assessment of the overall 
uncertainty in the model output. It may also be beneficial to explore which particular 
parameters are driving this uncertainty to guide the research effort. An analysis of expected 
value of partial perfect information is designed to identify single or multiple parameters whose 
uncertainty most materially impacts on a decision(49).   
 
Implementing probability sensitivity analysis and conducting a full uncertainty analysis, as 
described previously, may provide particular challenges for policy models. To reiterate, the 
rationale for a policy model is to have a single generic model that can be used to evaluate 
and model a wide range of interventions; both individually and together as part of package of 
interventions. The crux of the issue is that as the number of modelling variables used within a 
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policy model increases it may be more difficult to know the covariance structure between 
variables in order to implement PSA.  
 
The first challenge is to understand the underlying relationship between risk factors and 
outcomes of interest. We saw in the previous chapter that current epidemiological research 
has used anywhere between 6 and 14 variables (as risk factors) when attempting to predict 
the risk of future CVD events. An economic model with aspirations to be a policy model would 
ideally need access to such a wide range of variables and know the underlying covariance 
structure. As we will discuss shortly, when reviewing existing policy models, that this is rarely 
the case.  
 
The second challenge is modelling the uncertainty in estimating the impact of multiple 
intervention(s) that are delivered simultaneously as part of CVD prevention programmes. A 
particular challenge in implementing PSA in modelling exercises is the lack of trial evidence 
regarding how interventions interact, and so the treatment effect on reducing risk factors. To 
explore uncertainty, there would need to be evidence (or less satisfactorily, reliable expert 
opinion) regarding the potential covariance relationship between interventions to explore 
uncertainty. At present, this knowledge is largely absent. Consequently, a sensitivity analysis 
may best default to an analysis of extremes prior to trial evidence becoming available. The 
assumptions regarding how interventions combine to reducing overall risk can be sensitised 
as part of a structural sensitivity analysis. Indeed using an analysis of extremes to articulate 
such uncertainties of impact may be a valuable output from a policy model to make the case 
for trial evidence.  
 
Therefore, there are challenges in implementing PSA in policy models. However, the 
fundamental issue is the lack of trial evidence regarding the impact multi-factorial 
programmes, rather than any intrinsic weakness of the rationale for, or application of, a policy 
model. To reiterate, clinical guidelines and policymakers are intent on continuing to roll-out 
multi-factorial programmes nationwide. These programmes need to be evaluated. Therefore, 
the rationale for a policy model in this context remains essential. The uncertainty regarding 
the predictions represents a challenge to the modelling, but the model can be used at least in 
a ‘pre-trial’ phase (as discussed previously) to articulate best guess and inform the need for 
policy to invest in actual trial evidence. 
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3.5.5 Modelling stage 5: Validation and reporting 
There are five different types of validity: (i) face validity is achieved when experts in the area 
corroborate that the model structure and the assumptions used are consistent with the 
problem at hand; (ii) internal validity is achieved if the model can reproduce outputs from the 
source data used in the construction of the model. This is sometimes referred to as 
verification and is a check on the coding used to generate the model; (iii) external validity is 
achieved if the model can accurately reproduce outcomes in a dataset and context not used 
in the construction of the model; (iv) predictive validity is where the model can accurately 
predict future outcomes.  If a model doesn’t accurately predict outcomes in a different context 
and / or time period, this does not necessarily invalidate the model. Recalibration can be 
undertaken to adjust model parameters systematically to allow predictions to match 
observations in a population of interest. In principle, there is a wide variety of ways to 
recalibrate a model, and no formal guidance exists. It is suggested here that a pragmatic and 
parsimonious approach may be best. For instance, if a regression is used to estimate key 
model parameters then perhaps the addition of an intercept may be sufficient, with the 
expectations that the slope coefficients are accurate. More sophisticated forms of 
recalibration should be clearly explained, such as multiplicative factors to parameters values. 
Finally, (v) cross-validity is the extent of agreement in the outcomes generated by different 
models using the same input datasets. If a model’s outputs differ appreciably from published 
or publically available results based on other models, the modelers should make a serious 
effort to explain the discrepancies(44). If possible, it would be important to distinguish 
between the discrepancies due to differences in model structure or input values. 
 
Within this process of validation it is important that the model’s ability to discriminate between 
individuals is carried out. The most common approach is to generate the C-Statistic and 
Hosmer-Lemenshow tests. These were discussed in Chapter 2 when reviewing CVD risk 
scores. To briefly reiterate, the C-Statistic is measure of how well the model discriminates 
between those incurring an outcome from interest from those who do not. The Hosmer–
Lemeshow test specifically identifies subgroups as the deciles of fitted risk values. Models for 
which expected and observed event rates in subgroups are similar are called well calibrated. 
 
Overall, it is strongly recommended that modelers make every effort to fully report how the 
model was constructed, and ideally provide enough information to enable third parties to 
replicate the model. To these ends, the dissemination should be easily accessible and 
comprehensible.  This may encounter limitations, such as commercial property rights if the 
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model was built for the purpose of profitability rather than knowledge dissemination and 
reporting may need to be updated over time if protocols and best practice guidance changes. 
External and predictive validity should be an on-going process where necessary, such as 
exploring whether the model can be used on a population not involved in constructing the 
model.  
 
Overall, the process of building a model can be complicated task conducted over a 
considerable period of time. Also models should never be regarded as complete. That is, 
models should be repeatedly updated, and sometimes abandoned and replaced, as new 
evidence becomes available to inform their structure or input values(43-44). 
 
3.6 Cardiovascular disease policy models: systematic 
review 
 
3.6.1 Approach taken for the systematic review  
An approach was taken to build upon a previous systematic review which covered the 
literature until 2003 and included models with a focus on CHD(244). This review searched 
MEDLINE and PUBMED, and found 6 models. Rather, than simply update the previous 
review using the same terms the review conducted here, was informed by, but sought to 
widen the search strategy.  
 
A search of the MEDLINE, PUBMED and EconLit electronic databases was undertaken from 
1970 to 2011. To decide on a suitable approach the important observation is that there are 
three relevant categories of search terms: ‘disease area’, model type’ and ‘economic 
evaluation’. Within each of these categories there were two options identified of relevance to 
the search.  First, within the category ‘disease area’ certain economic evidence concentrates 
on ‘CVD’ and ‘CHD’. Second, within the category ‘model type’ the search included ‘policy 
model’ and ‘generic model’. The rationale being that a generic modelling approach (i.e. 
incorporating a wide range of risk factors) was the key approach that allows a policy model to 
inform wide range of prevention interventions focussed on different risk factors 
(independently or simultaneously). Third, the category ‘economic evidence’ includes the 
terms ‘economic evaluation’ and ‘cost effectiveness’, the former being the generalisable 
approach to generate economic evidence and the latter the specific approach developed by 
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health economics to generate evidence for health service interventions. Table 3-2 
summarises the search terms used. 
 
Table 3-2 Search terms used in Systematic review of policy models 
Disease area Model type Economic evidence 
CVD Policy model Economic evaluation 
CHD Generic model Cost effectiveness 
 
An iterative approach was taken, where different searches were conducted sequentially 
rather than inputting all terms. In each round of searching a term was chosen from each of 
the categories, and so three terms in total were included in a single search. An exhaustive set 
of searches was undertaken with all combinations of these terms were combined (one from 
each category). In total 5 searches were conducted. The expectation was that there would 
considerable overlap in the articles picked up between specific searches; but that this 
approach would provide a comprehensive attempt at detecting all relevant models in peer 
reviewed journals.  
 
The search was restricted to terms in the title and abstract only. In total the searches 
identified 4,261 articles. All records were imported to ‘End-note’. Figure 18 summarise the 
review process. Articles were excluded in two stages. First, models were excluded if they did 
not relate to human beings, or focussed on single risk factors/interventions, as these cannot 
be described as policy models following the definition made previously. There were 118 
articles retained. Second, articles were excluded if either the models description was unclear 
to give at least an overview of its characteristics relative to best practice guidance; or articles 
referred to an application of the model, rather than a description itself. 
 
A final list of thirteen models was identified for critical appraisal. This is in contrast to the six 
models detected in the previous systematic review outlined above, published in 2010. The 
contrast in findings appears to confirm the comprehensive nature of the search, as several of 
the models identified could have been detected by the published review given the model pre-
date the search that had been undertaken. 
 
The following provides a detailed description of twelve models. A model that was developed 
in Australia is essentially a replica of a previously published model developed by the NICE 
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PDG, but was populated with local data. This is a perfectly valid approach, and the Australian 
model is briefly discussed when reviewing the NICE PDG model. 
 
The extent of the reporting of the models was inconsistent, with certain models being 
extremely transparent and others less so. This is reflected in the review in terms of the detail 
that can be conveyed. An additional model is discussed that was detected in the review that 
while not an economic model, provided an interesting approach to converting risk profiles into 
estimates of life expectancy. This was influential in conceptualising the approach taken to 
estimate life expectancy in the Scottish CVD Policy Model. 
 
Figure 3-1 Systematic review of CVD or CHD policy models 
Search result
4,261
Screened
123
Models Other
13 110
 
 
To review the models, the best practice guidance described earlier was used. The order that 
the models are reviewed is with reference to the model type employed, beginning with the 
simplest types. Of note, is that models perform quite differently relative to the criteria. The 
prose concentrates (mainly) on what the model does relative to best practice, rather than 
what is omitted. An accompanying table summarises how the model performs against all best 
practice criteria. 
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3.6.2 Review of existing policy models 
The order in which the models are reviewed is an attempt to begin with the simplest model 
and end with the most complicated, consistent with the earlier discussion on model types. 
There is no value judgement associated with the term simple in this context, but rather refers 
to the model structure and transparency of the approach used to estimate transition risks. 
Indeed, as will discussed later simplicity is considered here as a virtue, conditional upon a 
model being capable of producing the outputs required commensurate with the decision 
problem.  
 
NICE Programme Development Group: “Modelling Strategies for the primary 
prevention of cardiovascular disease”  
(i) Conceptualising the model problem: The NICE Programme Development Group 
commissioned and developed a model to inform the potential cost effectiveness of 
population-wide interventions(35). This model formed part of the (on-going) response by 
NICE to a request by England’s Department of Health for NICE to developed guidance on a 
public health programme aimed at the primary prevention cardiovascular disease.  
 
The perspective taken by the model was from the health service and the objective was to 
predict the gains in life expectancy from changes to modifiable risk factors from a range of 
legislative interventions including salt reduction and a ban on trans-fats. The time horizon of 
the model was 10-years. This is very conservative, given impacts will be expected over a 
lifetime. Nonetheless, this is a long enough to illustrate that the huge potential benefits from 
population wide interventions, and that even over a short horizon these interventions are 
likely to be very cost effective.   
 
(ii) Conceptualising the model structure: The analysts built what they termed a “cell-based” 
model which is reclassified here as a tabular model for consistency with best practice 
guidelines. The model uses the Framingham 10-year risk score with risk factor information 
and estimates the risk of CVD event. This 10-year estimate is then interpolated to generate 
annual event risks. The model then estimates the particular type of CVD event which included 
7 different events (including different severities of angina and stroke). The event predictions 
in turn determines the relative risk of subsequent death which is used to adjust the 
background life expectancy estimates of an individual profile, defined by age and sex (taken 
from national lifetables). Event predictions are also used to quality adjust life expectancy 
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estimates of a non-fatal event; however, no account is taken of background quality of life 
(population norms). The model does not estimate the health service costs associated with the 
incurrence of fatal and non-fatal events. 
 
(iii) Data identification and incorporation: The model is then populated with the English 
population risk factor distributions using cross-sectional surveys. First, the population is 
divided into sex and 10-year age bands. The average risk profile for each subgroup is then 
taken from a separate survey. Each subgroup (number and risk profile) is then inserted into 
the model and estimates baseline life expectancy, quality adjusted life expectancy and health 
service costs. The model then simulates the effect of the intervention (e.g. salt reduction) by 
reducing the relevant risk factor (e.g. blood pressure) by a certain amount and estimating the 
impact on extending life expectancy and avoiding event costs.  All outcomes were discounted 
at 3.5%. 
 
(iv) Uncertainty analysis: The model only takes into account the mean values from the 
Framingham parameters coefficients when estimating the impact on CVD events. 
 
(v) Validation and reporting: No internal or external validation was conducted of the model 
predictions as the interventions considered were speculative. The accuracy of the 
Framingham equation itself has already been tested separately and recalibrated for an 
English population (see Chapter 2). The model is well reported, with on-line technical 
appendixes and third parties could easily replicate the model. 
 
(vi) Applications: The model has been used to simulate the impact of population interventions, 
including potential reductions of systolic blood pressure, cholesterol and salt(35). This 
exercise has shown the potential of population interventions. However, the benefits may be 
an underestimate given the 10-year horizon of the model and that the total impact on health 
service costs may be underestimated also if longer life expectancy results in higher cost in 
the long term.   
 
Strengths of the model are the simple approach, that it can rapidly simulate intervention and 
can be communicated simply. The model could, in principle, be used to inform the targeted 
approach to primary prevention, by estimating the potential economic impacts of prioritising 
different groups. In this case the time horizon of 10-years would become a serious weakness 
as it would be important to compare the impact of prevention in the young and old. 
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Weaknesses of the model include the absence of quality adjustment to account for non-fatal 
events avoided, costs saved only include the avoidance of CVD events, and the time horizon 
of the model is just 10-years rather than a lifetime.   
 
This modelling approach has been replicated in Australia, with the only differences being that 
the Framingham score was then calibrated to an Australian population, and that local cost 
data are used to estimate intervention costs and events costs(175-176). This version of the 
model has been used to identify what may be the most cost effective interventions, including 
drugs and diet. The most notable finding is that a shift away from lifestyle counselling to 
legislation and drugs was estimated to be more cost effective(175). However, the difficulty in 
generalising from this finding is that the model is only estimated over 10 years, and it could 
be argued that lifestyle intervention deals with the underlying aetiology.  
 
Markov model to estimate cost effectiveness of EUROACTION  
(i) Conceptualising the model problem: An economic evaluation was conducted of the 
EUROACTION intervention that was reviewed in Chapter 2. The aim was to extrapolate the 
one-year trial results and assess the likely cost effectiveness of the intervention over a longer 
time horizon(179).  
 
(ii) Conceptualising the model structure: A Markov model was constructed that estimated 
event risks over an 11–year period, within annual cycles and final outcomes reported in 
quality adjusted life years and event costs (net of interventions). From a CVD free state an 
individual can incur one of 7 events: stable angina, unstable angina, myocardial infarction, 
CHD death, transient ischaemic attack, stroke, CVD death and non-CVD death. Following a 
non-fatal first event, individuals can then move to any of these states in subsequent years 
within the model.  
 
(iii) Data identification and incorporation: The Framingham study was used to define risk 
factors and the risk of incurring a CVD event over 10-years. The risk factors used were: age, 
sex, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for hypertension, 
smoking status and diabetes. The 10-year risk was interpolated to estimate annual risk. To 
apportion global CVD risk between events a variety of different sources were used, and used 
to also estimate how individual transit between different types of non-fatal events. The utility 
decrements associated with events were taken from a UK study. The cost estimates were 
particular to EUROACTION. All outcomes were discounted at 3.5%.   
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(iv) Uncertainty analysis: To account for sampling variation in the original EUROACTION trial. 
Using non-parametric bootstrapping; the model sampled individuals from the study with 
replacement and generating 10,000 replications. The final results report 95% confidence 
intervals and the model reports results by different subgroups. 
 
(v) Validation and reporting: The Framingham risk prediction was calibrated to the 
EUROACTION observed event rates. The model was very clearly reported within its single 
application to date.  
 
(vi) Applications: The model was built for the evaluation of HEARTSCORE. However, the 
generic structure means it can be applied to any risk factor intervention that impact on the 
Framingham risk factors. 
 
The IMPACT model 
(i) Conceptualising the model problem: The IMPACT model was first developed in Scotland in 
the mid-1990s and now several country specific versions exists, such as England(190), 
Canada, China(245). The general method is to use historical data on risk factors and event 
trends to explain the decline in CHD prevalence.  
 
(ii) Conceptualising the model structure: IMPACT is a tabular model which estimates the 
relationships between risk factors, CHD events and life expectancy. The scope of the model 
is comprehensive.  For primary prevention, the model includes smoking, cholesterol, blood 
pressure deprivation, obesity, diabetes and physical activity.  
 
(iii) Data identification and incorporation: The model was estimated from cross-sectional data 
sources which were collated over time.  The model then uses trends in these risk factors to 
explain historical trends for a very wide range of specific CHD events (e.g. cardiopulmonary 
resuscitation and thrombolysis).  The authors outline that multivariate regression was used to 
estimate a range of beta coefficients for each risk factor’s contribution to the historical 
declines in CHD prevalence. However, the estimation procedure is unclear. The underlying 
epidemiological relationships between risk factors and events appear to have taken from 
individual studies in the literature. What is unclear is how these estimates were all combined 
and then calibrated, or not, to match historical observations. Further, no quality adjustment is 
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made, the impact of risk factors on CBVD and non-CVD outcomes are not considered, and 
the cost impact of longer life expectancies are not included  
 
(iv) Uncertainty analysis: Uncertainty in the model outputs is represented by confidence 
intervals in the reported results. Sensitivity analysis is undertaken via an analysis of 
extremes. 
 
(v) Validation and reporting: Internal validation was performed for the models in each of the 
settings that variants were created, and the authors qualitatively report accuracy in findings.  
It is unclear how validation was conducted. While technical appendices are available on 
request there is a lack of transparency in how data was modeled, and whether (how) 
predictions in events and life expectancy were calibrated to official sources.  
 
(vi) Applications: A wide range of publications has been generated to explain historical 
declines in CHD prevalence, and distinguish between risk factor reductions and secondary 
prevention interventions. In particular, the model makes a powerful case for primary 
prevention and for population interventions, such as incremental reductions in risk factors.  
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Table 3-3 Appraisal of policy models 
Modelling stages Elements within each stage NICE Programme Brunel / IMPACT DisMod II CHD policy model RISC  RIVM  POHEM Coronary heart disease Cardiovacular life PREVENT PRISM Archimedes
Development Group EuroAction policy analysis model expectancy model
Policy context √ √ √ √ √ √ √ √ X X X √ √
Consultation of experts and stakeholders √ √ √ √ √ √ √ √ √ √ X √ √
Statement of decision problem √ √ √ √ ? √ √ √ √ √ √ √ √
Statement of model scope √ √ √ √ √ √ √ √ √ √ X √ √
Statement of model  perspective √ √ √ √ √ √ √ √ √ √ X √ √
Target population √ √ √ √ √ √ √ √ √ √ √ √ √
Health outcomes √ √ √ √ √ √ √ √ √ √ √ √ √
Intervention strategies/comparators √ √ √ √ √ √ √ √ √ √ X √ √
Time horizon √ √ √ √ √ √ √ √ √ √ √ √ √
Cycle length √ √ √ √ √ √ √ √ √ √ √ √ √
Converting the model problem into a model structure X X X √ √ √ X X √ √ ?
Choosing a model type
          Tabular model √ √ √
           Decision tree
√ √ √
           State transition √
√ √ √ ?
           Discrete event simulation
           Dynamic transmission model √ √
           Hybrid models
Stage 1:Conceptualising the problem
Stage 2: Conceptualising the model
 
Key:  √ = done; X = not done;? = unclear or partially done
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Table 3-4 Appraisal of policy models - continued 
 
Modelling stages Elements within each stage NICE Programme Brunel / IMPACT DisModII CHD policy model RISC  RIVM  POHEM Coronary heart disease Cardiovacular life PREVENT PRISM Archimedes
Development Group EuroAction policy analysis model expectancy model
Data identification √ √ √ √ √ √ √ ? √ ? ? √ √
Data modelling √ √ √ √ √ √ √ ? √ ? ? √ √
Baseline data √ √ √ √ √ √ √ ? √ ? ? √ √
Costs √ √ √ X √ √ √ √ √ √ ? √ √
Quality of life weights (utilities) X X X X X √ ? √ ? √ ? X √
Treatment effects √ √ √ √ √ √ √ √ √ √ ? √ √
Incremental cost effectiveness ratio X X X X √ √ √ √ √ √ ? X √
Discounting √ √ √ √ √ √ √ √ √ √ ? ? √
Stochastic (first-order) uncertainty √ √ √ √ √ √ √ √ √ X √ √ √
Parameter (second order) uncertainty √ √ √ √ √ √ √ √ √ X √ √ √
Heterogeniety X X X X √ √ √ √ ? X ? √ √
Structural uncertainty X X X X X X X X X X X X X
Face validity √ √ X X X X X X √ X X ? ?
Internal validity X X X X X √ X X ? X X √ √
External validity X X X X X X X X X X X ? √
Cross validity X X X X X X X X X X X X X
Predictive validity X X X X X X X X X X X √ √
Reporting and dissemination √ √ √ ? ? ? ? ? ? √ X √ √
Stage 3: Data identification and incorporation
Stage 4: Uncertainty analysis
Stage 5: Validation and reporting
 
Key:  √ = done; X = not done;? = unclear or partially done
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WHO Global Burden of Disease Model  
(i) Conceptualising the model problem: WHO Global Burden of Disease (DisModII) was 
created to model the burden of premature mortality and disability by all major diseases at the 
global level and across 14 regions or the world(246). CVD was a sub-section of the model. 
 
(ii) Conceptualising the model structure: A tabular model was developed which estimates the 
relationship between 25 risk factors and the incidence, prevalence, duration, and case fatality 
of over 200 disease and injuries. In all, DisMod consists of 500 cells to calculate the 
relationship between risk factors and disease outcomes, for age ranges between 0 to 85+ 
years.  
 
(iii) Data identification and incorporation: To identify the risk factors, expert working groups 
conducted a comprehensive review of published literature as well as other sources 
(government reports, international databases, etc) to obtain data on the prevalence of risk 
factor exposure and hazard size (relative risk or absolute hazard size) for 14 sub-regions of 
the model.  
 
The criteria for the selection of risk factors included were: likely to be among the global or 
regional leading causes of disease burden; not too specific (e.g. chemical exposures) or too 
broad (e.g. environment or food); high likelihood of causality based on scientific knowledge; 
reasonably complete data on exposure and risk levels or methods for extrapolation when 
needed; potentially modifiable.  The risk factors used to drive cardiovascular events are blood 
pressure, cholesterol, body mass index (BMI), fruit and vegetable intake and physical 
inactivity. These were dichotomised and relative risk applied to the proportion of the 
population with high risk factor levels.  
 
To use the model, country or regional population statistics (numbers, ages and sex) are 
inputted and the model develops projections of mortality and non-fatal health outcomes over 
the next 30 years. The model then contains active cells for the user to insert relevant 
interventions and costs, with the latter including intervention and event costs. The model 
generates life expectancy estimates and produces Disability Adjusted Life Years. However, it 
is unclear how the weights were derived or applied in the model. 
 
(iv) Uncertainty analysis: Uncertainty in the model outputs is represented by confidence 
intervals in the reported results. Sensitivity analysis is undertaken via an analysis of extremes 
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using the upper and lower bounds of the confidence intervals for the relative risk ratios. This 
generates scenarios analysis of expected, best and worst case scenarios.   
 
(v) Validation and reporting: The model undertakes internal validation with mortality 
predictions calibrated to lifetables each region or country. No validation of its predictions 
appear to have been undertaken; however, the model literature makes clear that users of the 
model should validate predictions relative to the local geography. The model is also available 
freely on-line as a web based tool.  
 
(vi) Applications: The model is intended for use by supra-national and national governments. 
Overall, the model is comprehensive, transparent and is used in WHO-CHOICE (CHOosing 
Interventions that are Cost Effective) research. This research attempts to generate a central 
resource regarding cost effective interventions in three ways: by collating economic 
evaluation from across the world; generating economic evidence of new interventions; 
tailoring results from previous economic evaluation to local conditions by for instance 
changing unit costs or compliance assumptions  The model has been used by the Millennium 
Development Commission for instance, to convert burden of disease estimates into health 
service costs, and also to estimate the macroeconomic impact of disease in terms of 
productivity loses and resultant losses in Gross Domestic Product. 
 
The Coronary Heart Disease Policy Model 
(i) Conceptualising the model problem: The Coronary Heart Disease Policy (CHDP) Model 
was the first model developed in this area and was self-titled as a policy model(205). The 
model was constructed in the 1980s with the aim to forecast population trends in CHD 
mortality and the associated costs in the United States.  The perspective taken is from the 
health service. Overall, the CHD Policy Model was the seminal policy model that others have 
since taken a lead from. 
 
(ii) Conceptualising the model structure: The model is described as a state-transition model. 
The model seeks to estimate the transition of the US population from a CHD free state to 
eventual death. The model was constructed using several cross-sectional datasets 
representative of the US population. It is comprised of three main parts. First, there is what 
the authors call a “demographical/ epidemiological model”, which represents the disease-free 
population aged 35-84 years. The population to be simulated is first stratified by sex, age 
groups and four cardiovascular risk factors including smoking status, total cholesterol, DBP 
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and relative weight (as a ratio of the population average). Age was split into 5 year bands and 
the other risk factors are inputted as categorical variables with three levels.  
 
The second stage of the model is the “bridge model”, which covers subjects for the first 30 
days after developing coronary disease. Using a CHD incidence data from Minnesota, the 
model initially determines whether the first event is angina, myocardial infarction or cardiac 
arrest. 
 
The third stage of the model is the “disease history model”, which includes the survivors after 
the first 30 days. Individuals surviving are then apportioned to one of 12 CHD events, 
including the post-intervention states of CABG and PTCA. Separate cells and risks are 
estimated for males and females, and also specific to different 5-year age bands. The risk of 
non-CHD death is included which is estimated from national lifetables.  
 
Overall the model uses over 5,000 separate cells to stratify the US population, with a CHD-
free population then moving between cells as the model cycles on an annual basis. The 
model can simulate the life expectancies of the CHD-free population for up to 30 years, and 
also the impact of interventions. Primary prevention interventions are simulated by changing 
the modifiable risk factors to slow the population transition from a CHD-free state into the 
bridge model. Secondary prevention interventions are then used to slow the transition to 
CHD-death, with background life expectancies (defined by national lifetables) unchanged by 
any risk factor adjustment. In other words, changing risk factors such as smoking only affects 
CHD events.  
 
(iii) Data identification and incorporation: The model uses a very wide range of cross-
sectional data sources, both national and at state level. The model then predicts the annual 
incidence of CHD events from each of the population cells using relative risk estimates from 
the Framingham Heart Study population. A proportion of each of the subgroups then 
experienced an event. While all individual parameter estimates are provided it can be unclear 
if and how these are combined to determine transition risks. Overall, the cost effectiveness of 
interventions is then estimated at the overall population level by looking the benefits of 
greater life expectancies from the costs of prevention interventions (net of the hospitalisation 
costs). No quality of life adjustments are made. 
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(iv) Uncertainty analysis:   Confidence intervals are given for all parameters and the model 
can undertake analysis of extremes sensitivity analysis.  
 
(v) Validation and reporting: The model has been calibrated to the 1980 census statistics on 
mortality, the year in which the model was built.  Authors do describe the intention to test the 
model to forecast future CHD trends, which is in a sense a form of external validation. 
However, this has not been reported. The model is relatively well described in published 
model appendixes.  
 
(vi) Applications: The model has been widely used mainly to forecast CHD events in whole 
populations, including the US(204, 247), Argentina(203) and China(207). It has not been 
used in patient level cost effectiveness analysis. This appears to be due to the nature of the 
model where is limited scope to assess patient heterogeneity, given limited risk factors have 
been grouped into broad categories. 
 
The Rotterdam Ischemic Heart Disease and Stroke Computer model 
(RISC) 
(i) Conceptualising the model problem: The Rotterdam Ischemic Heart Disease and Stroke 
Computer model (RISC) is an economic model designed to predict the risk of CVD and the 
cost effectiveness of primary and secondary prevention initiatives from the perspective of the 
health sector(248). It is unclear how the model development was funded.   
 
(ii) Conceptualising the model structure: The model was developed from the Rotterdam Study 
a 7-year cohort follow-up of individuals aged 55 years and over. A sample of 3,501 individuals 
was used to construct the model. A Markov state transition model was developed where the 
model predicts the risk of fatal CVD, non-fatal IHD, non-fatal stroke and CVD death within a 
competing risk analysis and using Cox-proportional hazards. Recurrence of non-fatal events 
is possible for up to 4 times, with a fifth event programmed to be fatal. The model cycles 
every 0.1 years and extends for 50 years. While the study data was for 7 years, estimates 
were made for how risk factors changes with age. In turn, as individuals age in the model the 
risk of events increase.  
 
(iii) Data identification and incorporation: There were 24 risk factors included in the Rotterdam 
study and different risk factors were selected to predict different events. Step-wise hazard 
analysis was used to include risk factors, with additional variables added following a tests 
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using the Akaike Information Criteria AIC, which considers the trade-off of predictive accuracy 
from increasing the number of variables from the loss in efficiency. The model can then be 
populated with utilities and event costs taken from secondary sources. This has not been 
published yet, but the appendix to the RISC model details the capability to produce QALE 
and costs saved from CVD events avoided.   
 
The key weaknesses of the model are that the follow-up data is only for 7 years, the model 
does not consider the impact from interventions on extending life expectancy on health 
service costs.  
 
(iv) Uncertainty analysis: Parameter uncertainty is represented by confidence intervals in the 
reported results. The model is programmed to undertake Monte-Carlo analysis. To model 
uncertainty regarding the transition probabilities, 100 bootstrap samples of the study 
population was undertaken. For each model simulation a mean and confidence interval can 
be generated.  The model also allows heterogeneity to be explored in terms of how individual 
risk factors affect the cost effectiveness of outcomes.  
 
(v) Validation and reporting: The internal validity of the model was tested by visually 
comparing the predicting cumulative incidence of events against observed rates, and there 
was found to be close match. This was done for the whole sample, rather than testing the 
models ability to discriminate between individuals.   
 
It is unclear how representative the Rotterdam study is of the Dutch population and therefore 
the validity of the model to be used at a national level. A full on-line appendix details the 
modelling assumptions and in principle the model appears that it could be replicated using 
the appendix. 
 
(vi) Applications: Overall, the RISC model is a rigorous and transparent model that can 
simulate the impact of a wide range of interventions. The model has been used only on one 
occasion to date, including modelling the cost effectiveness of statin therapy(249). In 
corresponding with the senior author the model was being updated and external validation 
was underway.  
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Dutch Chronic Disease Model (RIVM) 
(i) Conceptualising the model problem: The RIVM is a chronic disease policy model that was 
commissioned and held by the Dutch Ministry of Health(250). The model is comprised of 28 
disease models, including COPD, CVD (with CHD and Stroke modelled separately), diabetes, 
and 15 forms of cancer. The aims of the model are to simulate the impacts on life expectancy 
and costs from population interventions aimed at risk factor changes. 
 
(ii) Conceptualising the model structure: The model is a Markov model which predicts the 
proportion of the population that reside in different disease states. The risk factors used in the 
model include age, sex, smoking, blood pressure, cholesterol and BMI. These are 
categorised into three levels and the model first estimates how risk factors change over time 
in the absence of interventions. Overall, the model predicts how risk factors change in the 
population and therefore predicts the proportion of the population that resides in each risk 
disease state of CVD free, CHD, stroke and death. The CHD and stroke states allow for three 
recurrences before an individual must transit to death. The model cycles on an annual basis, 
and runs for 50 years. 
 
(iii) Data identification and incorporation: The model combines cross-sectional and 
longitudinal sources. It is not straightforward to follow how the modelling was undertaken. The 
relationship between risk variables and different disease states are specified as relative risks 
and taken from multiple sources. The model appendix states that the event risks are linear 
and time-invariant.  
 
Further, it appears that no competing risks are included, where the probability of being in one 
state influences the probability of being in another. This would appear to be a major omission 
given the breadth of states included. It is unclear whether and how a ‘fix’ is applied to account 
for competing risk. It is also unclear how predictions are calibrated.  
 
The model simulates the impact of changes to risk factors in terms of incremental life 
expectancy. Adjustments are made for quality of life; however it is unclear how utility weights 
were either derived or taken from the literature. The model also includes the cost of residing 
in different disease states. Given the breadth of co-morbidities that are included perhaps the 
model accounts for the impact on health service from longer life expectancies from CVD 
primary preventions. This isn’t made explicit in the model literature however.  
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(iv) Uncertainty analysis: Parameter uncertainty is represented by confidence intervals in the 
reported results. The model is also programmed to undertake Monte-Carlo analysis. 
 
(v) Validation and reporting: It is unclear whether any validation has been conducted; 
however, model outputs have been calibrated to national health survey data. 
 
(vi) Applications: The model has been used to estimate the cost effectiveness of a wide range 
of preventive interventions, including diet, exercise, smoking and estimating the impact on a 
range of chronic conditions going beyond simply CVD outcomes(251-252).  
 
Coronary Heart Disease Policy Analysis Model 
(i) Conceptualising the model problem: The Coronary Heart Disease Policy Analysis Model, 
was developed 2004 at the London School of Hygiene and Tropical Medicine. The aim was to 
estimate the cost effectiveness of population-wide prevention strategies. The model was 
commissioned by England’s Department of Health(253).                                      
 
(ii) Conceptualising the model structure: The model is closely resembles the CHD Policy 
Model developed in the US. There are three-parts: a primary prevention model and a 
secondary prevention model that was estimated independently, and “linked model” which 
brings the primary and secondary components together. The primary and secondary parts of 
the models exist independently at present. The perspective of the model was from the health 
service with the aim to predict the impact on prevention strategies on quality adjusted life 
expectancy and event costs avoided. 
 
The primary prevention component of the model includes four risk factors, namely systolic 
blood pressure, total cholesterol and smoking. The authors had access to the Framingham 
cohort. However, rather than taking the Framingham coefficients over 10-years as some 
other models have done, they estimated coefficient afresh. A parametric approach was used 
to estimate risk factor coefficients and the authors assumed a Gompertz ancillary parameter 
to allow estimation of CVD risks to change in time. Annual global risk estimates are then 
apportioned to 3 non-fatal CHD events (myocardial fraction, stable angina and unstable 
angina) and two death states (CHD and stroke). Further, the model literature reports that a 
competing risk was undertaken; however, it is unclear how this was done.. Nonetheless, this 
was a very interesting approach and influenced the modelling used within the Scottish CVD 
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Policy Model.  Overall, the model cycles until all-patients reach 85 years and is truncated 
thereafter.  
 
Following a non-fatal event the model then estimates the transition to 6 subsequent states, 
including the treatment states of angiogram, angioplasty, bypass graft, unstable angina 
admission,   myocardial infarction and sudden death. Patients can remain within or move 
between any states. The transition risks and distribution were taken from various datasets 
from national and regional datasets. The treatment arm of the model includes primary and 
secondary care interventions, waiting times, lag times in treatment effects. The model also 
includes intervention specific estimates of treatment uptake and compliance. Estimates are all 
taken from a wide variety of the secondary sources.  
 
(iii) Data identification and incorporation: The model is then populated with a range of English 
sources. Event costs are taken from various English sources for primary care (e.g. GP visits) 
and secondary care (e.g. cost of CABG). Utility adjustments are made for incurring non-fatal 
events, where one utility adjustment is made for any CHD event and another for a stroke 
event. Model predictions are calibrated to the Health Survey for England for 1998.  
 
(iv) Uncertainty analysis: All parameters have associated confidence interventions, and the 
model can undertake an analysis of extremes. 
 
(v) Validation and reporting: Model predictions over 5 years were then validated against the 
Framingham cohort, British Regional Heart study, and a population survey of Bromely. 
Calibration to English lifetables in 1988 was reported, though  it is unclear how this was done.  
The authors state that there was reasonable accuracy but that more will be done in the future. 
In particular, there is no validation of treatment impacts, and there is no test discrimination for 
individual risk profiles.   
 
Model appendices are available on request; however, the justification of the complexity of a 
discrete event simulation is unclear. Overall, the model is potentially very policy relevant and 
appears to be extremely comprehensive. However, the modelling can be quite opaque. 
  
(vi) Applications: To date, the model has not been used and through correspondence with the 
senior author there are no immediate plans to do so. Given calibration is to 1998, the model 
does not appear equipped at present to be used in contemporary settings.  
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NorCaD 
(i) Conceptualising the model problem: The Norwegian Cardiovascular Disease Model 
(NorCad) was developed in 2008(254). The aim was to estimate the cost effectiveness of 
primary and secondary prevention strategies 
 
(ii) Conceptualising the model structure: A Markov model was built simulating individuals 
aged between 30 to 100 years, and cycles annually. Individuals begin from an asymptomatic 
state and are at risk of myocardial infarction, stroke, angina and heart failure. Post first event, 
individuals can transit between any these states or directly to death. Transition risks are 
specific to first and subsequent events, with the latter using tunnel states. The perspective of 
the model was from the health service with the aim to predict the impact of prevention 
strategies that change risk factors on life expectancy and event costs avoided. 
 
(iii) Data identification and incorporation: A wide range of national and international data 
sources are used. The risk factors used to determine transition between states are age, sex, 
smoking status, cholesterol, systolic blood pressure, and diabetes. Transition probabilities 
rely mainly on international registries (longitudinal data) and trials. The relationship between 
individual risk factors and particular event rates is taken from different sources, mainly RCTs. 
However, the method used to calibrate the impact of the complete risk factor set on event 
rates is unclear. Unit costs are derived from Norwegian sources and include primary care and 
secondary care costs. The impact of event rates on resource utilisation (e.g. length of stay) 
was determined by expert opinion. Overall, data incorporation is very complicated, and nearly 
200 parameters are used to estimate baseline risk of events. The model is intended to 
estimate the impact of changes to risk factors on event rates. All outcomes are discounted at 
4% in line with guidance from the Norwegian Ministry of Finance.  
 
(iv) Uncertainty analysis: The model provides confidence intervals and conducts 
heterogeneity analysis by sub-group (ranges of different risk factors). The model can 
undertake extensive sensitivity analysis including one-way, multi-way and probabilistic 
sensitivity analysis.   
(v) Validation and reporting: Internal validation was conducted and outputs of life expectancy 
calibrated to Norwegian life tables where 10 year age bands were used. The model has been 
disseminated and available on-line.  
 
161 
 
(vi) Application of the model: The most comprehensive application of the model was to 
estimate the cost effectiveness of a range of individually administered drugs for primary 
prevention, including aspirin, statins and anti-hypertensives(172). The model has not been 
used to evaluate behavioural interventions, nor multi-factorial interventions.  
  
Cardiovascular Life Expectancy Model 
(i) Conceptualising the model problem: The model was developed in Canada to examine the 
cost-effectiveness of the primary prevention of CHD (rather than also CVD)(255).  
 
(ii) Conceptualising the model structure: A Markov model was constructed where from a CVD 
free state an individual can transit to fatal CHD, non-fatal CHD and non CHD death. 
Following, a non-fatal event an individual can incur CHD death or non-CHD death. The model 
cycles annually and for individuals aged between 35 and 84 years. End-points of interest are 
CHD events and life expectancy.  
 
(iii) Data identification and incorporation: An early version of the Framingham risk scores was 
used that includes the risk factors of age, sex, diastolic blood pressure, total cholesterol, HDL 
cholesterol level, left ventricular hypertrophy, glucose intolerance and smoking status. 
Further, risk is project over 8 years, within annual risks an eighth of the global risk score. 
Non-CHD death was estimated from life tables. Following a first CHD event, the Framingham 
risk score was applied again to estimate further event risks. It is unclear how competing risk 
of events are accounted for, especially given CHD risk and non-CHD death come from 
different sources. 
 
(iv) Uncertainty analysis: Parameter uncertainty is represented by confidence intervals, as are 
final outcomes. An analysis of extremes can be undertaken. 
 
(v) Validation and reporting: The model was not subject to internal validation, but it was tested 
for external validation. The model performed well in external validation predicting outcomes 
observed in Helsinki Heart Study, Multiple Risk Factor Intervention Trial (MRFIT), and the 
Lipids Centre Clinics Coronary Prevention Trial.  This was done by comparing observations 
and predictions across predicted deciles. 
 
(vi) Applications: The model has been used to widely to simulate the potential benefits for 
statins, and diet and exercise for instance by using efficacy evidence in the wider 
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literature(206, 255-258). Outcomes were life years free of CHD and life years saved. It has 
not been used in recent years, and appears to have been replaced by an alternative model 
POHEM, discussed next. 
 
POpulation HEalth Model (POHEM)  
(i) Conceptualising the model problem: POHEM was built by Statistics Canada, with the aim 
of identifying key drivers in the causes of multiple chronic diseases (including CHD, cancers, 
dementia and arthritis)(259).  
 
(ii) Conceptualising the model structure: A discrete event simulation model was developed. 
However, it is unclear how the model was built e.g. statistical estimation, and therefore how 
the model functions e.g. interactions between individuals, disease incidence. This lack of 
transparency may be a function of how complicated the relationships are assumed to be. 
 
(iii) Data identification and incorporation: The variables used in the modelling as risk factors 
for future disease incidence are demographic factors (age, sex etc), socioeconomic status 
variables (e.g. education, marital status, labour force participation, income), more orthodox 
risks factors (e.g., smoking cholesterol, blood pressure, obesity, disease history), health 
system variables (e.g. service delivery) and include a range of health sector costs for events 
and services. The aims are to predict the incidence of events for both individuals and 
populations in continuous time. 
 
The model has been created using multiple longitudinal and cross-sectional datasets; and 
can simulate the cost effectiveness of different interventions, and aims to look at the impact of 
risk factors and disease incidence across the health sector as a whole. Outcomes include 
disease events, life expectancy and disability free life expectancy. Quality adjustment is made 
using the Health Utilities Index III(260). 
 
(iv) Uncertainty analysis: The model can undertake Monte Carlo microsimulation. This 
generate a distribution of the impacts of an intervention(s) and associated mean and 
confidence intervals. 
 
(v) Validation and reporting: There does not appear to have been any validation of the model 
outputs, although it seems reasonable to assume that the model has been calibrated to 
national statistics regarding disease prevalence. 
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Overall, the model appears to be comprehensive in its inputs and intended outputs; however 
but it is equally as complicated. The rationale for building such a complicated structure is 
unclear. 
 
(vi) Applications: The model has used to simulate the economic impacts of several 
cancers(259, 261-265). There are no publications regarding CVD. However, in conversation 
with authors of POHEM a module is being developed specifically to predict the relationship 
between risk factors and myocardial infarction.  
 
PREVENT Model 
(i) Conceptualising the model problem:  The PREVENT Model(266-267) was developed in the 
Netherlands, and pre-dates the RISC model previously reviewed. It is a model that simulates 
the impacts of prevention on CHD, cancers and respiratory diseases. The model is not 
particularly well-reported and in particular it is difficult to verify the model type and how it 
functions. 
  
(ii) Conceptualising the model structure:  The model is described as a microsimulation. 
However, it is unclear what the authors mean by this definition. The model cycles annually 
and events are incurred discretely; where individuals transit from states defined by risk of 
exposure to an event and then consequent death.   
 
(iii) Data identification and incorporation: To inform how individuals transit in the model the 
estimates between exposure to risk factors and events are estimated using a population 
attributable fraction (PAF). However, there are several ambiguities including the data sources 
used to estimate the PAF; the unit is analysis (individuals or cohorts) and how heterogeneity 
is modelled, rather than applying a single PAF to all units. It appears that individuals are 
divided into 10 year age bands where the risk exposure varies between age bands, rather 
than (also) the transition risks to events. It is unclear how costs are incorporated into the 
model. Estimated life years gained from prevention are not quality adjusted. 
 
(iv) Uncertainty analysis: It does not appear that the model estimates uncertainty in 
predictions. However, presumably in estimating PAF confidence intervals could be estimated, 
and it should be straightforward to undertake one way sensitivity analysis or an analysis of 
extremes. 
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(v) Validation and reporting: No formal validation tests have been reported, including 
corroboration of model structure through face validity checks. 
 
(vi) Applications: Simulations of the model have been conducted; however the model does 
not appear to have been used in evaluation.  There have only been two studies that were 
found regarding the application of the model, one to validate its predictions(268), and another 
to simulate the potential benefits of prevention(195).There are no publications in recent years, 
and perhaps other more recently created Dutch models (i.e. RIVM and RISC) may have 
superseded PREVENT.   
 
Prevention Impacts Simulation Model (PRISM) 
(i) Conceptualising the model problem:  The PRSIM model was developed in the United 
States for use initially in Texas, and broaden to the US. The model was developed by a 
Homer Consultancy((209), jointly with the Centres of Disease and Control (CDC). The model 
was developed specifically to inform the prevention of CVD, both primary and secondary.  
  
(ii) Conceptualising the model structure:   The model is described as a Systems Dynamics 
(SD) model, and simulates multiple risk factors, direct and indirect impacts on behaviour, the 
impacts on mortality and consequent impacts on health service costs. It is not clear why a SD 
model was used, as the advantages of using this approach do not seem to have been taken 
advantage of. That is, the modelling framework can be intuitively appealing to model non-
linear relationships, continuous-time interactions, feedback loops and tipping points. None of 
these features appear to have been used to date.  
 
(iii) Data identification and incorporation: The model uses cross-sectional data sources dating 
from the early 1990s, in order to specify the US population of risk factors and proportion of 
population who have CVD. The model uses a wide range of risk factors and estimates of the 
relationship between risk factors and events are taken from the literature, and include the 
Framingham score from 1991 (the first score developed for primary prevention, as discussed 
in Chapter 2), and add other variable such as exposure to second hand smoke and access to 
junk food, though its less clear how transmission risk were estimated for these variables. 
Individuals in the model are grouped by age category and sex, and simulated as units that 
age in the model. While not explicitly stated, it is assumed here that the model also simulates 
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demographic changes so that cohorts are renewed by the next generation.  Only intervention 
CVD events costs were included. 
 
(iv) Uncertainty analysis: In the one demonstration of the model to date(209), mean estimates 
are varied in a scenario analysis. However, no reporting of stochastic or parameter 
uncertainty is given. The focus of the model is to simulate impacts on the population, rather 
than investigating heterogeneous impacts.  
 
(v) Validation and reporting: The model is has not been validated before use. The model 
reports that calibration has been performed, however it is unclear how or on which outcomes. 
The absence of an appendix means that reporting is limited. 
 
(vi) Applications: The model was used to simulate the potential impacts of 19 interventions on 
the population as a whole; including improved air quality, improve mental health services, 
regulation changes. The model found that 15 interventions could be cost saving.  
 
Archimedes 
(i) Conceptualising the model problem:  The Archimedes model was developed in the United 
States, and is owned by a Kaiser Permanente, a private Managed Care Organisation. The 
model was developed over a period of five years and involved a wide number of specialists in 
term of academic background (including natural scientists, computer programmers, 
mathematicians, economists), and  professions (including medics to health service managers, 
policymakers). The ambitious aim is to create a ‘virtual world’ and simulate the entire US 
health care system, including the future disease rates and health services implications(269). 
The model is in continual evolution. 
  
(ii) Conceptualising the model structure:  The Archimedes model is a large-scale simulation 
model that attempts to simulate the whole health care system in the United States. The model 
essentially operates as a series of interrelated modules, including physiology, disease, and 
health care systems. The model simulates individuals and is incredibly detailed. The 
physiology model is detailed down to the organ and chemical level when simulating risk 
factors. Currently, the model includes coronary artery disease (CAD), stroke, diabetes and its 
complications, congestive heart failure, obesity, smoking, asthma, and the metabolic 
syndrome in a single integrated model.  The health care systems model also models 
individuals and individual events to then predict downstream clinical events, utilization, and 
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costs, including signs and symptoms; patient encounters with the health care system (e.g. 
emergency room visits, office visits, and admissions); protocols and guidelines; tests and 
treatments; patient adherence to treatment recommendations; and clinical events that affect 
logistics, utilization, and financial costs.  
 
While there are three modules there are inter-relationships between modules and between 
different risk factors, diseases and health care utilisation. Relationship are estimated in 
continuous time through a set of ordinary and differential equations that represent the 
physiological pathways pertinent to diseases and their complications. The model is run on a 
network of computers. 
 
(iii) Data identification and incorporation: The model uses person-specific data from real 
populations (e.g. the National Health and Nutrition Education Survey [NHANES]) to create 
simulated populations that match the real populations, person by person. Each individual can 
be matched to variables such as demographics, risk factors, biological variables, current and 
past medical histories, and current treatments.   
 
(iv) Uncertainty analysis: The model reporting to date is for mean estimates, and 
heterogeneity rather than parameter uncertainty. However, given the authors of the model, it 
is assumed that a full parameter uncertainty analysis is feasible.  
(v) Validation and reporting: The model’s accuracy is checked by using it to simulate clinical 
trials that have been conducted in the real world and comparing the predicted results with the 
real results. This has been done successfully for several hundred treatments and outcomes in 
48 randomized controlled trials thus far.  
 
(vi) Applications: The model appears to be used (or is at least reported) on the sub-model 
defined by disease areas. For example, the diabetes model has generated a range of 
publications(270-271). There is one publication to date with respect to the impact of statin 
treatment on asymptomatic individuals(272). 
 
 
3.8.3 Additional modelling approaches of relevance 
In addition, to identifying policy models capable of economic evaluation, the systematic 
review also identified an important paper that was influential to inform the approach that was 
taken ultimately creating the Scottish CVD Policy Model, discussed in the next chapter. This 
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was a model developed in the UK in 2004 with the aim of developing a clinical tool that could 
predict the life expectancy based upon CVD risk factors(273). The rationale was to replace 
10-year risk scores and identify individuals at risk of premature death. Further, the aims of the 
model were to respond to perceived weaknesses in other models that the impact of smoking 
should be modelled using the competing risk of non-CVD death; and should have the ability 
to discriminate between individuals rather than modelling the impact of interventions at the 
population level. 
 
A Markov model was constructed that used the Framingham 10-year risk score CVD and is 
intended to be used for subjects aged between 35 and 85 years. First, linear interpolation 
was used to estimate the annual risk of CHD, and this was divided equally into four first 
events, namely myocardial infarction, other CHD, stroke and other CVD. All cause death was 
modelled conditional upon incurring one of the first four events rather than as a competing 
first event risk. Post-first event individuals either remain in the current state (no secondary 
events were modelled) to transit directly to death. The annual risk of death was taken from 
various secondary sources. Adjustments for death risk conditional upon smoking status was 
estimated using relative risk estimates from the US Cancer Society’s 4 year follow-up. 
Relative risks were applied on an annual basis. The model cycles until all individuals are 85 
years old.  The model generated predictions of life expectancies using the Health Survey for 
England (1998) 
 
The model was not designed to generate economic information in terms of quality 
adjustments to life expectancy estimates or costs. Further, the model also does not illustrate 
the benefits from changes to modifiable risk in terms of additional life expectancy. However, 
this could easily be done using secondary sources that other models have used (e.g. Barton 
et al) and simply simulate the impact of changes to say smoking status. The life expectancy 
predictions have been externally validated using the Wickham study (from the 1970s) which 
was nationally representative survey of adults 18 years and over, where asymptomatic 
individuals were followed-up for 20 years. The model accurately replicated the results from 
this survey and showed an ability to discriminate accurately between 35 different covariate 
subgroups.  
 
Overall, the key strength of the model was in creating a model using a risk score in current 
practice in England and having an ability to predict life expectancy at both the population and 
individual level. The model is also simple and the estimation procedure was very clear. A 
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weakness was that model could have taken an extra step and estimated the potential lifetime 
benefits from changes to risk factors. Further, the scope of the model could have been 
widened to develop a full economic model and simulate the cost effectiveness of primary 
interventions.  
 
In referring back to the model’s developed by NICE PDP and EUROACTION these groups 
could have developed similar methods to estimate the lifetime impact of the intervention. The 
cost in not doing so may have led to the EUROACTION team concluding that the intervention 
was not cost effective. 
 
3.8.4 Relevant models found in the grey literature 
In addition, an opportunistic search of the grey literature was undertaken for policy 
organisations that may not have published in academic journals (or not yet). These models 
are not reviewed in detail, but it is important that chapter acknowledges their existence, 
development and possible applications. The search included website of the World Bank, 
WHO and OECD. Further, the search of the UK database ‘Idox’, which collates UK based 
policy documents, was made. There was prior awareness of England’s Department of Health 
economic model that was used to simulate the potential cost effectiveness of England’s mass 
screening population to identify high risk individuals for intervention.  
 
WHO / OECD Chronic Disease Prevention Model  
The OECD, in collaboration with the WHO, developed a dynamic micro-simulation model 
named the Chronic Disease Prevention to assess the health outcomes, impact on health 
expenditure, and cost-effectiveness at the population level. The structure appears to be a 
microsimulation model designed to simulate the behaviours and life histories(19-20). The 
models scope is global, and the associated literature suggests that the model simulates 4 
billion individuals from 30 countries and across all 5 continents. The model is information 
intensive requiring information on demographic and socioeconomic conditions, health-related 
behaviours, and current and past disease history. The interaction between risk factors and 
disease is modelled dynamically and in continuous time.  The intended application of the 
model is to be the first model to address obesity and chronic diseases as a global issue. 
 
PRISM – Prevention Impacts Simulation Model  
PRISM is a system dynamics (SD) simulation model for evaluating multiple approaches to 
preventing and managing cardiovascular risks, developed by Centers for Disease Control and 
169 
 
Prevention and the National Institutes of Health (Homer et al. 2010; Homer et al. 2008). SD 
models help decision makers anticipate the likely effects of interventions in dynamically 
complex situations, where the pathways from interventions to outcomes may be indirect, 
delayed, and possibly affected by nonlinearities or feedback loops. PRISM has been used in 
the US by public health leaders at the national and local levels to inform strategic planning, 
and will soon be broadly available as a web-based tool. It is also being used by the US 
government for evaluation of the half-billion dollar, 50-community stimulus program known as 
Communities Putting Prevention to Work.  
 
PRISM, like most SD models, is compartmental, operating at the level of population 
subgroups rather than individuals, and consists of hundreds of interconnected differential and 
algebraic equations. PRISM incorporates data from many sources to represent leading 
cardiovascular risk factors in adults, including key chronic disorders (hypertension, 
hyperlipidemia, and hyperglycemia), smoking (and former smoking), obesity, diet, exercise, 
and psychological distress. It also represents obesity, diet, and exercise in children. Dynamic 
stock (state) variables are used to model changes in the prevalence of many of these risk 
factors and in the total population. The population is subdivided by gender, age group 
(children ages 2-5y, 6-11y, and 12-17y; adults ages 18-29y, 30-64y, and >65 y), and 
cardiovascular disease status (non-CVD, post-CVD).  
 
Multi-level Modular Agent-based Modelling for the Study of Childhood Obesity  
This is a multi-level modular individual-based model currently in development by the Center 
on Social Dynamics and Policy at The Brookings Institution(106-107). It is motivated by the 
complex set of drivers that are implicated in the obesity epidemic. Increasing calls for 
multilevel studies and systems approaches to obesity reflect a widespread perception that 
research paradigms focused on single factors in isolation have failed to provide the insights 
needed to stop the growing epidemic. The goal of this project is the development and 
application of a novel modular agent-based modelling approach for the multilevel study of 
childhood obesity. The technique of agent-based computational modelling (ABM) offers 
unparalleled flexibility to incorporate individual heterogeneity, complex social structures, and 
a range of dynamic adaptive behaviours. Our multi-level modular approach permits modelling 
of multiple mechanisms simultaneously, across several levels of scale, with inclusion of 
important sources of diversity. This effort is part of the newly assembled Comparative 
Modelling network of the National Collaborative on Childhood Obesity Research (a joint 
venture of the National Institutes of Health, the Centers for Disease Control, the US 
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Department of Agriculture, and the Robert Wood Johnson Foundation). In addition to 
directing modelling on the Brookings/McGill project, Hammond serves on the steering 
committee of this innovative network which is applying diverse systems approaches to the 
common topic of childhood obesity. 
 
3.7 Summary of the strengths and weaknesses of existing 
policy models 
The models that were reviewed all have merits. There purpose of this section is to attempt to 
collate common themes in terms of strengths and weaknesses that can be used to inform the 
development of the Scottish CVD Policy Model.  
 
All models share take a health sector perspective to assess the cost effectiveness of 
interventions, with the exception of DisMod and the CHD Policy Model that estimate the 
broader macroeconomic consequences from risk factor changes. However, quite how this is 
done is not clear.    
 
The modelling approaches differed considerably; with respect to risk factors used, event 
focus (CHD or CVD), model structure (Markov models, discrete event simulations and tabular 
models), datasets used (cross sectional, longitudinal), reliance on secondary data sources, 
the final outcome focus (life expectancy, QALYs, DALYs, disability free years), the extent of 
sensitivity analysis and validation undertaken.   
 
Notable strengths of the NICE PDG and Australian CVD Model were that the models are 
simple and transparent; and to estimate the transition from an asymptomatic to a CVD state 
they used the Framingham risk coefficients that are used in clinical screening. The model 
developed by the authors evaluating EUROACTION also used the Framingham score. 
However, the projections of outcomes for all three of these models were limited to the 10 
years.  A key strength of the CHD Life Expectancy model was the extensive external 
validation that was conducted on three trials. This was the only model to have done so.  
 
All models share key weaknesses. No model estimates the impact of extending life 
expectancy on health service costs. That is, the costs considered are only the avoidance of 
the particular event, net of any intervention costs. However, prevention should really be 
termed the prevention of premature events, as interventions essentially delay mortality and 
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most individuals will eventually die of CVD, cancers or respiratory diseases. Further, 
extending life expectancy tends to result in a rise of co-morbidities and an increase in use of 
health sector resources. This presents a genuine challenge for the health sector, on a par 
with fears of an obesity epidemic(45). The co-morbidities that accumulate include the ‘big 
killers’ (see figure 2-1) of CVD, cancers, and respiratory diseases (e.g. COPD), but extend to 
a wide number of other conditions including musculoskeletal to mental health problems (e.g. 
depression) which can also greatly affect quality of life(45-46).  
 
Health care systems are in general set up to detect and respond to single diseases(46), and 
yet as the population ages it is increasing recognised that, it is multimorbidity, defined as 2 + 
conditions(47), that it is greatest concern to health service planners(45). In Scotland, the 
prevalence of multiple morbidity quadruples from 8% in the 20-44 year old to 33% in those 65 
years and over(47). Further, there is a stark deprivation gradient(46-47). The onset of 
multimorbidity occurred 10–15 years earlier in people living in the most deprived areas 
compared with the most affluent, with socioeconomic deprivation(46).  
 
Overall, it is contended here that economic evaluation needs to account for the impact of 
longer life expectancy on patient quality of life and the impact of health service costs when 
assessing the cost effectiveness of primary prevention interventions. Put another way, 
primary prevention may be part of a solution to address an obesity epidemic, but in so doing 
a potential consequence is to contribute to the concern of ageing populations and 
multimorbidity. Otherwise, it may be erroneous of economic evaluation to infer that an 
intervention is cost effective with respect to health sector resources if the impact of longer life 
expectancy is not considered. An integrated systems approach to prevention, service 
planning and evaluation may be a more productive approach rather than a traditional focus 
on disease silos(45-46).  
 
Economic modelling can help inform this exercise. The risk factors that CVD prevention 
seeks to address are also important in explaining the onset of a full range of chronic disease, 
including cancers and respiratory diseases etc. There is a need to inform CVD policy, but 
also use a model to help inform wider chronic disease policy, including the implications of 
interventions beyond CVD. 
 
Finally, a common weakness is that external validation and predictive validation is rarely 
done. No models, even those that have been in existence for some time, have undergone 
172 
 
cross-validation checks. Further, the practice of fully reporting and disseminating the model 
and assumptions is inconsistency done. 
 
3.8 The need for a Scottish CVD Policy Model 
To reiterate, policymakers are presently focused on a dual approach to primary prevention 
which includes a population policies and more recently the focus has been on a targeted 
approach on screening population to identify and treat high risk individuals. Chapter 2 
formulated three key research questions that remain, namely: (i) how to identify the optimal 
screening approach if 10-year risk scores continue to be used? (iii) how to develop an 
approach to prioritisation based on potential benefit rather than risk? and; (iii) how best to 
combine targeted and population wide interventions to reduce premature mortality, morbidity, 
reduce health inequalities. Existing policy models are not ideally placed to address these 
issues, and this is particularly the case for Scotland.  
 
For a model to inform both the targeted and population approach to primary prevention it 
needs to use the same risk factors as employed by clinicians to screen and prioritise 
individuals. In Scotland, the ASSIGN risk tool is used, and no existing models use these 
variables. 
 
It is important that the policy model can also estimate the lifetime impacts of interventions on 
life expectancy, quality adjusted life expectancy, health inequalities and health service costs. 
No existing model can produce all of this information.   
 
Further, in considering how a Scottish CVD Model should be built the approach can usefully 
follow the latest ISPOR Guidelines. From the literature review of existing models the major 
weakness concern validation and reporting. Most models perform internal validation, however 
external and predictive validity is rarely performed. Yet, this is vital if there is to be confidence 
in model predictions. Finally, it is important to attempt to produce comprehensive outputs 
from a model that is simple to understand and disseminate. Existing models perform 
inconsistently. There tends to be a relationship where as the demands on a model increase 
the more complicated and less transparent it becomes.   
 
Overall, there is a need for a Scottish CVD Policy Model that can provide congruence 
between clinical practice in the way individuals are prioritised, and with evaluation and policy 
173 
 
in the way interventions impacts are judged and decisions made. In developing the model 
there is scope to learn from the strengths and weaknesses of existing models in an attempt to 
follow the latest ISPOR Guidelines as well as possible. 
 
3.9 Summary 
The chapter was focussed on the role and application of modelling, and how these can be 
applied to help generate the economic evidence required by health technology agencies to 
help inform value for money decision making.  
 
Models are not a substitute for trials, but rather best used hand-in-hand.  Trials are often 
short term and focussed on internal validity, and models can be used to extrapolate findings 
and help generalise findings.   Whereas models are unavoidable in many situations in order 
to produce economic information, there are many potential pitfalls in developing a model. 
Best practice guidance exists to help the modeller design, populate and disseminate models 
that are fit for purpose, user friendly and encourage peer review.  There are a dozen policy 
models in existence and they vary quite markedly, such as the type of model employed, and 
the evidence produced. Most models have been used to help inform primary prevention either 
through undertaking evaluation using trial evidence, or conducting what-if simulation 
exercises.  Judged by best practice guidelines these models perform inconsistently. All have 
strengths, but also share common weaknesses such as lack of assessment of lifetime health 
service costs from prevention that extends life expectancy.  
 
No existing policy model is ideally suited for use in Scotland.  A key policy concern is health 
inequalities and the ASSIGN risk tool was developed that includes socioeconomic deprivation 
as a risk variable to detect the underlying social gradient in CVD incidence. It is important that 
a policy model builds upon this work to use the ASSIGN variables also in the underlying 
projections. This would then provide a degree of congruence between policy aims, clinical 
practice and how interventions are evaluated. Further, in attempting to build a Scottish CVD 
Policy Model there is scope to develop, test and communicate a model that can meet the 
latest standards of best practice. 
 
 
 
 
174 
 
Part 2 – Building the Scottish Cardiovascular 
Disease Policy Model 
Overview 
In taking stock of the thesis so far, the Scottish Government has made the primary prevention 
of cardiovascular disease (CVD) a national priority; with the overall objectives to reduce the 
premature morality, morbidity, avoid associated downstream resource costs and tackle health 
inequalities. Chapter 2 identified uncertainty regarding three key issues, including: what is the 
optimal screening strategy is to identify high risk individuals; how to move away from risk 
scores to develop a screening approach where individuals are prioritised for intervention on 
the basis of potential benefit; and how to choose between or rationally combine targeted and 
population interventions. It was contended that economic evidence should underpin all three 
issues, however this evidence can be lacking.  Chapter 3 then discussed the key role of 
modelling to help develop the economic evidence base, but that there was a need for a new 
comprehensive economic model that could be used in Scotland to address the key issues 
above, and inform the development and evaluation of interventions.  
 
The purpose of Part 2 of the thesis is to develop the Scottish CVD Policy Model in an effort to 
influence the approach to primary prevention in Scotland. Chapter 4 details how the model 
structure was developed and the statistical approach to estimating individuals’ life expectancy 
from a set of risk factor variables. Crucially, the model uses the same variables employed in 
the ASSIGN 10-year risk score, which is used in Scotland to screen and prioritise individuals 
for intervention. This approach is intended to provide a degree of congruence between 
clinical and economic models, such that the same variables used to prioritise individuals can 
now be used evaluate interventions aimed at modifying risk factors to extend life expectancy.  
Chapter 5 details how estimates of life expectancy are quality adjusted to generate quality 
adjusted life expectancy (QALE), and also how lifetime hospitalisation costs are estimated. 
The chapter ends by illustrating how the model can be used to undertake economic 
evaluation to estimating the impact of changes to modifiable risk factors on life expectancy, 
quality adjusted life expectancy, life hospital costs and the impacts on health inequalities. 
Estimates can be undiscounted or discounted. The overall intention of Part 2 is to describe 
that the model is fit-for-purpose and ready to be used to inform the development of and 
selection of interventions that may produce best value for money.  
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Chapter 4: Estimating life expectancy from risk 
factors 
4.1 Introduction 
The overall objective of the Chapter is to describe the statistical approach to building the 
Scottish CVD Policy Model and how life expectancy estimates are generated. The structure 
of the chapter largely follows the five stages to building and reporting an economic model that 
were discussed under best practice guidelines in Chapter 3. The conceptualisation of the 
model is discussed in section 4.2, followed by section 4.3 which describes the model 
structure. Section 4.4 then details the main dataset used to develop the model, and discusses 
the statistical approach taken to convert risk factors into lifetime risk of CVD and estimates of 
life expectancy.  The ability of the model to investigate uncertainty in predictions is discussed 
under Section 4.5, before the chapter describes how predictions were validated and 
recalibrated to contemporary Scottish lifetables. Finally, section 4.6 concludes with a 
discussion of the main strengths and limitations of the approach adopted.  
 
4.2 Modelling stage 1: Conceptualising the model problem 
The policy context and rationale behind creating the model was to respond to the perceived 
need for a Scottish specific model (as discussed in Part 1 of the thesis) capable of influencing 
the entire approach to primary prevention. Existing policy models vary in terms of their 
comprehensiveness and transparency, and none can fully assess the impact of interventions 
on reducing inequalities. The main funds that were used to help develop the model came 
from the Chief Scientist Office (CSO) of Scotland that funded a two-year project.  The CSO 
project included funds to help bring together a team of experts and stakeholders on 4 
occasions over the 2-year period. This enabled on-going discussion among experts regarding 
the focus, structure and functioning of the model problem.  
 
The decision problem under consideration was to help guide clinicians and policymakers to 
develop and chose interventions offer best value for money in the primary prevention of CVD. 
The CSO did not put any restrictions on the modelling process. The model scope was the 
primary prevention of CVD and on adults. 
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A key objective was to build the policy model using the nine risk factors employed in the 
ASSIGN 10-year risk score that is used in clinical practice in Scotland to screen individuals 
and prioritise the high risk (≥ 20% risk of a CVD event over 10 year) for intervention. The aim 
was to access the underlying data sources that were used to create ASSIGN and re-estimate 
the coefficients for the nine risk factors to predict lifetime CVD risk, (quality adjusted) life 
expectancy and lifetime health service costs by predicting all events, CVD and non-CVD. 
Consequently, the model is intended to estimate the impact of changes to modifiable risk 
factors on lifetime CVD risk, (quality adjusted) life expectancy and lifetime health service 
costs.  
 
This approach to building the policy model uses the ASSIGN risk factors then provides 
consistency between how individuals are identified and prioritised in clinical settings for 
interventions, and then approach to estimate the impact of interventions over an individual’s 
lifetime. By taking a generic modelling approach (i.e. using a wide set of risk factors to predict 
a comprehensive set of outcomes) the intention is that the policy model could potentially 
inform the entire approach to primary prevention and to function as a: clinical screening tool 
and as an evaluation tool to assess the cost effectiveness single and/or multi-factorial 
interventions and those that are targeted on high risk individuals and/or the whole population.  
 
The perspective taken was that of the health sector. Consequently, the model assesses the 
impact of interventions on health outcomes and costs incurred by the health service. This is 
the standard approach of cost utility and cost effectiveness analysis. However, this is a 
restricted set of outcomes compared to a societal perspective that attempts to account for all 
impacts, extending beyond health sector considerations, such as the impact on carers and 
estimating knock-on productivity impacts. A cost effectiveness approach assumes that health 
sector decision makers are only interested in outcomes that impacts on patients and health 
sector budgets. 
 
The target population in terms of the recipients of the interventions was asymptomatic adults, 
both men and women. The key policy focus in Scotland is on a targeted approach from 40 to 
74 year old individuals and the illustration of model also focuses on these groups for 
exposition. However, an important aim was to develop a model that could estimate the impact 
of both individually targeted and population interventions.  
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The intention was that the model should produce outcomes consistent with the aims of 
prevention, namely: to reduce premature morality, morbidity, avoid associated downstream 
resource costs and tackle health inequalities. Consequently, the model is intended to 
estimate the impact of changes to modifiable risk factors on life expectancy, quality adjusted 
life expectancy, lifetime hospital costs and the how these outcomes differ by individuals 
identified by socioeconomic deprivation. Estimates are intended to be either undiscounted or 
discounted. Producing these outcomes prepares the model to be used in economic 
evaluation. 
 
The time horizon of the model is over an individual’s lifetime, in an attempt to project the full 
impact of interventions. The aim was also to build a model that can cycle on an annual basis. 
Annual cycles with a half-cycle correction was felt sufficient by the advisory group to estimate 
the risk of events and life expectancy.  The key application of the model, as will be discussed, 
is how to estimate the cumulative life expectancy (and costs) at baseline screening, and how 
this changes if risk factors are modifiable. It was felt that a time step of 1 year with half cycle 
correction was sufficient to enable cumulative life expectancy estimates, and these were 
calibrated to contemporary lifetables. 
 
4.3 Modelling stage 2: Conceptualising the model structure 
In conceptualising a model structure the guiding principles where the delivery of the 
outcomes discussed above but parsimony: that is, to build a model that is fit for purpose but 
also as simple as possible relative to these objectives. The model structure that was 
developed was the result of an iterative process between clarifying the modelling problem 
and exploring the available datasets.  Consistent with the best practice guidelines discussed 
in Chapter 3, the structure of the resultant model is presented first, before discussing data 
sources and statistical approaches to populating the model. This presentation order is 
intended to set the direction of travel regarding intended model outputs, and to develop 
rationale regarding the decisions taken in choosing source data and statistical methods. 
 
To build the model four features were of key importance. First, there was the need to 
estimate the risk of a first CVD event and the consequences for life expectancy. Second, in 
estimating the first event the expert panel advised disaggregating CVD into non-fatal and fatal 
events. The expectation was that incurring a particular type of event has different 
consequences for subsequent life expectancy. Third, to estimate overall life expectancy there 
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is a need to take into account the competing risk of death from non-CVD events. The risk 
factors that drive CVD are also in common with the other main mortality causes such of 
cancers and respiratory diseases. Fourth, a key simplifying feature of the model is that once 
an individual has incurred a first event the model directly predicts the consequences for life 
expectancy. This feature is congruent with primary prevention and avoids the need to model 
recurrent events and the consequences for life expectancy conditional upon the number of 
events incurred. The key is having an adequate dataset to enable the generation of accurate 
event and life expectancy predictions. As will be discussed shortly, the modelling was done 
using a longitudinal dataset with lifetime patient histories, thus providing the opportunity to 
estimate life expectancy direct from the first event.  
 
Figure 4-1 illustrates the structure of the resultant policy model. A state transition model was 
developed, where individuals enter the model at screening and are CVD event free. 
Subsequent event states are represented by ovals and transitions between states are 
denoted by arrows and the model cycles on an annual basis. 
 
An individual enters the model CVD-free and in each annual cycle of the model the individual 
has five options: to remain in a CVD-free state or move to one of the four first events: non-
fatal Coronary Heart Disease (CHD), non-fatal Cerebrovascular Disease (CBVD), fatal 
Cardiovascular Disease (CVD), and fatal non-CVD. If the first event was non-fatal, then an 
individual transits directly to death (from all cause).  
 
The nine ASSIGN risk factors were divided into non-modifiable and modifiable risk factors. 
The distinction refers to which risk factors can be directly augmented via intervention with the 
expectation of delaying the onset of events and improving life expectancy. Non-modifiable 
risk factors include; age, sex, diabetes, family history and SIMD. Modifiable risk factors 
include: systolic blood pressure, total cholesterol, HDL cholesterol and cigarettes per day 
were defined as modifiable. The risk of first events is driven by all nine ASSIGN risk factors, 
and the risk of death post first event is driven by non-modifiable risk factors. This will be 
further explained shortly. Finally, separate models were built for men and women, in the 
sense that while the structure of the model was retained equation 1 and 2 were estimated 
conditional upon sex. 
 
In general, a simple state transition model structure was developed. However, it is not a 
Markov model which is often used interchangeably with the term state transition model.   As 
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will be discussed in detail as the chapter progresses the model combines the transparent 
structure of a state transition model with features most commonly associated with certain 
other models in terms in terms of how the model functions. In effect, a ‘hybrid model’ was 
developed using the terminology of the best practice guidance that was discussed in Chapter 
3. 
 
Figure 4-1 Scottish CVD Policy Model – estimating life expectancy 
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Equation 1: Function (age at survey, SBP, TC, HDL, CPD, family history, SIMD) 
 
Equation 2: Function (age at event, family history, SIMD) 
  
 
4.3 Modelling stage 3: Data identification and incorporation  
The dataset that was used was an extended version of the longitudinal dataset used in 
creating the ASSIGN 10-year risk score. The dataset consists of two separate parts, which 
were combined into one longitudinal dataset: a baseline dataset containing CVD risk factors 
for individuals free of CVD linked to dataset that recorded all hospitalisations (CVD and non-
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CVD events) and death. Each dataset is described in turn before discussing the data linkage 
that was made.  
 
4.3.1 Data identification  
 
Scottish Heart Health Extended Cohort (SHHEC) – baseline screening: 
The baseline dataset was called the Scottish Heart Health Extended Cohort (SHHEC).  
SHHEC recruited from overlapping random samples of the Scottish population in the 1980s 
and 1990s. The Scottish Heart Health Study(124, 274). recruited random samples of men 
and women (aged 40–59 years) across 25 districts of Scotland from 1984 to 1987. The 
Scottish MONICA Project(275) which recruited in Edinburgh and north Glasgow in 1986, 
(ages 25–64) and North Glasgow again in 1989 and 1995 (ages 25–64), and 1992 (ages 25–
74).  
 
All individuals in SHHEC attended a survey clinic. Individuals were identified as “CVD free” if 
they did not report having had CVD events in the past. To reiterate, nine cardiovascular risk 
factors were recorded. These included age at survey, sex, self-reported diabetes, self-
reported family history of heart disease, residential postcode, systolic blood pressure (mm 
Hg), total cholesterol (mmol/l), HDL cholesterol (mmol/l), and cigarettes smoked per day. 
Family history was defined as whether either parent or any siblings had developed heart 
disease below age 60. The postcode was used to give an individual a deprivation score.  
Deprivation in Scotland is measured through the Scottish Index of Multiple Deprivation 
(SIMD). This is an aggregated measure of material deprivation derived from 37 indicators in 
seven domains (income, employment, health, education, access to services, housing and 
crime). This is determined at datazone level (postal geographical areas with a population of 
769). Overall, an important feature of the data is that the modifiable risk factors were all 
measured on a continuous scale. This is important when considering a modelling approach, 
discussed shortly.  
 
Scottish Morbidity Records (SMR) – all hospitalisations 
Patient records: The Information Services Division (ISD) of National Health Service (NHS) 
Scotland maintains an electronic database called the Scottish Morbidity Records (SMRs). 
This records all hospitalised events, cancer registrations and discharges from NHS hospitals 
in Scotland. Each individual in the dataset is given a unique patient identifier. SMR hold 
information including the reason for the visit, up to five secondary diagnoses, length of stay 
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and waiting time. Emergency, transferred and elective admissions are included in total 
hospital admission. The SMR are collated into 7 categories defined by the primary reason for 
contact (admission or discharge) – see Table 4-1 
 
Table 4-1 Scottish Morbidity Records 
SMR Scheme Code Record type 
SMR 00 Outpatient 
SMR01 General/acute inpatient/day case 
SMR02 Maternity 
SMR04 Mental health inpatient/day case 
SMR05 Geriatric (long stay) 
SMR06 Cancer register 
SMR11 Neonatal discharge 
Source: Scottish Morbidity Records 
 
Specific hospital events with each SMR scheme code are defined according to the 
International Classification of Disease (ICD). ISD provide guidance as to which codes refer to 
which diseases to enable continuity in tracing incident cases. ISD hold records from 1980.  
 
Process and timeliness: Hospital records are first collated at the regional level by the 14 
Scottish Health Boards.  Records are submitted to ISD every 6 weeks (or 42 days).  
 
Completeness: Historically, audits have shown 99% completeness on average over time. The 
latest set of data available was for 2009 and showed 100% completeness(276).   
 
Accuracy: ISD maintains a high degree of accuracy of SMR records by applying a set of 
validation rules to all SMR records, both locally, prior to submission to ISD. Each SMR record 
is checked against the validation criteria and, should errors and/or queries be found, 
appropriate messages are generated to indicate the cause of any error or query(277).   
Validation includes both simple and more complicated checks. Simple validation includes 
checking whether a recorded postcode exists on the U.K. national postcode directory. 
Complicated validation includes performing a cross-check of several data fields such as 
checking whether the consultant attributed to an episode worked in the provider at the time of 
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admission). Further, checks can require additional calculations (e.g. whether patient age at 
admission was consistent with the diagnosis).  
 
4.3.2 Data incorporation: Linking SHHEC and SMR  
 
ISD Linkage facility 
ISD's Record Linkage (RL) team(278) provides a specialist data linkage service to clinical and 
academic staff and their researchers. ISD regularly produce linkages between baseline 
datasets such as the Scottish Health Survey(78) and the SMR. In addition, the RL team are 
also remitted to consider requests from researchers to link other source dataset with SMR 
records 
 
Previous linkage 
SHHEC participants then gave permission to be followed up through routine record linkage. 
ISD subsequently, linked SHHEC to SMR.  Previous linkages of SHHEC-SMR occurred in 
1993, 1997 and 2006, keeping the same baseline but updating with new hospital records. 
This latter dataset was used to develop the ASSIGN score.  
 
Opportunity for further linkage  
At the time of developing the model and identifying SHHEC-SMR as the key data source, the 
latest SMR records available were until end-2009. This provided the opportunity for a linkage 
that was three years more that the linkage made by the creators of the ASSIGN score. 
 
An application for updating the SHHEC-SMR linkage until end-2009 was then made to the 
Privacy Advisor Committee (PAC), in collaboration with Professor Hugh Tunstall-Pedoe, one 
of the original creators of ASSIGN. Unlike the application made to create the ASSIGN score 
which only linked to CVD event, a request was made to SHHEC patients for all admissions, 
recorded in SMR01 (general/acute), 04 (mental health) and 06 (cancers) – see Table 4-1 
above.  
 
Managing the dataset 
The dataset was received in STATA 11. All manipulation and analysis of data was also done 
using STATA 11. Each individual had a unique identifier within SHHEC and SMR. To identify 
a first CVD event any diagnosis of CVD was taken whether this was the primary reason for 
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admission, a secondary diagnosis or an event within a hospital episode. If death occurred 
within 28 days of a CVD event this was classified as fatal, otherwise this was classified as a 
non-fatal event. 
 
Manipulating the dataset I: events of interest 
Consistent with the model structure (Figure 20) individuals within the dataset were stratified 
according to what the first event was: non-fatal CHD, non-fatal CBVD, fatal CVD, fatal non-
CVD.  The corresponding ICD codes are shown in Table 4-2. 
 
Table 4-2 ISD codes used in the model 
Event of interest ICD codes 
CHD ICD9 410-414; ICD10 I20-I25 
CVBD ICD9 430-438; ICD10 G45, I60-I69 
CVD death ICD9 390-459; ICD10 I00-I99 
Non-CVD death Any death except: ICD9 390-459; ICD10 I00-I99 
 
A first CVD event was defined as the first recording of CVD in any diagnostic position, 
whether the primary cause for entering hospital (1st diagnostic position), and also CVD events 
experiencing within a single length of stay, or events incurred outside of hospital and 
recorded by SMR as a comorbidity. 
 
Manipulating the dataset II: Missing data  
The ISD records were complete. However, there was missing data in the ASSIGN risk factors 
for 24% of individuals, in one of more of the ASSIGN risk factors. Missing data were primarily 
limited to cholesterol (total and HDL) as a result of SHHEC participants refusing bloods to be 
taken by the nurse.  
 
Missing data was addressed by using the multiple imputation of chained equations technique 
(MICE) (279). Intuitively, this method estimates the relationship between risk factors 
variables, by setting up a series of regression equations where each risk factor in turn is a 
dependent variable and regressed on all the others variables. The process then cycles 
through all estimates of the missing variables and averages over the estimates. The 
subsequent analysis to determine how risk is associated with events proceeded using the 
imputed dataset.  
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Final dataset used 
Table 28 outlines the baseline SHHEC population using the ASSIGN risk factors.   A total of 
16,560 SHHEC participants were free of cardiovascular disease at baseline. There was 
approximate balance between males (7,949) and females (8,611) with an average age of 49 
years. Most notably, there were elevated levels of total cholesterol and a high prevalence of 
smokers. Further, a third of the study population were classified within the lowest fifth of 
socioeconomic deprivation, defined by the Scottish Index of Multiple Deprivation (SIMD 5). 
The distribution of risk factors was similar between men and women although of those who 
smoked men reported, on average, a higher number of cigarettes smoked per day and a 
higher proportion of women had reported family history of heart disease. 
 
Table 4-3: Demographics of SHHEC participants free of cardiovascular disease at baseline 
  
Men 
 
 
Women 
 
 
Cohort size 
 
7,949 
 
8,611 
 
Age (years) 48.6 (9.3) 48.6 (9.3) 
SIMD groups (fifths), n (%):   
1 (least deprived) 1,390 (17.5) 1,467 (17.0) 
2 1,197 (15.1) 1,214 (14.1) 
3 1,264 (15.9) 1,364 (15.8) 
4 1,479 (18.6) 1,675 (19.5) 
5 (most deprived) 2,619 (32.9) 2,891 (33.6) 
Diabetes, n (%) 125 (1.6) 117 (1.4) 
Family history, n (%) 2,061 (25.9) 2,788 (32.4) 
Cigarette smokers, n (%) 3,083 (39.2) 3,317 (38.9) 
CPD 20.4 (10.2) 16.8 (7.9) 
SBP (mm Hg) 133.6 (19.3) 129.7 (21.0) 
TC (mmol/l) 6.2 (1.2) 6.4 (1.3) 
HDL (mmol/l) 1.3 (0.5) 1.6 (0.4) 
Notes: statistics are mean (SD) unless otherwise stated; cigarettes per day (CPD) statistics are 
reported for smokers only 
 
 
Table 4-4 illustrates observed events when following-up SHHEC participants using SMR. The 
total follow-up period possible was 25 years, with an average follow-up of 21 years. A total of 
7,270 people (43.9%) had a first event observed during the follow-up period with more events 
observed for men than women.  
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Table 4-4 Follow-up hospitalised events  
Number % of baseline cohort Number % of baseline cohort
Alive and "CVD free" 4,450 57% 5,935 69%
First events
CHD hosp 1,354 17% 985 11%
CBVD hosp 463 6% 382 4%
fatal CVD 696 9% 469 5%
fatal non-CVD 986 13% 840 10%
2nd events in model
Death post CHD 455 6% 293 3%
Death post stroke 200 3% 147 2%
                                Men                                 Women
 
 
The most common first event was CHD hospitalisations – men 17%, women 11%, followed 
by fatal non-CVD (13%, 10%), fatal CVD (9%, 5%) and CBVD hospitalisation (6%, 4%). 
Overall, 655 males and 440 females subsequently died following non-fatal CVD events, 
representing 9% and 5% of the baseline study population.    
 
4.3.4 Data modelling I: estimating the risk of having first event 
Key considerations 
In choosing an appropriate statistical approach two considerations were important. First, in 
estimating risk of the four first events, there was a need to take into accounting competing 
risks of non-CVD death. Second, the modelling should adjust for an individuals’ time to event, 
as age at event is likely to be a key determinant of which event is incurred and whether an 
event was fatal.   
 
Given these considerations, Gompertz parametric regression survival analysis was used to 
model the cause specific hazards of the competing first events, where age at event was a 
covariate(280). Gompertz is the standard choice when modelling the risk of death(110). The 
cause specific hazards are modelled continuously as a function of time to give the 
instantaneous probability of incurring a particular event, taking into account the risk of other 
events of interest.   
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Cause Specific Hazards (CSH) approach 
hk(tj) is the cause specific hazard (CSH) for event type k which for the Gompertz regression 
has the expression: 
 
hk(tj) = exp(xb)exp(γt) 
 
Where xb is the linear predictor from the regression and γ is the ancillary parameter 
estimated from the data. 
 
Table 4-5 details the CSH for each of the first four events for men. The CSH vary between 
events, providing justification for splitting CVD into component parts.   Coefficients above 1 
mean that for continuous variables a unitary change in the risk factor is associated with an 
increased (instantaneous) risk of event; and for binary variables (e.g. diabetes, family history) 
a positive identification results in higher instantaneous risk of events.  Notably, the 
coefficients for diabetes, family history and cigarettes per (CPD) are the consistently the 
greatest across all four events. The exception is the relationship between family history and 
non-fatal CHD, which is just below 1. The coefficient for the hazard of total cholesterol and 
fatal non-CVD event is also below 1, suggesting a protective effect of fatal non-CVD.   This 
result for cholesterol seems at first to be counter-intuitive. However, research elsewhere also 
showed a protective associative between total cholesterol and non-fatal CVD(281-282). 
Nonetheless, the expert panel advised that these relationships were unlikely to be causal. For 
example, an increase (decrease) in total cholesterol (HDL) is unlikely to lead to reductions 
(increases) in fatal non-CVD events.  
 
Several estimates were not significant. Nonetheless, all estimates are used in the modelling 
as these are known risk factors in CVD. The key issue is the combined impact (and statistical 
uncertainty) of the covariates taken together in predicting events and life expectancy. The 
model will be extensively tested in comprehensive validation checks which are discussed 
later in the chapter.  
 
The C-statistics were above 0.7 suggesting the model has good discriminatory ability: being 
able to distinguish case and non-case using the ASSIGN risk factors as covariates. However, 
as discussed in Chapter 3, the C-statistic is not a complete test for prognostic models, 
despite its widespread use in risk models. Later in the chapter we will test model predictions 
further by including calibration tests.  
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Table 3 details the CSH for women. The hazards signs remain the same, however the 
magnitude can differ. In particular, the impact of smoking is much stronger in increasing the 
hazards of all four events. For instance, the hazard of cigarettes per day (CPD) for CVD 
death is 2.62 for women and 1.87 for men. Regarding non-CVD death, the protective effect 
for total cholesterol remained. Again there were several estimates that were not significant, 
but to reiterate the modelling uses all estimates and that key test of the model is the ability to 
generate accurate event life expectancy predictions. The C-statistics for women also convey 
good discriminatory ability, with typically higher values than for the model developed 
specifically for men. A comprehensive validation and calibration check for the model 
constructed for women will be undertaken similar to the model built for men. 
 
Tables 3 and 4 show the mean and confidence intervals, and to prepare the model for 
probabilistic sensitivity analysis the covariance relationship between the variables in the 
estimating the hazards was also estimated. Appendix 2 provides the associated Cholesky 
Decomposition matrixes. In application, this allows the model to vary the hazard and explore 
the uncertainty in event predictions of the model. 
 
To iterate these estimates were derived in the model that used multiple imputation to adjust 
for missing data. As an internal verification check, Appendix 1 compares the CSH derived 
from the imputation compared to a complete case analysis. Minimal differences in the 
hazards were found.  
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Table 4-5: Modelling cause specific hazards of first event and survival following non-
fatal first event 
 
a) Men - cause specific hazards of first event 
 
Covariate Non-fatal CHD 
(1354 events, 
17.0% of cohort) 
Non-fatal CBVD 
(463, 5.8%) 
Fatal CVD 
(696, 8.8%) 
Fatal non-CVD 
(986, 12.4%) 
 HRs p 
value 
HRs p 
value 
HRs p 
value 
HRs p 
value 
Age 1.05 
(1.04, 
1.05) 
<0.001 1.07 
(1.06, 
1.08) 
<0.001 1.10 
(1.09, 
1.11) 
<0.001 1.10 
(1.09, 
1.11) 
<0.001 
SIMD. 1.04 
(1.01, 
1.07) 
0.002 1.10 
(1.05, 
1.15) 
<0.001 1.07 
(1.03, 
1.10) 
<0.001 1.10 
(1.07, 
1.13) 
<0.001 
Diabetes 1.93 
(1.34, 
2.76) 
<0.001 3.22 
(1.94, 
5.33) 
<0.001 2.37 
(1.48, 
3.81) 
<0.001 1.40 
(0.84, 
2.31) 
0.2 
Fam. his. 1.50 
(1.34, 
1.69) 
<0.001 0.98 
(0.79, 
1.21) 
0.8 1.18 
(1.00, 
1.39) 
0.05 0.99 
(0.85, 
1.14) 
0.8 
CPD 1.42 
(1.31, 
1.55) 
<0.001 1.61 
(1.40, 
1.86) 
<0.001 1.87 
(1.67, 
2.10) 
<0.001 1.84 
(1.68, 
2.02) 
<0.001 
SBP 1.08 
(1.05, 
1.11) 
<0.001 1.12 
(1.08, 
1.17) 
<0.001 1.16 
(1.13, 
1.20) 
<0.001 0.99 
(0.95, 
1.02) 
0.4 
TC 1.29 
(1.23, 
1.35) 
<0.001 1.09 
(1.00, 
1.18) 
0.06 1.13 
(1.05, 
1.21) 
0.001 0.95 
(0.90, 
1.01) 
0.09 
HDL 0.68 
(0.62, 
0.75) 
<0.001 0.94 
(0.82, 
1.07) 
0.4 0.93 
(0.83, 
1.04) 
0.2 1.21 
(1.11, 
1.32) 
<0.001 
 
c-statistic 
 
0.70 
(0.69, 
0.71) 
  
0.73 
(0.71, 
0.75) 
  
0.77 
(0.76, 
0.79) 
  
0.74 
(0.72, 
0.75) 
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b) Women - cause specific hazards of first event 
 
Covariate Non-fatal CHD 
(985, 11.4%) 
Non-fatal CBVD 
(382, 4.4%) 
Fatal CVD 
(469, 5.4%) 
Fatal non-CVD 
(840, 9.8%) 
 HRs p 
value 
HRs p 
value 
HRs p 
value 
HRs p 
value 
Age 1.06 
(1.05, 
1.07) 
<0.001 1.08 
(1.07, 
1.10) 
<0.001 1.11 
(1.09, 
1.12) 
<0.001 1.09 
(1.08, 
1.11) 
<0.001 
SIMD  1.09 
(1.06, 
1.12) 
<0.001 1.14 
(1.09, 
1.19) 
<0.001 1.04 
(1.00, 
1.09) 
0.05 1.08 
(1.04, 
1.11) 
<0.001 
Diabetes 2.07 
(1.41, 
3.03) 
<0.001 3.01 
(1.81, 
4.99) 
<0.001 3.14 
(1.97, 
5.00) 
<0.001 0.96 
(0.51, 
1.81) 
0.9 
Fam. his. 1.68 
(1.48, 
1.90) 
<0.001 1.43 
(1.16, 
1.75) 
0.001 1.27 
(1.05, 
1.53) 
0.01 0.98 
(0.85, 
1.14) 
0.8 
CPD 1.51 
(1.34, 
1.71) 
<0.001 1.71 
(1.41, 
2.08) 
<0.001 2.61 
(2.24, 
3.03) 
<0.001 2.14 
(1.91, 
2.41) 
<0.001 
SBP 1.06 
(1.03, 
1.10) 
<0.001 1.15 
(1.09, 
1.20) 
<0.001 1.19 
(1.14, 
1.24) 
<0.001 1.03 
(0.99, 
1.06) 
0.1 
TC 1.21 
(1.15, 
1.27) 
<0.001 0.95 
(0.86, 
1.05) 
0.3 1.06 
(0.98, 
1.15) 
0.2 0.93 
(0.87, 
0.99) 
0.02 
HDL 0.69 
(0.63, 
0.76) 
<0.001 0.84 
(0.73, 
0.97) 
0.02 0.92 
(0.81, 
1.04) 
0.2 0.98 
(0.89, 
1.07) 
0.6 
 
c-statistic 
 
0.74 
(0.73, 
0.75) 
  
0.76 
(0.73, 
0.78) 
  
0.80 
(0.78, 
0.82) 
  
0.72 
(0.70, 
0.74) 
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Cumulative incidence approach 
Further, by summing cause specific hazards over time the cumulative incidence function 
(CIF). This is simply the (cumulative) probability of incurring a particular event before a 
particular time.  
 
The predicted cumulative incidence estimates of the first events can be obtained from the 
Gompertz regression as follows: 
 
CIk (t) = Σ pk(tj) 
 
i.e., the cumulative incidence at time t, CIk (tj), is the cumulative sum of the unconditional 
probabilities of having event type k at time tj, Σ pk(tj), up to and including time t. The 
unconditional probabilities are obtained by: 
 
pk(tj) = hk(tj)S(tj – 1) 
 
Where hk(tj) is the cause specific hazard for event type k which for the Gompertz regression 
has the expression: 
 
hk(tj) = exp(xb)exp(γt) 
 
Where xb is the linear predictor from the regression and γ is the ancillary parameter 
estimated from the data.  
 
S(t) is the probability of surviving from any of the four events at time t and is obtained by: 
 
S(t) = Π(1 – Σ hk(tj)) 
 
Where Σ hk(tj) is the sum of the four cause specific hazards at time tj. 
 
Illustrating the cumulative incidence approach  
Figures 4-2 and 4-3 illustrate the cumulative incidence curves for men within the highest and 
lowest quintiles of deprivation. Given modifiable risk factors were able to be modelled 
continuously this means that different predictions result from different risk profiles. The result 
 191 
is that the model can estimate and discriminate risk by individual profiles, rather than for sub-
groups which is a common feature in Markov models.   
 
The profiles selected was that of a 60 year old, residing in SIMD 1 (SIMD score = 4) or SIMD 
5 (SIMD score = 4 or 60), with no family history, no diabetes, a smoker of 20 cigarettes per 
day, total cholesterol of 7 and HDL Cholesterol of 1.2.  
 
In comparing figures, the deprivation gradient is apparent with the probability of remaining 
alive and CVD free higher for the least deprived male. Notably non-CVD death is the event 
with the highest risk, which underlines the importance that the model estimates the impact of 
the risk factors beyond CVD. Further, the order of events in terms of probability also varies 
slightly between profiles. For the least affluent, non-fatal CHD carried the higher risk; and for 
the most deprived it is non-CVD death. 
 
Figure 4-2 Cumulative incidence of first events – male, least deprived fifth 
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Figure 4-3: Cumulative incidence of first events – male, most deprived fifth 
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Figures 4-4 and 4-5 illustrate the cumulative incidence curves for women using the same 
covariate profile as for men, and for the least and most deprived quintiles. Again the 
deprivation 
 
Figure 4-4: Cumulative incidence of first events – female, least deprived fifth 
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gradient is apparent with the least deprived remaining free of CVD for longer. Also, and in 
contrast to men, the order of events in terms of probability is consistent, with the highest risk 
of fatal non-CVD death.  Further, the risk of CVD death is lower in the most deprived over 
time. In comparing men and women, the probability of remaining alive and CVD free in 
women in the most deprived quintile is similar to men in the most affluent. 
 
Figure 4-5: Cumulative incidence of first events – female, most deprived fifth 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 10 20 30 40 50 60
P
ro
b
a
b
il
it
y
Years since screening
Alive CVD free
Non-fatal CHD
Non-fatal CBVD
CVD death
Non-CVD death
 
 
4.3.5 Data modelling II – estimating survival following non-fatal CHD 
and CBVD events 
If the first event incurred was a non-fatal CHD or CVD event, then survival from death was 
estimated from the following Gompertz regression: 
 
S(t) = exp(–exp(xb)γ–1(exp(γt) –1)) 
 
where xb is the linear predictor from the regression and γ is the ancillary parameter estimated 
from the data. The non-modifiable risk factors were used in the model with age at event 
replacing age at SHHEC (used in equation 1). The expert panel advising on the model 
approach suggested that survival would be more influenced by age at event rather than the 
age at which individuals entered the baseline survey.  To reiterate, SHHEC did not rescreen 
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individuals to track modifiable risk factors over time post-screening. Therefore, to estimate 
survival post first event only the non-modifiable risk factors were used. 
 
Table 4-6 Modelling the hazard of death post non-fatal event 
a) Men - survival following non-fatal first event 
 
Covariate After non-fatal CHD After non-fatal CBVD 
 HRs p value HRs p value 
Age at event 1.08 (1.07, 1.09) <0.001 1.07 (1.05, 1.09) <0.001 
SIMD sc. 1.14 (1.09, 1.19) <0.001 1.09 (1.03, 1.16) 0.004 
Fam. his. 0.97 (0.79, 1.18) 0.7 1.06 (0.77, 1.47) 0.7 
 
c-statistic 
 
0.68 (0.65, 0.71) 
  
0.65 (0.61, 0.69) 
 
 
 
b) Women - survival following non-fatal first event 
Covariate After non-fatal CHD After non-fatal CBVD 
 HRs p value HRs p value 
Age at event 1.08 (1.06, 1.09) <0.001 1.07 (1.05, 1.09) <0.001 
SIMD sc. 1.08 (1.03, 1.13) 0.003 1.00 (0.93, 1.08) 0.9 
Fam. his. 0.75 (0.60, 0.95) 0.02 1.20 (0.86, 1.67) 0.3 
 
c-statistic 
 
0.67 (0.63, 0.70) 
  
0.66 (0.61, 0.71) 
 
 
 
Notes: 95% confidence intervals in brackets; HRs for continuous covariates are for 0.5 unit 
increases (HDL), 1 unit increases (age, TC), 10 unit increases (SIMD, SBP), and 20 unit 
increases (CPD) 
 
The hazards do vary between men and women, with the exception of age. Noticeably, the 
estimate for family history is not significant; nonetheless all estimates are used in the 
modelling. Appendix 3 provides the associated Cholesky decomposition for 2nd events. 
 
The model generates survival curves for each individual covariate profile and conditional 
upon the age at which a particular non-fatal event occurs.  
 
Illustrating the model - Survival conditional upon first event 
Figure 4-6 and 4-7 illustrates the survival curves that the model can generate. For 
consistency, of exposition the same covariate profiles as for first events are used.  
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Figure 4-6: Survival post nonfatal event – men, least deprived fifth 
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In comparing the figures, survival is higher for post-CHD than post-CBVD and also across the 
most and least and most deprived fifth. For the least deprived fifth survival post-CHD is higher 
  
Figure 4-7: Survival post nonfatal event – men, most deprived fifth 
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compared to survival post CHD. These patterns are also observed for men in the most 
deprived fifth. Further, the deprivation gradient is evident with the most deprived lower 
survival across following both CHD and CBVD non-fatal events.   
 
Figure 4-8 and 4-9 shows survival estimates for women, again using the same covariate 
profiles as for first events and for men. A similar results pattern is also obtained, with survival 
post-CHD higher and the appearance of the deprivation gradient. In addition, survival for 
women is higher than for men, in both events and within the deprivation fifths also. 
 
Figure 4-8: Survival post nonfatal event – women, least deprived fifth 
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Overall, the gender and deprivation gradient is driven by incidence of the first events, rather 
than risk of death post first event. 
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Figure 4-9: Survival post nonfatal event – women, most deprived fifth 
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4.3.4 Data modelling III: estimating average life expectancy  
The next stage in the modelling is to estimate average life expectancy. The illustrations above 
estimated the risk of first events over a lifetime, but and the survival curves if either a non-
fatal CHD or non-fatal CVBD event occurred in the first year post screening. However, 
individuals are at risk of any of the first four events at anytime post screening, and survival is 
conditional upon which first event occurs and when.  Therefore, there is a need to model all 
possible scenarios an individual faces and weight these possibilities to generate average life 
expectancy. 
 
Four stage process 
There are four stages involved to estimate the average life expectancy of an individual as 
they enter the model free of CVD. First, the model conduct a “what-if analysis” to estimate the 
additional life years that can be expected if a particular event was incurred at a particular 
time. The time (in years) that elapsed before the first event is counted and if the first event is 
non-fatal this is added to the area under the predicted survival curve to estimate remaining 
life years.  To estimate this area under the survival curve, the area is divided into a series of 
horizontal segments defined by the annual cycles of the model. The area under each 
segment is estimated by using the trapezoid method (essentially divided each segment into a 
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rectangle and triangles. The sum across each segment then gives an estimate under the 
survival curve.  
 
Overall, this process is repeated for an exhaustive set of scenarios. Given one of four first 
events can occur in any of 100 annual cycles of the model this generates a total of 400 
scenarios an individual faces upon entering the model. Table 4-7 a-c illustrates this process 
for the 60 year male living in the most deprived fifth that was introduced earlier. 4.7a shows 
the life years remaining for an individual upon entering the model at time 0 up to incurring one 
of the first four events. For instance, if the male profile incurred a non-fatal CHD event in the 
first year post screening then the life years remaining would be 15.7. This is one year being 
CVD free before the first event, and 14.7 years survival from the first event. If a non-fatal 
CBVD event were to occur in year 22 post screening, then the life years remaining are 25.8. 
This is the 22 years CVD free prior to the first event, and 3.8 years survival post first event. 
On the other hand, if the first event is fatal, then the life years remaining in the model is the 
time before the event. For instance, if a CVD death occurs in year 24, then life years 
remaining from entering the model is 24 years. 
 
Table 4-7 a) Life years remaining upon entering model [for non-fatal outcomes = time before 
event + time after event] 
 
1 15.7 14.0 1.0 1.0
2 15.9 14.3 2.0 2.0
3 16.2 14.7 3.0 3.0
.
.
22 25.8 25.8 22 22
23 26.6 26.6 23 23
24 27.3 27.4 24 24
.
.
100 100.5 100.5 100.0 100.0
Cycle (time in years) nonCVD deathCVD deathNon-fatal CBVDNon-fatal CHD
 
 
The second stage estimates the probability of actually incurring a particular event within a 
particular cycle. This probability is then derived from the cause specific hazards and is the per 
cycle addition to the cumulative incidence estimates (i.e. the difference between the 
cumulative estimates of adjacent cycles) that were illustrated previously.  
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b) Probability of event occuring [event type and timing] 
 
1 0.026 0.006 0.014 0.013
2 0.026 0.006 0.014 0.013
3 0.026 0.007 0.015 0.013
.
.
22 0.004 0.002 0.003 0.003
23 0.003 0.002 0.003 0.003
24 0.002 0.001 0.002 0.002
.
.
100 0.000 0.000 0.000 0.000
nonCVD deathCVD deathNon-fatal CBVDNon-fatal CHDCycle (time in years)
 
 
Note, that the sum of the probability of events across all model cycles is always equal to 1. 
This provides an internal verification check when running the model and denotes that an 
individual must experience one of the four first events over the course of a lifetime. 
  
The third stage is to then create an overall estimate of life years remaining by weighting stage 
1 (all 400 scenarios) by stage 2 (probability of scenarios). This process gives an overall 
expectation of the additional life expectancy that an individual can expect.  
 
c) Weighted remaining life years [estimates from a) multiplied by estimates from b)] 
 
1 0.407 0.087 0.014 0.013 0.521
2 0.411 0.092 0.029 0.026 0.558
3 0.414 0.097 0.044 0.040 0.595
.
.
22 0.103 0.050 0.076 0.072 0.301
23 0.081 0.041 0.062 0.059 0.244
24 0.062 0.033 0.050 0.047 0.192
.
.
100 0.000 0.000 0.000 0.000 0.000
14.42
74.42
Total life years remaining  (Cumulative sum over each model cycle) =    
Overall life expectancy  (age upon entering model plus remaining life years) =    
Non-fatal CBVDNon-fatal CHD nonCVD deathCVD death SumCycle (time in years)
 
 
Fourth, to calculate the overall life expectancy of an individual as they entered the model 
CVD free, we take the sum of the expected additional life years (calculated above) and add 
this to the age of the person as they entered the model.  Continuing with the example of the 
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60 year deprived male, he can expect to live an additional 14.42 years, giving him a life 
expectancy of 74.42 years.  
 
4.4 Modelling Stage 4: Uncertainty analysis 
As discussed in chapter 3 under best practice guidelines, there are four main aspects to 
uncertainty, namely, (i) stochastic, (ii) parameter; (iii) heterogeneity; and (iv) structural. The 
estimates of the event hazards given previously provide an illustration of (i) and (ii). No 
structural uncertainty was undertaken such as reformulating the model structure. The focus in 
the exposition of uncertainty analysis in this thesis is heterogeneity. That is, to illustrate how 
the model can discriminate between individuals in terms of risk of CVD using the ASSIGN risk 
factors. The intention is to illustrate that the policy model may be thought of as a natural 
extension to 10-year risk scores but rather than discriminate individuals on the basis of 10 
year risk, the policy model can discriminate on the basis of lifetime risk (including 10-year risk 
if desired) and life expectancy.   
 
Standard 10-year risk tables as used by JBS2(120) was used to define a set of individual risk 
factor profiles. These were then fed into the Scottish CVD Policy Model individually and life 
expectancies were estimated. Smokers were assumed to smoke 20 cigarettes per day. For 
exposition purposes, all risk profiles were attributed a family history of 0.26 and diabetes of 
0.15 - the average proportions found within the SHHEC baseline screening survey. Estimates 
of risk and life expectancy were made for men and women and for the highest and lowest 
quintiles of SIMD (SIMD score of 4 and 60 respectively). Separate tables were also estimated 
conditional upon smoking status. 
 
Figure 4-10 illustrates the life expectancy estimates for men residing in the least deprived fifth 
(SIMD 1) and the most deprived fifth (SIMD 5). Overall, the model shows an ability to 
discriminate between risk profiles resulting in different life expectancies. First, we see an age 
gradient for equivalent risk factors profiles, in that conditional upon reaching a certain age life 
expectancy improves. Secondly, life expectancy improves (in general) as risk factors are 
reduced. The risk profile resulting in the highest life expectancy estimate is a non-smoker 
accompanied with the lowest systolic blood pressure and cholesterol ratio. This profile is 
consistent with recommendations in clinical guidelines. 
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Figure 4-10 Life expectancies for multiple risk profiles – men 
Least deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 85.0 84.7 84.6 84.4 84.4 81.5 81.6 81.7 81.8 81.8
160 85.9 85.6 85.6 85.4 85.3 82.2 82.3 82.5 82.5 82.5
140 86.7 86.5 86.5 86.3 86.2 82.8 83.0 83.2 83.2 83.2
120 87.3 87.3 87.3 87.1 87.0 83.2 83.5 83.8 83.9 83.9
100 87.8 87.9 88.0 87.9 87.8 83.6 84.1 84.4 84.5 84.5
Age 60 years Age 60 years
180 82.9 82.4 82.4 82.2 82.1 78.8 78.8 79.1 79.2 79.2
160 83.9 83.5 83.4 83.2 83.1 79.5 79.8 80.0 80.0 80.1
140 84.8 84.5 84.4 84.2 84.1 80.3 80.5 80.8 80.8 80.9
120 85.5 85.4 85.3 85.1 85.0 80.8 81.2 81.5 81.6 81.6
100 86.1 86.2 86.2 86.0 85.8 81.2 81.8 82.1 82.2 82.3
Age 50 years Age 50 years
180 82.0 81.5 81.5 81.3 81.3 77.6 77.9 78.2 78.5 78.5
160 83.1 82.7 82.5 82.4 82.3 78.5 78.8 79.1 79.3 79.4
140 84.1 83.7 83.6 83.3 83.2 79.3 79.6 79.9 80.1 80.1
120 84.9 84.6 84.5 84.2 84.1 79.9 80.3 80.7 80.8 80.8
100 85.6 85.4 85.4 85.1 85.0 80.4 81.0 81.3 81.4 81.4
Age 40 years Age 40 years
180 82.0 81.6 81.5 81.5 81.4 77.7 78.1 78.6 79.0 79.1
160 83.1 82.6 82.5 82.4 82.3 78.6 78.9 79.4 79.6 79.8
140 84.0 83.5 83.5 83.2 83.1 79.3 79.7 80.1 80.3 80.4
120 84.8 84.5 84.3 84.0 84.0 80.0 80.4 80.7 80.9 81.0
100 85.6 85.3 85.2 85.0 84.8 80.4 81.0 81.3 81.5 81.5
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Most deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 81.3 81.0 80.8 80.6 80.4 78.4 78.3 78.3 78.2 78.2
160 82.1 81.8 81.6 81.4 81.3 78.9 78.9 78.9 78.9 78.8
140 82.7 82.5 82.4 82.2 82.1 79.3 79.4 79.5 79.5 79.4
120 83.2 83.2 83.2 83.0 82.8 79.7 79.9 80.1 80.0 80.0
100 83.6 83.8 83.8 83.7 83.6 80.0 80.3 80.5 80.6 80.5
Age 60 years Age 60 years
180 78.1 77.5 77.3 77.0 76.8 74.3 74.2 74.2 74.1 74.1
160 79.1 78.5 78.3 78.0 77.8 75.0 75.0 75.0 74.9 74.9
140 79.8 79.5 79.3 78.9 78.7 75.6 75.7 75.8 75.7 75.6
120 80.5 80.3 80.2 79.9 79.7 76.2 76.3 76.4 76.4 76.3
100 81.1 81.0 81.0 80.7 80.5 76.5 76.9 77.1 77.0 77.0
Age 50 years Age 50 years
180 76.4 75.6 75.3 75.0 74.8 72.1 71.9 72.0 71.9 71.9
160 77.5 76.7 76.4 76.0 75.8 73.0 72.8 72.9 72.8 72.7
140 78.3 77.7 77.4 77.0 76.8 73.6 73.7 73.7 73.6 73.5
120 79.2 78.7 78.4 78.0 77.8 74.3 74.4 74.5 74.4 74.3
100 79.8 79.6 79.3 79.0 78.8 74.7 75.0 75.2 75.1 75.0
Age 40 years Age 40 years
180 75.6 74.7 74.4 74.1 74.0 71.3 71.1 71.3 71.2 71.2
160 76.7 75.9 75.5 75.1 74.9 72.2 72.0 72.1 72.0 72.0
140 77.7 77.0 76.5 76.1 75.9 72.9 72.9 72.9 72.9 72.8
120 78.6 78.0 77.6 77.1 76.9 73.6 73.6 73.7 73.6 73.5
100 79.4 78.8 78.6 78.0 77.8 74.1 74.3 74.4 74.3 74.2
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Figure 4-11 Life expectancies for multiple risk profiles - women 
Least deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 86.7 86.5 86.1 86.1 86.0 81.9 81.9 81.9 81.9 81.9
160 87.9 87.7 87.4 87.2 87.1 82.9 83.0 82.9 82.9 82.9
140 89.0 88.8 88.5 88.3 88.2 83.9 84.0 83.9 83.9 83.9
120 90.2 90.0 89.5 89.3 89.2 84.8 85.0 84.8 84.8 84.8
100 91.2 91.0 90.6 90.3 90.2 85.7 85.9 85.7 85.7 85.7
Age 60 years Age 60 years
180 84.4 84.2 83.9 83.7 83.7 78.9 79.0 79.0 79.0 79.1
160 85.8 85.6 85.1 84.9 84.9 80.1 80.2 80.2 80.2 80.2
140 87.1 86.8 86.3 86.1 86.0 81.2 81.4 81.3 81.3 81.3
120 88.3 87.9 87.5 87.2 87.1 82.3 82.5 82.4 82.3 82.4
100 89.3 89.1 88.6 88.3 88.2 83.4 83.5 83.4 83.3 83.4
Age 50 years Age 50 years
180 83.2 82.9 82.7 82.5 82.5 77.3 77.5 77.6 77.7 77.8
160 84.6 84.3 83.9 83.7 83.7 78.6 78.8 78.8 78.9 79.0
140 85.9 85.5 85.1 84.9 84.8 79.9 80.0 80.0 80.0 80.1
120 87.1 86.7 86.3 86.0 85.8 80.9 81.2 81.1 81.1 81.1
100 88.3 87.9 87.4 87.0 86.9 82.0 82.3 82.1 82.1 82.0
Age 40 years Age 40 years
180 82.6 82.3 82.1 81.9 81.9 76.7 77.0 77.2 77.4 77.4
160 83.9 83.6 83.3 83.0 83.0 78.0 78.3 78.4 78.5 78.6
140 85.2 84.8 84.4 84.1 84.1 79.2 79.5 79.5 79.6 79.6
120 86.4 86.0 85.4 85.1 85.1 80.4 80.6 80.5 80.6 80.6
100 87.6 87.1 86.5 86.1 86.0 81.4 81.6 81.4 81.4 81.5
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Most deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 84.0 83.8 83.5 83.4 83.3 80.0 80.1 80.0 80.0 80.0
160 85.0 84.8 84.4 84.3 84.2 80.8 80.9 80.8 80.7 80.8
140 85.9 85.7 85.4 85.1 85.1 81.6 81.6 81.5 81.5 81.5
120 86.9 86.6 86.2 86.0 85.9 82.3 82.4 82.3 82.2 82.2
100 87.7 87.5 87.1 86.8 86.7 83.0 83.1 82.9 82.9 82.9
Age 60 years Age 60 years
180 81.2 81.0 80.6 80.4 80.4 76.4 76.5 76.5 76.5 76.5
160 82.3 82.0 81.6 81.4 81.3 77.4 77.5 77.4 77.4 77.4
140 83.4 83.1 82.6 82.3 82.3 78.3 78.4 78.2 78.3 78.2
120 84.5 84.0 83.6 83.3 83.2 79.1 79.2 79.1 79.0 79.1
100 85.4 85.0 84.5 84.2 84.0 80.0 80.1 79.9 79.8 79.8
Age 50 years Age 50 years
180 79.6 79.3 78.9 78.8 78.6 74.4 74.6 74.6 74.6 74.7
160 80.8 80.4 80.0 79.7 79.6 75.5 75.6 75.5 75.6 75.6
140 81.9 81.4 81.0 80.7 80.5 76.5 76.5 76.5 76.4 76.5
120 83.0 82.5 81.9 81.6 81.5 77.3 77.5 77.3 77.3 77.2
100 83.9 83.5 82.8 82.5 82.4 78.2 78.4 78.1 78.1 78.0
Age 40 years Age 40 years
180 78.8 78.4 78.0 77.9 77.8 73.6 73.8 73.8 73.9 74.0
160 79.9 79.5 79.0 78.8 78.7 74.6 74.8 74.8 74.8 74.9
140 81.0 80.5 80.0 79.7 79.5 75.6 75.7 75.6 75.6 75.7
120 82.0 81.5 80.9 80.6 80.4 76.4 76.6 76.4 76.4 76.4
100 83.0 82.4 81.8 81.3 81.2 77.3 77.5 77.2 77.2 77.2
3 5 7 9 10 3 5 7 9 10
S
y
s
to
lic
 B
lo
o
d
 P
re
s
s
u
re
 (
m
m
/H
g
)
Total/HDL cholesterol ratio  
 
More specifically, smoking is the single most important risk factor. For instance, the difference 
in life expectancies between smokers and non-smokers with an otherwise identical risk factor 
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profile is as much as 5.3 years – comparing life expectancies for 40 year old men with risk 
profiles consisting of the highest SBP and total-to-HDL cholesterol reading. 
 
The model can also sensitise life expectancy predictions. This can take the form of univariate, 
analysis of extremes, or multi-variate sensitivity. In particular, using the Cholesky 
decomposition matrixes the model can perform probabilistic sensitivity analysis in estimating 
life expectancy. When running the model, it is straightforward to switch from a deterministic 
analysis (using mean hazards rates) to a probabilistic analysis, where an individual profile is 
run through the model multiple times in a series of loops and coefficients are randomly 
selected using the Cholesky decomposition.  That is, to select a coefficient random draws are 
made from the Cholesky decomposition where all parameters are allowed to vary 
simultaneously. This process generates a confidence interval for the resultant life expectancy 
estimate.  
 
For example, using the male profile in the most deprived fifth that was introduced earlier, the 
average life expectancy was estimated to be 74.42 within a deterministic analysis (using 
means). After 10,000 loops of the model the life expectancy prediction had a 95% confidence 
interval that ranged from 73.12-75.78. 
 
4.5. Modelling stage 5: Validating and reporting  
4.5.1 Face validity 
Face validity of the model was achieved by drawing upon the expert panel of advisors. The 
model objective, structure and functioning were corroborated as valid representations of the 
problem of primary prevention and the process of estimating life expectancy using the 
methods described. 
   
4.5.2 Internal Validity 
Discrimination 
The discrimination of all statistical models was good with c-statistics in the range 0.65-0.80, 
for models predicting first and second events. Discrimination was better for the first event 
models than the models following a first non-fatal event, better for the fatal CVD outcome 
compared to the other competing first events, and generally better for the model developed 
for women. 
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Calibration 
The observed number of events in the SHHEC-SMR dataset was compared to model 
predictions, both for modelling stages 1 and 2. This was done for all individuals at SHHEC 
baseline, and separately for men and women.  Observations and predictions were compared 
for first and second events (death following a non-fatal CVD event), and across fifths of linear 
predictors. The latter then tests the model across predicted levels of risk (e.g. the highest fifth 
of linear predictors are those individuals at higher predicted risk) to provide a more rigorous 
test of goodness of fit rather than overall event rates. Tables 4-8 to 4-11 provide the results 
for men and women, for first events and death post non-fatal event. 
 
In comparing the observed and predicted values a p-value in excess of 0.05 means that the 
null hypothesis that the model is not a good fit can be rejected. Overall, the model fits the 
data well with p-values generally in excess of 0.05. The exception is for non-fatal CHD events 
in the lowest fifth of linear predictors. The model tends to over predict the number of events at 
the lower end of risk, with evidence of lack of fit also seen in the fourth quintile of the linear 
predictor.  
 
Table 4-8 Comparison of observed first events against predicted events - men 
a) non-fatal CHD 
Quintile - lowest fifth of linear predictors   1 73 (70, 76) 109 (107, 111) 0.001 (0, 0.002)
Quintile - lowest fifth of linear predictors   2 196 (188, 204) 194 (191, 195) 0.797 (0.338, 0.932)
Quintile - lowest fifth of linear predictors   3 277 (267, 289) 258 (256, 261) 0.270 (0.052, 0.555)
Quintile - lowest fifth of linear predictors   4 382 (370, 394) 326 (322, 328) 0.004 (0, 0.022)
Quintile - highest fifth of linear predictors  5 426 (419, 434) 468 (462, 472) 0.055 (0.016, 0.086)
Observed Predicted P-value
 
 
 
b) Non-fatal CBVD 
Quintile - lowest fifth of linear predictors   1 32 (31, 34) 34 (33, 34) 0.782 (0.658, 0.974)
Quintile - lowest fifth of linear predictors   2 48 (47, 51) 63 (62, 64) 0.070 (0.036, 0.148)
Quintile - lowest fifth of linear predictors   3 90 (84, 95) 88 (88, 89) 0.703 (0.448, 0.902)
Quintile - lowest fifth of linear predictors   4 130 (125, 138) 113 (112, 114) 0.160 (0.023, 0.291)
Quintile - highest fifth of linear predictors  5 163 (160, 165) 165 (163, 166) 0.882 (0.694, 0.989)
Observed Predicted P-value
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c) fatal CVD 
Quintile - lowest fifth of linear predictors   1 20 (18, 22) 29 (29, 30) 0.093 (0.044, 0.21)
Quintile - lowest fifth of linear predictors   2 62 (57, 64) 70 (69, 71) 0.338 (0.134, 0.477)
Quintile - lowest fifth of linear predictors   3 124 (120, 127) 116 (115, 116) 0.445 (0.245, 0.732)
Quintile - lowest fifth of linear predictors   4 186 (183, 191) 171 (170, 173) 0.266 (0.1, 0.398)
Quintile - highest fifth of linear predictors  5 305 (302, 308) 310 (308, 312) 0.735 (0.599, 0.834)
Observed Predicted P-value
 
 
d) Non-fatal CVD 
Quintile - lowest fifth of linear predictors   1 45 (43, 46) 52 (51, 52) 0.333 (0.223, 0.432)
Quintile - lowest fifth of linear predictors   2 120 (116, 127) 112 (111, 112) 0.443 (0.158, 0.701)
Quintile - lowest fifth of linear predictors   3 161 (158, 163) 174 (173, 176) 0.318 (0.178, 0.418)
Quintile - lowest fifth of linear predictors   4 247 (243, 250) 247 (245, 248) 0.882 (0.779, 0.98)
Quintile - highest fifth of linear predictors  5 413 (408, 417) 402 (398, 403) 0.565 (0.454, 0.699)
Observed Predicted P-value
 
 
Table 4-9 Comparison of observed first events against predicted events - women 
a) Non-fatal CHD 
Quintile - lowest fifth of linear predictors   1 39 (36, 43) 55 (53, 55) 0.052 (0.01, 0.128)
Quintile - lowest fifth of linear predictors   2 98 (94, 102) 112 (110, 113) 0.193 (0.084, 0.354)
Quintile - lowest fifth of linear predictors   3 184 (173, 195) 169 (167, 171) 0.290 (0.056, 0.787)
Quintile - lowest fifth of linear predictors   4 281 (269, 288) 249 (248, 251) 0.074 (0.013, 0.226)
Quintile - highest fifth of linear predictors  5 383 (375, 397) 400 (396, 402) 0.422 (0.237, 0.818)
Observed Predicted P-value
 
 
b) Non-fatal CBVD 
Quintile - lowest fifth of linear predictors   1 15 (14, 17) 18 (17, 18) 0.545 (0.358, 0.878)
Quintile - lowest fifth of linear predictors   2 39 (36, 42) 39 (39, 40) 0.783 (0.612, 0.985)
Quintile - lowest fifth of linear predictors   3 62 (58, 66) 62 (62, 63) 0.831 (0.612, 0.991)
Quintile - lowest fifth of linear predictors   4 98 (93, 101) 93 (92, 93) 0.583 (0.38, 0.952)
Quintile - highest fifth of linear predictors  5 168 (164, 170) 170 (169, 172) 0.865 (0.639, 0.991)
Observed Predicted P-value
 
 
c) Fatal CVD 
Quintile - lowest fifth of linear predictors   1 9 (8, 10) 12 (12, 12) 0.442 (0.268, 0.627)
Quintile - lowest fifth of linear predictors   2 27 (24, 28) 34 (34, 35) 0.198 (0.087, 0.29)
Quintile - lowest fifth of linear predictors   3 71 (66, 75) 65 (65, 66) 0.527 (0.208, 0.931)
Quintile - lowest fifth of linear predictors   4 119 (113, 124) 113 (112, 113) 0.567 (0.269, 0.991)
Quintile - highest fifth of linear predictors  5 244 (239, 247) 245 (244, 246) 0.892 (0.727, 0.961)
Observed Predicted P-value
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 d) Non-fatal CVD 
Quintile - lowest fifth of linear predictors   1 52 (49, 54) 45 (45, 46) 0.350 (0.208, 0.567)
Quintile - lowest fifth of linear predictors   2 95 (91, 97) 98 (97, 98) 0.760 (0.508, 0.963)
Quintile - lowest fifth of linear predictors   3 136 (133, 140) 150 (149, 151) 0.264 (0.135, 0.387)
Quintile - lowest fifth of linear predictors   4 210 (204, 215) 215 (215, 216) 0.741 (0.429, 0.994)
Quintile - highest fifth of linear predictors  5 347 (344, 349) 331 (330, 333) 0.393 (0.318, 0.529)
Observed Predicted P-value
 
 
Table 4-10 Comparison of observed fatal event against predicted events - men 
a) From non-fatal CHD 
Observed Expected P-value
Quintile - lowest fifth of linear predictors   1 66 65 0.868
Quintile - lowest fifth of linear predictors   2 90 85 0.603
Quintile - lowest fifth of linear predictors   3 86 95 0.350
Quintile - lowest fifth of linear predictors   4 104 103 0.883
Quintile - highest fifth of linear predictors  5 109 108 0.887  
 
b) From  non-fatal CBVD 
Observed Expected P-value
Quintile - lowest fifth of linear predictors   1 28 29 0.844
Quintile - lowest fifth of linear predictors   2 44 37 0.277
Quintile - lowest fifth of linear predictors   3 39 46 0.332
Quintile - lowest fifth of linear predictors   4 48 46 0.821
Quintile - highest fifth of linear predictors  5 41 42 0.928  
 
Table 4-11 Comparison of observed fatal event against predicted events - women 
a) From non-fatal CHD 
Observed Expected P-value
Quintile - lowest fifth of linear predictors   1 40 45 0.471
Quintile - lowest fifth of linear predictors   2 55 58 0.718
Quintile - lowest fifth of linear predictors   3 68 57 0.157
Quintile - lowest fifth of linear predictors   4 65 62 0.663
Quintile - highest fifth of linear predictors  5 65 72 0.438  
 
b) From non-fatal CBVD 
 
 
Observed Expected P-value
Quintile - lowest fifth of linear predictors   1 21 21 0.967
Quintile - lowest fifth of linear predictors   2 28 31 0.560
Quintile - lowest fifth of linear predictors   3 37 30 0.207
Quintile - lowest fifth of linear predictors   4 33 34 0.826
Quintile - highest fifth of linear predictors  5 28 31 0.642  
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4.5.3 External validation – predicting results from a clinical trial 
Access was granted to the West of Scotland Coronary Prevention Study (WOSCOPS) study, 
through a colleague on the expert panel, Professor Ian Ford who leads the Robertson Centre 
at the University of Glasgow which holds the dataset. WOSCOPS was a randomised, 
doubled-blinded, trial investigating the effectiveness of pravastatin in preventing coronary 
heart disease in asymptomatic males between 45-64 years old. Participants were recruited 
between 1989 and 1991, which is a slightly more recent cohort of patients than SHHEC 
(1984-1995). The trial period averaged 4.9 years. Risk profiles for individuals recruited to 
WOSCOPS were run through the model and predictions were compared against 
observations. This was done for both the placebo and intervention groups separately. 
 
For the placebo group baseline risk factors were inputted into the model, and the model’s 
ability was assessed by checking whether the predicted cumulative incidence curves fell 
within the 95% confidence interval limits of the observed cumulative incidence curves.  The 
predicted line falls well within the confidence interval limits for non-fatal CBVD and fatal CVD 
events. However, the model under-predicts for non-fatal CHD and over-predicts for fatal non-
CVD. The latter may be explained by the fact that WOSCOPS is a clinical trial and that 
stringent exclusion criteria often result in a lower other cause mortality due to the exclusion of 
prevalent terminal disease (e.g. cancer).  
 
For the intervention group, validation proceeded through the effect of treatment on total 
cholesterol in order to mimic the intended use of the model.  WOSCOPS reported that 
pravastatin reduced total cholesterol by 20% and increased HDL by 5% on average. These 
changes were used to change individual risk profiles.  In running the augmented risk profiles 
through the model to predict event rates, the impact of total cholesterol on non-CVD death 
was held constant. To reiterate, a protective association was found in the SHHEC-SMR data; 
however on the advice of the expert panel this was not considered to be a causal 
relationship. 
 
For the intervention group, the model also performs quite well, with cumulative incidence 
predictions within the confidence intervals of CHD, stroke and CVD death. For non-CVD 
death the model systematically under-predicts. Perhaps, this can also be explained by the 
exclusion criteria employed by WOSCOPS.  The insertion of an intercept (negative) would 
then lead to accurate predictions.  
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Figure 4-12 Predicting outcomes in the placebo group 
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Figure 4-13 Predicting outcomes in the intervention group 
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4.5.4 Recalibrating model predictions to contemporary Scottish life 
expectancy estimates 
The model performed reasonably well regarding internal validation predicting first and second 
events of the SHHEC and WOSCOPS populations (1980s). However, the model performed 
less well in predicting life expectancy in more contemporary populations. Table 4-12 
illustrates life expectancy predictions for 40, 60 and 80 year old men and women using 
average risk factor profiles taken from the Scottish Health Survey (SHeS) 2009. These are 
compared with 2009 lifetables from General Registrar’s Office for Scotland(283). The original 
model predictions are denoted with a linear predictor multiplication factor of 1. 
 
A judgement was made to keep the calibration exercise as simple and parsimonious as 
possible. The aim was to develop a single calibration factor (one for men, and one for 
women) that can be applied across all profiles, rather than a range of calibration factors for 
different age and socioeconomic deprivation profiles. The consequent assumption is that 
while the age and socioeconomic gradients have remained unchanged in contemporary 
Scottish populations, compared to the original SHHEC population (from the mid-1980s).   
 
Further, a pragmatic approach was taken to recalibration, where the linear predictor was 
adjusted for the first four events. An algorithm was created to run through different linear 
predictor multiplication factors using the three different age profiles. This started with 0.99 
and worked down to 0.90. This process was done separately for men and women. A Root 
Mean Square Error (RMSE) was to estimate the difference in life expectancy between 
predictions and observations across all three ages. The algorithm stopped when a 
multiplicative factor resulted in a fit of less than one year across all profiles. Multiplying the 
linear predictor by 0.96 produced a RMSE of 0.26 and 0.89 years for men and women, 
respectively. All model estimates after this calibration factor had been applied were within half 
a year of the life table estimates with the exception of 80 year old women. 
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Table 4-12 Recalibrating life expectancy predictions to Scottish Lifetables 2009 
 
a) Men 
 
Linear predictor 
multiplication 
factor 
  
Age (years) 
 
RMSE 
  40 60 80  
 
1 Model life 
expectancy 
80.31 81.82 88.38  
 Life table life 
expectancy 
 
78.01 80.66 87.66  
 Difference 2.30 1.16 0.72 1.54 
years 
      
0.96 Model life 
expectancy 
78.21 80.26 87.76  
 Life table life 
expectancy 
 
78.01 80.66 87.66  
 Difference 0.20 −0.40 0.10 0.26 
years 
 
 
 
b) Women 
 
Linear 
predictor 
multiplication 
factor 
  
Age (years) 
 
RMSE 
  40 60 80  
 
1 Model life 
expectancy 
83.49 85.62 91.33  
 Life table life 
expectancy 
 
81.73 83.57 89.02  
 Difference 1.76 2.05 2.31 2.05 years 
      
0.96 Model life 
expectancy 
81.20 83.90 90.42  
 Life table life 
expectancy 
 
81.73 83.57 89.02  
 Difference −0.53 0.33 1.40 0.89 years 
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Re-estimating average life expectancy 
Following recalibration of the model, the following illustrates how this affects the life 
expectancy estimate of the 60 year old male introduced earlier. To reiterate, the estimation of 
average life expectancy is undertaken in four steps, as follows. First, the remaining life 
expectancy is estimated from an individual entering a particular first event state in every cycle 
of the model (Table 4-13). The estimate is the sum of event free years until the first event and 
cumulative survival if the first event was non-fatal.  
 
Table 4-13  a) Life years remaining upon entering model [for non-fatal outcomes = time 
before event + time after event] 
 
1 15.7 14.0 1.0 1.0
2 15.9 14.3 2.0 2.0
3 16.2 14.7 3.0 3.0
.
.
22 25.8 25.8 22 22
23 26.6 26.6 23 23
24 27.3 27.4 24 24
.
.
100 100.5 100.5 100.0 100.0
Cycle (time in years) nonCVD deathCVD deathNon-fatal CBVDNon-fatal CHD
 
  
Second, the probability of the first event (table 2) is taken, which the period addition to the 
cumulative incidence estimates. 
 
b) Probability of event occuring [event type and timing] 
 
1 0.026 0.008 0.017 0.013
2 0.026 0.008 0.017 0.013
3 0.025 0.008 0.017 0.013
.
.
22 0.003 0.002 0.003 0.002
23 0.002 0.001 0.002 0.002
24 0.002 0.001 0.002 0.001
.
.
100 0.000 0.000 0.000 0.000
nonCVD deathCVD deathNon-fatal CBVDNon-fatal CHDCycle (time in years)
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Third, the product of Table 4-13 a and b then generates weighted remaining life expectancy 
Table 4-13 c. 
 
    c) Weighted remaining life years [estimates from a) multiplied by estimates from b)] 
 
1 0.407 0.107 0.017 0.013 0.544
2 0.409 0.113 0.034 0.026 0.582
3 0.410 0.118 0.051 0.040 0.620
.
.
22 0.078 0.047 0.068 0.055 0.249
23 0.060 0.037 0.054 0.044 0.195
24 0.044 0.029 0.042 0.034 0.148
.
.
100 0.000 0.000 0.000 0.000 0.000
13.98
73.98
Total life years remaining  (Cumulative sum over each model cycle) =    
Overall life expectancy  (age upon entering model plus remaining life years) =    
Non-fatal CBVDNon-fatal CHD nonCVD deathCVD death SumCycle (time in years)
 
 
Fourth, age at screening is then added to remaining life expectancy. The estimate of overall 
life expectancy in the recalibrate model is 73.98 years, compared to 74.42 in the original 
model. 
 
Note that in comparing Tables 4-13 with Tables 4-7 it is the difference in the probabilities of 
the first event rather than the consequences for life expectancy which is reason for the 
reduction in life expectancy in the recalibrated model. This is consistent with the approach to 
recalibration which was to adjust the linear predictors of the first event risk. 
 
For consistency in exposition, figures 4-14 and 4-15 illustrate the impact of recalibration 
across a variety of risk profiles by revising the estimates made previously using the format of 
the 10-year risk tables. Life expectancies across all risk profiles are reduced following 
recalibration. 
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Figure 4-14 Recalibrated life expectancies for multiple risk profiles – men 
Least deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 83.9 83.7 83.7 83.6 83.6 80.8 80.9 81.1 81.2 81.3
160 84.7 84.5 84.5 84.4 84.4 81.4 81.6 81.8 81.9 81.9
140 85.3 85.3 85.3 85.2 85.2 81.9 82.2 82.4 82.5 82.5
120 85.9 86.0 86.1 86.0 85.9 82.3 82.7 83.0 83.1 83.1
100 86.4 86.6 86.7 86.7 86.6 82.6 83.1 83.4 83.6 83.6
Age 60 years Age 60 years
180 81.4 81.1 81.2 81.2 81.1 77.6 77.9 78.3 78.5 78.5
160 82.2 82.1 82.1 82.0 82.0 78.3 78.7 79.0 79.2 79.2
140 83.0 82.9 83.0 82.9 82.8 78.9 79.4 79.7 79.9 79.9
120 83.7 83.7 83.8 83.7 83.6 79.4 80.0 80.3 80.5 80.5
100 84.2 84.4 84.5 84.4 84.4 79.8 80.4 80.8 81.1 81.1
Age 50 years Age 50 years
180 80.0 80.0 80.2 80.2 80.2 76.2 76.7 77.3 77.6 77.7
160 81.1 80.9 81.1 81.1 81.0 76.9 77.5 78.0 78.3 78.4
140 81.9 81.8 81.9 81.9 81.8 77.6 78.2 78.6 78.9 79.0
120 82.6 82.6 82.7 82.6 82.5 78.0 78.8 79.3 79.5 79.6
100 83.2 83.4 83.4 83.4 83.3 78.5 79.2 79.8 80.0 80.1
Age 40 years Age 40 years
180 79.9 79.9 80.2 80.4 80.4 76.1 76.9 77.6 78.1 78.3
160 80.8 80.8 81.0 81.0 81.0 76.8 77.5 78.2 78.6 78.8
140 81.6 81.6 81.7 81.8 81.8 77.3 78.1 78.8 79.1 79.3
120 82.3 82.3 82.4 82.4 82.4 77.8 78.7 79.3 79.6 79.8
100 82.9 83.0 83.1 83.1 83.0 78.2 79.1 79.7 80.1 80.2
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Most deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 80.5 80.2 80.1 79.9 79.8 77.8 77.7 77.8 77.8 77.8
160 81.1 80.9 80.8 80.6 80.5 78.3 78.3 78.4 78.3 78.3
140 81.7 81.5 81.5 81.3 81.2 78.6 78.8 78.9 78.9 78.9
120 82.1 82.1 82.1 82.0 81.9 79.0 79.2 79.4 79.4 79.3
100 82.5 82.7 82.7 82.6 82.5 79.2 79.6 79.8 79.8 79.8
Age 60 years Age 60 years
180 76.8 76.4 76.2 76.0 75.9 73.3 73.3 73.4 73.4 73.4
160 77.6 77.2 77.1 76.8 76.7 74.0 74.0 74.1 74.1 74.1
140 78.3 78.0 77.9 77.7 77.6 74.5 74.6 74.8 74.8 74.8
120 78.9 78.8 78.7 78.5 78.4 74.9 75.2 75.4 75.4 75.4
100 79.4 79.4 79.4 79.2 79.1 75.2 75.7 75.9 76.0 75.9
Age 50 years Age 50 years
180 74.6 74.1 73.9 73.7 73.6 70.7 70.8 71.0 71.0 71.0
160 75.6 75.0 74.9 74.6 74.5 71.5 71.6 71.7 71.7 71.7
140 76.3 75.9 75.8 75.5 75.4 72.1 72.3 72.4 72.4 72.4
120 77.1 76.8 76.6 76.4 76.3 72.6 72.9 73.1 73.1 73.1
100 77.6 77.5 77.4 77.2 77.0 73.0 73.4 73.7 73.7 73.7
Age 40 years Age 40 years
180 73.6 73.1 73.0 72.8 72.7 69.7 69.8 70.1 70.2 70.3
160 74.6 74.0 73.9 73.6 73.5 70.4 70.6 70.8 70.9 70.9
140 75.3 74.9 74.7 74.5 74.3 71.0 71.2 71.5 71.6 71.6
120 76.1 75.7 75.6 75.3 75.1 71.6 71.9 72.1 72.2 72.2
100 76.7 76.5 76.4 76.1 75.9 72.0 72.4 72.7 72.8 72.7
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Figure 4-15 Recalibrated life expectancies for multiple risk profiles - women 
Least deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 85.5 85.3 85.1 85.1 85.0 81.1 81.2 81.2 81.3 81.3
160 86.6 86.4 86.1 86.1 86.0 82.0 82.1 82.2 82.2 82.2
140 87.6 87.4 87.2 87.1 87.0 82.9 83.0 83.0 83.1 83.1
120 88.6 88.5 88.2 88.0 88.0 83.8 83.9 83.9 83.9 83.9
100 89.6 89.4 89.1 88.9 88.9 84.5 84.8 84.7 84.7 84.7
Age 60 years Age 60 years
180 82.8 82.7 82.5 82.4 82.4 77.7 77.9 78.0 78.1 78.2
160 84.0 83.9 83.7 83.5 83.5 78.8 79.0 79.1 79.1 79.2
140 85.2 85.1 84.8 84.6 84.5 79.8 80.1 80.1 80.2 80.2
120 86.3 86.2 85.7 85.6 85.5 80.8 81.1 81.1 81.1 81.2
100 87.3 87.1 86.8 86.5 86.5 81.7 82.0 81.9 82.0 82.0
Age 50 years Age 50 years
180 81.2 81.2 81.0 81.0 81.0 75.8 76.1 76.3 76.5 76.6
160 82.5 82.4 82.2 82.1 82.1 76.9 77.4 77.4 77.6 77.7
140 83.7 83.5 83.3 83.1 83.1 78.1 78.4 78.5 78.6 78.7
120 84.8 84.6 84.3 84.1 84.0 79.1 79.4 79.5 79.5 79.6
100 85.8 85.7 85.2 85.0 85.0 80.0 80.4 80.4 80.5 80.5
Age 40 years Age 40 years
180 80.4 80.4 80.3 80.3 80.4 74.9 75.4 75.7 76.0 76.1
160 81.6 81.6 81.4 81.3 81.4 76.1 76.6 76.8 77.1 77.2
140 82.8 82.7 82.4 82.3 82.3 77.2 77.7 77.8 78.1 78.1
120 83.8 83.7 83.4 83.2 83.1 78.1 78.7 78.7 78.9 79.0
100 84.9 84.6 84.3 84.1 84.0 79.1 79.6 79.6 79.7 79.8
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Most deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 83.0 82.9 82.7 82.6 82.6 79.4 79.5 79.5 79.5 79.6
160 83.9 83.8 83.5 83.4 83.3 80.1 80.2 80.2 80.2 80.2
140 84.8 84.6 84.3 84.2 84.1 80.8 80.9 80.8 80.9 80.9
120 85.6 85.4 85.1 85.0 84.9 81.5 81.6 81.5 81.5 81.5
100 86.4 86.2 85.9 85.7 85.6 82.1 82.2 82.1 82.1 82.1
Age 60 years Age 60 years
180 79.9 79.7 79.5 79.4 79.3 75.5 75.7 75.7 75.8 75.8
160 80.9 80.7 80.4 80.2 80.2 76.4 76.5 76.5 76.6 76.6
140 81.8 81.6 81.3 81.1 81.0 77.1 77.3 77.3 77.3 77.3
120 82.7 82.5 82.2 82.0 81.8 77.9 78.1 78.0 78.0 78.1
100 83.7 83.4 83.0 82.7 82.7 78.7 78.9 78.8 78.7 78.8
Age 50 years Age 50 years
180 77.9 77.8 77.6 77.5 77.5 73.1 73.4 73.6 73.7 73.7
160 79.0 78.7 78.5 78.3 78.3 74.0 74.4 74.4 74.5 74.5
140 80.0 79.7 79.4 79.2 79.1 74.9 75.2 75.2 75.3 75.3
120 80.9 80.6 80.3 80.0 79.9 75.8 76.0 76.0 76.0 76.0
100 81.8 81.5 81.0 80.8 80.7 76.5 76.8 76.7 76.7 76.8
Age 40 years Age 40 years
180 76.9 76.8 76.6 76.5 76.5 72.0 72.4 72.6 72.9 72.9
160 77.9 77.7 77.4 77.3 77.2 72.9 73.3 73.5 73.6 73.7
140 78.8 78.6 78.3 78.1 78.0 73.8 74.1 74.2 74.4 74.4
120 79.7 79.4 79.1 78.8 78.8 74.5 74.9 74.9 75.0 75.1
100 80.6 80.3 79.8 79.6 79.5 75.3 75.7 75.6 75.7 75.8
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4.6 Summary and discussion  
 
Summary 
The aim of the chapter was to describe the first part in building the Scottish CVD Policy 
Model. The focus was to build a model that could take individuals defined by the ASSIGN risk 
factors to predict the risk of CVD events and life expectancy.  The intention is that the model 
is a natural extension of the ASSIGN score, so that there is consistency between the clinical 
tool that is currently used to screen and prioritise individuals for intervention and the policy 
model that is intended to be used to evaluate the impact of changes to modifiable risk factors. 
This chapter focused on the statistical approach to estimating lifetime risk and life 
expectancy. The next chapter will then detail how economic outcomes are generated and 
how the model is prepared for use in evaluation of interventions aimed at changing modifiable 
risk factors.  
 
Strengths  
Source data: To develop the Scottish CVD Policy Model we had access to the linked SHHEC-
SMR dataset used to create the ASSIGN score. This allowed direct estimation of the lifetime 
risks of CVD events and life expectancy for individuals.  In contrast, most policy models have 
been built using multiple cross-sectional data sources (Chapter 3) which can lead to models 
being complex, lacking transparency, and where the statistical estimation of event risks can 
be opaque. In contrast, having access to SHHEC-SMR offered the opportunity for a simple 
model to be developed, using a single longitudinal dataset and where the statistical methods 
are straightforward. 
 
Consistency with clinical practice: By choosing to build the Scottish CVD Policy Model using 
the variables of the ASSIGN score the intention is to provide a degree of continuity between 
the clinical practice of prioritising individuals using the ASSIGN 10-year score. This is 
intended to help in the encouraging the future use of the policy model.  
 
Modelling approach: A state transition model was developed, where individuals entering the 
model are simulated in discrete time steps, defined by annual cycles of the model with half-
cycle correction. However, it is not a Markov model. The literature tends to use the term state 
transition and Markov models interchangeably. However, the modelling approach combines 
positive features of several modelling types which are often treated as mutually exclusive in 
 217 
the literature.   In contrasting the features of the model with more standard Markov models, 
the novelties and advantages of the approach taken may be become clearer.  
 
First, the estimates of transition risks are estimated using modifiable risk factors (systolic 
blood pressure, total cholesterol, smoking, HDL-cholesterol) that are continuous, rather than 
discrete. Therefore, the model can estimate transition risks tailored to individuals risk profiles. 
This enhances the discriminatory power of the model. Often Markov models rely on data that 
are categorical and so individuals are assigned to a subgroup, and consequently 
discrimination becomes limited. In this sense, perhaps the policy model can be described as 
an individual state transition model. 
 
Second, the approach of estimating cause specific hazards (within a competing risk analysis) 
means that the probability of incurring a particular event at a particular time is estimated 
directly and can simply be read into the model. Further, the cumulative incidence of all events 
must always sum to 1, providing an automatic check that the model is functioning properly. 
This hasn’t been done before for economic models, to the best of my knowledge. In 
application, this enables a more elegant approach that is common for state transition models 
which rely on multiple data sources for different events. Consequently, a “fix” is normally 
applied in the model were a manual adjustment reduces the size of the event free population 
in each cycle by accounting for the hazards in the previous period. This is a straightforward 
but crude adjustment. 
 
Third, the model has the simplifying feature of modelling death directly from the first non-fatal 
CVD event. This enabled the model to avoid the need to model recurrent events, and 
individuals moving between non-fatal states; both of which can complicate the structure with 
the loss of transparency. This enabled the model to maintain a simple structure, and still 
enable accurate prediction to be made.  
 
Fourth, risk was estimated in continuous time and time to event was modelled. This means 
that the model can track patient history with life expectancy estimates conditional on an 
individual profile and event history. Consequently, this avoids the “memoryless” feature 
common in Markov models. This feature of time to event is normally associated with discrete 
event simulation. 
 
Fifth, while risk is modelled continuously the model takes an approach where events take 
place within time steps of one year. In effect, the model could run continuously or for any size 
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of time step. However, the key modelling decision regarding how the choice of time step was 
pragmatic, and as a balance between keeping the modelling simple to aid transparency and 
generating accurate predictions.  Crucially, the model performed well under validation tests 
and was recalibrated to a contemporary population.  
 
Sixth, the model has been extensively validated and, in particular, accurately predicted 
outcomes from an intervention trial. This form of external validation is unusual for economic 
models, with only the Archimedes model providing very extensive external validation tests for 
diabetes predictions and the model performing well(270).  
 
Limitations 
There were several weaknesses. First, over half of the SHHEC cohort were still alive and 
CVD-free and yet to experience one of the four first events.  Also of those who experience a 
non-fatal event over 66% were still alive. There was still sufficient power to undertake the 
parametric analysis. These two limitations represent an opportunity to make updates to the 
SHHEC-SMR data to re-estimate life expectancy predictions.  
 
Second, the linked data is only to hospitalised events.  This is likely to underestimate the 
risks of non-fatal events, as we do not detect endpoints that occur in primary care settings. 
This is especially relevant to stroke patients who are increasing treated in community 
settings.   
 
Third, the SHHEC study over-represents deprived patients. However, this is not a problem 
as such. While this means that the study population is not representative of Scotland, the 
sample size was large (over 16,000 people) and the analysis has adjusted for deprivation 
status. Therefore, the estimates remain unbiased.  
 
Fourth, it was not asked with SHHEC whether participating individuals were taking relevant 
medications. For instance, anti-hypertensives were commonly prescribed at the time of the 
survey (from 1980s), though statins were not routinely used for primary prevention at the 
time.    
 
Fifth, SHHEC did not report physical activity behaviour in the screening of individuals. This is 
potentially a limitation as physical activity has been found to be an independent risk factor. 
While there are diminishing returns in including additional risk factors to predict events(81), 
this may be a limitation in estimating the impact of physical activity on reducing the risk of 
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CVD and related conditions. A potential area for future research is to look for a dataset that 
includes physical activity and all of the other ASSIGN risk factors, link this to hospital records 
and re-estimate model to test whether the inclusion of physical activity (and other variables) 
improve the model. This could be done for both the ASSIGN score and the Scottish CVD 
Policy Model. A good candidate as a dataset would be the Scottish Health Survey, a cross-
sectional survey of the Scottish population that dates from 1995. Survey respondents all give 
permission for hospital records to be accessed and the maximum record linkage at present 
would extend to 2010, giving 15 years of follow-up. 
 
Fifth, survival post event was calculated by estimating the area under the survival curve, 
using the trapezoid method that is recommended by NICE. Regardless of how small the time 
steps taken the state transition the use of trapezoid will always leave an area between the 
curve and the hypotenuse of the triangle. An alternative approach would have been to 
estimate the integral, which is possible given that survival was modelled in continuous time. 
However, model predictions can simply be recalibrated, although this is a less elegant 
solution. 
 
Finally, the model is limited to a focus on primary prevention. The SHHEC-SMR dataset did 
not include rescreening of risk factors and so we do not know how risk factors changed 
once an SHHEC individual experienced a first event. Opportunities for expanding the scope 
of the model to make it a secondary prevention model will be discussed further in the 
concluding chapter, when considering a future research agenda.  
 
The model is calibrated to be used specifically in Scotland. It is expected to have high internal 
validity, but low external validity. In particular, a key strength of the policy model in a Scottish 
context is that it uses the ASSIGN risk factors and a measure of socioeconomic deprivation, 
this measure is not applicable outside of Scotland. In principle, however, the model could be 
recalibrated, as for instance the use of Framingham in the UK is recommended with 
associated calibration factors(120). Further, SIMD as a variable could be removed and the 
model equations re-estimated. 
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Appendix 1 – Cause specific hazards: comparing imputed 
results to a complete case analysis 
In comparing the CSH for the imputed and complete case analysis it is evident that 
imputation changes the coefficients, but marginally.  
 
Imputed results (in logs) - Males  
 
Risk of non-fatal CHD 
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.045 0.004 12.620 0.000 0.038 0.052
SIMD 0.004 0.001 3.090 0.002 0.001 0.007
Diabetes 0.653 0.184 3.560 0.000 0.292 1.014
Family history 0.408 0.058 7.050 0.000 0.295 0.522
Cigarettes per day 0.018 0.002 8.070 0.000 0.013 0.022
Systolic blood pressure 0.008 0.001 5.580 0.000 0.005 0.011
Total cholesterol 0.255 0.024 10.630 0.000 0.208 0.302
HDL cholesterol -0.760 0.094 -8.080 0.000 -0.947 -0.574
Constant -9.539 0.293 -32.500 0.000 -10.115 -8.963
Gamma 0.057 0.004 13.580 0.000 0.049 0.065  
 
Male - Risk of non-fatal CVD 
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.066 0.006 10.680 0.000 0.054 0.078
SIMD 0.009 0.002 4.460 0.000 0.005 0.014
Diabetes 1.168 0.257 4.550 0.000 0.664 1.673
Family history -0.021 0.109 -0.190 0.847 -0.235 0.193
Cigarettes per day 0.024 0.004 6.570 0.000 0.017 0.031
Systolic blood pressure 0.012 0.002 5.250 0.000 0.007 0.016
Total cholesterol 0.083 0.043 1.920 0.056 -0.002 0.168
HDL cholesterol -0.125 0.137 -0.910 0.362 -0.394 0.144
Constant -12.505 0.491 -25.460 0.000 -13.469 -11.541
Gamma 0.091 0.007 12.390 0.000 0.076 0.105  
 
Male – Risk of fatal CVD  
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.093 0.005 17.450 0.000 0.082 0.103
SIMD 0.006 0.002 3.730 0.000 0.003 0.010
Diabetes 0.863 0.240 3.590 0.000 0.389 1.337
Family history 0.165 0.085 1.930 0.054 -0.003 0.332
Cigarettes per day 0.031 0.003 10.880 0.000 0.026 0.037
Systolic blood pressure 0.015 0.002 9.070 0.000 0.012 0.019
Total cholesterol 0.120 0.035 3.380 0.001 0.050 0.189
HDL cholesterol -0.143 0.115 -1.240 0.218 -0.370 0.085
Constant -14.128 0.407 -34.750 0.000 -14.926 -13.330
Gamma 0.079 0.006 13.280 0.000 0.068 0.091  
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Male – Risk of fatal non CVD  
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.094 0.004 21.940 0.000 0.085 0.102
SIMD 0.009 0.001 6.500 0.000 0.007 0.012
Diabetes 0.335 0.257 1.310 0.192 -0.169 0.839
Family history -0.015 0.075 -0.200 0.845 -0.162 0.133
Cigarettes per day 0.031 0.002 12.710 0.000 0.026 0.035
Systolic blood pressure -0.001 0.002 -0.860 0.391 -0.005 0.002
Total cholesterol -0.051 0.030 -1.690 0.092 -0.111 0.008
HDL cholesterol 0.384 0.086 4.450 0.000 0.214 0.554
Constant -11.217 0.352 -31.910 0.000 -11.907 -10.527
Gamma 0.081 0.005 16.170 0.000 0.071 0.091  
 
Imputed results (in logs) - females  
 
Female – Risk of non fatal CHD 
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.058 0.005 12.380 0.000 0.049 0.067
SIMD 0.009 0.002 5.810 0.000 0.006 0.012
Diabetes 0.725 0.195 3.720 0.000 0.343 1.108
Family history 0.516 0.065 7.980 0.000 0.389 0.643
Cigarettes per day 0.021 0.003 6.560 0.000 0.014 0.027
Systolic blood pressure 0.006 0.002 3.910 0.000 0.003 0.009
Total cholesterol 0.188 0.026 7.140 0.000 0.136 0.240
HDL cholesterol -0.746 0.097 -7.720 0.000 -0.937 -0.555
Constant -10.516 0.317 -33.200 0.000 -11.138 -9.894
Gamma 0.083 0.005 16.410 0.000 0.073 0.093  
 
Female – Risk of non fatal CVD 
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.080 0.008 10.570 0.000 0.065 0.095
SIMD 0.013 0.002 5.620 0.000 0.009 0.018
Diabetes 1.101 0.258 4.270 0.000 0.595 1.607
Family history 0.356 0.105 3.380 0.001 0.150 0.562
Cigarettes per day 0.027 0.005 5.410 0.000 0.017 0.037
Systolic blood pressure 0.014 0.002 5.720 0.000 0.009 0.018
Total cholesterol -0.051 0.050 -1.020 0.308 -0.150 0.048
HDL cholesterol -0.346 0.147 -2.360 0.020 -0.636 -0.056
Constant -13.010 0.514 -25.300 0.000 -14.020 -12.000
Gamma 0.096 0.008 11.590 0.000 0.080 0.112  
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Female – Risk of fatal CVD 
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.102 0.007 14.060 0.000 0.087 0.116
SIMD 0.004 0.002 1.930 0.054 0.000 0.009
Diabetes 1.144 0.237 4.830 0.000 0.680 1.609
FH 0.239 0.096 2.490 0.013 0.050 0.428
CPD 0.048 0.004 12.490 0.000 0.040 0.056
SBP 0.018 0.002 8.450 0.000 0.013 0.022
TC 0.057 0.040 1.410 0.159 -0.022 0.136
HDL -0.174 0.125 -1.390 0.166 -0.420 0.073
Constant -15.424 0.491 -31.390 0.000 -16.388 -14.459
Gamma 0.099 0.007 13.250 0.000 0.084 0.114  
 
Female – Risk of fatal non CVD 
Risk factor Coef. Std. Err. z P>z [95% Conf. Interval]
Age at SHHEC 0.091 0.005 17.770 0.000 0.081 0.101
SIMD 0.007 0.002 4.530 0.000 0.004 0.010
Diabetes -0.037 0.322 -0.120 0.908 -0.668 0.594
FH -0.018 0.075 -0.240 0.814 -0.165 0.129
CPD 0.038 0.003 12.720 0.000 0.032 0.044
SBP 0.003 0.002 1.590 0.112 -0.001 0.006
TC -0.076 0.032 -2.380 0.018 -0.140 -0.013
HDL -0.045 0.093 -0.490 0.626 -0.229 0.138
Constant -11.257 0.344 -32.710 0.000 -11.932 -10.581
Gamma 0.089 0.006 16.100 0.000 0.078 0.099  
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Complete case analysis results (in logs) - Males  
 
Risk of non-fatal CHD 
________________________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________ 
   age_shhec |   .0447733   .0038734    11.56   0.000     .0371815    .0523651 
      simd04 |   .0032335   .0014153     2.28   0.022     .0004596    .0060075 
     diab_sr |   .6633511   .1959497     3.39   0.001     .2792968    1.047405 
      famhis |   .3382739   .0628869     5.38   0.000     .2150178      .46153 
         cpd |   .0182862   .0023263     7.86   0.000     .0137268    .0228456 
         sbp |   .0078895   .0015213     5.19   0.000     .0049079    .0108711 
      chol_c |   .2660048   .0252047    10.55   0.000     .2166046     .315405 
       hdl_c |   -.784403   .0882417    -8.89   0.000    -.9573536   -.6114524 
       _cons |  -9.584036   .3155063   -30.38   0.000    -10.20242   -8.965655 
      /gamma |   .0593799   .0045252    13.12   0.000     .0505108    .0682491 
______________________________________________________________________________ 
 
 
Risk of non-fatal CBVD 
________________________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________ 
   age_shhec |   .0649273    .006741     9.63   0.000     .0517151    .0781395 
      simd04 |   .0086602   .0023125     3.75   0.000     .0041279    .0131925 
     diab_sr |   1.146499   .2747514     4.17   0.000     .6079959    1.685002 
      famhis |  -.0811428    .119133    -0.68   0.496    -.3146392    .1523536 
         cpd |   .0242973   .0039145     6.21   0.000     .0166249    .0319696 
         sbp |   .0110776   .0024625     4.50   0.000     .0062511     .015904 
      chol_c |   .0809856   .0461376     1.76   0.079    -.0094424    .1714137 
       hdl_c |  -.1691968   .1392056    -1.22   0.224    -.4420348    .1036412 
       _cons |  -12.24458   .5365432   -22.82   0.000    -13.29619   -11.19297 
      /gamma |   .0883115   .0079447    11.12   0.000     .0727401    .1038829 
________________________________________________________________________________________ 
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Risk of CVD death 
________________________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________ 
 
   age_shhec |   .1000427   .0060285    16.59   0.000     .0882271    .1118584 
      simd04 |   .0063982   .0019421     3.29   0.001     .0025918    .0102047 
     diab_sr |   .9782542   .2364766     4.14   0.000     .5147686     1.44174 
      famhis |   .1630035   .0941893     1.73   0.084    -.0216041    .3476111 
         cpd |   .0324238   .0031917    10.16   0.000     .0261682    .0386795 
         sbp |   .0148519   .0018566     8.00   0.000      .011213    .0184908 
      chol_c |   .1317112    .038514     3.42   0.001     .0562251    .2071972 
       hdl_c |  -.1505994   .1135343    -1.33   0.185    -.3731225    .0719237 
       _cons |  -14.62659   .4567759   -32.02   0.000    -15.52185   -13.73132 
      /gamma |   .0816066   .0066497    12.27   0.000     .0685734    .0946398 
 
Risk of fatal non-CVD death 
________________________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________ 
 
   age_shhec |   .0959212   .0046444    20.65   0.000     .0868184     .105024 
      simd04 |    .008862   .0015587     5.69   0.000      .005807    .0119169 
     diab_sr |   .4073542   .2705641     1.51   0.132    -.1229416      .93765 
      famhis |  -.0231099   .0800474    -0.29   0.773    -.1799999      .13378 
         cpd |   .0309909   .0025609    12.10   0.000     .0259716    .0360102 
         sbp |  -.0015506   .0017711    -0.88   0.381    -.0050218    .0019206 
      chol_c |  -.0525316   .0325887    -1.61   0.107    -.1164043    .0113411 
       hdl_c |   .3606832   .0887723     4.06   0.000     .1866927    .5346738 
       _cons |  -11.27387   .3781938   -29.81   0.000    -12.01511   -10.53262 
      /gamma |   .0824772   .0053709    15.36   0.000     .0719505     .093004 
_______________________________________________________________________________________ 
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Complete case analysis results (in logs) - Women  
 
Risk of non-fatal CHD 
______________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________          
age_shhec   |    .0601541    .005201    11.57   0.000     .0499604    .0703478 
      simd04 |   .0096483   .0016647     5.80   0.000     .0063854    .0129111 
     diab_sr |   .7650296   .2230639     3.43   0.001     .3278324    1.202227 
      famhis |   .5382325   .0721364     7.46   0.000     .3968478    .6796172 
         cpd |   .0216402   .0034463     6.28   0.000     .0148855    .0283949 
         sbp |   .0056178   .0017798     3.16   0.002     .0021294    .0091061 
      chol_c |   .1873546    .027795     6.74   0.000     .1328775    .2418318 
       hdl_c |  -.7009756   .0940833    -7.45   0.000    -.8853755   -.5165757 
       _cons |  -10.72338   .3489158   -30.73   0.000    -11.40725   -10.03952 
______________________________________________________________________________ 
 
 
Risk of non-fatal CBVD 
 
______________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________ 
   age_shhec |   .0829577    .008351     9.93   0.000       .06659    .0993254 
      simd04 |   .0117021   .0026174     4.47   0.000      .006572    .0168322 
     diab_sr |   1.143402   .2989557     3.82   0.000     .5574594    1.729344 
      famhis |    .342425   .1181066     2.90   0.004     .1109403    .5739097 
         cpd |   .0285492   .0053795     5.31   0.000     .0180056    .0390928 
         sbp |   .0132375   .0026913     4.92   0.000     .0079626    .0185124 
      chol_c |  -.0641339   .0489562    -1.31   0.190    -.1600863    .0318184 
       hdl_c |  -.3396796   .1481795    -2.29   0.022    -.6301061   -.0492531 
       _cons |  -13.04117   .5618587   -23.21   0.000     -14.1424   -11.93995 
______________________________________________________________________________ 
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Risk of CVD death 
______________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________   
age_shhec |   .1083116   .0080751    13.41   0.000     .0924847    .1241386 
      simd04 |   .0034479   .0025059     1.38   0.169    -.0014636    .0083595 
     diab_sr |   1.151733   .2765128     4.17   0.000     .6097776    1.693688 
      famhis |   .2094482   .1086949     1.93   0.054    -.0035898    .4224863 
         cpd |   .0452936   .0043783    10.35   0.000     .0367123    .0538749 
         sbp |   .0178031   .0023242     7.66   0.000     .0132478    .0223585 
      chol_c |   .0600561   .0421366     1.43   0.154    -.0225301    .1426422 
       hdl_c |  -.0645549   .1266885    -0.51   0.610    -.3128598    .1837499 
       _cons |  -16.03345   .5518618   -29.05   0.000    -17.11508   -14.95182 
      /gamma |   .1016689   .0084041    12.10   0.000     .0851973    .1181406 
 
 
 
Risk of fatal non-CVD death 
________________________________________________________________________________________ 
Risk Factor |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
________________________________________________________________________________________   
age_shhec |   .0944633   .0057592    16.40   0.000     .0831755    .1057511 
      simd04 |   .0064458   .0018588     3.47   0.001     .0028028    .0100889 
     diab_sr |   .2125953   .3373178     0.63   0.529    -.4485354     .873726 
      famhis |   .0263424   .0846597     0.31   0.756    -.1395876    .1922724 
         cpd |   .0365315   .0034034    10.73   0.000      .029861     .043202 
         sbp |   .0021377   .0019835     1.08   0.281    -.0017499    .0060253 
      chol_c |  -.0721331   .0336588    -2.14   0.032    -.1381031   -.0061631 
       hdl_c |  -.0553507   .0972073    -0.57   0.569    -.2458736    .1351721 
       _cons |  -11.41056   .3873402   -29.46   0.000    -12.16973   -10.65138 
      /gamma |   .0882224   .0062412    14.14   0.000     .0759898     .100455 
________________________________________________________________________________________ 
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Appendix 2 - Cholesky decompositions: 1st events 
 
Men 
Non-fatal CHD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0035
SIMD -1.59E-05 0.0013
Diabetes -5.43E-03 -0.0076 0.1835
FH 3.71E-03 -0.0012 0.0008 0.0579
CPD 2.50E-04 -0.0003 0.0001 0.0000 0.0021
SBP -3.82E-04 -0.0001 -0.0001 0.0000 0.0001 0.0013
TC -5.13E-04 0.0023 -0.0013 -0.0010 0.0296 -0.0037 -0.0180
HDL -5.46E-03 0.0030 0.0011 0.0005 0.0091 -0.0034 0.0281 0.0891
Constant -1.26E-01 -0.0472 0.0073 -0.0111 -0.0418 -0.1689 0.1339 -0.1482 -0.0480
Gamma 4.35E-04 0.0005 0.0003 0.0000 0.0003 0.0003 0.0002 -0.0003 0.0057 0.0042  
 
Non-fatal CBVD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0062
SIMD -1.65E-04 0.0021
Diabetes -9.07E-03 -0.0164 0.2559
FH 6.08E-03 -0.0018 0.0018 0.1089
CPD 5.33E-04 -0.0005 0.0003 -0.0001 0.0035
SBP -6.41E-04 -0.0002 -0.0001 -0.0001 0.0001 0.0021
TC -1.20E-03 0.0044 -0.0007 -0.0014 0.0476 -0.0056 -0.0213
HDL -4.83E-03 0.0011 0.0115 -0.0026 0.0068 -0.0095 0.0513 0.1255
Constant -2.33E-01 -0.0728 -0.0208 -0.0027 -0.0681 -0.2697 0.3691 -0.3070 -0.3557
Gamma 9.51E-04 0.0010 0.0006 0.0000 0.0005 0.0008 0.0008 -0.0006 0.0032 0.0064  
 
Fatal CVD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0053
SIMD -2.64E-04 0.0017
Diabetes -5.40E-03 -0.0134 0.2398
FH 5.42E-03 -0.0017 0.0012 0.0852
CPD 5.44E-04 -0.0004 0.0001 -0.0001 0.0028
SBP -5.04E-04 -0.0002 0.0000 -0.0001 0.0000 0.0016
TC 6.02E-04 0.0040 -0.0013 -0.0009 0.0294 -0.0018 0.0192
HDL -5.68E-03 -0.0010 -0.0009 -0.0033 0.0035 -0.0181 -0.0382 0.1071
Constant -2.23E-01 -0.0526 0.0004 0.0018 -0.0559 -0.2014 -0.2899 -0.2281 -0.2583
Gamma 8.85E-04 0.0008 0.0005 0.0000 0.0004 0.0007 -0.0005 -0.0004 0.0023 0.0053  
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Non-fatal CVD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0043
SIMD -1.84E-04 0.0014
Diabetes -3.87E-03 -0.0096 0.2566
FH 4.05E-03 -0.0013 0.0018 0.0752
CPD 4.02E-04 -0.0004 0.0001 -0.0001 0.0023
SBP -3.82E-04 -0.0002 0.0000 0.0000 0.0001 0.0016
TC -5.79E-04 0.0032 -0.0004 -0.0010 0.0348 -0.0041 -0.0179
HDL -3.81E-03 0.0005 0.0042 0.0000 0.0039 -0.0068 0.0229 0.0827
Constant -1.77E-01 -0.0491 -0.0077 -0.0041 -0.0528 -0.1950 0.2073 -0.1626 -0.1434
Gamma 7.66E-04 0.0007 0.0002 0.0000 0.0003 0.0005 0.0006 -0.0003 0.0031 0.0037  
 
 
Women 
Non-fatal CHD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0047
SIMD -1.71E-04 0.0015
Diabetes -6.11E-03 -0.0071 0.1947
FH 3.86E-03 -0.0010 0.0005 0.0646
CPD 5.69E-04 -0.0005 0.0001 -0.0001 0.0030
SBP -5.26E-04 -0.0001 0.0000 0.0000 0.0002 0.0015
TC -7.86E-03 0.0025 -0.0015 -0.0015 0.0380 -0.0089 0.0300
HDL -7.95E-03 0.0191 0.0114 0.0000 0.0158 0.0003 -0.0303 0.0872
Constant -1.16E-01 -0.0795 -0.0125 -0.0144 -0.0601 -0.1738 -0.0674 -0.1443 0.1447
Gamma 6.15E-04 0.0006 0.0002 0.0001 0.0002 0.0004 -0.0002 -0.0006 -0.0026 0.0042  
 
Non-fatal CBVD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0075
SIMD -3.99E-04 0.0023
Diabetes -1.15E-02 -0.0149 0.2572
FH 7.10E-03 -0.0004 0.0036 0.1051
CPD 1.01E-03 -0.0007 0.0002 -0.0001 0.0048
SBP -7.81E-04 -0.0003 -0.0001 0.0000 0.0002 0.0022
TC -1.54E-02 0.0041 -0.0016 -0.0031 0.0863 -0.0194 -0.0748
HDL -1.23E-02 0.0263 0.0140 0.0025 0.0244 -0.0011 0.0380 0.1360
Constant -1.89E-01 -0.1194 -0.0187 -0.0276 -0.1015 -0.2529 0.0837 -0.2100 -0.2966
Gamma 1.27E-03 0.0012 0.0005 0.0001 0.0003 0.0008 0.0001 -0.0008 0.0032 0.0074  
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Fatal CVD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0053
SIMD -2.64E-04 0.0017
Diabetes -5.40E-03 -0.0134 0.2398
FH 5.42E-03 -0.0017 0.0012 0.0852
CPD 5.44E-04 -0.0004 0.0001 -0.0001 0.0028
SBP -5.04E-04 -0.0002 0.0000 -0.0001 0.0000 0.0016
TC 6.02E-04 0.0040 -0.0013 -0.0009 0.0294 -0.0018 0.0192
HDL -5.68E-03 -0.0010 -0.0009 -0.0033 0.0035 -0.0181 -0.0382 0.1071
Constant -2.23E-01 -0.0526 0.0004 0.0018 -0.0559 -0.2014 -0.2899 -0.2281 -0.2583
Gamma 8.85E-04 0.0008 0.0005 0.0000 0.0004 0.0007 -0.0005 -0.0004 0.0023 0.0053  
 
Non-fatal CVD 
age SIMD Diabetes FH CPD SBP TC HDL constant gamma
age 0.0051
SIMD -2.40E-04 0.0016
Diabetes -1.06E-02 -0.0095 0.3212
FH 3.68E-03 -0.0003 0.0005 0.0749
CPD 6.30E-04 -0.0006 0.0000 0.0000 0.0029
SBP -5.62E-04 -0.0002 -0.0001 0.0000 0.0002 0.0016
TC -9.55E-03 0.0019 0.0002 -0.0016 0.0505 -0.0111 -0.0418
HDL -4.06E-03 0.0144 0.0026 0.0026 0.0145 -0.0007 0.0291 0.0860
Constant -1.37E-01 -0.0689 -0.0053 -0.0151 -0.0616 -0.1853 0.0696 -0.1398 0.1791
Gamma 7.81E-04 0.0008 0.0002 0.0001 0.0002 0.0005 0.0001 -0.0004 -0.0024 0.0048  
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Appendix 3 – Cholesky decompositions: 2nd events 
Men 
Survival post-CHD 
age SIMD FH constant gamma
age 0.0063
SIMD 2.06E-04 0.0021
FH 9.24E-03 -0.0060 0.1001
constant -4.37E-01 -0.0681 -0.0313 0.4437
gamma 4.16E-03 0.0006 0.0007 -0.0013 0.0098  
 
Survival post-CBVD 
age SIMD FH constant gamma
age 0.0098
SIMD 2.76E-04 0.0031
FH 1.26E-02 -0.0009 0.1647
constant -6.99E-01 -0.1055 -0.0355 0.7079
gamma 7.41E-03 0.0007 0.0048 -0.0019 0.0173  
 
Women 
Survival post-CHD 
age SIMD FH constant gamma
age 0.0078
SIMD 1.03E-04 0.0025
FH 6.45E-03 -0.0023 0.1192
constant -5.60E-01 -0.0843 -0.0437 0.5677
gamma 5.77E-03 -0.0001 0.0023 -0.0014 0.0125  
 
Survival post-CBVD 
age SIMD FH constant gamma
age 0.0103
SIMD -2.52E-04 0.0037
FH 2.35E-02 -0.0052 0.1680
constant -7.53E-01 -0.1337 -0.0643 0.7632
gamma 9.51E-03 0.0008 0.0023 -0.0023 0.0200  
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Chapter 5:  Generating economic outcomes and 
preparing the model for evaluation  
 
5.1 Introduction  
Chapter 5 details the second part in the development of the Scottish CVD Policy Model. The 
previous chapter developed the model structure and statistical approach to estimating the 
lifetime risk of CVD and life expectancy. However, it is not only longevity that is of concern to 
individuals but also quality of life. Consequently, it is important to weight length of life by the 
expected health related quality of life (HRQoL). Further, as life expectancy of individuals and 
populations increase it is expected there will implications for health service costs, given 
comorbidities tend to cluster in older age groups(46).  
 
The aim of the chapter is to detail how the model uses the survival estimates generated from 
Chapter 4 to then quality adjust survival and attach health service costs. With reference to the 
best practice guidelines in building an economic model, the empirical work of the chapter 
essentially falls under “Modelling stage 3:  data identification and incorporation”. In effect, 
economic information is layered on top of survival estimates. This then enables the outcomes 
of the policy model outputs to be broadened from the risk of CVD and life expectancy to 
quality adjusted life expectancy (QALE) and cumulative lifetime health service costs.  
 
To set the chapter in context, Section 5.2 provides a brief overview of the approach taken to 
generate QALE and costs, and how the model is populated with this information. All 
estimates were derived using routine Scottish data sources, rather than populating the model 
using secondary literature. Section 5.3 to section 5.6 details the approach to estimating 
HRQoL and illustrates how survival in the model is quality adjusted to generate QALE. This 
process of quality adjustment consists of background morbidity and the impact of 
experiencing non-fatal CVD events. Discounting is also introduced to the model and the 
chapter illustrates how the model can produce discounted QALE and specific to individual risk 
profiles. Section 5.7 details how total health service costs (accounting for all CVD and non-
CVD events) are estimated as a function of individual risk profiles. Further, in a similar 
process to quality adjustment, section 5.8 shows how survival in the model is used to 
generate expected (discounted and undiscounted) lifetime health service costs. The 
penultimate section 5.9 then illustrates how the model can be used to evaluate the impact of 
interventions aimed at changing modifiable risk factors to estimate impacts on life expectancy 
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and lifetime health service costs. Section 5.10 then provides a summary and discussion of 
the chapter as a whole. 
 
5.2 Overview: Generating economic outcomes 
Figure 5-1 illustrates the structure the policy model. Chapter 4 detailed how equation 1 was 
derived to estimate the risk of first events, and also how equation 2 was derived to estimate 
survival from a first non-fatal CVD event. Chapter 5 estimates how individual survival in the 
model states are quality adjusted and how individuals accumulate hospital costs. As the 
chapter progresses the text refers back to this figure to fully describe the process of 
generating QALE and the estimation of lifetime health service costs.  
 
Quality adjustment consists of three elements. First, it is important to account for the 
background morbidity of individuals as they enter and age within the model. The vast majority 
of individuals do not exist in perfect health prior to death. Individuals suffer from a range of 
co-morbidities which accumulate with age. Second, it is important to account for morbidity 
impacts of incurring a first non-fatal CVD event, and not only the consequence for an 
individual’s length of life.  Third, it is then necessary to predict the risk of incurring further non-
fatal CVD event post a first non-fatal event, and further quality adjust survival.  
 
In reference to figure 5.1, quality adjustment is applied as follows.  As individuals remain in a 
CVD free state the only quality adjustment required is to account for background morbidity 
(equation 3). As individuals move from a CVD event free state and enter states that denote a 
first non-fatal CVD event then quality adjustment is comprised of both background morbidity 
and the impacts of incurring the first event, either CHD or CVBD (equation 3 + 4). Further, 
individuals who survive a first event are at risk of subsequent non-fatal CVD events prior to 
death. Therefore, it is also important to also estimate the risk of events and account for the 
HRQoL impact (equations 3 + 4 + 5).   
 
Regarding the cost side, individuals are also expected to accumulate health service costs 
over their lifetime. On average, costs will increase with life expectancy as a result of 
increasing co-morbidities associated with longevity. Costs are estimating separately for those 
who are within a CVD event free state (equation 6), and those who have experienced a first 
non-fatal event (equation 7). 
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Figure 5-1 CVD model: quality adjusting life expectancy and estimating lifetime health service 
costs  
 
CVD event f ree
(3), (6)
Non-fatal
CHD
(3),(4),(5),(7)
Non-fatal
CBVD
(3),(4),(5),(7)
Fatal CVD Fatal non-CVD
Fatal
All cause
Fatal
All cause
1 1 1 1
2 2
 
 
Equation 3: Background morbidity = Function (age, deprivation) 
Equation 4: Morbidity impact of non-fatal CVD events = Function (age, CVD events, SIMD) 
Equation 5: Risk of subsequent CVD events = Function (age, family history, SIMD) 
Equation 6: Costs prior to 1
st
 event = Function (age, family history, SIMD) 
Equation 7: Costs post 1
st
 event = Function (age, family history, SIMD) 
NB Equation 1 and 2 estimate transition between model states, and were described in Chapter 4. 
 
 
 
 
.  
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5.3 Health related quality of life: background 
 
5.3.1 Measuring health related of life 
(i) Generic measures versus disease specific measures:  
Quality of life is the perceived quality of an individual's daily life, or well-being. This concept 
includes all emotional, social, and physical aspects of an individual's life(284). However, 
operationalising this concept to measure quality of life is a contested area within and between 
disciplines(284-288). Although there is no consensus on the definition of the concept of 
health related quality of life (HRQL)(66), definitions usually refer to physical, emotional and 
social well-being. HRQL is a distinct construct which refers to the impact that health 
conditions and their symptoms have on an individual’s quality of life.  
 
HRQL instruments have evolved in order to measure and assess the impact of disease, the 
effect of treatment, and other variables that impact upon individual lives(289). These 
instruments can provide an assessment of the patient’s experience of his or her health 
problems in areas such as physical, emotional or social function, role performance, pain and 
fatigue; the functional effect of an illness and its consequent therapy upon a patient, as 
perceived by the individual(286).   
 
There are two types of HRQL instrument: ‘generic’ and ‘disease-specific’. Disease-specific 
instruments measure the multiple aspects of HRQL relevant to a specific disease group and 
are more clinically sensitive and potentially more responsive in detecting change. Generic 
instruments are designed to address multiple aspects of HRQL across a range of different 
patient or disease groups. Thus, they focus on general issues of health (or ill health), such as 
functional capacity, disability and distress, rather than specific features of a particular disease 
Economists prefer the use of generic measures to allow for direct comparability of HRQoL 
across different diseases. The use of generic measures of HRQoL will be further discussed 
below; first, it is discussed what the desirable features of any HRQoL measure are. 
 
(ii) Desirable features of health related quality of life measures 
It is desired that health related quality of life measures have both reliability and validity. 
Reliability of an instrument is normally assessed in two ways: internal consistency and test-
retest(284). Internal consistency is an estimate of the homogeneity of the items measuring a 
specific health concept or domain and is the extent to which individual items are inter-
correlated with each other. The former is an estimate of the homogeneity of items measuring 
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a specific health domain and is normally measured using Cronbach's alpha coefficient. The 
closer the coefficient is to 1, the greater the homogeneity between the items and, therefore, 
the greater the confidence that can be attributed that items relate to the domain under 
investigation. However, caution should be noted as alpha coefficients of >0.95 can mean that 
several of the items are in fact measuring the same thing(290). 
  
Test-retest reliability is a measure of an instrument’s ability to produce data that are 
consistent or stable over time when there is no change in the measured variable or health 
state. It is normally determined using Cohen's Kappa or Pearson's or Spearman's correlation 
coefficient. Normally, levels in excess of 0.6 indicate an adequate test-retest reliability(290). 
 
Validity refers to the ability of a measure to quantify the item or dimension it is supposed to 
measure(284). The three most important aspects of validity are content validity, criterion 
validity and construct validity(66). Content validity relates to the choice, appropriateness, 
importance and representativeness of the instrument’s content. However, as there is no 
universal agreement on the defined content of quality of life instruments, validity is largely 
based on how well and broadly the content has been sampled and derived. Construct validity 
is supported when expected patterns of relationships are identified between the measured 
construct (such as physical functioning) and other variables (such as disease severity). 
Discriminative validity is the instrument's ability to detect changes in the observed variable 
without provoking a 'floor' or 'ceiling' effect that reflects an inability to detect clinically 
significant changes at the lower or higher spectrum of quality of life(66). 
 
(iii) Commonly used health related quality of life measures in cardiovascular research 
There are a variety of possible measuring tools available.  In terms of disease specific tools, a 
review(290) found that a very wide range have been used, including Seattle Angina 
Questionnaire (SAQ), Quality of Life after Myocardial Infarction (QLMI) questionnaire, 
Minnesota Living with Heart Failure (MHFQ) Questionnaire, Myocardial Infarction 
Dimensional Scale (MIDAS), and the Cardiovascular Limitations and Symptoms Profile 
(CLASP). All have been used widely and have performed with mixed success relative to the 
criterion described above. 
 
The most commonly used generic tools used in cardiovascular disease research are the 
EuroQol EQ-5D index(138) and the Short Form 36 or 12 (SF-36 or SF-12(137, 238). Other 
measures using in CVD research, but less widely applied as the Quality and Well-Being 
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(QWB) scale, and the health utilities index (HIU)(65). The consequent discussion is 
constrained to SF-3612 and EQ-5D. 
 
The EQ-5D is consists of five dimensions (mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression), each with three levels of response or severity (no problems, some 
problems, or extreme problems). There are two possible questionnaire options: the EQ-5D-3L 
refers to there being 5 health dimensions (5D) and three possible responses, or levels (3L). A 
recently developed measure is the EQ-5D-5L, which has the same five health dimensions but 
with 5 levels (5L) of possible responses. This can produce 243 different health states i.e. 
different combinations of responses to the question. 
 
The SF-36 consists of 36 questions covering eight domains, including physical functioning 
(PF), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role 
emotional (RE) and mental health (MH). The SF-12 is a more parsimonious version 
consisting of 12 questions to measure the same eight health domains. 
 
(iv) Potential limitations of generic health related quality of life measures 
It is important that HRQoL are tested for the above attributes of reliability, validity and 
responsiveness. Measures which do not perform well are necessarily limited. In general, 
disease specific measures should be expected to perform better, as they have been 
developed with the specific condition in mind.  However, the key limitation of using disease 
specific measures is the difficulty of directly comparing the HRQoL impact from different 
conditions. Generic measures are designed to allow for direct comparisons in HRQoL across 
disease areas, but may come at the cost of less reliability and validity, as described above.  
 
Encouragingly, both the EQ-5D and the SF-36/12 have been found to perform well in CVD 
research. However, the mean HRQoL between studies differ(65). The key issue is whether 
the magnitude of change in HRQoL is adequately measured, rather than baseline HRQoL. In 
this regard, the used of a generic score seems to adequately evidenced. A review of the use 
of EQ-5D supports the reliability and validity of the instrument in (291). Further, it has been 
found that the SF-36 may perform relatively better than the EQ-5D, with better internal 
consistency and a higher test-retest reliability(66). Importantly, it has been shown that  the 
SF-12 has a similar responsiveness to change as the SF-36 in patients with CHD(292). 
Therefore, in choosing the SF-36 or SF-12, the latter may be the preferred measure given 
parsimony.  
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The debate between generic and disease specific tools is likely to be continuous. The next 
section will discuss the potential of using both types of measures, and/or mapping between 
one measure and another.  
 
5.3.2 The process of estimating health utility from health related 
quality of life measures 
(i) Two-stages: From an economics perspective generic HRQoL measures are the preferred 
measure. Economics is concerned the allocation of scarce resources amongst alternative 
uses, and a generic measure is intended to enable comparisons of between different 
interventions and disease areas.  However, using a generic questionnaire itself is not 
sufficient, as a very wide of possible states can result. These states need to be rank ordered 
in terms of the desirability of one state over another.  
 
So the first stage is to administer a generic health questionnaire and the second stage is to 
convert responses into a single score summarising overall HRQoL. Economists call this score 
a health utility score. The process of ranking different HRQoL states involves either direct 
elicitation methods, or generic preference-based methods(293). The former is applied 
bespoke to each study and includes the methods of time-trade off and standard gamble 
where individuals trade-off health state scenarios. The latter simply takes ‘off-the-shelf’ 
preference weights from previous studies.   Both the EQ-5D and the SF-12 can be converted 
into utilities using ‘off-the-shelf’ preference-weights(294). The latter is converted to the utilities 
using the SF-6D algorithm. The EQ-5D can produce 243 states and the SF-6D can produce 
18,000 states. 
 
(ii) Comparison of health utility measures and limitations: The existing literature is in 
agreement that there is reasonable correlation between EQ-5D and SF-6D ranking of health 
states on average(239, 295-296). However, neither the EQ-5D not the SF-6D is ideal: neither 
score measures all possible health states. The EQ-5D has been shown to suffer from ‘ceiling 
effects’ as the score ranges from -0.54 (worst that a death state of 0) to 0.88(best health). As 
such, it has difficulty discriminating between healthier states. The SF-6D suffers from ‘floor 
effects’ as the score measures health state utilities from 0.29 (worst health) to 1 (perfect 
health). As such, it has difficulty discriminating between states of poorer health. It has been 
argued that the EQ-5D is more appropriate in ‘sicker’ populations, and the SF-6D better in 
‘healthier’ populations (200, 248,249).  
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Overall, while mean EQ-5D and SF-6D scores are often similar, depending on the patient 
group there can be wide variation in estimates depending on the degree of health of the 
individuals. In CVD patients, the SF-36/12 has been shown to have less ceiling and floor 
effects that other generic measures, including the EQ-5D(292). 
 
A key issue is whose preferences should be used to rank health states, with the choice 
between the general population, or the patients affected by the condition under consideration. 
NICE recommends that preference weights be derived from general population 
preferences(37). This reflects the fact that the ultimate purpose of economic evaluation of 
health sector interventions in the UK is to influence how public funds are spent. However, this 
can raise objections, with respect to whether the healthy general public can properly 
empathise with the health states of different conditions(66).  
 
On the other hand, directly asking patients may not be ideal either, as individuals may have 
adapted to their condition which could also be influence by peer group, and social context. 
Therefore, there may be an apparent inconsistency between so called subjective and 
objective measures of well-being.  This phenomenon has been described as ‘adaptive 
expectations’ (Sen, 1999 pg 62)(297) and is often cited in the context of developing countries, 
where groups may not necessarily ‘feel’ disadvantaged even though the absolute level of 
health and poverty for instance may be low(298).  
 
(ii) Estimating utility in practice: Overall, there is not a perfect measure of HRQoL. As 
discussed, there is disagreement over the concept, its operationalisation, whether to use 
generic or disease specific measures, and whether patients and/or the general population 
should be canvassed. 
 
Practical ways forward in the debate whether to use disease specific or generic measures of 
HRQoL is to either map between one and the other, or to include both in a study.  ‘Mapping’ 
is the development and use of an algorithm (or algorithms) to predict health-state utility 
values using data on other indicators or measures of health. The algorithm can be applied to 
data from clinical trials, other studies or economic models containing the source predictive 
measure(s) to predict utility values even though the target preference-based measure was 
not included in the original source study of effectiveness(299).  
 
This mapping exercise may be important to convert past study findings that are for disease 
specific findings to utility values. For new studies, however, it practical solution is to include 
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both disease specific and generic measures in so-called pragmatic trial designs(38), as 
discussed in Chapter 3. This would then test for the agreement between disease and generic 
measures, and validate wider mapping exercises.  
 
It is contended here that perhaps the key issue is not necessarily for one measure (e.g. 
disease specific versus generic) to assert dominance, but to recognise they have different 
immediate purposes. This would be more in keeping with a multi-disciplinary approach to 
evaluation, and may help further encourage clinicians and health professionals to engage 
with economists more routinely.  
 
5.4 Estimating background morbidity and the impact of 
experiencing CVD events   
 
5.4.1 Limited existing research  
To reiterate, background morbidity is a term used to describe the average HRQoL in a 
population. This can also be termed populations. Kind et al(300) conducted a representative 
survey of the UK general population using 3,395 households to estimate background 
morbidity. Respondents completed both the EQ-5D questionnaire and also the Visual 
Analogue Scale, which asked individuals to rate their health from 0 (worst imaginable) to 100 
(best imaginable). The creators of the EQ-5D recommend that when conducting economic 
evaluation and undertaking cost utility analysis, the VAS estimates should not be used to 
refer to population norms(138).  Rather, the EQ-5D should be used and responses 
preference weighted, as described above.  
 
However, it is important to note that while the generic EQ-5D questionnaire was applied, 
responses were not preference weighted. Rather, Kind’s analysis reports on the VAS 
responses, which were weighted using a survey of patient preferences, not the general 
population. Consequently, the estimates produce by Kind are not strictly economic measure 
of background morbidity (or norms / utilities). Nonetheless, there is an absence of alternative 
estimates of health status in the general population. Recently, a demonstration of how to 
generate norms using the SF-6D was published(301), and norms have been derived in 
Australia using the SF-6D(302). Therefore, there is a need to estimate population norms 
using preference-weighted HRQoL, and the SF-6D may be the most appropriate measure. 
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The impact of experiencing CVD events on reducing HRQOL is called utility decrements. 
There are few studies estimating decrements for specific CVD events and no studies, that we 
are aware of, drawing upon the general population or using the SF-6D. The main study is 
Clarke et al (2002) where utilities were derived from the EQ-5D in a population with diabetes.  
Therefore, is also need to estimate the impact of CVD events in a general population.  
 
The following details how background morbidity and event utility decrements were estimated 
in a Scottish population and compares results to the studies highlighted above. 
 
5.4.2 An opportunity to estimate health related quality of life in a 
Scottish Population: the Scottish Health Survey  
There was an opportunity to generate background morbidity(population norms)  and estimate 
utility decrements directly for the Scottish general population. The Scottish Health Survey 
(SHeS) is a periodic cross sectional survey of the Scottish population, and has cardiovascular 
disease as its principle focus. SHeS uses multi-stage, stratified sampling to provide a 
representative sample of the Scottish population, and includes face-to-face interviews and 
physical measurements.  
 
The SHeS 2003 is the only version of the SHeS that included the SF-12 (or any generic) 
HRQoL questionnaire that can be used to generate health state utilities. The SHeS 2003 had 
11,472 respondents, with 7,780 over 20 years and asked for SF-12 responses.  There were 
7,054 individuals with sufficient SF-12 responses (the 6 question used by the SF-6D) to 
generate utilities. This represented 91% of eligible respondents. There were no systematic 
differences between respondents with and without missing data, by age, sex and fifths of 
SIMD. Given missing data was relatively minor and there was a large sample size, the 
analysis proceeded with a complete case analysis.  
 
Using the same dataset, there was also an opportunity to estimate the HRQoL impact of 
experiencing events, or utility decrements. The SHeS 2003 collected information on six CVD 
events: angina, myocardial infarction, irregular heartbeat, other heart conditions, stroke and 
intermittent claudication. Events were self-reported with respondents asked, for each event in 
turn, whether a doctor had made a positive diagnosis and, if so, whether it was in the 
previous 12 months of the interview date. The exception was intermittent claudication where 
there was no survey question regarding time from doctor diagnosis.  
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5.4.3 Estimating background morbidity / population norms 
Table 5-1 outlines the final dataset used in the analysis, with 44% males and 56% females. 
There was a slight under-representation of the more deprived groups (SIMD 4 and 5), 
although the sample size remained large.  
 
Table 5-1 Scottish Health Survey 2003 - Population characteristics  
All % Male % Female %
Total 7054 100% 3,105 100% 0 100%
1418 20% 634 20.4% 784 19.9%
1574 22% 701 22.6% 873 22.1%
1549 22% 691 22.3% 858 21.7%
1346 19% 597 19.2% 749 19.0%
1167 17% 482 15.5% 685 17.3%Most deprived fifth - SIMD 5
Less deprived fifth
Less deprived fifth - SIMD 1
Less deprived fifth
Less deprived fifth
 
 
The SF-6D is used to convert SF-12 responses into utilities. First, the algorithm chooses 6 
questions: (i) physical functioning; (ii) role limitation; (iii) social functioning; (iv) bodily pain; (v) 
vitality; and (vi) mental health. The percentage of respondents experiencing a ‘problem’ is 
shown in table 5.2 and was defined here as where the respondent provided a score less than 
the mode (e.g. ticking boxes 1 or 2 on a 5 point Likert scale). Average responses are shown 
with respect to the whole sample and across seven age groups used by Kind, to provide a 
degree of consistently. 
 
Across all age groups, approximately a third of respondents suffered physical symptoms and 
felt limited in social functioning. Notably, two thirds of respondents had a mental health 
problem, with almost everyone limited in terms of vitality. 
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Table 5-2 Summary of SF6D dimensions – percentage experiencing problem  
Age band Physical Role Social Bodily Mental Vitality
functioning limitation functioning pain health
Total 27% 30% 34% 37% 66% 94%
Male 26% 27% 31% 36% 61% 93%
Female 29% 31% 37% 38% 69% 96%
<25
Total 15% 20% 35% 22% 74% 93%
Male 15% 14% 30% 17% 71% 95%
Female 16% 20% 39% 26% 76% 92%
25-34
Total 12% 23% 32% 26% 71% 94%
Male 11% 19% 27% 29% 66% 95%
Female 12% 23% 35% 23% 75% 94%
35-44
Total 14% 23% 33% 30% 70% 95%
Male 11% 21% 29% 30% 66% 93%
Female 14% 23% 35% 30% 74% 97%
45-54
Total 21% 31% 34% 36% 72% 95%
Male 20% 24% 30% 36% 68% 92%
Female 22% 31% 37% 37% 76% 97%
55-64
Total 34% 31% 32% 43% 62% 94%
Male 31% 31% 30% 40% 58% 92%
Female 36% 31% 34% 45% 65% 96%
65-74
Total 45% 40% 35% 50% 57% 94%
Male 46% 40% 35% 49% 52% 93%
Female 45% 40% 34% 51% 61% 95%
> 74
Total 63% 59% 45% 53% 53% 94%
Male 54% 46% 39% 44% 48% 93%
Female 68% 59% 49% 59% 56% 95%  
 
Across most categories there is an age gradient, where the percentage reporting a problem 
increased with respondent age. The notable exception is mental health where the percentage 
experiencing a problem declines with age. 
 
The SF-6D algorithm was then applied to the SHeS population. Estimates of background 
morbidity were stratified by sex, age groups and SIMD quintiles. This was a descriptive 
analysis, reporting on mean scores and confidence intervals. Modelling made very minor 
differences to mean utility scores.   
 
Table 5-3 reports on mean scores for the population split by age group and sex, 95% 
confidence intervals and the sample size. Average scores, across age groups, were 0.795 
(0.791-0.80) for the population and 0.807 (0.802-0.811) for males, and 0.787 (0.787-0.791) 
for females. There is an expected, though gradual, age gradient in the population with the 
greatest step change in the over 74 year olds, where utilities are 0.74.   Males consistently 
report higher health status, though the difference varies across age groups.  
 
 243 
Table 5-3: Background morbidity in the general population 
Age band All Male Female
All 0.795 (0.791, 0.8) 0.807 (0.802, 0.811) 0.787 (0.782, 0.791)
7054 3105 3949
<25 0.818 (0.806, 0.829) 0.831 (0.814, 0.847) 0.809 (0.794, 0.824)
350 140 210
25-34 0.816 (0.809, 0.823) 0.823 (0.812, 0.834) 0.811 (0.801, 0.82)
998 425 573
35-44 0.81 (0.804, 0.817) 0.82 (0.811, 0.83) 0.802 (0.793, 0.811)
1525 687 838
45-54 0.794 (0.787, 0.802) 0.806 (0.795, 0.818) 0.785 (0.776, 0.795)
1319 571 748
55-64 0.794 (0.786, 0.802) 0.801 (0.789, 0.813) 0.787 (0.777, 0.798)
1270 577 693
65-74 0.782 (0.773, 0.792) 0.788 (0.774, 0.802) 0.777 (0.763, 0.79)
935 446 489
> 74 0.742 (0.73, 0.754) 0.774 (0.757, 0.792) 0.721 (0.704, 0.737)
657 259 398  
 
There is a clear deprivation gradient in scores all age groups and for males and females, with 
the latter affected to a greater extent (Tables 5-4 and 5-5). On average, the health status of 
men falls from 0.831 in the lowest deprived fifth (SIMD1) to 0.754 in the highest deprived fifth 
(SIMD5) a drop of 9%.  For females, the difference in health status moves from 0.826 to 
0.737 – a fall of 11%.  For both sexes, the impact of deprivation status is lowest in the 
youngest age group, increases approximately fourfold until 55-64 years and falls thereafter. In 
general,  males tend to self-report higher health status than women across all age groups and 
SIMD status, with the exception of SIMD1 where women tend to self-report higher health 
status (excluding the over 74). This corroborates a recent study in Australia where norms fell 
the more poorly educated individuals were(302). 
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Table 5-4 Background morbidity across fifths of deprivation - men 
Age band SIMD 1 SIMD 2 SIMD 3 SIMD 4 SIMD 5
All 0.831 (0.808, 0.854) 0.826 (0.803, 0.849) 0.81 (0.785, 0.836) 0.795 (0.766, 0.825) 0.754 (0.719, 0.79)
634 701 691 597 482
<25 0.822 (0.787, 0.857) 0.853 (0.824, 0.881) 0.834 (0.795, 0.873) 0.857 (0.828, 0.887) 0.787 (0.745, 0.83)
23 27 27 32 31
25-34 0.848 (0.826, 0.871) 0.849 (0.83, 0.867) 0.823 (0.796, 0.85) 0.816 (0.794, 0.839) 0.774 (0.741, 0.807)
75 88 88 104 70
35-44 0.834 (0.816, 0.852) 0.838 (0.82, 0.855) 0.823 (0.805, 0.841) 0.811 (0.787, 0.835) 0.777 (0.744, 0.81)
146 164 155 125 97
45-54 0.825 (0.805, 0.845) 0.827 (0.806, 0.849) 0.808 (0.783, 0.833) 0.791 (0.756, 0.826) 0.762 (0.729, 0.794)
128 139 126 82 96
55-64 0.845 (0.826, 0.865) 0.803 (0.78, 0.826) 0.82 (0.796, 0.843) 0.782 (0.751, 0.813) 0.718 (0.68, 0.757)
138 127 121 111 80
65-74 0.813 (0.784, 0.841) 0.822 (0.791, 0.853) 0.802 (0.775, 0.83) 0.761 (0.729, 0.792) 0.732 (0.697, 0.768)
86 89 107 92 72
> 74 0.797 (0.75, 0.843) 0.802 (0.77, 0.835) 0.756 (0.722, 0.791) 0.775 (0.731, 0.818) 0.732 (0.685, 0.779)
38 67 67 51 36
Male
 
 
Table 5-5 Background morbidity across fifths of deprivation - women 
Age band SIMD 1 SIMD 2 SIMD 3 SIMD 4 SIMD 5
All 0.826 (0.806, 0.846) 0.807 (0.786, 0.828) 0.785 (0.761, 0.809) 0.769 (0.743, 0.795) 0.737 (0.707, 0.766)
784 873 858 749 685
<25 0.846 (0.813, 0.88) 0.81 (0.779, 0.842) 0.78 (0.739, 0.821) 0.799 (0.765, 0.832) 0.816 (0.787, 0.845)
30 37 36 48 59
25-34 0.839 (0.822, 0.856) 0.816 (0.795, 0.836) 0.822 (0.803, 0.841) 0.803 (0.78, 0.825) 0.775 (0.749, 0.8)
105 122 114 128 104
35-44 0.837 (0.823, 0.852) 0.827 (0.812, 0.841) 0.794 (0.773, 0.815) 0.788 (0.769, 0.808) 0.748 (0.722, 0.774)
176 198 172 150 142
45-54 0.827 (0.812, 0.843) 0.793 (0.773, 0.812) 0.78 (0.758, 0.802) 0.769 (0.745, 0.792) 0.736 (0.708, 0.764)
180 166 157 128 117
55-64 0.835 (0.816, 0.854) 0.815 (0.798, 0.832) 0.791 (0.768, 0.814) 0.769 (0.742, 0.796) 0.701 (0.67, 0.732)
133 162 167 126 105
65-74 0.827 (0.803, 0.851) 0.803 (0.776, 0.83) 0.792 (0.766, 0.818) 0.742 (0.709, 0.776) 0.702 (0.668, 0.736)
96 102 118 86 87
> 74 0.741 (0.702, 0.779) 0.765 (0.732, 0.798) 0.715 (0.681, 0.748) 0.693 (0.655, 0.731) 0.689 (0.652, 0.726)
64 86 94 83 71
Female
 
 
 
The background morbidity scores derived in this study using the SF-6D are notably different 
from Kind’s analysis which was based upon the Euro-Qol Visual Analogue Scale (VAS) – 
figure 5-2.   
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Figure 5-2: Comparison of background morbidity scores: SF-6D and EQ-5D 
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The scores generated by SF-6D tend to be lower and have a shallower age gradient than 
responses derived from the EQ-5D VAS. Average scores using the SF-6D were 0.80 
compared to 0.86 in Kind. Differences were most pronounced in the youngest age groups. 
However, as age increases the scores converge and by 65 years estimates between studies 
were virtually identical.  A similar set of findings were evident in a study conducted in Greece, 
where both the EQ-5D VAS and the SF-6D was administered to a representative sample 
(1,005) of the general population(303). This analysis suggests that in older and sicker age 
groups using either SF-6D or EQ-5D VAS may provide consistent results. However, it is 
important to reiterate that creators of the EQ-5D VAS have stated it should not be used in 
economic evaluation. 
 
More generally, despite close correlation between the EQ-5D and the SF-6D across most 
values, it is contended here that perhaps the SF-6D may be more appropriate to estimate 
background morbidity in the general population. It has been shown that the EQ-5D 
(preference-weighted scores) suffers from ceiling effects, and may not adequately 
discriminate between states were individuals are in relatively good health. The SF-6D in 
contrast suffers from floor effects, being bound by 0.29, and so cannot adequately 
discriminate between poorer health states. However, given the general population is in 
relatively good health on average perhaps the SF-6D is a more discriminatory measure to 
estimate background morbidity scores. 
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5.4.4 Estimating the impact of experiencing non-fatal CVD events: 
utility decrements 
An average utility score is called background morbidity or population norms, and the 
difference between a utility score and perfect health (a score of 1) is called an overall utility 
decrement. The impact of an experiencing a specific CVD is called an event utility decrement, 
as this contributes to the overall utility decrement. This section details how utility decrements 
were estimated. 
 
Table 5-6 outlines event history with the SHeS 2003. Average age was 50.4 years (s.e. 16.6), 
with males composing 44% of total respondents and females 56%. In total, there were 1,068 
survey respondents with a CVD event history, 15% of the eligible sample population, with 
approximately one third having incurred multiple events.  
 
Table 5-6: Summary of Scottish Health Survey 2003 
Total/Average Male (proportion) Female (proportion)
Sample population 7054 3105 (44%) 3949 (55%)
Age (SD) 50.4 (16.6) 50.5 (16.3) 50.3 (16.8)
Respondents with CVD 
                    Single event 703 307 (44%) 396 (56%)
                    Multiple events 365 206 (56%) 159 (44%)
                    Total 1068 513 (48%) 555 (52%)
Event types
                    Angina 451 243 (54%) 208 (46%)
                    Myocardial infraction 252 156 (62%) 96 (38%)
                    Irregular heart beat 393 173 (44%) 220 (56%)
                    Other heart condition 134 74 (55%) 60 (45%)
                    Stroke 155 75 (48%) 80 (48%)
                    Intermittent claudication 182 76 (42%) 106 (58%)
                    Total 1567 797 (51%) 770 (49%)  
 
Overall, there were 1567 separate events balanced evenly between males (51%) and 
females (49%). Angina was the most frequent event (451 cases) followed by irregular 
heartbeat (393 cases) and myocardial infarction (252 cases), together accounting for 70% of 
all 1,567 events. Males had the greatest share of total angina and myocardial infarctions, with 
females relatively more dominant in those incurring strokes and having an irregular heartbeat. 
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Time from event: Table 5-6 illustrates the number and proportion of events that occurred 
within and over 12 months, for both the sample as a whole and separately for males and 
females.  For total events, angina was the only condition where most events (59%) were 
within one year of the interview date. Respondents incurring myocardial infarction and strokes 
overwhelmingly reported these as occurring over one year from the interview date (88% for 
MI and 79% for strokes).  The pattern regarding the incidence of events was very similar 
between males and females.   
 
Table 5-7 CVD events within and over 12 months of interview 
Total % Male % Female %
Angina
Within 12 months 268 59% 134 55% 134 64%
Over 12 months 183 41% 109 45% 74 36%
Total 451 100% 243 100% 208 100%
Myocardial infraction
Within 12 months 30 12% 16 10% 14 15%
Over 12 months 222 88% 140 90% 82 85%
Total 252 100% 156 100% 96 100%
Irregular heart beat
Within 12 months 206 52% 96 55% 110 50%
Over 12 months 187 48% 77 45% 110 50%
Total 393 100% 173 100% 220 100%
Other heart condition
Within 12 months 70 52% 39 53% 31 52%
Over 12 months 64 48% 35 47% 29 48%
Total 134 100% 74 100% 60 100%
Stroke
Within 12 months 33 21% 13 17% 20 25%
Over 12 months 122 79% 62 83% 60 75%
Total 155 100% 75 100% 80 100%
CVD Event
Breakdown per event Breakdown per event by gender
 
 
To estimate the utility decrements of experiencing CVD events explore an appropriate 
modelling approach, Generalized Linear Modelling (GLM) was used(304).  GLMs encompass 
the general linear model and also enlarge the class of linear least-squares models 
considered. In choosing a model type there are two key decisions to make. First, an 
appropriate “family” is required to be selected and secondly an appropriate “link function”. 
The family refers to the distributional assumptions regarding the variance around mean 
coefficients and the error term. The distribution of Y for fixed x is assumed to be from the 
exponential family of distributions, which includes important distributions such as the 
binomial, Poisson, exponential, and gamma distributions, in addition to the normal 
distribution. The link function defines the linear predictor and the power terms are required (if 
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any) to achieve best fit with the dependent variable. The only restrictions are that the 
functions are required to be monotonic and differentiable.  
 
To use GLM a positive scale is required for the dependent variable. However, the overall 
utility decrement is by definition on a negative scale. Therefore, a positive right skew was 
created by subtracting the overall utility decrement for each responded from (essentially the 
distribution is flipped over). Figure 5-3 illustrates the overall utility decrements (i.e. 1 - utility 
score) in the 7,054 respondents. The left skew reflects the frequency of respondents in very 
good health, and the long right tail is limited at 0.71. This reflects that the SF-6D has a floor 
effect of 0.29, and so when scores from 1 there is now a ceiling of 0.71.  
 
Figure 5-3 Distribution of overall utility decrements  
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The next step is to choose the form of the regression model, where the dependent variable is 
the overall utility decrement and the independent variables were the six events, with sex and 
also age included, with the latter defined as a continuous variable.  
 
A series of “families” were tested and the Modified-Park’s test was used to suggest the most 
appropriate family that the most robust model specification was defined by a Gaussian family. 
Next, to choose the power function for the linear predictor, the iterative procedure suggested 
by Glick was undertaken to manually test different powers and the choice was guided by 
using the three diagnostic tests (Pearson, Pregibon and modified Hosmer-Lemeshow)(305). 
A link function was the most appropriate choice.  
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A Gaussian with a link function, is equivalent to Ordinary Least Square (OLS). Despite the 
skewed data, this appeared to be an appropriate choice given the purpose of the analysis 
was to estimate mean event decrements and normality can be assumed in large samples 
such as the SHeS 2003 (7,054 individuals)(306). 
 
Using the Gaussian with a link function the six CVD events were regressed on the overall 
utility decrement to estimate the contribution by experiencing CVD events (i.e. event utility 
decrements). A separate model was run to investigate whether event utility decrements within 
and over 12 months were significantly different. Next, the presence of interactions between all 
possible event combinations was tested, and also the interaction of event type with age as a 
continuous variable. Significance tests for time from event and interactions were conducted 
using the log-rank test.  Finally, it was investigated whether event utility decrements are 
specific to sex, age group and also fifths of SIMD.  
 
Table 5-8 provides estimated event decrements, all of which were significant at the 1% level. 
Mean decrements were: angina 0.089, myocardial infarction 0.040, irregular heartbeat 0.050, 
other heart conditions 0.034, stroke 0.094 and intermittent claudication 0.020. When 
considering the impact of multiple events on an overall utility decrement there was an additive 
relationship. For instance, intermittent claudication followed by stoke would result in a 
combined decrement of 0.098 (0.02 plus 0.096). The only interaction found to be significant 
was the combination of angina and myocardial infarction which results in a decrement of 
0.037 (p = 0.05) – which is less that either angina or myocardial infarction separately. This 
may be explained by the fact that a non-fatal heart attack may remove the dead heart tissue 
that causes angina pain.  
 
 
 
 
 
 
 
 
 
 
 
 
 250 
Table 5-8 The impact of experiencing CVD - event utility decrements 
Overall Within 12 months Over 12 months
Age 0.0005 (0.0001) 0.0005 (0.0001) 0.0005 (0.0001)
Male  -0.024  (0.003)  -0.024  (0.003)  -0.024  (0.003)
Angina 0.089 (0.007) 0.113 (0.009) 0.058 (0.011)
Myocardial infraction 0.04 (0.01) 0.014 (0.025) 0.04 (0.01)
Irregular heart beat 0.05 (0.007) 0.067 (0.01) 0.028 (0.067)
Other heart condition 0.034 (0.012) 0.071 (0.016) -0.002 (0.017)
Stroke 0.094 (0.011) 0.128 (0.023) 0.077 (0.012)
Intermittent claudication 0.02 (0.01)  -  -
Constant 0.177 (0.005) 0.177 (0.005) 0.177 (0.005)  
* Estimates were all significant at 1% level, with exception of MI within 1 year, and other heart condition over 1 year 
 
In terms of the other estimates, the constant refers to the overall impact of other co-
morbidities, age has a positive but minor impact, and males tend to experience lower event 
utility decrements (-0.024) on average than females. The latter is consistent with findings from 
the previous section where males report higher health utility than females, on average. 
 
Time from event is generally important, with event utility decrements substantially and 
significantly higher if the event occurred within 12 months of the interview date. For instance, 
the impact of angina is almost double (0.113 versus 0.058). Time from event was not 
significant for myocardial infarction within 12 months and other heart conditions over 12 
months. This is likely to be the result of a lower number of events 
 
There were no significant results when the analysis was repeated for men and women 
separately, across different age groups and for different levels of socioeconomic status.  
 
There are few studies estimating decrements for specific CVD events and no studies, that we 
are aware of, drawing upon the general population or using the SF-6D. The main study is 
Clarke et al (2002) where utilities were derived from the EQ-5D in a population with diabetes.  
The modelling approach was to use a Tobit model and where event decrements were: MI 
0.055, CHD 0.090 and stroke 0.164. These estimates are reasonably similar to those 
estimated in the thesis, though stroke is substantially higher. This may be because the SHeS 
as a general population survey relies on individuals to self-report and those with more severe 
strokes perhaps could not participate. 
 
The finding that the impacts of events are greater within the first year, with the exception of 
myocardial infarction, likely reflects the initial shock post event followed by consequent 
adaptation by healthy survivors(307). A similar trend was also found by Clarke et al.  
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5.5 Estimating the risk of subsequent non-fatal CVD events 
 
5.5.1 Source data 
Following a non-fatal first event the model predicts survival and consequent life expectancy, 
as detailed in Chapter 4. However, individuals who survive a first event are at risk of further 
non-fatal events as they transit in the model towards death. Using the Scottish Morbidity 
Records (SMR) there was the opportunity to estimate the probability of subsequent CVD 
events following a first non-fatal event. Within the SMR data each hospital admission has 
diagnostic points: principal diagnosis (the primary reason for hospitalisation) and five 
secondary diagnoses. An individual was identified as having an experiencing a new CVD 
event if it was recorded in any diagnostic position for the first time. Therefore, this includes 
hospitalisation for a CVD event, events incurred while in-stay, and events that may have 
been recorded outside of secondary care.  
 
The events considered were CHD, stroke, intermittent claudication, heart failure and other 
heart events. Following the structure of the model, separate datasets were created that 
followed patients who had experienced either CHD or CBVD as the first non-fatal event. 
Further, this was repeated men and women separately. Therefore, four different datasets 
were created. Within each of the dataset, the average event count per annual cycle of the 
model was estimated, by dividing the number of individuals experiencing an event by the 
total number of SHHEC participants still alive. This is termed the observed proportions. The 
following figures show the observed proportions of events following a CHD and CBVD 
events: Figures 5-4 to 5-8 for men and Figures 5-9 to 5-13 for women.  
 
The observed proportions of events are erratic, particularly as years since first event 
increase, where the observed follow-up of SHHEC participants falls. Overall, the most 
common subsequent events are CHD for men and women 
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Figure 5-4 Observed proportions of CHD hospitalisations since first event - men 
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Key: Circles = post CHD; Diamonds = post CBVD 
 
Figure 5-5 Observed proportions of CBVD hospitalisations since first event - men 
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Key: Circles = post CHD; Diamonds = post CBVD 
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Figure 5-6 Observed proportions of heart failure hospitalisations since first event - men 
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Key: Circles = post CHD; Diamonds = post CBVD 
 
Figure 5-7 Observed proportions of PAD hospitalisations since first event - men 
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Key: Circles = post CHD; Diamonds = post CBVD 
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Figure 5-8 Observed proportions of other heart event hospitalisations since first event -men 
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Key: Circles = post CHD; Diamonds = post CBVD 
 
Figure 5-9 Observed proportions of CHD hospitalisations since first event - women 
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Key: Circles = post CHD; Diamonds = post CBVD 
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Figure 5-10 Observed proportions of CBVD hospitalisations since first event - women 
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Key: Circles = post CHD; Diamonds = post CBVD 
 
Figure 5-11 Observed proportions of heart failure hospitalisations since first event - women 
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Key: Circles = post CHD; Diamonds = post CBVD 
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Figure 5-12 Observed proportions of PAD hospitalisations since first event - women 
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Key: Circles = post CHD; Diamonds = post CBVD 
 
Figure 5-13 Observed proportions of other heart event hospitalisations since first event -
women 
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Key: Circles = post CHD; Diamonds = post CBVD 
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5.5.2 Modelling to estimate subsequent non-fatal CVD events  
The aim of the modelling was to predict the probability that an individual who has experienced 
a first non-fatal event would incur any of the five non-fatal CVD events - conditional upon 
being alive at a point in time. Invoking the assumption of non-informative censoring (i.e. that 
there is no systematic differences between individuals still alive and those who have died) the 
modelled average observed event count is assumed representative of all individuals that 
have the same  risk profile defined by the ASSIGN risk factors.  
 
The ultimate aim of the analysis was to model lifetime risk of subsequent non-fatal CVD 
events for patient profiles. Given the maximum follow-up in the SHHEC-SMR data was 25 
years. Before developing a regression approach the observed data was first extrapolated to 
allow regression across 100 years that the model runs for. 
 
In choosing an extrapolation approach, a key observation is that observed event proportions 
were highly erratic. For the purpose of prediction it is common to take an extrapolation 
approach that both smoothes predictions, and fits to the underlying ‘curvature’ of the data.  
This was the rationale for taking the parametric approach of restricted cubic splines (RCS) to 
extrapolate observations. First, the observed time period was divided into equally space 
percentiles and within each percentile the frequency of first event rates was estimated. The 
next stage is to choose a set of knots which groups the data into segments. Following 
Harrell’s guidance(308) three knots were chosen to generate three segments. This then 
allows piecewise regression between adjacent knots. When using restricted cubic splines one 
obtains a continuous smooth function that is linear before the first knot, a piecewise cubic 
polynomial between adjacent knots, and linear again after the last knot. The RCS function in 
STATA selects the knots automatically based on the events frequencies across percentiles. 
The empirical approach is intended to enable smoothing across the whole predicted function, 
rather than simply extrapolating from the end of the observations.   
 
The advantage of the restricted cubic method is that the shape of the function is less 
influenced at the edges of the data than a fractional polynomial approach, which can be a 
popular alternative. This is particularly important in this setting where events at the end of the 
observed period are few and the observations are erratic.  
 
A probit model was then chosen to regress the average event count per period on the four 
non-modifiable CVD risk factors of age, sex, family history and SIMD. Further, the time 
splines were used in the modelling to then project how risk is related to time.  
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The probit model was chosen because the model assumes that the event proportions are 
continuous, ranging from 0 to 1 and following a standard normal distribution. In this way the 
model generates probabilities of CVD events that can be used directly to estimate risk of 
subsequent events.  
 
Overall this modelling approach generates the following generic expression: 
 
Expected proportion = F(xb(t)) 
 
where F is the cumulative standard Normal distribution and xb(t) is the linear predictor from 
the probit regression at time period t.  
 
To reiterate, the modelling to predict the 5 events post CHD and post CBVD was done 
separately for each event and also for men and women. The resultant coefficients and 
associated time splines are shown on Tables 5-9 to 5-16.  
 
The estimated coefficients regarding the risk of subsequent events following a first non-fatal 
event provide some justification for having separate models that estimated event coefficients 
separately with respect to the 5 events and with different models for men and women. Note, 
that the time splines are similar, or identical, across events and between men and women. 
This is simply a function of the frequency of the observed counts and the approach of RCS. 
 
Intuitively, the modelling results suggest that individual event history matters, and the risk     
of future events is conditional not only upon the ASSIGN risk factors but also with respect      
to which event occurred first and at what time. 
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Table 5-9 Modelling the probability of non-fatal CVD events: men post CHD event 
 
 
Covariate 
CHD 
 
coeff. (95% CI) 
 
 
p value 
Stroke 
 
coeff. (95% CI) 
 
 
p value 
Inter. claudication 
 
coeff. (95% CI) 
 
 
p value 
Other heart condition 
coeff. (95% CI) 
 
 
p value 
         
ti1 -0.019 (-0.040, 0.002) 0.073 -0.101 (-0.147, -0.055) <0.001 -0.049 (-0.104, 0.006) 0.080 -0.060 (-0.091, -0.028) <0.001 
ti2 0.071 (0.045, 0.098) <0.001 0.098 (0.035, 0.161) 0.002 0.034 (-0.039, 0.107) 0.363 0.050 (0.008, 0.092) 0.019 
Age 0.010 (0.005, 0.016) <0.001 0.001 (-0.007, 0.009) 0.821 -0.001 (-0.012, 0.010) 0.888 0.005 (-0.002, 0.013) 0.150 
SIMD sc. 0.003 (0.001, 0.005) 0.004 0.003 (0.000, 0.007) 0.051 0.002 (-0.003, 0.006) 0.444 0.003 (0.001, 0.006) 0.012 
Fam. his. 0.106 (0.019, 0.193) 0.016 -0.011 (-0.168, 0.145) 0.886 -0.136 (-0.350, 0.077) 0.211 0.174 (0.051, 0.297) 0.006 
Constant -2.012 (-2.420, -1.605) <0.001 -2.085 (-2.640, -1.530) <0.001 -2.137 (-2.903, -1.371) <0.001 -2.187 (-2.680, -1.693) <0.001 
 
 
Covariate 
HF 
 
coeff. (95% CI) 
 
 
p value 
   
ti1 -0.152 (-0.195, -0.110) <0.001 
ti2 0.160 (0.098, 0.223) <0.001 
Age 0.014 (0.004, 0.023) 0.004 
SIMD sc. 0.002 (-0.002, 0.006) 0.297 
Fam. his. 0.044 (-0.121, 0.210) 0.599 
Constant -2.626 (-3.260, -1.992) <0.001 
Note: ‘Age’ is age at first event; ‘ti1’ and ‘ti2’ are time spline function variables 
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Table 5-10 Time spline variables: Men post-CHD 
Cycle (year) ti1 ti2 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2
1 1 0 35 35 32.30769 68 68 70.38461
2 2 0.0059172 36 36 33.46154 69 69 71.53846
3 3 0.0473373 37 37 34.61538 70 70 72.69231
4 4 0.1597633 38 38 35.76923 71 71 73.84615
5 5 0.3786982 39 39 36.92308 72 72 75
6 6 0.7396449 40 40 38.07692 73 73 76.15385
7 7 1.268491 41 41 39.23077 74 74 77.30769
8 8 1.952663 42 42 40.38462 75 75 78.46154
9 9 2.76997 43 43 41.53846 76 76 79.61539
10 10 3.698225 44 44 42.69231 77 77 80.76923
11 11 4.715237 45 45 43.84615 78 78 81.92308
12 12 5.798817 46 46 45 79 79 83.07692
13 13 6.926775 47 47 46.15385 80 80 84.23077
14 14 8.076923 48 48 47.30769 81 81 85.38461
15 15 9.230769 49 49 48.46154 82 82 86.53846
16 16 10.38461 50 50 49.61538 83 83 87.69231
17 17 11.53846 51 51 50.76923 84 84 88.84615
18 18 12.69231 52 52 51.92308 85 85 90
19 19 13.84615 53 53 53.07692 86 86 91.15385
20 20 15 54 54 54.23077 87 87 92.30769
21 21 16.15385 55 55 55.38462 88 88 93.46154
22 22 17.30769 56 56 56.53846 89 89 94.61539
23 23 18.46154 57 57 57.69231 90 90 95.76923
24 24 19.61539 58 58 58.84615 91 91 96.92308
25 25 20.76923 59 59 60 92 92 98.07692
26 26 21.92308 60 60 61.15385 93 93 99.23077
27 27 23.07692 61 61 62.30769 94 94 100.3846
28 28 24.23077 62 62 63.46154 95 95 101.5385
29 29 25.38461 63 63 64.61539 96 96 102.6923
30 30 26.53846 64 64 65.76923 97 97 103.8462
31 31 27.69231 65 65 66.92308 98 98 105
32 32 28.84615 66 66 68.07692 99 99 106.1538
33 33 30 67 67 69.23077 100 100 107.3077
34 34 31.15385
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Table 5-11 Modelling the probability of non-fatal CVD events: men post CBVD event 
 
 
Covariate 
CHD 
 
coeff. (95% CI) 
 
 
p value 
Stroke 
 
coeff. (95% CI) 
 
 
p value 
Inter. claudication 
 
coeff. (95% CI) 
 
 
p value 
Other heart condition 
coeff. (95% CI) 
 
 
p value 
         
ti1 -0.069 (-0.150, 0.012) 0.095 -0.035 (-0.087, 0.017) 0.183 0.020 (-0.085, 0.125) 0.712 -0.070 (-0.134, -0.006) 0.032 
ti2 0.063 (-0.049, 0.174) 0.270 0.046 (-0.030, 0.123) 0.235 -0.108 (-0.305, 0.090) 0.285 0.077 (-0.016, 0.170) 0.103 
Age -0.003 (-0.016, 0.010) 0.613 0.010 (-0.001, 0.021) 0.075 0.001 (-0.016, 0.019) 0.873 0.004 (-0.009, 0.017) 0.537 
SIMD sc. -0.002 (-0.008, 0.004) 0.455 0.003 (-0.000, 0.006) 0.073 0.007 (0.001, 0.014) 0.030 0.002 (-0.002, 0.007) 0.315 
Fam. his. 0.144 (-0.085, 0.373) 0.218 0.019 (-0.154, 0.191) 0.833 0.024 (-0.340, 0.389) 0.895 0.053 (0.169, 0.275) 0.641 
Constant -1.506 (-2.420, -1.605) 0.001 -2.109 (-2.891, -1.327) <0.001 -2.744 (-4.034, -1.454) <0.001 -1.923 (-2.789, -1.058) <0.001 
 
 
Covariate 
HF 
 
coeff. (95% CI) 
 
 
p value 
   
ti1 -0.129 (-0.275, 0.017) 0.083 
ti2 0.159 (-0.021, 0.340) 0.084 
Age 0.039 (0.009, 0.070) 0.012 
SIMD sc. -0.010 (-0.021, 0.001) 0.079 
Fam. his. 0.353 (-0.063, 0.770) 0.097 
Constant -4.697 (-6.983, -2.410) <0.001 
 
Note: ‘Age’ is age at first event; ‘ti1’ and ‘ti2’ are time spline function variables 
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Table 5-12 Time spline variables: Men post-CBVD 
Cycle (year) ti1 ti2 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2
1 1 0 35 35 31.63636 68 68 67.63636
2 2 0.0082645 36 36 32.72727 69 69 68.72727
3 3 0.0661157 37 37 33.81818 70 70 69.81818
4 4 0.2231405 38 38 34.90909 71 71 70.90909
5 5 0.5289256 39 39 36 72 72 72
6 6 1.020071 40 40 37.09091 73 73 73.09091
7 7 1.681228 41 41 38.18182 74 74 74.18182
8 8 2.484061 42 42 39.27273 75 75 75.27273
9 9 3.400236 43 43 40.36364 76 76 76.36364
10 10 4.401417 44 44 41.45454 77 77 77.45454
11 11 5.459268 45 45 42.54546 78 78 78.54546
12 12 6.545455 46 46 43.63636 79 79 79.63636
13 13 7.636364 47 47 44.72727 80 80 80.72727
14 14 8.727273 48 48 45.81818 81 81 81.81818
15 15 9.818182 49 49 46.90909 82 82 82.90909
16 16 10.90909 50 50 48 83 83 84
17 17 12 51 51 49.09091 84 84 85.09091
18 18 13.09091 52 52 50.18182 85 85 86.18182
19 19 14.18182 53 53 51.27273 86 86 87.27273
20 20 15.27273 54 54 52.36364 87 87 88.36364
21 21 16.36364 55 55 53.45454 88 88 89.45454
22 22 17.45455 56 56 54.54546 89 89 90.54546
23 23 18.54545 57 57 55.63636 90 90 91.63636
24 24 19.63636 58 58 56.72727 91 91 92.72727
25 25 20.72727 59 59 57.81818 92 92 93.81818
26 26 21.81818 60 60 58.90909 93 93 94.90909
27 27 22.90909 61 61 60 94 94 96
28 28 24 62 62 61.09091 95 95 97.09091
29 29 25.09091 63 63 62.18182 96 96 98.18182
30 30 26.18182 64 64 63.27273 97 97 99.27273
31 31 27.27273 65 65 64.36364 98 98 100.3636
32 32 28.36364 66 66 65.45454 99 99 101.4545
33 33 29.45455 67 67 66.54546 100 100 102.5455
34 34 30.54545  
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Table 5-13 Modelling the probability of non-fatal CVD events: women post CHD event 
 
 
Covariate 
CHD 
 
coeff. (95% CI) 
 
 
p value 
Stroke 
 
coeff. (95% CI) 
 
 
p value 
Inter. claudication 
 
coeff. (95% CI) 
 
 
p value 
Other heart condition 
coeff. (95% CI) 
 
 
p value 
         
ti1 -0.003 (-0.033, 0.027) 0.823 -0.072 (-0.144, 0.000) 0.051 -0.078 (-0.152, -0.004) 0.040 -0.045 (-0.087, -0.003) 0.037 
ti2 0.057 (0.011, 0.103) 0.016 0.026 (-0.102, 0.155) 0.688 0.106 (-0.015, 0.228) 0.086 0.026 (-0.045, 0.096) 0.477 
Age 0.010 (0.004, 0.016) 0.002 0.007 (-0.006, 0.019) 0.281 0.016 (-0.001, 0.033) 0.061 0.012 (0.003, 0.021) 0.009 
SIMD sc. 0.001 (-0.001, 0.004) 0.198 0.005 (0.001, 0.009) 0.014 0.001 (-0.005, 0.008) 0.705 0.001 (-0.002, 0.004) 0.484 
Fam. his. 0.056 (-0.046, 0.158) 0.279 -0.014 (-0.221, 0.194) 0.898 -0.129 (-0.379, 0.122) 0.314 -0.138 (-0.270, -0.005) 0.041 
Constant -2.137 (-2.580, -1.694) <0.001 -2.638 (-3.492, -1.783) <0.001 -3.274 (-4.558, -1.990) <0.001 -2.407 (-3.00, -1.810) <0.001 
 
 
Covariate 
HF 
 
coeff. (95% CI) 
 
 
p value 
   
ti1 -0.119 (-0.176, -0.061) <0.001 
ti2 0.133 (0.039, 0.227) 0.005 
Age 0.018 (0.00, 0.029) 0.003 
SIMD sc. 0.004 (-0.000, 0.009) 0.077 
Fam. his. -0.038 (-0.246, 0.170) 0.721 
Constant -3.017 (-3.857, -2.177) <0.001 
 
Note: ‘Age’ is age at first event; ‘ti1’ and ‘ti2’ are time spline function variables 
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Table 5-14 Time spline variables: Women post-CHD  
year ti1 ti2 year ti1 ti2 year ti1 ti2
1 1 0 35 35 26.15385 68 68 56.61538
2 2 0.005917 36 36 27.07692 69 69 57.53846
3 3 0.047337 37 37 28 70 70 58.46154
4 4 0.159763 38 38 28.92308 71 71 59.38462
5 5 0.378698 39 39 29.84615 72 72 60.30769
6 6 0.731098 40 40 30.76923 73 73 61.23077
7 7 1.20973 41 41 31.69231 74 74 62.15385
8 8 1.798817 42 42 32.61538 75 75 63.07692
9 9 2.482577 43 43 33.53846 76 76 64
10 10 3.245233 44 44 34.46154 77 77 64.92308
11 11 4.071006 45 45 35.38462 78 78 65.84615
12 12 4.944116 46 46 36.30769 79 79 66.76923
13 13 5.848783 47 47 37.23077 80 80 67.69231
14 14 6.769231 48 48 38.15385 81 81 68.61539
15 15 7.692307 49 49 39.07692 82 82 69.53846
16 16 8.615385 50 50 40 83 83 70.46154
17 17 9.538462 51 51 40.92308 84 84 71.38461
18 18 10.46154 52 52 41.84615 85 85 72.30769
19 19 11.38461 53 53 42.76923 86 86 73.23077
20 20 12.30769 54 54 43.69231 87 87 74.15385
21 21 13.23077 55 55 44.61538 88 88 75.07692
22 22 14.15385 56 56 45.53846 89 89 76
23 23 15.07692 57 57 46.46154 90 90 76.92308
24 24 16 58 58 47.38462 91 91 77.84615
25 25 16.92308 59 59 48.30769 92 92 78.76923
26 26 17.84615 60 60 49.23077 93 93 79.69231
27 27 18.76923 61 61 50.15385 94 94 80.61539
28 28 19.69231 62 62 51.07692 95 95 81.53846
29 29 20.61539 63 63 52 96 96 82.46154
30 30 21.53846 64 64 52.92308 97 97 83.38461
31 31 22.46154 65 65 53.84615 98 98 84.30769
32 32 23.38461 66 66 54.76923 99 99 85.23077
33 33 24.30769 67 67 55.69231 100 100 86.15385
34 34 25.23077  
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Table 5-15 Modelling the probability of non-fatal CVD events: women post CBVD event 
 
 
Covariate 
CHD 
 
coeff. (95% CI) 
 
 
p value 
Stroke 
 
coeff. (95% CI) 
 
 
p value 
Inter. claudication 
 
coeff. (95% CI) 
 
 
p value 
Other heart condition 
coeff. (95% CI) 
 
 
p value 
         
ti1 0.078 (-0.028, 0.183) 0.150 -0.023 (-0.077, 0.030) 0.392 0.008 (-0.137, 0.152) 0.916 -0.053 (-0.138, 0.032) 0.222 
ti2 -0.088 (-0.225, 0.049) 0.209 0.056 (-0.020, 0.132) 0.150 -0.069 (-0.275, 0.137) 0.513 0.034 (-0.071, 0.140) 0.524 
Age -0.0004 (-0.014, 0.013) 0.951 0.022 (0.013, 0.030) <0.001 -0.011 (-0.031, 0.009) 0.279 0.006 (-0.005, 0.017) 0.302 
SIMD sc. 0.004 (-0.003, 0.011) 0.304 0.001 (-0.002, 0.004) 0.525 0.0004 (-0.013, 0.014) 0.955 -0.001 (-0.006, 0.004) 0.749 
Fam. his. 0.068 (-0.222, 0.359) 0.644 0.042 (-0.192, 0.108) 0.582 -0.303 (-0.798, 0.192) 0.230 0.281 (0.044, 0.517) 0.020 
Constant -2.531 (-3.653, -1.409) <0.001 -2.777 (-3.424, -2.130) <0.001 -1.714 (-3.543, 0.115) 0.066 -2.178 (-2.983, -1.373) <0.001 
 
 
Covariate 
HF 
 
coeff. (95% CI) 
 
 
p value 
   
ti1 -0.186 (-0.319, -0.054) 0.006 
ti2 0.227 (0.069, 0.386) 0.005 
Age -0.002 (-0.017, 0.014) 0.839 
SIMD sc. 0.001 (-0.007, 0.010) 0.757 
Fam. his. 0.036 (-0.360, 0.432) 0.859 
Constant -1.881 (-3.219, -0.542) 0.006 
 
Note: ‘Age’ is age at first event; ‘ti1’ and ‘ti2’ are time spline function variables 
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Table 5-16 Time spline variables: Women post-CBVD  
Cycle (year) ti1 ti2 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2
1 1 0 35 35 31.63636 68 68 67.63636
2 2 0.0082645 36 36 32.72727 69 69 68.72727
3 3 0.0661157 37 37 33.81818 70 70 69.81818
4 4 0.2231405 38 38 34.90909 71 71 70.90909
5 5 0.5289256 39 39 36 72 72 72
6 6 1.020071 40 40 37.09091 73 73 73.09091
7 7 1.681228 41 41 38.18182 74 74 74.18182
8 8 2.484061 42 42 39.27273 75 75 75.27273
9 9 3.400236 43 43 40.36364 76 76 76.36364
10 10 4.401417 44 44 41.45454 77 77 77.45454
11 11 5.459268 45 45 42.54546 78 78 78.54546
12 12 6.545455 46 46 43.63636 79 79 79.63636
13 13 7.636364 47 47 44.72727 80 80 80.72727
14 14 8.727273 48 48 45.81818 81 81 81.81818
15 15 9.818182 49 49 46.90909 82 82 82.90909
16 16 10.90909 50 50 48 83 83 84
17 17 12 51 51 49.09091 84 84 85.09091
18 18 13.09091 52 52 50.18182 85 85 86.18182
19 19 14.18182 53 53 51.27273 86 86 87.27273
20 20 15.27273 54 54 52.36364 87 87 88.36364
21 21 16.36364 55 55 53.45454 88 88 89.45454
22 22 17.45455 56 56 54.54546 89 89 90.54546
23 23 18.54545 57 57 55.63636 90 90 91.63636
24 24 19.63636 58 58 56.72727 91 91 92.72727
25 25 20.72727 59 59 57.81818 92 92 93.81818
26 26 21.81818 60 60 58.90909 93 93 94.90909
27 27 22.90909 61 61 60 94 94 96
28 28 24 62 62 61.09091 95 95 97.09091
29 29 25.09091 63 63 62.18182 96 96 98.18182
30 30 26.18182 64 64 63.27273 97 97 99.27273
31 31 27.27273 65 65 64.36364 98 98 100.3636
32 32 28.36364 66 66 65.45454 99 99 101.4545
33 33 29.45455 67 67 66.54546 100 100 102.5455
34 34 30.54545
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5.5.3 Using the model to predict subsequent non-fatal CVD events 
To illustrate the ability of model to predict subsequent non-fatal CVD events, a risk profile of a 
60 year man living in the most deprived fifth (SIMD 60) is used where it is also assumed that 
he has with no family history, no diabetes, a smoker of 20 cigarettes per day, total cholesterol 
of 7 and HDL Cholesterol of 1.2. It is assumed that a non-fatal CHD event occurred in the first 
year upon entering the model.  This was the same risk profile selected in Chapter 4 to 
illustrate how the model predicts life expectancy.  
 
Figures 5-14 to 5-18 show the probability of incurring one of the five non-fatal events, where 
the x-axis of time from non-fatal event is denominated in years. Overall, the process of using 
RCS now results in smoothed predictions compared to observed proportions as witnessed 
earlier. In terms of event predictions, the scale and shape of the curves are quite different 
across the five events of CHD, CBVD, heart failure, intermittent claudication and other heart 
events. Following a first CHD event, the probability of incurring CHD events is the highest of 
all the events, with a steady increase over time. The probability of stroke remains quite low 
and is highest in the years immediately following a non-fatal event. The probability of heart 
failure falls and then increases sharply after 25 years. The probability of intermittent 
claudication and other heart events follow similar trends, although the risk of the former is 
higher.  
 
Figure 5-14 Probability of CHD post-CHD hospitalisation 
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Figure 5-15 Probability of CBVD post CHD hospitalisation  
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Figure 5-16 Probability of heart failure post-CHD hospitalisation  
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Figure 5-17 Probability of intermittent claudication post CHD hospitalisation  
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Figure 5-18 Probability of other heart events post CHD hospitalisation  
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It is interesting to reflect on a plausible rationale for such event patterns. From first principles, 
increasing age is associated with a deterioration in the CVD system in general. This may first 
result in more minor (yet still potentially serious) conditions of irregular heartbeat and 
intermittent claudication, for instance. Major events such as CHD and stroke may follow as 
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the system weakens. However, if the first event experienced is an initial CHD event for 
instance, then perhaps the system is so damaged that it is more likely that other associated 
and major CHD and stroke events are more likely to occur than the relatively less serious 
events. This may explain the relative magnitude of the risks of different events at each point 
in time. Further, what is also interesting to explore is how the risk of events change in time. 
Risks are relatively higher in the immediate aftermath of a first event, leading to a fall and 
then a steady increase. The initial decline may reflect a healthy survivor effect, where patients 
with a weaker constitution have died early post-event. The subsequent increase in event risk 
may then reflect the effect of age given the independent relationship of age with events and 
inevitable breakdown of the CVD system and mortality. Note, that a very similar pattern was 
found for patient post-CBVD, with the exception that following a first CBVD event, the main 
risk was further CBVD, followed by CHD and then the other more minor events.  
 
5.6 Generating quality adjusted life expectancy 
 
5.6.1 Approach to quality adjustment   
Now that we have estimated background morbidity/population norms, utility decrements for 
CVD events, and the risk of incurring first and subsequent CVD events, this section details 
how these estimates are incorporated into the model to quality adjust the life expectancy 
predictions that were made in Chapter 4.  
 
Figure 5-1 shows that quality adjustment is made in three states of the policy model. Within a 
CVD free state survival is adjusted for background morbidity only. In contrast, within a non-
fatal CHD and a non-fatal CBVD state quality adjustment accounts for background morbidity, 
the impact of experiencing a first non-fatal event and the impact of experiencing further non-
fatal CVD events. 
 
A Kaplan-Meier Sample Average (KMSA) estimator(309) approach is used, where the 
survival probability of the individual within a model state over time is multiplied by the 
associated quality of life from existing in that state. Summing across time generates quality 
adjusted life expectancy (QALE). This is summarised, as follows: 
 
QALE = ∑[S(t) * Ut]  
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Where S(t) is the survival probability in period t and Ut is the associated health state utility, 
which in turn is a function of background morbidity, and the impact of experiencing first and 
subsequent events. This process of quality adjusting a survival is described, as below.   
 
(i) Adjusting for background morbidity: Estimates of background morbidity were made specific 
to the age, sex and fifths of SIMD. These estimates are used weight the time spent in a CVD 
free state.  With reference to the KMSA estimator, the assumption is that St = 1 before a first 
event. Note, that as the person ages in the model, a different norm may be selected given 
norms were estimated across seven age groups.  
 
(ii) Adjusting for first non-fatal CVD event: The impact of experiencing a first non-fatal event is 
subtracted from background morbidity. If the first event was non-fatal CHD then the utility 
decrement of myocardial infarction was used. For a first event that was CBVD then the utility 
decrement of stroke was used. This is simply subtracted from background morbidity / health 
utility. 
 
(iii) Adjusting for subsequent non-fatal events: The previous section estimated the probability 
of incurring five non-fatal events in each cycle of the model post-first event. These 
probabilities are then weighted (multiplied) by the associated event decrement. For heart 
failure the estimate from Clarke(310) of -0.108 was used. This process creates five weighted 
utility decrements.  
 
The following illustrates a model scenario where the 60 year old male profile introduced 
previously incurred a non-fatal CHD event upon entering the model. Figures 5-19 to 5-23 
illustrates that the expected utility impact (probability of event weighted by associated utility 
decrement). The curves retain the same shape as the event predictions made earlier, but are 
essentially rescaled.  
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Figure 5-19 Utility impact (decrement) of incurring a CHD event – post non-fatal CHD 
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Figure 5-20 Utility impact (decrement) of incurring a CBVD event – post non-fatal CHD 
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Figure 5-21 Utility impact (decrement) of incurring a heart failure – post non-fatal CHD 
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Figure 5-22 Utility impact (decrement) of incurring other-heat event – post non-fatal CHD 
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Figure 5-23 Utility impact (decrement) of incurring intermittent claudication – post non-fatal 
CHD 
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To use these estimates to quality adjust survival within a non-fatal CVD state three steps are 
taken consistent with a KMSA estimator approach. First, the sum of the five utility decrements 
is taken in each year of the model. This creates an overall composite decrement. Second, 
this composite decrement is weighted by the probability that the individual is actually alive to 
experience events. This probability is read off an individual’s survival curve, which was 
estimated in Chapter 4, and laid-on top of the composite decrement (Figure 5-24). Third, with 
the survival curve not quality adjusted, the area under the curve is estimated and summed to 
give remaining QALE.   
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Figure 5-24 Composite with survival curve – post first CHD 
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5.6.2 Estimating expected quality adjusted life expectancy  
Having illustrated how quality adjustment is undertaken in a CVD free state (background 
morbidity), and a non-fatal CVD state (event decrement plus the weighted decrement of 
further events), it is now possible to generate overall expected QALE.    
 
A similar process is adopted as shown in Chapter 4 when estimating average life expectancy.   
To reiterate as an individual enters the model CVD free they are at risk of incurring one the 
competing first four events. This risk is estimated over 100 cycles. Life expectancy is 
conditional on the type and timing of the first event. Therefore, in total, an individual faces 400 
possible scenarios (i.e. four events multiplied by 100 cycles).  
 
To generate average QALE, these scenarios are re-run but this time with quality adjustment, 
and consequently each particular scenario leads to a different estimate of QALE. The 
following three tables follow exactly the same logic as outlined in Chapter 4. That is, for each 
annual cycle of the model we estimate the QALE that can be expected from incurring one the 
first four events (Table 8). All estimates are discounted at 3.5% in line with guidance from 
NICE(37).  
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For consistency of exposition, this process uses the same 60 year old male profile as before.  
First, table 5-17a estimates the remaining QALE across each model scenario. Survival before 
and after the first event (if non-fatal) has been quality adjusted. 
 
Table 5-17 a) Remaining discounted quality adjusted life expectancy upon entering model 
[time before event + plus time after event] 
1 7.8 6.1 0.8 0.8
2 8.0 6.7 1.5 1.5
3 8.9 7.6 2.2 2.2
.
.
22 15.4 14.7 11.7 11.7
23 16.0 15.2 12.1 12.1
24 15.9 15.2 12.4 12.4
.
.
100 21.0 21.4 21.0 21.0
Cycle (time in years) Non-fatal CHD Non-fatal CBVD CVD death nonCVD death
 
 
Second, the probability that a particular event occurs at a particular time is estimated table 5-
17b. These are the same probabilities as illustrated in Chapter 4. The probabilities are not 
affected by quality adjustment.  
 
b) Probability of event occurring [event type and timing] 
1 0.026 0.008 0.017 0.013
2 0.026 0.008 0.017 0.013
3 0.025 0.008 0.017 0.013
.
.
22 0.003 0.002 0.003 0.002
23 0.002 0.001 0.002 0.002
24 0.002 0.001 0.002 0.001
.
.
100 0 0 0 0
Non-fatal CBVDNon-fatal CHDCycle (time in years) nonCVD deathCVD death
 
 
Third, the product of Tables 5-17 a and 5-17 b then generates a weighted discounted QALE 
estimate for each scenario in the model Table 5-17 c. 
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c) Weighted remaining discounted quality adjusted life expectancy [ estimates from table a) 
multiplied by estimated from table b) ] 
1 0.202 0.047 0.013 0.010 0.272
2 0.205 0.053 0.026 0.020 0.303
3 0.226 0.061 0.038 0.030 0.355
.
.
22 0.047 0.027 0.037 0.029 0.139
23 0.036 0.021 0.029 0.023 0.109
24 0.026 0.016 0.022 0.017 0.081
.
.
100 0.000 0.000 0.000 0.000
8.46
68.46
CVD death nonCVD death
Sum
Cycle (time in years)
Total life years remaining  (Cumulative sum over each model cycle) =    
Overall life expectancy  (age upon entering model plus remaining life years) =    
Non-fatal CHD Non-fatal CBVD
 
 
Fourth, by summing across all possible realisations of the model we find that the 60 year man 
is now expected to have an additional 8.46 discounted QALEs remaining upon entering the 
model. By added the initial age of the man upon entering the model an overall discounted 
QALE of 68.46 is generated. This is contrasted with an undiscounted life expectancy estimate 
of 73.98 years that was made in Chapter 4 in the recalibrated model. 
 
Figures 5-25 and 5-26 illustrates the model estimates of discounted QALEs across individual 
risk profiles for men and women. Most notably, the age gradient is increased sharply 
reflecting discounting, and quality adjustment; given younger individuals have greater 
remaining life expectancy so have a longer time period over which to experience events. 
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Figure 5-25 Discounted quality adjusted life expectancy - men 
Lowest deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 78.6 78.5 78.5 78.4 78.4 76.8 76.8 76.9 76.9 76.9
160 78.9 78.9 79.0 78.9 78.9 77.2 77.3 77.4 77.4 77.4
140 79.2 79.3 79.4 79.4 79.3 77.4 77.6 77.7 77.8 77.8
120 79.5 79.6 79.7 79.8 79.7 77.7 77.9 78.1 78.1 78.1
100 79.6 79.9 80.0 80.1 80.1 77.8 78.1 78.3 78.4 78.5
Age 60 years Age 60 years
180 72.4 72.4 72.5 72.5 72.5 70.6 70.7 70.9 70.9 70.9
160 72.7 72.9 73.0 73.0 73.0 70.9 71.2 71.3 71.4 71.4
140 72.9 73.2 73.4 73.4 73.4 71.2 71.5 71.7 71.8 71.8
120 73.1 73.5 73.7 73.7 73.8 71.3 71.8 72.0 72.2 72.2
100 73.2 73.7 73.9 74.0 74.0 71.4 72.0 72.3 72.4 72.5
Age 50 years Age 50 years
180 66.3 66.6 66.8 66.8 66.8 64.6 65.0 65.2 65.3 65.3
160 66.5 66.9 67.1 67.2 67.3 64.9 65.4 65.7 65.8 65.8
140 66.6 67.1 67.4 67.6 67.6 65.1 65.7 66.0 66.2 66.2
120 66.7 67.3 67.6 67.8 67.9 65.2 65.8 66.2 66.4 66.5
100 66.7 67.4 67.7 68.0 68.1 65.2 66.0 66.4 66.6 66.7
Age 40 years Age 40 years
180 60.1 60.6 60.9 61.1 61.1 58.7 59.3 59.6 59.8 59.8
160 60.2 60.8 61.2 61.4 61.4 58.9 59.6 60.0 60.1 60.2
140 60.2 60.9 61.4 61.6 61.6 58.9 59.8 60.2 60.5 60.5
120 60.1 61.0 61.5 61.7 61.8 58.9 59.8 60.3 60.6 60.7
100 60.0 60.9 61.5 61.8 61.9 58.8 59.8 60.4 60.7 60.9
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Highest deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 76.8 76.6 76.5 76.4 76.4 75.2 75.1 75.1 75.1 75.0
160 77.1 77.0 77.0 76.9 76.8 75.5 75.5 75.5 75.5 75.4
140 77.4 77.4 77.4 77.3 77.2 75.7 75.8 75.8 75.8 75.8
120 77.6 77.7 77.7 77.7 77.6 75.9 76.0 76.1 76.1 76.1
100 77.8 77.9 78.0 78.0 77.9 76.0 76.2 76.4 76.4 76.4
Age 60 years Age 60 years
180 70.3 70.2 70.1 70.0 70.0 68.5 68.5 68.5 68.5 68.4
160 70.6 70.6 70.6 70.5 70.4 68.8 68.9 69.0 68.9 68.9
140 70.9 71.0 71.0 70.9 70.9 69.1 69.2 69.4 69.3 69.3
120 71.1 71.2 71.3 71.3 71.2 69.3 69.5 69.7 69.7 69.7
100 71.2 71.5 71.6 71.6 71.6 69.4 69.7 69.9 70.0 70.0
Age 50 years Age 50 years
180 64.1 64.1 64.1 64.1 64.1 62.3 62.5 62.6 62.6 62.6
160 64.3 64.4 64.5 64.5 64.5 62.6 62.9 63.0 63.0 63.0
140 64.5 64.7 64.9 64.9 64.9 62.8 63.2 63.4 63.4 63.4
120 64.7 65.0 65.1 65.2 65.2 63.0 63.4 63.6 63.7 63.7
100 64.7 65.1 65.3 65.4 65.4 63.1 63.5 63.8 64.0 64.0
Age 40 years Age 40 years
180 57.8 58.1 58.3 58.3 58.3 56.4 56.7 56.9 57.0 57.0
160 58.0 58.4 58.6 58.7 58.7 56.6 57.0 57.3 57.4 57.4
140 58.1 58.6 58.8 58.9 58.9 56.7 57.2 57.6 57.7 57.7
120 58.1 58.7 59.0 59.1 59.2 56.7 57.4 57.7 57.9 58.0
100 58.1 58.7 59.1 59.2 59.3 56.7 57.4 57.8 58.1 58.1
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Figure 5-26 Discounted quality adjusted life expectancy - women  
Least deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 79.3 79.3 79.2 79.2 79.2 77.0 77.0 77.0 77.0 77.0
160 79.8 79.9 79.8 79.8 79.7 77.5 77.6 77.6 77.6 77.6
140 80.3 80.4 80.3 80.3 80.3 78.0 78.1 78.1 78.1 78.1
120 80.7 80.8 80.7 80.7 80.7 78.4 78.6 78.6 78.6 78.6
100 81.1 81.2 81.1 81.1 81.1 78.8 79.0 79.0 79.0 79.0
Age 60 years Age 60 years
180 73.0 73.1 73.1 73.1 73.2 70.6 70.8 70.8 70.8 70.9
160 73.4 73.6 73.6 73.7 73.7 71.1 71.3 71.4 71.4 71.5
140 73.8 74.1 74.1 74.1 74.2 71.6 71.8 71.9 72.0 72.0
120 74.2 74.4 74.5 74.5 74.6 72.0 72.3 72.4 72.5 72.5
100 74.5 74.8 74.8 74.9 74.9 72.4 72.7 72.8 72.9 72.9
Age 50 years Age 50 years
180 66.6 66.9 67.1 67.2 67.3 64.4 64.7 64.9 65.0 65.1
160 66.9 67.3 67.5 67.6 67.7 64.9 65.3 65.4 65.6 65.7
140 67.2 67.7 67.9 68.0 68.1 65.3 65.7 65.9 66.1 66.1
120 67.5 68.0 68.2 68.3 68.4 65.6 66.1 66.3 66.5 66.6
100 67.7 68.2 68.4 68.6 68.7 65.8 66.4 66.6 66.8 66.9
Age 40 years Age 40 years
180 60.0 60.6 60.9 61.1 61.2 58.1 58.7 59.0 59.2 59.3
160 60.3 60.9 61.2 61.4 61.5 58.5 59.1 59.4 59.7 59.7
140 60.5 61.2 61.5 61.7 61.8 58.8 59.4 59.8 60.1 60.2
120 60.6 61.4 61.7 61.9 62.1 59.0 59.7 60.1 60.4 60.5
100 60.7 61.5 61.8 62.1 62.2 59.1 60.0 60.3 60.6 60.8
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Most deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 78.1 78.1 77.9 77.9 77.8 76.0 76.0 76.0 75.9 75.9
160 78.6 78.5 78.4 78.3 78.3 76.4 76.5 76.4 76.4 76.4
140 79.0 79.0 78.9 78.8 78.8 76.9 76.9 76.9 76.8 76.8
120 79.4 79.4 79.3 79.2 79.2 77.2 77.3 77.3 77.3 77.3
100 79.7 79.8 79.7 79.6 79.6 77.6 77.7 77.6 77.6 77.6
Age 60 years Age 60 years
180 71.8 71.9 71.8 71.7 71.7 69.5 69.6 69.6 69.6 69.6
160 72.3 72.3 72.2 72.2 72.2 70.0 70.1 70.1 70.1 70.1
140 72.6 72.7 72.7 72.6 72.6 70.4 70.6 70.6 70.6 70.6
120 73.0 73.1 73.0 73.0 73.0 70.8 71.0 71.0 71.0 71.0
100 73.2 73.4 73.4 73.4 73.4 71.1 71.4 71.4 71.4 71.4
Age 50 years Age 50 years
180 65.6 65.8 65.9 65.9 65.9 63.5 63.7 63.7 63.8 63.9
160 66.0 66.2 66.3 66.3 66.3 63.9 64.1 64.2 64.3 64.4
140 66.3 66.5 66.6 66.7 66.7 64.2 64.5 64.7 64.7 64.8
120 66.5 66.8 66.9 66.9 67.0 64.5 64.9 65.0 65.1 65.1
100 66.7 67.1 67.1 67.2 67.3 64.8 65.2 65.3 65.4 65.5
Age 40 years Age 40 years
180 59.4 59.8 59.9 60.0 60.0 57.4 57.8 58.0 58.1 58.2
160 59.6 60.0 60.2 60.3 60.3 57.7 58.2 58.4 58.5 58.6
140 59.8 60.3 60.4 60.6 60.6 58.0 58.5 58.7 58.9 59.0
120 59.9 60.5 60.7 60.8 60.9 58.2 58.8 59.0 59.2 59.3
100 60.0 60.6 60.8 61.0 61.0 58.3 59.0 59.3 59.5 59.6
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5.7 Estimating lifetime hospitalisation costs 
 
5.7.1 Source data – identifying hospitalisations 
There was the opportunity to further utilise the linked dataset of the Scottish Heart Health 
Extended Cohort and the Scottish Morbidity Records (SHHEC-SMR). To reiterate, SHHEC 
defined individuals by the nine ASSIGN risk factors and the SMR records all hospitalisations 
(up to 6 diagnostic positions) and death events using ICD codes. The datasets were linked by 
a unique patient identifier through CHI numbers. 
 
Both datasets were detailed in Chapter 4. To reiterate, the hospitalisations that were recorded 
in the linked dataset included were all outpatient stays, general/acute (inpatient/day case), 
maternity, mental health (inpatient/day case), geriatric, cancer and neonatal. All events were 
recorded using the International Classification of Diseases.   For each admission, the dataset 
records the dominant cause of admission and up to a further 5 events incurred within an 
inpatient stay, if relevant. This provided a detailed dataset from which to then estimate costs. 
 
5.7.2 Costing hospital episodes   
The overall objective was to use the SHHEC-SMR dataset to predict an individual’s annual 
hospital costs conditional upon the individual’s risk profile, as defined by the ASSIGN risk 
factors, and to project total future hospitalisation costs over the course of an entire lifetime.  
 
A cost function is driven by events incurred, their associated costs and the overall length of 
stay (LOS) of the entire visit.  Taken together, these elements comprise a Continuous 
Inpatient Stay (CIS).  A costing method detailed by Geue (method 1)(277, 311) was 
employed estimate the costs of CIS and applied to the SHHEC-SMR dataset.  For each 
individual in the dataset, and up to a maximum of 24 years of follow-up, every hospital 
admission was recorded and the associated costs of the CIS were estimated.  
 
The estimation approach consists of two stages. First, the HRGv3.5 Grouper software (where 
HRG denotes Hospital Related Group) was used to assign an HRG code to every episode 
within patient record. This software was available from the Health and Social Care 
Information Centre in England(312). This assigns an HRG code to each hospital admission 
based on principle diagnosis, procedure(s) performed, gender, age, LOS and the discharge 
method.  
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Healthcare resource groups (HRGs) are similar to Diagnostic Related Groups, which were 
first developed in the USA in the early 1980s for Medicare to use as a prospective payment 
system for hospitals. Since the 1990s, HRGs have routinely been used to cost hospital 
activities in England(313). HRGs are a measure of case mix presenting standard groupings 
for clinically similar treatments, which consume a common set of health care resources. 
Based on procedure, diagnosis, LOS, complications, co-morbidity, discharge method, age 
and gender, each patient record is grouped in an HRG and reflects one finished consultant 
episode (FCE). 
 
Second, the costs associated with each episode are taken from the English tariff which 
provides cost data for elective and non-elective hospital episodes. Within these estimate LOS 
is a key driver of costs and for each episode an average LOS is estimate, called the ‘trim-
point’. In addition, if LOS for a particular episode exceeds the trim-point additional per diem 
cost are also available and can be applied. Estimated costs are reported as a national 
schedule of reference costs. Tariffs are estimated for individual episodes, as if they occur 
independently(313). 
 
Third, having information on all admission, episodes and episode costs it was then necessary 
to estimate the overall costs of each CIS that may involved multiple episodes. Simply 
summing over the cost of each episode incurred would likely overestimate the cost of a CIS. 
The tariff costs are estimated ‘as if’ the episodes occur in isolation; however in a CIS 
episodes occur together. While total the length of a CIS is likely to increase with multiple 
episodes, this is unlikely to be the linear sum of average LOS of independent episodes(277, 
311).  
 
To estimate costs of a CIS a dominant HRG is selected by simultaneously taking into account 
any other ‘non-dominant’ episodes within this CIS, again using the method 1 in Geue(277, 
311). This was done using the ‘Spell Converter’ software which utilises information on the 
date of admission for the first episode of a CIS, the date of discharge of the last episode 
within that CIS, the episode order, episode LOS and the HRG and so selects the dominant 
episode within each CIS. A relevant tariff was then assigned to each CIS.  
 
 
 
 282 
5.7.3 Estimating mean hospital costs before and after a first event 
Having costed all hospital admissions for all individuals in the SHHEC-SMR database, the 
next stage was to manipulate the dataset to match the structure of the policy model (see 
page 186). Consequently, the SHHEC-SMR dataset was stratified into separate datasets to 
match patient pathways in the policy model. First, all individuals were divided into four 
datasets from the SHHEC baseline to one of the first four hospitalised events represented in 
the model (i.e. CHD hospitalisation, CBVD hospitalisation, fatal CVD and fatal non-CVD). 
Second, for those individuals who incurred a non-fatal event, two datasets were generated 
that followed individuals from a non-fatal CHD or CVBD event to eventual death.    
 
Given all hospital admissions were costed, this allowed mean costs across all individuals to 
be calculated for every year since SHHEC screening. If an individual in SHHEC was alive in a 
given year but had no hospitalisations then a zero cost was included in the calculation.  
 
Figures 5-27 and 5-28 illustrates these “observed” mean costs for all men and women before 
each of the first four events. Costs increase with time (as the SHHEC sample ages), and as 
we approach the 25 year maximum follow-up the data become more erratic reflecting fewer 
patent numbers. Patients who eventually go onto experience a fatal non-CVD event incur the 
greatest expense, with similar pre-event costs of other events.   
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Figure 5-27 Observed mean costs over time since screening before each of the first events - 
men 
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Key: Circles = prior to CHD; Diamonds = prior to CBVD; Squares = prior to CVD Death; Triangles = prior to non-
CVD death 
 
Figure 5-28 Observed mean costs over time since screening before each of the first events - 
women 
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Key: Circles = prior to CHD; Diamonds = prior to CBVD; Squares = prior to CVD Death;  Triangles = prior to non-
CVD death 
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Figure 5-29 and 5-30 illustrates “observed” mean costs for men and women post non-fatal 
CHD and non-fatal CBVD. Costs are higher it the immediate few years post events, fall and 
then tend  
 
Figure 5-29 Observed mean costs over time since first non-fatal CVD event - men 
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Key: Circles = post CHD; Diamonds = post CBVD 
 
Figure 5-30 Observed mean costs over time since first non-fatal CVD event - women 
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to rise thereafter. Again the data is quite erratic as we approach the maximum follow up 
period in the SHHEC-SMR of 25 years. 
 
5.7.4 Discussion of the costing methods 
A key strength of the costing analysis is that there was a comprehensive longitudinal dataset 
(SHHEC-SMR) that followed over 16,000 individuals for a maximum follow-up of 24 years, 
and recorded each hospitalisation incurred. For each hospitalisation up to 6 diagnoses were 
made and recorded using ICD codes.  Further, records are routinely validated by the 
Information Services Division (ISD) finding over 99% accuracy in correct identification of 
diagnosis and linkage from SHHEC to SMR(277, 311), as discussed in Chapter 4. The 
costing method employed, as described previously, which was based on research by 
Geue(311) takes into account a patients continuous inpatient stay (CIS), including principle 
diagnosis, entire length of stay (LOS), and additional per diem costs to account for additional 
diagnoses. 
 
However, it is important to discuss the potential limitations of the costing methods employed. 
First, the historical nature of the SHHEC-SMR dataset, which dates from the 1980s, was 
necessary to follow patients over time but it may be that this introduces bias in inferring 
similar episode patterns in contemporary patients. Given care is likely to have improved over 
time and perhaps the incidence of multiple episodes is less likely. If so, this may mean that 
overall LOS of a CIS may be overestimated. It is difficult to verify or quantify this. Again the 
key issue is that, in using the costing methods described previously, the tariffs values should 
be continually updated which would then account for such changes. 
 
Second, the HRG codes and tariffs represent average costs for English hospitals. Equivalent 
data for Scotland is not available. It is quite possible that average hospital costs in Scotland 
differ from England; however the direction and magnitude of any estimation bias is difficult to 
estimate. 
 
Third, the English tariff values used in the model date from 2010. This is relatively recent; 
however, the important point is that over time the model will need to update tariff values to 
maintain contemporary relevance. In particular, there is an historical trend that LOS falls over 
time, and LOS plays a key role in tariff values. If tariffs are not updated then this may result in 
bias where perhaps costs are overestimated. On the other hand, unit costs may increase due 
to improved technology for instance, implying that the using historical tariffs may 
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underestimate costs. Nonetheless, the key issue is that the tariffs values in the model should 
be continually updated. 
 
Fourth, a potential limitation in the SHHEC-SMR dataset is whether the multiple diagnoses 
actually represent incident cases, and rather than simply historical records. It is not expected 
that this itself has introduced systematic bias into the costing analysis, however. The method 
chosen is driven by the dominant HRG code which is typically the primary diagnostic position 
which would most likely be an incident case.  
 
Fifth, a potential weakness in the approach is that the principal diagnosis drives costs and if 
the overall length of a CIS was greater than the average LOS of the principal diagnosis then it 
would be sufficient to cost ‘extra’ days in hospital at a per diem rates that are intended to 
approximate hotelier costs. This may have underestimated costs if event episodes were 
incurred, than cost more than simply extra bed days. The practical issue though is that there 
is not a perfect costing method to cost CIS. Further, in using the model to under cost 
effectiveness analysis the key issue is the difference in costs between intervention options.   
 
Sixth, the main weakness in the approach to cost the impact of CVD on lifetime patient costs 
is that it is limited to hospitalisation costs. What is omitted is primary care and community 
care costs. This may be particularly important for costing the impact of stroke, which is 
increasing treated at the community level.  
 
5.7.5 Modelling to estimate hospitalisation costs pre and post event 
To model costs, a similar approach was taken as when predicting non-fatal CVD events 
following a first event.  That is, there was a need to extrapolate beyond the observed follow-
up period. Restricted cubic splines, with 3 knots, were used again.  Linear regression was 
used to predict mean hospital costs using the non-modifiable risk factors of age at SHHEC, 
family history, and socioeconomic status. Separate models were generated for men and 
women, and before each of the first four events and after the two non-fatal events. So, in 
total, 12 models were generated. 
 
Figure 5-31 to 5-38 provide the results of the modelling which estimated the costs pre and 
post first event, and separately for men and women. The results show the coefficients and 
95% confidence intervals. Further, the time splines that were generated are also shown.  
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In summary, the strength of the relationship between the coefficients and mean costs varies 
pre and post event, is specific to the event type experienced and is different for men and 
women. This provides further justification for splitting events and running separate models for 
men and women. Estimates are often not significant though these were still incorporated into 
the model.  
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Table 5-18 a) Costs pre-event - men 
 
 
Covariate 
non-fatal CHD 
 
coeff. (95% CI) 
 
 
p value 
non-fatal CBVD 
 
coeff. (95% CI) 
 
 
p value 
fatal CVD 
 
coeff. (95% CI) 
 
 
p value 
fatal non-CVD 
 
coeff. (95% CI) 
 
 
p value 
         
ti1 18.6 (-2.0, 39.2) 0.077 5.5 (-38.0, 49.0) 0.804 26.1 (-7.1, 59.3) 0.123 42.1 (-4.5, 88.7) 0.076 
ti2 115.0 (70.3, 159.8) <0.001 156.6 (72.0, 241.2) <0.001 114.6 (56.8, 172.5) <0.001 237.2 (157.1, 317.4) <0.001 
Age 22.7 (16.4, 29.0) <0.001 17.3 (5.8, 28.9) 0.003 27.7 (16.5, 38.89) <0.001 24.7 (9.0, 40.5) 0.002 
SIMD sc. 5.2 (3.0, 7.4) <0.001 6.6 (2.9, 10.3) <0.001 3.8 (-0.1, 7.8) 0.059 4.7 (-0.5, 10.0) 0.078 
Fam. his. 93.8 (1.5, 186.1) 0.046 -161.9 (-328.5, 4.8) 0.057 67.4 (-120.9, 255.7) 0.483 116.9 (-198.7, 432.6) 0.468 
Constant -1121 (-1446, -795) <0.001 -832.8 (-1483, -182.4) 0.012 -1345 (-1981, -709.2) <0.001 -1029 (-1890, -169.2) 0.019 
 
b) Costs  pre-first event - women 
 
 
Covariate 
non-fatal CHD 
 
coeff. (95% CI) 
 
 
p value 
non-fatal CBVD 
 
coeff. (95% CI) 
 
 
p value 
fatal CVD 
 
coeff. (95% CI) 
 
 
p value 
fatal non-CVD 
 
coeff. (95% CI) 
 
 
p value 
         
ti1 -7.3 (-94.3, 79.8) 0.870 14.2 (-23.3, 51.6) 0.458 23.9 (-18.4, 66.2) 0.269 59.0 (11.5, 106.4) 0.015 
ti2 172.2 (-64.6, 408.9) 0.154 121.8 (57.7, 185.8) <0.001 144.7 (72.2, 217.3) <0.001 202.6 (125.8, 279.4) <0.001 
Age 0.5 (-25.1, 26.2) 0.967 26.3 (15.0, 37.6) <0.001 33.7 (18.4, 49.0) <0.001 16.0 (-3.5, 35.4) 0.107 
SIMD sc. 10.6 (2.3, 19.0) 0.013 8.4 (2.4, 14.4) 0.006 5.5 (0.8, 10.2) 0.022 11.9 (5.6, 18.3) <0.001 
Fam. his. 337.8 (-235.7, 911.4) 0.248 22.7 (-176.6, 222.0) 0.823 105.5 (-125.0, 336.0) 0.370 47.7 (-229.7, 325.2) 0.736 
Constant -214.2 (-1359, 930.8) 0.714 -1462 (-2123, -800.5) <0.001 -1727 (-2643, -809.9) <0.001 -832.0 (-1894, 230.1) 0.125 
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Table 5-19 Time spline variables: men pre-first event 
year ti1 ti2 year ti1 ti2 year ti1 ti2
1 1 0 35 35 31.2 68 68 70.8
2 2 0 36 36 32.4 69 69 72
3 3 0.004444 37 37 33.6 70 70 73.2
4 4 0.035556 38 38 34.8 71 71 74.4
5 5 0.12 39 39 36 72 72 75.6
6 6 0.284445 40 40 37.2 73 73 76.8
7 7 0.555556 41 41 38.4 74 74 78
8 8 0.96 42 42 39.6 75 75 79.2
9 9 1.517037 43 43 40.8 76 76 80.4
10 10 2.216296 44 44 42 77 77 81.6
11 11 3.04 45 45 43.2 78 78 82.8
12 12 3.97037 46 46 44.4 79 79 84
13 13 4.98963 47 47 45.6 80 80 85.2
14 14 6.08 48 48 46.8 81 81 86.4
15 15 7.223704 49 49 48 82 82 87.6
16 16 8.402963 50 50 49.2 83 83 88.8
17 17 9.6 51 51 50.4 84 84 90
18 18 10.8 52 52 51.6 85 85 91.2
19 19 12 53 53 52.8 86 86 92.4
20 20 13.2 54 54 54 87 87 93.6
21 21 14.4 55 55 55.2 88 88 94.8
22 22 15.6 56 56 56.4 89 89 96
23 23 16.8 57 57 57.6 90 90 97.2
24 24 18 58 58 58.8 91 91 98.4
25 25 19.2 59 59 60 92 92 99.6
26 26 20.4 60 60 61.2 93 93 100.8
27 27 21.6 61 61 62.4 94 94 102
28 28 22.8 62 62 63.6 95 95 103.2
29 29 24 63 63 64.8 96 96 104.4
30 30 25.2 64 64 66 97 97 105.6
31 31 26.4 65 65 67.2 98 98 106.8
32 32 27.6 66 66 68.4 99 99 108
33 33 28.8 67 67 69.6 100 100 109.2
34 34 30  
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Table 5-20 Time spline variables: women pre-first event 
year ti1 ti2 year ti1 ti2 year ti1 ti2
1 1 0 35 35 31.2 68 68 70.8
2 2 0 36 36 32.4 69 69 72
3 3 0.004444 37 37 33.6 70 70 73.2
4 4 0.035556 38 38 34.8 71 71 74.4
5 5 0.12 39 39 36 72 72 75.6
6 6 0.284445 40 40 37.2 73 73 76.8
7 7 0.555556 41 41 38.4 74 74 78
8 8 0.96 42 42 39.6 75 75 79.2
9 9 1.517037 43 43 40.8 76 76 80.4
10 10 2.216296 44 44 42 77 77 81.6
11 11 3.04 45 45 43.2 78 78 82.8
12 12 3.97037 46 46 44.4 79 79 84
13 13 4.98963 47 47 45.6 80 80 85.2
14 14 6.08 48 48 46.8 81 81 86.4
15 15 7.223704 49 49 48 82 82 87.6
16 16 8.402963 50 50 49.2 83 83 88.8
17 17 9.6 51 51 50.4 84 84 90
18 18 10.8 52 52 51.6 85 85 91.2
19 19 12 53 53 52.8 86 86 92.4
20 20 13.2 54 54 54 87 87 93.6
21 21 14.4 55 55 55.2 88 88 94.8
22 22 15.6 56 56 56.4 89 89 96
23 23 16.8 57 57 57.6 90 90 97.2
24 24 18 58 58 58.8 91 91 98.4
25 25 19.2 59 59 60 92 92 99.6
26 26 20.4 60 60 61.2 93 93 100.8
27 27 21.6 61 61 62.4 94 94 102
28 28 22.8 62 62 63.6 95 95 103.2
29 29 24 63 63 64.8 96 96 104.4
30 30 25.2 64 64 66 97 97 105.6
31 31 26.4 65 65 67.2 98 98 106.8
32 32 27.6 66 66 68.4 99 99 108
33 33 28.8 67 67 69.6 100 100 109.2
34 34 30
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Table 5-21 a) Cost post non-fatal CHD event - men 
 
Covariate coeff. (95% CI) p value 
ti1 -552.6 (-638.7, -466.6) <0.001 
ti2 654.9 (554.5, 755.3) <0.001 
Age at event 84.6 (66.9, 102.4) <0.001 
SIMD score 14.2 (7.6, 20.8) <0.001 
Family history 239.8 (-80.4, 560.0) 0.142 
Constant -1024 (-2107, 59.0) <0.001 
 
b)  Costs post non-fatal CBVD event - men 
 
Covariate coeff. (95% CI) p value 
ti1 -680.0 (-854.7, -505.2) <0.001 
ti2 787.7 (555.7, 1020) <0.001 
Age at event 112.6 (81.2, 144.0) <0.001 
SIMD score 6.8 (-4.5, 18.1) 0.236 
Family history -102.2 (-717.2, 512.9) 0.745 
Constant -1836 (-4010, 338.3) 0.098 
 
 
c) Costs post non-fatal CHD event - women 
 
Covariate coeff. (95% CI) p value 
ti1 -548.6 (-652.4, -444.8) <0.001 
ti2 745.4 (600.4, 890.3) <0.001 
Age at event 90.7 (68.5, 112.9) <0.001 
SIMD score 13.6 (6.0, 21.3) <0.001 
Family history -227.9 (-596.5, 140.7) 0.226 
Constant -1321 (-2900, 257.1) <0.001 
 
d) Costs post non-fatal CBVD event - women 
 
Covariate coeff. (95% CI) p value 
ti1 -542.3 (-744.1, -340.4) <0.001 
ti2 595.6 (357.4, 833.9) <0.001 
Age at event 97.1 (67.0, 127.2) <0.001 
SIMD score 7.7 (-4.7, 20.0) 0.223 
Family history -93.9 (-656.1, 468.4) 0.743 
Constant -1251 (-3593, 1092) 0.295 
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Table 5-22 Time spline variables: Men post-CHD 
 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2
1 1 0 35 35 32.30769 68 68 70.38461
2 2 0.0059172 36 36 33.46154 69 69 71.53846
3 3 0.0473373 37 37 34.61538 70 70 72.69231
4 4 0.1597633 38 38 35.76923 71 71 73.84615
5 5 0.3786982 39 39 36.92308 72 72 75
6 6 0.7396449 40 40 38.07692 73 73 76.15385
7 7 1.268491 41 41 39.23077 74 74 77.30769
8 8 1.952663 42 42 40.38462 75 75 78.46154
9 9 2.76997 43 43 41.53846 76 76 79.61539
10 10 3.698225 44 44 42.69231 77 77 80.76923
11 11 4.715237 45 45 43.84615 78 78 81.92308
12 12 5.798817 46 46 45 79 79 83.07692
13 13 6.926775 47 47 46.15385 80 80 84.23077
14 14 8.076923 48 48 47.30769 81 81 85.38461
15 15 9.230769 49 49 48.46154 82 82 86.53846
16 16 10.38461 50 50 49.61538 83 83 87.69231
17 17 11.53846 51 51 50.76923 84 84 88.84615
18 18 12.69231 52 52 51.92308 85 85 90
19 19 13.84615 53 53 53.07692 86 86 91.15385
20 20 15 54 54 54.23077 87 87 92.30769
21 21 16.15385 55 55 55.38462 88 88 93.46154
22 22 17.30769 56 56 56.53846 89 89 94.61539
23 23 18.46154 57 57 57.69231 90 90 95.76923
24 24 19.61539 58 58 58.84615 91 91 96.92308
25 25 20.76923 59 59 60 92 92 98.07692
26 26 21.92308 60 60 61.15385 93 93 99.23077
27 27 23.07692 61 61 62.30769 94 94 100.3846
28 28 24.23077 62 62 63.46154 95 95 101.5385
29 29 25.38461 63 63 64.61539 96 96 102.6923
30 30 26.53846 64 64 65.76923 97 97 103.8462
31 31 27.69231 65 65 66.92308 98 98 105
32 32 28.84615 66 66 68.07692 99 99 106.1538
33 33 30 67 67 69.23077 100 100 107.3077
34 34 31.15385
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Table 5-23 Time spline variables: Men post-CBVD 
Cycle (year) ti1 ti2 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2
1 1 0 35 35 31.63636 68 68 67.63636
2 2 0.0082645 36 36 32.72727 69 69 68.72727
3 3 0.0661157 37 37 33.81818 70 70 69.81818
4 4 0.2231405 38 38 34.90909 71 71 70.90909
5 5 0.5289256 39 39 36 72 72 72
6 6 1.020071 40 40 37.09091 73 73 73.09091
7 7 1.681228 41 41 38.18182 74 74 74.18182
8 8 2.484061 42 42 39.27273 75 75 75.27273
9 9 3.400236 43 43 40.36364 76 76 76.36364
10 10 4.401417 44 44 41.45454 77 77 77.45454
11 11 5.459268 45 45 42.54546 78 78 78.54546
12 12 6.545455 46 46 43.63636 79 79 79.63636
13 13 7.636364 47 47 44.72727 80 80 80.72727
14 14 8.727273 48 48 45.81818 81 81 81.81818
15 15 9.818182 49 49 46.90909 82 82 82.90909
16 16 10.90909 50 50 48 83 83 84
17 17 12 51 51 49.09091 84 84 85.09091
18 18 13.09091 52 52 50.18182 85 85 86.18182
19 19 14.18182 53 53 51.27273 86 86 87.27273
20 20 15.27273 54 54 52.36364 87 87 88.36364
21 21 16.36364 55 55 53.45454 88 88 89.45454
22 22 17.45455 56 56 54.54546 89 89 90.54546
23 23 18.54545 57 57 55.63636 90 90 91.63636
24 24 19.63636 58 58 56.72727 91 91 92.72727
25 25 20.72727 59 59 57.81818 92 92 93.81818
26 26 21.81818 60 60 58.90909 93 93 94.90909
27 27 22.90909 61 61 60 94 94 96
28 28 24 62 62 61.09091 95 95 97.09091
29 29 25.09091 63 63 62.18182 96 96 98.18182
30 30 26.18182 64 64 63.27273 97 97 99.27273
31 31 27.27273 65 65 64.36364 98 98 100.3636
32 32 28.36364 66 66 65.45454 99 99 101.4545
33 33 29.45455 67 67 66.54546 100 100 102.5455
34 34 30.54545  
 294 
 
Table 5-24 Time spline variables: Women post-CHD  
year ti1 ti2 year ti1 ti2 year ti1 ti2
1 1 0 35 35 26.15385 68 68 56.61538
2 2 0.005917 36 36 27.07692 69 69 57.53846
3 3 0.047337 37 37 28 70 70 58.46154
4 4 0.159763 38 38 28.92308 71 71 59.38462
5 5 0.378698 39 39 29.84615 72 72 60.30769
6 6 0.731098 40 40 30.76923 73 73 61.23077
7 7 1.20973 41 41 31.69231 74 74 62.15385
8 8 1.798817 42 42 32.61538 75 75 63.07692
9 9 2.482577 43 43 33.53846 76 76 64
10 10 3.245233 44 44 34.46154 77 77 64.92308
11 11 4.071006 45 45 35.38462 78 78 65.84615
12 12 4.944116 46 46 36.30769 79 79 66.76923
13 13 5.848783 47 47 37.23077 80 80 67.69231
14 14 6.769231 48 48 38.15385 81 81 68.61539
15 15 7.692307 49 49 39.07692 82 82 69.53846
16 16 8.615385 50 50 40 83 83 70.46154
17 17 9.538462 51 51 40.92308 84 84 71.38461
18 18 10.46154 52 52 41.84615 85 85 72.30769
19 19 11.38461 53 53 42.76923 86 86 73.23077
20 20 12.30769 54 54 43.69231 87 87 74.15385
21 21 13.23077 55 55 44.61538 88 88 75.07692
22 22 14.15385 56 56 45.53846 89 89 76
23 23 15.07692 57 57 46.46154 90 90 76.92308
24 24 16 58 58 47.38462 91 91 77.84615
25 25 16.92308 59 59 48.30769 92 92 78.76923
26 26 17.84615 60 60 49.23077 93 93 79.69231
27 27 18.76923 61 61 50.15385 94 94 80.61539
28 28 19.69231 62 62 51.07692 95 95 81.53846
29 29 20.61539 63 63 52 96 96 82.46154
30 30 21.53846 64 64 52.92308 97 97 83.38461
31 31 22.46154 65 65 53.84615 98 98 84.30769
32 32 23.38461 66 66 54.76923 99 99 85.23077
33 33 24.30769 67 67 55.69231 100 100 86.15385
34 34 25.23077  
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Table 5-25 Time spline variables: Women post-CBVD  
Cycle (year) ti1 ti2 Cycle (year) ti1 ti2 Cycle (year) ti1 ti2
1 1 0 35 35 31.63636 68 68 67.63636
2 2 0.0082645 36 36 32.72727 69 69 68.72727
3 3 0.0661157 37 37 33.81818 70 70 69.81818
4 4 0.2231405 38 38 34.90909 71 71 70.90909
5 5 0.5289256 39 39 36 72 72 72
6 6 1.020071 40 40 37.09091 73 73 73.09091
7 7 1.681228 41 41 38.18182 74 74 74.18182
8 8 2.484061 42 42 39.27273 75 75 75.27273
9 9 3.400236 43 43 40.36364 76 76 76.36364
10 10 4.401417 44 44 41.45454 77 77 77.45454
11 11 5.459268 45 45 42.54546 78 78 78.54546
12 12 6.545455 46 46 43.63636 79 79 79.63636
13 13 7.636364 47 47 44.72727 80 80 80.72727
14 14 8.727273 48 48 45.81818 81 81 81.81818
15 15 9.818182 49 49 46.90909 82 82 82.90909
16 16 10.90909 50 50 48 83 83 84
17 17 12 51 51 49.09091 84 84 85.09091
18 18 13.09091 52 52 50.18182 85 85 86.18182
19 19 14.18182 53 53 51.27273 86 86 87.27273
20 20 15.27273 54 54 52.36364 87 87 88.36364
21 21 16.36364 55 55 53.45454 88 88 89.45454
22 22 17.45455 56 56 54.54546 89 89 90.54546
23 23 18.54545 57 57 55.63636 90 90 91.63636
24 24 19.63636 58 58 56.72727 91 91 92.72727
25 25 20.72727 59 59 57.81818 92 92 93.81818
26 26 21.81818 60 60 58.90909 93 93 94.90909
27 27 22.90909 61 61 60 94 94 96
28 28 24 62 62 61.09091 95 95 97.09091
29 29 25.09091 63 63 62.18182 96 96 98.18182
30 30 26.18182 64 64 63.27273 97 97 99.27273
31 31 27.27273 65 65 64.36364 98 98 100.3636
32 32 28.36364 66 66 65.45454 99 99 101.4545
33 33 29.45455 67 67 66.54546 100 100 102.5455
34 34 30.54545  
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5.7.6 Using the model to predict hospitalisation costs 
To estimate cumulative lifetime costs a Kaplain-Meier Sample Average (KMSA) estimator 
was used again, similar to the process of quality adjustment. This gives the generic 
expression:  
 
Expected cost = ∑S(t)xb(t)) 
 
where xb(t) is the linear predictor from the linear regression at time period t, and S(t) is the 
survival probability.  
 
Prior to the first event, the survival probability is 1. Post first event, the probability of survival 
declines with time, as estimated in Chapter 4.  Costs in each time period is weighted by 
survival to the end of that time period. To estimate cumulative costs the KMSA estimator 
simply sums expected costs across time periods. The following four figures 5-31 to 5-34 
illustrates how the model estimates costs for the same 60 year male profiles as introduced 
previously. 
 
(i)  Cost pre-event: In summary, the figures show that the model smoothes the observed data 
which was erratic.  
 
Figure 5-31 Predicted costs pre-nonfatal CHD 
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Figure 5-32 Predicted costs pre-nonfatal CVBD 
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Figure 5-33 Predicted costs pre-fatal CVD 
0
1000
2000
3000
4000
5000
6000
7000
8000
Time in model
T
o
ta
l 
h
o
s
p
it
a
lis
a
ti
o
n
 c
o
s
ts
  
 .
Pre-fatal CVD
50250
 
 
 
 
 
 
 
 298 
Figure 5-34 Predicted costs pre-fatal non CVD 
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To incorporate the annual costs estimates before the first four events, then are summed 
across to the period when a particular first event occurs. That is, the survival probability is 
assumed to be 1 up until the period in which an event occurs.  
 
(ii) Costs post event: Figures 5-35 and 5-36 illustrate modelled lifetime costs for the 60 male 
we have used throughout the thesis so far. The assumption is that a CHD or CBVD event 
occurs in year 1 upon entering the model.  Similar to the process of quality adjustment, a 
KMSA estimator approach is adopted whereby the estimates in each year of the model are 
weighted by the probability of actually being alive and then summed. This provides an 
estimate of cumulative costs over a remaining lifetime. 
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Figure 5-35 Predicted costs post non-fatal CHD hospitalisation  
0
2
4
6
8
10
12
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
1.00
£
'0
0
0
 (
S
te
rl
in
g
) 
P
(S
u
rv
iv
a
l)
Years from event
Predicted annual costs
Survival post non-fatal CHD
0 50
25
 
 
Figure 5-36 Predicted costs post non-fatal CBVD hospitalisation  
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The next section provides an illustration how these cost predictions are combined to estimate 
expected cumulative lifetime hospitalisation costs. 
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5.8 Generating expected cumulative lifetime hospitalisation 
costs  
To then estimate average expected lifetime costs, all event scenarios need to be run and 
weighted in a similar process to quality adjusting life expectancy. First, an estimate of the 
lifetime costs are made for each model scenario defined by type and timing of the first event – 
table 5-26a. Each of the 400 scenarios (4 first events multiple by 100 cycles) has its own cost 
estimate.  
 
Table 5-26 a) Remaining discounted lifetime costs upon entering model [pre-first event + post 
first event] 
1 87 78 6 6
2 88 78 12 13
3 88 79 17 18
.
.
22 91 84 32 35
23 93 86 37 39
24 95 88 41 44
.
.
100 249 263 39 40
Cycle (time in years) CVD death nonCVD deathNon-fatal CHD Non-fatal CBVD
 
 
b) Probability of first event 
1 0.026 0.008 0.017 0.013
2 0.026 0.008 0.017 0.013
3 0.025 0.008 0.017 0.013
.
.
22 0.003 0.002 0.003 0.002
23 0.002 0.001 0.002 0.002
24 0.002 0.001 0.002 0.001
.
.
100 0 0 0 0
Cycle (time in years) Non-fatal CHD Non-fatal CBVD CVD death nonCVD death
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Table 5-26b give the probability of each event scenario, and table 5.26c provides weighted 
costs by multiply tables a and b together. All estimates are discounted at 3.5%.  
 
c) Weighted discounted lifetime costs [estimates from table a) multiplied by estimated from 
table b) ] 
1 1.082 0.238 0.032 0.075 1.426
2 1.111 0.254 0.066 0.154 1.585
3 1.143 0.272 0.101 0.237 1.752
.
.
22 0.722 0.333 0.175 0.427 1.659
23 0.658 0.316 0.183 0.447 1.604
24 0.591 0.296 0.184 0.452 1.523
.
.
100 0.000 0.000 0.000 0.000 0.000
45.8Total lifetime costs (pre and post event) =    
Sum
Cycle (time in years) CVD death nonCVD deathNon-fatal CHD Non-fatal CBVD
 
 
For the 60 year old male, life time discounted hospital costs was estimated to be a discounted 
£45,800. 
 
Figures 5-37 to 5-38 illustrate the model’s ability to estimate lifetime costs specific to 
individual risk profiles as defined by the ASSIGN risk factors. The standard format of 10-year 
risk tables is again used.  For consistency, this is also shown for men and women and for the 
highest and lowest fifths of SIMD. These are shown in discounted terms. In general, for a 
given age band healthier profiles (lower modifiable risk factors) are associated with higher 
costs given longer life expectancies. Costs also rise with age groups. While younger age 
groups have a longer to live and absolute costs are higher, discounting results in distant costs 
valued much less is present day terms. This will be further illustrated shortly.  
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Figure 5-37 Discounted lifetime hospital costs - men 
Least deprived fifth – SIMD 1 
Non-Smoker Smoker
Age 70 years Age 70 years
180 46.4 44.8 44.5 44.6 44.7 41.6 41.5 42.1 42.7 43.1
160 48.1 45.9 45.2 45.0 45.0 43.1 42.7 43.0 43.4 43.7
140 49.7 47.1 46.0 45.4 45.3 44.5 43.8 43.8 44.0 44.2
120 51.5 48.5 47.0 46.0 45.8 45.9 44.9 44.8 44.6 44.7
100 53.2 49.9 48.2 46.9 46.5 47.2 46.2 45.7 45.4 45.2
Age 60 years Age 60 years
180 53.5 52.4 52.6 53.3 53.7 52.2 52.6 53.7 54.9 55.6
160 54.5 52.5 52.2 52.5 52.8 53.2 52.9 53.6 54.5 55.0
140 55.7 52.9 52.0 51.9 52.0 54.3 53.4 53.5 54.1 54.4
120 57.2 53.6 52.1 51.6 51.5 55.6 54.0 53.6 53.8 54.0
100 58.8 54.7 52.7 51.6 51.4 56.9 54.8 54.0 53.8 53.8
Age 50 years Age 50 years
180 55.1 55.0 56.0 57.5 58.4 57.7 59.0 60.7 62.6 63.7
160 55.4 54.2 54.5 55.6 56.3 58.0 58.2 59.4 61.0 61.9
140 56.0 53.7 53.4 53.9 54.4 58.5 57.7 58.3 59.4 60.1
120 57.2 53.7 52.7 52.7 52.9 59.4 57.7 57.5 58.1 58.6
100 58.6 54.2 52.5 51.9 51.9 60.6 57.9 57.2 57.2 57.5
Age 40 years Age 40 years
180 52.0 53.2 54.9 57.1 58.3 57.5 59.8 62.2 64.8 66.2
160 51.6 51.5 52.6 54.4 55.4 57.1 58.1 59.9 62.1 63.3
140 51.8 50.4 50.8 52.0 52.8 57.0 56.9 57.9 59.6 60.7
120 52.4 49.8 49.4 50.1 50.7 57.5 56.1 56.4 57.6 58.4
100 53.6 49.8 48.6 48.7 49.0 58.4 55.9 55.4 56.0 56.5
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Most deprived fifth – SIMD 5 
Non-Smoker Smoker
Age 70 years Age 70 years
180 40.3 37.8 36.8 36.2 35.9 34.4 33.5 33.3 33.2 33.3
160 42.3 39.4 38.1 37.2 36.8 36.1 34.9 34.6 34.3 34.3
140 44.3 41.1 39.5 38.3 37.8 37.7 36.3 35.9 35.4 35.3
120 46.2 42.9 41.0 39.6 39.0 39.2 37.9 37.1 36.6 36.2
100 48.1 44.8 42.7 41.0 40.3 40.6 39.3 38.4 37.7 37.4
Age 60 years Age 60 years
180 49.2 46.7 45.9 45.7 45.7 46.2 45.2 45.3 45.6 45.9
160 50.9 47.6 46.3 45.7 45.6 47.7 46.1 45.8 45.8 46.0
140 52.7 48.7 46.9 45.9 45.7 49.2 47.2 46.5 46.2 46.2
120 54.7 50.2 47.9 46.5 46.0 50.8 48.5 47.4 46.7 46.6
100 56.7 51.8 49.2 47.4 46.8 52.4 49.8 48.4 47.5 47.1
Age 50 years Age 50 years
180 53.3 51.5 51.4 51.9 52.3 54.1 53.7 54.4 55.4 55.9
160 54.3 51.4 50.7 50.8 51.0 55.1 53.7 53.8 54.4 54.9
140 55.6 51.8 50.4 50.0 50.0 56.3 54.0 53.5 53.7 54.0
120 57.4 52.6 50.5 49.6 49.4 57.7 54.7 53.6 53.3 53.3
100 59.4 53.8 51.1 49.7 49.2 59.3 55.6 54.0 53.3 53.1
Age 40 years Age 40 years
180 52.3 51.8 52.6 53.9 54.8 56.7 57.3 58.7 60.5 61.5
160 52.6 50.8 50.9 51.8 52.5 56.8 56.3 57.0 58.4 59.3
140 53.3 50.4 49.7 50.1 50.6 57.5 55.7 55.8 56.7 57.3
120 54.7 50.5 49.1 48.9 49.1 58.6 55.7 55.0 55.3 55.7
100 56.4 51.2 49.0 48.2 48.1 60.0 56.1 54.7 54.4 54.5
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Figure 5-38 Discounted lifetime hospital costs - women 
Least deprived fifth – SIMD 1 
Non-Smoker Smoker
Age 70 years Age 70 years
180 50.4 49.0 47.9 48.1 48.1 41.7 41.6 41.5 41.9 42.2
160 52.9 50.6 49.0 48.9 48.7 44.4 43.7 43.3 43.4 43.7
140 55.5 52.4 50.2 49.7 49.4 47.2 45.9 44.8 44.8 45.0
120 58.5 54.5 51.7 50.5 50.2 50.3 48.3 46.6 46.3 46.1
100 61.9 57.0 53.4 51.7 51.3 53.3 50.8 48.6 47.7 47.6
Age 60 years Age 60 years
180 56.4 55.9 55.4 56.0 56.6 51.7 52.0 52.2 53.1 53.8
160 58.1 56.5 55.4 55.6 56.1 53.8 53.4 53.1 53.7 54.3
140 60.1 57.3 55.5 55.3 55.4 56.2 54.8 53.9 54.1 54.6
120 62.6 58.5 55.8 55.3 55.1 58.7 56.4 54.9 54.7 55.0
100 65.5 60.0 56.7 55.4 55.2 61.5 58.2 56.0 55.5 55.4
Age 50 years Age 50 years
180 57.0 57.4 57.8 59.2 60.1 56.5 57.4 58.3 59.8 60.8
160 57.7 56.9 56.8 57.7 58.6 57.7 57.9 58.0 59.2 60.2
140 59.0 56.8 55.9 56.4 57.1 59.3 58.2 57.9 58.7 59.5
120 60.7 57.2 55.5 55.5 55.7 61.3 59.0 57.9 58.3 58.8
100 62.8 58.1 55.4 54.8 54.9 63.4 60.2 58.3 58.1 58.5
Age 40 years Age 40 years
180 53.0 54.7 56.0 58.0 59.3 55.7 57.8 59.5 61.6 62.7
160 53.0 53.5 54.1 55.9 57.0 56.1 57.2 58.2 60.1 61.2
140 53.5 52.7 52.6 53.8 54.8 57.0 56.8 57.2 58.7 59.5
120 54.5 52.3 51.5 52.2 52.8 58.1 56.8 56.3 57.3 58.1
100 56.1 52.4 50.9 51.0 51.3 60.0 57.2 56.0 56.4 57.0
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Most deprived fifth – SIMD 5 
Non-Smoker Smoker
Age 70 years Age 70 years
180 49.7 47.7 46.2 45.8 45.9 41.4 40.9 40.6 40.8 41.0
160 52.3 49.4 47.4 46.6 46.5 43.9 42.8 41.9 42.0 42.1
140 55.4 51.6 48.8 47.5 47.3 46.7 44.9 43.5 43.2 43.0
120 58.9 53.8 50.4 48.8 48.2 49.7 47.3 45.3 44.4 44.4
100 62.5 56.8 52.6 50.4 49.7 52.7 49.7 47.3 46.2 45.9
Age 60 years Age 60 years
180 58.4 56.6 55.7 55.9 56.3 53.8 53.7 53.4 54.3 54.6
160 60.3 57.4 55.7 55.5 55.6 55.8 54.6 54.0 54.5 54.7
140 62.5 58.6 56.1 55.3 55.1 58.1 56.1 54.7 54.6 54.8
120 65.5 60.3 56.9 55.6 55.1 61.0 57.9 55.8 55.2 55.2
100 69.0 62.4 58.2 56.2 55.6 64.2 60.2 57.4 56.1 56.0
Age 50 years Age 50 years
180 60.8 60.4 60.4 61.5 62.4 60.9 61.6 62.3 63.8 64.6
160 61.8 60.0 59.2 59.8 60.5 62.1 61.7 61.7 62.7 63.4
140 63.5 60.1 58.5 58.5 58.7 63.8 62.2 61.2 61.9 62.4
120 65.8 60.9 58.3 57.7 57.6 66.2 63.0 61.3 61.2 61.7
100 68.5 62.4 58.7 57.4 57.2 68.8 64.6 61.9 61.2 61.4
Age 40 years Age 40 years
180 58.1 59.2 60.2 62.3 63.6 61.9 63.8 65.4 67.8 69.1
160 58.3 57.9 58.1 59.7 60.6 62.3 62.9 63.8 65.7 66.7
140 59.1 57.2 56.5 57.4 58.2 63.3 62.4 62.5 63.8 64.7
120 60.7 57.0 55.5 55.6 56.2 64.8 62.5 61.5 62.2 63.0
100 63.0 57.7 55.1 54.6 54.9 67.1 63.2 61.3 61.3 61.7
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5.9 Preparing the model for economic evaluation 
In taking stock of the modelling so far in Part 2 of thesis, the model has the ability to estimate 
the lifetime risk CVD, life expectancy, QALE and lifetime hospitalisation costs. The next step 
is to prepare the model to be ready for economic evaluation. This is the purpose of this 
section. 
 
5.9.1 Inputs to the model  
The purpose of the evaluation module is to estimate the lifetime impact of changes to 
modifiable risk factors on life expectancy, QALE and costs. The model can be used either to 
conduct “what-if” analysis to simulate the potential impact of modifying risk factor(s),  or 
alongside trial evidence of intervention(s) to project the expected lifetime impacts from 
evidenced changes to risk factors. 
 
Three main inputs are used in the model:  (i) the intervention(s), (ii) associated evidence 
regarding the interventions impact on reducing risk factors, and (iii) intervention costs. The 
model can include any primary interventions, including pharmaceuticals, behavioural change 
interventions and legislative changes. Evidence can either relate to efficacy or effectiveness.  
Further, the model can be used flexibly to manually include relevant compliance assumptions 
which may be important when making long term predictions. Compliance assumptions can be 
tailored to particular individual risk profiles where relevant, such as age, sex and 
socioeconomic deprivation. Intervention costs may include one-off costs (e.g. legislation) or 
periodic costs (e.g. pharmaceuticals) where the model includes / estimates annual costs for 
each year that an individual is alive in the model. 
 
The model can also incorporate evidence relating to the impact of intervention(s) on event 
rates (e.g. CHD). To do this, the model estimates the necessary changes to relevant ASSIGN 
risk factors to observe reported event rates. This can be done on a case-by-case basis using 
appropriate literature and expert opinion regarding how particular risk factor(s) may be 
affected by an intervention.  In converting observed event rates into assumed risk factor 
reductions the model is able to estimate the impact of interventions on all four first events of 
the model (non-fatal CHD, non-fatal CBVD, fatal CVD and fatal non-CVD) rather than a single 
event. 
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5.9.2 Illustrating the model: simulate the potential impacts of risk 
factor modification  
To estimate the impact of interventions two scenarios are run for each individual risk profile.  
First, baseline risk profiles are run through the model to estimate life expectancy, QALE and 
costs. Second, risk profiles are adjusted (using evidence or conducting a what-if analysis), 
and re-run through the model.  The difference in life expectancy, QALE and costs (net of 
intervention costs) are then calculated.  This prepared the model to be used to assess the 
cost-effectiveness of interventions as recommended by health technology agencies (such as 
NICE). All estimates can be discounted and undiscounted.  
 
To illustrate this process, the Scottish Health Survey (SHeS) 2009 was used to estimate 
average risk profiles for 60 year old men and women across fifths of socioeconomic 
deprivation. This served as baseline risk profiles and entered into the model. The model is 
used to first produce both undiscounted life expectancy and discounted QALE. This is shown 
in Figure 5-46 as the dark columns, denoted as “before” risk factor modification. 
 
To then demonstrate the capability of the evaluation module, all profiles were switched to a 
“perfect” risk factor profile defined with reference to standard 10-year risk tables, where 
individuals are non-smoking, have a systolic blood pressure of 100, and a ratio of total 
cholesterol to HDL cholesterol of 3.  
 
Next, individuals with perfect profiles are run through the module. For illustration purposes, 
the simplifying assumptions are made that individuals immediately switch risk profiles and 
acquire the associated life expectancy and QALE.  
 
Figure 5-39 and 5-40 illustrates the potential gains from reducing risk factors for average 60 
year men and women across fifths of socioeconomic deprivation. This is shown for both life 
expectancy and discounted QALE. The gain are shown as extensions to the columns 
denoted as being “after” risk factor modification, and the figure at the top the columns 
represents the overall life expectancy and QALE following modification. 
  
Overall, the potential gains in life expectancy are greater for those in lower socioeconomic 
status and higher for women. The exception is men within the most deprived fifth who gain 
more than women. Before risk factor modification, men in the least deprived (SIMD1) fifth 
have a 7% higher life expectancy than the most deprived (SIMD 5) fifth and a 3.5% higher 
discounted QALE. After risk factor modification the gradient closes to 4.8% and 2.7% 
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respectively. For women, the least deprived fifth have 5.5% higher life expectancy than the 
most deprived fifth and 2.3% higher QALE. Following risk factor modification the gradient 
closes to 2.7% and 1.9% respectively.  
 
Using the same process of running baseline and modified risk factor profiles through the 
model, estimates of discounted and undiscounted lifetime hospitalisation costs are also 
made. Cost increase post risk factor modification, consistent with longer life expectancies. 
Discounting reduces the absolute cost estimate and narrows the gradient between women 
and men, and by fifth of socioeconomic deprivation.   
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Figure 5-39 Modifying risk factors for average 60 year old men and women by fifths of socioeconomic deprivation (SIMD)  
– the potential impact on undiscounted life expectancy and discounted quality adjusted life expectancy 
 
a) Men: undiscounted life expectancy                                                                                        b)  Women: undiscounted life expectancy  
a) Men: discounted quality adjusted life expectancy                                                                                                 b)  Women: discounted quality adjusted life expectancy  
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Figure 5-40 Modifying risk factors for average 60 year old men and women by fifths of socioeconomic deprivation (SIMD)  
– the potential impact on undiscounted lifetime costs and discounted lifetime costs 
 
a) Men: undiscounted costs                                                                                        b)  Women: undiscounted costs
c) Men: discounted costs                                                                                               d)  Women: discounted costs
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This short section was intended to provide a brief illustration that the model can be used 
easily to assess the impact of risk factor modification that may be the result of intervention. 
The next final part of the thesis provides a fuller demonstration of the model.  
 
5.10 Summary and discussion 
The aim of this chapter was to build upon the underlying epidemiology of the policy model to 
illustrate how we could generate economic outputs. The previous chapter estimated the 
lifetime risk of CVD and overall life expectancy. We first quality adjusted life expectancy 
estimates, by accounting for the background health utility, and the utility impact of incurring 
non-fatal secondary CVD events.  The chapter detailed how costs were estimated across an 
individual’s lifetime, and incorporated into the model. Overall, the model can now predict 
quality adjusted life expectancy, and cumulative lifetime hospital costs; and these estimates 
can be discounted or undiscounted.  
 
Strengths and limitations 
There were several perceived strengths in the analysis. First, to make quality adjustments 
and estimate hospitalisation costs comprehensive Scottish data sources were used. The 
SHeS 2003 was used to estimate the background morbidity and the utility impact of incurring 
5 CVD events. The SHHEC-SMR dataset was used to estimate the risk of subsequent non-
fatal events following a first non-fatal CVD event.  Overall, this enabled quality adjustment to 
be comprehensive. In contrast, most policy models do not undertake the same extent of 
quality adjustment. 
 
Second, the SHHEC-SMR dataset also enabled modelling of the annual risk and mean cost 
of all hospitalised events, including CVD and non-CVD events. This then enabled the 
cumulative lifetime costs to be estimated over an individual’s lifetime. The only other model 
that can estimate how hospitalisation costs vary according to life expectancy is the 
Archimedes model. 
  
Third, the use Scottish data sources are intended to increase the applicability of the model to 
a Scottish context.  
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Third, in general, the modelling is intended to be transparent. This was made possible due to 
the longitudinal SHHEC-SMR data source.  Most other models combine multiple cross-
sectional data sources in an effort to estimate event risks, which is perfectly valid but can 
result in a loss of transparency. 
 
A potential limitation is that the SHeS 2003 relied upon individuals self-reporting CVD 
conditions. Future research could investigate the accuracy of self-reporting by acquiring 
linked hospital data to patient ID. This type of linkage is readily available in Scotland for the 
purposes of research, subject to Government permission. Further, the main event not 
captured in the SHeS 2003 was heart failure. The decrement associated with heart failure 
has been estimated by Clarke to be 0.074 within the first year and 0.058 over 12 months.  
 
The main weakness in the approach to cost the impact of CVD on lifetime patient costs is that 
it is limited to hospitalisation costs. What is omitted is primary care and community care 
costs. This may be particularly important for costing the impact of stroke, which is increasing 
treated at the community level.  
 
Overall, Part 2 of the thesis was intended to build the Scottish CVD Policy Model to using the 
same ASSIGN risk factors as employed in clinical screening to prioritise individuals for 
targeted interventions, the focus of primary prevention in Scotland. The model estimation is 
intended to be comprehensive, transparent and as simple as possible. The opportunity to 
achieve these features was greater enhanced by having access to excellent data sources.  
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Part 3 - Demonstrating the Scottish CVD Policy 
Model 
Overview 
The final part of the thesis builds upon Part 1 and 2 to demonstrate how the policy model can 
be used to inform the development and evaluation of primary prevention interventions. This 
overview first takes stock of the thesis so far before describing the approach taken in Part 3.  
 
Part 1 of the thesis described the considerable burden that results from the onset of CVD. 
While rates have been falling throughout the general population, CVD remains the number 
one cause of death, has major morbidity impacts and remains a key driver of health 
inequalities. Further CVD also results in considerable health and wider economic costs. 
Policymakers are attempting to respond with a focus on primary prevention. However, there 
is a lack of evidence underpinning approaches and, in particular, there the targeted multi-
factorial approaches on individuals deemed to be at high risk.  
 
The thesis has sought to build the Scottish CVD Policy Model for the purpose of helping 
policymakers develop and evaluate primary prevention interventions. Three key research 
questions were offered to challenge the application of model: (i) can the model  identify 
optimal screening approaches to identify individuals at high risk of a CVD event; (ii) can the 
model be used to  develop a new targeted approach that prioritises individuals for intervention 
based upon potential benefit from changes to modifiable risk factors; and (iii) can the model 
be used consistently to evaluate both targeted and population interventions to inform optimal 
prevention strategies.  
 
Part 2 developed the Scottish CVD Policy Model with these research questions in mind. A 
generic modelling approach was adopted where the model takes the nine ASSIGN risk 
factors currently used in clinical practice to screen and estimate lifetime risk, life expectancy, 
quality adjusted life expectancy and cumulative lifetime hospital costs. The intention was to 
then use the policy model to help address each of the current weaknesses in primary 
prevention that exist at present.  
 
Part 3 of the thesis now attempts to provide a demonstration of how the policy model could 
be applied to help address the research questions. The questions deal with a particular 
problem and the model is used in a particular way to address the problem. For the purposes 
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of exposition, four short chapters follow with each focused on a particular illustration of the 
model.  
 
Chapter 6 is concerned with identifying efficient screening strategies to identify high risk 
individuals. Chapter 7 focuses on the developing a new clinical tool that can discriminate 
between individuals on the basis of the potential benefit from interventions. Chapter 8 
demonstrates how the model can be used to evaluate Scotland’s flagship primary prevention 
initiative, which is a multi-factorial programme of interventions.   Chapter 9 then illustrates that 
the model can also be used to evaluate population-wide interventions. 
 
The intention of separate chapters is to reflect the fact that these address different problems, 
and use the model in different ways. That is, each chapter essentially draws upon a particular 
element of the discussions in Chapter 2 and 3 that identified a key weakness or uncertainty in 
current primary prevention approaches. Further, to address the identified weakness the 
model is used in a particular way, drawing on either Chapter 4 Chapter 5 as appropriate, 
depending on the outcome required from the model.  
 
Each chapter is structured in a similar fashion consisting of 4 sections, similar in manuscript 
style. This is intended to help the flow of the chapter and orientate the reader, given that the 
volume of material covered so far as been quite substantial. Beginning with the background 
to a particular problem (e.g. sub-optimal screening strategies) a summary of the relevant 
discussion of Chapter 2 is provided. A methods section then discusses how the policy model 
is used in a particular way to help address the particular issues under consideration, drawing 
upon Chapter 4 and/or 5. The results section applies the model and details relevant findings, 
and the implications for decision making. Finally, a discussion section focuses on the 
strengths and weaknesses of the policy model regarding the extent to which it can be used to 
address the identified problem area.  
 313 
Chapter 6 Identifying efficient screening strategies to 
target high risk individuals 
6.1 Background 
Current clinical guidelines advise that primary prevention is most effective if people are 
selected for intervention on the basis of their overall cardiovascular risk(9). The Scottish 
Intercollegiate Guidelines Network (SIGN) recommends treatment of anyone with more than 
20% risk of a cardiovascular event over the subsequent 10-years. Since 2007 the ASSIGN 
score has been used in Scotland(124). However, determining which members of the general 
population have a high cardiovascular risk is problematic.  
 
Mass screening of the whole population is one option. Alternatively, screening could be 
targeted at sub-groups of the population known to have higher rates of cardiovascular 
disease. Deprived communities have a higher prevalence of cardiovascular risk factors and a 
higher incidence of cardiovascular events. Similarly, people with a family history of premature 
cardiovascular disease have a two-fold risk of developing the condition, due to a combination 
of shared genetic predisposition and shared lifestyle.   
 
In 2007, Scotland began piloting a screening and intervention programme focusing only in the 
communities who reside with the most deprived fifth, and aged between 45-64 years. 
However, Scottish policymakers have been considering widening the programme to the entire 
population aged between 40-74 years in an attempt capture high risk individuals throughout 
the entire population. This approach would be consistent with SIGN Guidelines. Further, 
England began such a national screening programme in 2009 with the intention to screen 
every 5-years, detecting and referring high risk individuals onto multi-factorial 
interventions(180).  
 
However, neither Scotland’s nor England’s programme has been evaluated to date; and, 
notably, both programmes state the same objective to help reduce health inequalities. This 
dichotomy of approaches begs the question which approaches may be the most cost 
effective, and have the most favourable impact on inequalities? 
 
The aim of this short Chapter is to use the Scottish Policy Model to compare the relative 
strengths and weaknesses of alternative screening approaches in terms of effectiveness, cost 
effectiveness and coverage.  
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6.2 Methods 
Source data: The Scottish Health Survey (SHeS) 2003 is a periodic cross sectional survey of 
the Scottish population, and has cardiovascular disease as its principle focus(314). The 
Survey uses multi-stage, stratified sampling to provide a representative sample of the 
Scottish population, and includes face to face interviews and physical measurements. This 
sample was used in the consequent analysis to test different screening strategies. More 
contemporary SHeS are available, but lack sufficient statistical power with huge amount of 
missing data on key ASSIGN variables. For instance, as much as 80% of cholesterol 
readings are missing from 2008 and 2009. Further, the full SHeS 2010 dataset was not 
available at the time of writing. 
 
Participants within the SHeS 2003 were included if they were between 40 and 74 years. 
Participants were excluded if they (self-reported) a prior diagnosis of a CVD event. In total, 
4,082 individuals were included in the analysis   
 
The SHeS contains information on all of the ASSIGN risk factors. However, in the Scottish 
Health Survey, a family history of premature cardiovascular disease was defined as death of 
either natural parent due to cardiovascular disease before the age of 65 years.  In the 
Scottish Heart Health Extended Cohort (SHHEC) used to define the ASSIGN risk factors, 
family history was a wider definition including the incidence of any CVD event and for 
parents, siblings and second degree relatives. 
 
Defining screening strategies: The Scottish Health Survey data were used to simulate the 
impact of five alternative screening strategies to identify those at high risk of cardiovascular 
events (i) mass screening of the whole population; (ii) screening individuals living in deprived 
communities; (iii) screening individuals with a family history of premature cardiovascular 
disease; (iv) screening individuals who either lived in deprived communities or had a family 
history of premature cardiovascular disease, and finally (v) screening individuals who both 
lived in deprived communities and had a family history of premature cardiovascular disease.  
 
The SHeS 2003 then stratified into these five groups then ran through the model one 
individual at a time to assess 10 year CVD risk. The results were then stratified by age group: 
by ages 40-74 years, and for those at risk of premature cardiovascular disease. The later was 
defined as men aged 40-54 years and women aged 40-64 years. This follows the definition of 
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family history of premature CVD used by JBS2 Guidelines(120).  The difference in the 
definition used in the clinical literature reflects shorter background life expectancy of men.  
 
Cost and cost-effectiveness: It was assumed that the screening process would be identical in 
all of the models studied and therefore that the unit costs would be common to all. Costs 
included contacting individuals and arranging appointments, a screening appointment 
undertaken by a practice-based nurse, the laboratory costs of assaying cholesterol and 
glucose concentrations, and the cost of a follow-up appointment at which the results would be 
fed back. Screening costs were based on the 2008 prices published by the Department of 
Health for England and Wales. Subsequent investigation and treatment costs were not 
included in the models.  
 
First, the absolute costs and effects associated with implementing each of the five screening 
strategies in isolation referent to no screening were determined. The effectiveness of each 
strategy was defined as the number needed to screen (NNS) to detect one person at high-
risk of cardiovascular disease. The cost of detecting one person was calculated as the unit 
cost per patient screened multiplied by the NNS for that strategy.  
 
Second, the additional costs and effects of each strategy referent to the other strategies was 
determined by assuming that more effective strategies were substituted in an incremental 
fashion, from the lowest population coverage (lowest overall cost) up to mass screening of 
the whole population (highest overall cost). The cost and NNS of detecting one additional 
person at high-risk was calculated and associated the incremental cost effectiveness ratio 
(ICER).  
 
Finally, any strategies that were both more costly and less effective (higher NNS) than the 
next incremental strategy were then excluded from the calculations as they were ‘dominated’ 
by the more effective strategy. Further, any strategies that were associated with a higher 
ICER than more effective (lower NNS) strategies were excluded from the calculations as they 
were ‘extended dominated.’ Where this occurred, the ICERs were then recalculated following 
the exclusion of the dominated or extended dominated strategy. The robustness of the results 
was tested by applying sensitivity analyses to the costs using an analysis of extremes. The 
ICERs were recalculated using the lower and upper bounds for screening costs quoted by the 
Department of Health (Table 6-1).  
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Table 6-1 Unit costs for cardiovascular screening 
  
Minimum (£) 
 
 
Maximum (£) 
 
Base case (£) 
 
Administration 
 
1.0 
 
3.5 
 
2.3 
Screening and feedback 
appointments 
9.3 23.3 16.3 
Laboratory costs 
 
3.0 6.0 4.5 
Total 
 
13.3 32.8 23.1 
 
The assumption is that the unit costs of screening are constant regardless of the screening 
strategy adopted. Further, the simplifying assumption is 100% engagement across all 
strategies. The main intention of the analysis is to identify efficient strategies; to identify 
where in the population the high risk are to ultimately challenge a mass screening approach, 
as recommended in clinical guidelines and being implemented in England (where 
engagement and costs assumptions were not sensitised for different population subgroups). 
The final chapter will return the issue of engagement to explore whether mass screening 
could increase inequalities. 
 
The overall costs at the level of the Scottish population were then estimated for different 
screening strategies. The analysis above estimates the percentage of the SHeS 2003 that 
were at high risk in each of the screening strategies. Holding these percentages constant the 
corresponding number of people in the 2009 Scottish population - the latest available from 
the General Registrar’s Office for Scotland (GROS) – was estimated. 
 
6.3 Results  
Source data: There were 4,082 individuals free of CVD and aged between 40 and 74 years, 
the eligible population for screening according to the SIGN Guidelines(315). A third of 
cholesterol readings were missing. Mean imputation was used to estimate these missing 
values conditional on age, sex and social deprivation stratifications.  
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Screening strategies – all population: Targeting deprived communities would result in 15% of 
the total population being screened but would identify 25% of the high-risk population (Table 
6-2). To identify one high-risk individual would require 3.0 people to be screened at a cost of 
£69. Targeting relatives of people who die prematurely from cardiovascular disease would 
result in 28% of the total population being screened but would identify 43% of the high-risk 
population (Table 6-3). To identify one high-risk individual would require 3.2 people to be 
screened at a cost of £75. Combining both strategies would enable 57% of the high-risk 
population to be identified by screening 39% of the general population. Moving directly from 
no screening to mass screening would identify all high-risk individuals and would require 4.9 
people to be screened to identify one high-risk individual at a cost of £113. 
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Table 6-2 Coverage, effectiveness and cost-effectiveness of alternative screening strategies applied to the population at risk of any 
cardiovascular disease (40-74 years of age)  
 
 
   
Targeted screening 
 
Mass screening 
   
Family members living in  
deprived communities 
 
 
Deprived 
communities 
 
Family 
members 
 
Family members and 
deprived communities 
 
 
 
Strategies implemented in isolation* 
 Coverage of general population 5% 15% 28% 39% 100% 
 Coverage of high risk population   10% 25% 43% 57% 100% 
 % of screened population at high-risk 44% 34% 31% 30% 21% 
 Number needed to screen 2.3 3.0 3.2 3.3 4.9 
 Mean cost per high-risk case detected (£) 53 69 75 76 113 
       
 
Strategies implemented incrementally**   
 Additional coverage of general population 5% - 23% 10% 61% 
 Additional coverage of high risk population   10% - 32% 15% 43% 
 % of additional screened population at high-risk 44% - 28% 26% 12% 
 Additional number needed to screen 2.3 3.8 3.5 3.9 8.6 
 Incremental cost-effectiveness ratio 53 (31, 75) 89 (51, 126) 81 (47, 116) 91 (52, 129) 199 (115, 283) 
 Revised incremental cost-effectiveness ratio*** 53 (31, 75) dominated 80 (46, 114) 91 (52, 129) 199 (115, 283) 
 
 
*referent to no screening 
**referent to screening strategy directly to the left (no screening for strategy 1) 
***referent to the next non-dominated screening strategy to the left (no screening for strategy 1)  
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Table 6-3 Coverage, effectiveness and cost-effectiveness of alternative screening strategies applied to the population at risk of premature 
cardiovascular disease (men 40-54 years of age; women 40-64 years of age)  
   
Targeted screening 
 
Mass screening 
   
Family members living in  
deprived communities 
 
 
Deprived 
communities 
 
Family members 
 
Family members and 
deprived communities 
 
 
 
Strategies implemented in isolation* 
 Coverage of general population 5% 17% 28% 41% 100% 
 Coverage of high risk population   23% 45% 61% 84% 100% 
 % of screened population at high-risk 31% 16% 14% 13% 6% 
 Number needed to screen 3.3 6.1 7.4 7.8 16.0 
 Mean cost per high-risk case detected (£) 75 141 170 180 370 
       
 
Strategies implemented incrementally**   
 Additional coverage of general population 5% - - 36% 59% 
 Additional coverage of high risk population   23% - - 61% 16% 
 % of additional screened population at high-
risk 
31% - - 12% 2% 
 Additional number needed to screen 3.3 8.8 - 8.5 58.8 
 Incremental cost-effectiveness ratio 75 (43, 107) 203 (117, 289) 225 (130, 321) 196 (113, 278) 1,358 (784, 1931) 
 Revised incremental cost-effectiveness 
ratio*** 
75 (43, 107) extended 
dominated 
extended 
dominated 
215 (124, 306) 1,358 (784,1,931) 
 
 
*referent to no screening 
**referent to screening strategy directly to the left (no screening for strategy 1) 
***referent to the next non-dominated screening strategy to the left (no screening for strategy 1) 
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In the incremental cost-effectiveness analysis, targeting deprived communities was 
dominated by targeting family members which was a more effective strategy, requiring fewer 
additional people to be screened to detect one additional high-risk person. Compared with the 
most effective targeted strategy (combining family members and deprived communities) the 
additional cost of expanding coverage to mass screening was £199 for every additional high-
risk person identified because an additional 8.6 people needed to be screened.   
 
Screening strategies – population at premature risk: Targeting deprived communities would 
result in 17% of the total population being screened but would identify 45% of the high-risk 
population (Table 6-3). To identify one high-risk individual would require 6.1 people to be 
screened at a cost of £141. Targeting relatives of people who die prematurely from 
cardiovascular disease would result in 28% of the total population being screened but would 
identify 61% of the high-risk population (Table 64). To identify one high-risk individual would 
require 7.4 people to be screened at a cost of £170. Combining both strategies would enable 
84% of the high-risk population to be identified by screening only 41% of the general 
population. Compared with no screening to mass screening would identify all high-risk 
individuals and would require 16.0 people to be screened to identify one high-risk individual at 
a cost of £370.  
 
In the incremental cost-effectiveness analysis, a combined strategy of targeting both family 
members and deprived communities extended dominated either strategy in isolation, because 
this more effective strategy could be secured for a lower cost per additional high-risk person 
identified. Compared with combined screening of family members and deprived communities, 
expanding coverage to mass screening would require an additional 58.8 people to be 
screened to identify each additional high-risk person at a cost of £1,358. In the 2009 Scottish 
population this would cost the government an additional £12 million just to detect the 
additional 16% that are still at high risk.  
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6.4 Discussion 
Mass screening is the best method to ensure complete coverage but the absolute cost may 
be prohibitive. Using the model, the cost of screening all 1.4 million people aged 40-74 in the 
2009 Scotland would have been £33 million.  
 
An alternative approach is to target screening at a sub-group of the population in which 
cardiovascular risk is over-represented and where there is more opportunity that risk can be 
reversed.  For instance, risk measured over 10 year is driven by age.   
 
If the aim of primary prevention is to identify those at high-risk of premature cardiovascular 
disease, then a combined strategy that targets both family members and deprived 
communities is more cost-effective model than either strategy in isolation. The cost-
effectiveness of targeted screening is not achieved at the expense of coverage since this 
combined strategy identifies the vast majority of high-risk people in the general population.  
That is 84% of the high risk are detected by screening just 41% of the population. Relative to 
mass screening of the entire population this would save over £18 million for each round of 
screening, which in SIGN Guidelines recommend is every five years.  
 
Limitations: The SHeS only provided information on parental death from cardiovascular 
disease. It did not provide information on parental premature, non-fatal disease or premature 
disease in siblings. Therefore, the analysis is likely to have underestimated the potential 
coverage of a strategy targeting family members. In the Utah family health tree study, families 
with a positive family history accounted for 48% of all cardiovascular events and 72% of 
premature events. In our study the figures were only 43% and 61% respectively(316). Use of 
more complete information on family history would have reduced still further the additional 
benefits of mass screening.   
 
The analysis assumed identical unit costs for screening. However, in practice, the costs may 
be higher in deprived than affluent communities because of poorer uptake requiring more 
stringent efforts to attract participants into screening appointments. This issue will be revisited 
in Chapter 9. 
 
Guidelines already exist recommending screening of people with a family history, but surveys 
suggest that only a minority are, in fact, screened. Identifying people with a family history 
from the general population is difficult. Using hospitalisation of a patient for premature 
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cardiovascular disease as the trigger to contact family members may be a more feasible 
mechanism and may improve the motivation of asymptomatic relatives. To date, there has 
been only one published study of this type of intervention. Further studies are required to 
devise effective methods of identifying family members and reducing their cardiovascular risk.  
 
Estimating QALEs and impact on health inequalities:  The analysis did not consider the 
impact of different approaches on either QALE or inequalities. To confidently estimate this 
would require evidence of engagement success and compliance with subsequent 
interventions (and how this varies across the population), and the impact of multi-factorial 
interventions on reducing CVD risk factors. At present, robust evidence of this key information 
is lacking. To provide a more robust analysis, the focus was on cost per case detected.   
Consequently, this analysis addresses technical efficiency, rather allocative efficiency issues.   
 
Nonetheless, for the purpose of exposition within this thesis, it is important to illustrate how 
the model can be used in economic evaluation where cost per QALY is the main output and 
estimated over a lifetime. Chapter 8 illustrates how the model can be used in economic 
evaluation to assess Scotland’s CVD primary prevention initiative which consists of screening 
and interventions.  
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Chapter 7 A new approach to prevention: prioritising 
individuals on the basis of potential benefit  
7.1 Background 
There appears to be an important contradiction in the current clinical approach to primary 
prevention. The ultimate aims of prevention are the avoidance of premature morbidity, 
mortality and the reduction of health inequalities. However, as Chapter 2 discussed, clinical 
guidelines currently recommend the use of risk scores to screen individuals 40-74 years and 
prioritise high risk individuals for targeted interventions. SIGN Guidelines identified ASSIGN 
10-year score as the most appropriate risk score for use in Scotland(9). ASSIGN was 
developed in Scotland and includes socioeconomic deprivation as an independent risk factor 
which then account for the social gradient in the incidence of CVD. 
 
Prioritising individuals on the basis of CVD risk scores is unlikely to result in the greatest 
treatment benefits. Risk scores are comprised of a mixture of modifiable and non-modifiable 
factors. For instance, risk scores over a 10-year period are driven by age, such that the 
elderly with normal risk factors would be automatically classified as high risk and prioritised 
for treatment. In contrast, relatively younger individuals with inflated risk factors may not be 
classified as high risk purely because of age – yet such individuals have potentially more to 
gain from early intervention.  
 
Further, risk factors are generic to an array of conditions beyond CVD, such as cancers and 
respiratory diseases. Consequently, it is important when estimating the potential benefit of 
interventions to account for competing risks and to estimate the impact of interventions on life 
expectancy. At present, concerns remain that interventions may simply change the cause of 
death especially in the elderly.  
 
Alternative approaches to 10-year risk scores to prioritise individuals for primary prevention 
are being explored in the literature. First, there has been recent interest in developing 30-year 
risk scores(117) or lifetime CVD risk scores(317).  However, it is unclear how such 
approaches directly address the aims of targeted prevention. For instance, the entire 
population has high lifetime risk of CVD and it is difficult to meaningfully discriminate among 
individuals(25, 318).  Second, Norway has recently developed an approach to primary 
prevention where individuals are prioritised based upon age-defined risk thresholds(319). 
Underlying the choice of threshold is the evidenced impact of particular interventions on CVD 
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death. This is a step in the right direction; however, benefits from risk factor interventions 
extend beyond CVD mortality. Further, if patient prioritisation is to be based upon expected 
lifetime benefits then perhaps this should be revealed explicitly rather than indirectly through 
risk thresholds.  
 
Ideally, the evidence base would be complete and be able to discriminate between individuals 
on the basis of the likely benefits from intervention in terms of effectiveness and cost 
effectiveness. However, as Chapter 2 discussed the evidence base is incomplete. There is 
considerable evidence of the impact of single, in particular pharmaceutical, interventions on 
CVD events. However, while it is postulated that polypill could reduce ischaemic heart 
disease by over 80%(34), trial evidence is awaited to observe such benefits [13, 14]. Overall, 
there is very little economic evidence regarding the impact of multi-factorial initiatives which is 
the focus of primary prevention at present.  
 
An alternative approach to using 10-year risk tools is to develop a modelling tool that can 
estimate the potential benefit from changes to risk factors. This chapter uses the policy model 
to develop an approach to patient prioritisation based on the maximum potential benefit that 
could be achieved if individuals switched to an optimal risk profile as defined by clinical 
guidelines. This was measured in terms of discounted life expectancy.  
 
From an economic perspective it would be better if individuals could be prioritised on the 
basis of cost effectiveness. However, in seeking to use the model to influence clinical 
practice, it is perhaps prudent to proceed incrementally. A switch from discriminating between 
patients on the basis of 10 year risk to one of cost effectiveness would represent a significant 
paradigm shift that may likely incur substantial resistance in the clinical community. Perhaps, 
in the short (to medium term) a move from risk to potential benefit based on life expectancy 
would be likely to be accepted, rather than cost effectiveness. A potential benefit approach 
would nonetheless represent a significant shift in practice, commensurate with Kuhn’s view of 
science and applied applications(320). 
 
 
7.2 Methods 
Source data: The same SHeS 2003 dataset was as in the previous section to identify cost 
effective screening strategies. In total, 4,082 individuals were aged between 40 and 74 years, 
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and free of CVD and so represented the eligible population for screening accordingly to the 
SIGN Guidelines.  
 
The ASSIGN variables were classified into modifiable and non-modifiable risk factors.  
Systolic blood pressure, total cholesterol, HDL cholesterol and cigarettes per day were 
defined as modifiable risk factors. Age, sex, diabetes, family history and deprivation were 
defined as non-modifiable risk factors. The latter was estimated by the Scottish Index of 
Multiple Deprivation (SIMD).  
 
10-year risk tables and life expectancies estimates:  Standard 10-year risk tables(120) were 
used to define a set of patient risk factor profiles; and, using the Scottish CVD Policy Model, 
both 10-year risk scores and life expectancy were estimated. Smokers were assumed to 
smoke 20 cigarettes per day. For exposition purposes, all risk profiles were attributed 
average family history (0.26) and diabetes (0.15) - the proportions found within the SHHEC 
baseline survey. Estimates of risk and life expectancy were made for males and females and 
for the lowest and highest fifths of SIMD; separate tables were also estimated conditional 
upon smoking status. 
 
Discounted maximum potential benefit: Consistent with the intuition of risk tables, the optimal 
modifiable risk factor profile is defined as the lowest systolic blood pressure, lowest total-to-
HDL cholesterol ratio and non-smoking. A theoretical “maximum potential benefit” was 
defined as the difference in estimated life expectancy between any given risk factor profile 
and that of the optimal modifiable profile. It was assumed that all individuals would instantly 
switch to a perfect profile. This assumption is unrealistic. However, at present there is a lack 
of research regarding the reversibility of risk (e.g. by age group) and compliance behaviour 
(e.g. by socioeconomic deprivation status). The modelling is flexible such that estimates can 
be easily updated with real world evidence of intervention efficacy and effectiveness as and 
when this becomes available. 
 
Maximum potential benefit was calculated in undiscounted and discounted terms at 3.5% in 
line with guidance from the NICE and SMC(321). Estimates were made for males and 
females and for the highest and lowest quintiles of SIMD; separate tables were also 
estimated conditional upon smoking status.  
 
Patient reprioritisation using a maximum potential benefit approach: The Scottish Health 
Survey (SHeS) 2003 was used to estimate the impact of a potential benefit approach in a 
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general population. The number and type of people who would be treated using the ASSIGN 
10-year risk score was first estimated. Then, holding the number to be treated constant, the 
extent of reprioritisation between individuals if there was a switch to a maximum potential 
benefit approach was estimated. The results are scaled up to the total 2003 Scottish 
population.  
 
7.3 Results 
10-year risk scores: Figures 7-1 and 7-2 shows 10-year risk scores for men and woman 
residing in highest and lowest deprivation quintiles. Cell values represent risk scores over 10 
years. Patients are denoted as high risk if the score is 20% or above (red); intermediate risk 
when the score is between 10-20% (yellow); and low risk with scores below 10% (green). 
Profiles towards the top right corner denote the highest systolic blood pressure and total to 
HDL cholesterol values, resulting in the highest risk. Separate tables are presented 
conditional upon smoking status. For exposition purposes, rather than have separate tables 
for diabetic patients and those with family history, patients were attributed the same 
proportion of diabetes (2%) and family history (26%) found within SHHEC.  
 
Both figures illustrate the age gradient that drives short term CVD risk scores, and men tend 
to have higher risk score than women for an otherwise equivalent risk factor profile. For the 
same modifiable risk factor profile, patients are only denoted as high risk in older age groups. 
We also observe the significant impact of smoking status in increasing risk and reclassifying 
patients.  
 
Life expectancy estimates: Figures 7-4 and 7-5 illustrates life expectancies for individual risk 
factor profiles defined by standard 10 year risk tables. Smoking is the single most important 
risk factor. For instance, the difference in life expectancies between smokers and non-
smokers with an otherwise identical risk factor profile is as much as 6 years for females, and 
5.2 years for males.  
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Figure 7-1 ASSIGN 10-year risk charts - Men 
Lowest deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 28 42 49 56 59 0 39 56 64 70 73
160 23 35 42 48 50 0 32 47 55 62 65
140 19 29 35 40 42 0 26 40 47 53 56
120 15 23 28 33 35 0 22 33 39 45 48
100 12 19 23 27 29 0 17 27 33 38 40
Age 60 years Age 60 years
180 17 26 32 37 39 0 24 37 44 50 53
160 14 22 26 31 33 0 20 30 37 42 45
140 11 17 21 25 27 0 16 25 30 35 37
120 9 14 17 20 22 0 13 20 25 29 31
100 7 11 14 16 18 0 10 16 20 23 25
Age 50 years Age 50 years
180 10 16 20 23 25 0 15 23 28 32 35
160 8 13 16 19 20 0 12 19 23 27 28
140 6 10 13 15 16 0 9 15 18 22 23
120 5 8 10 12 13 0 7 12 15 17 19
100 4 7 8 10 10 0 6 10 12 14 15
Age 40 years Age 40 years
180 6 9 12 14 15 0 9 14 17 20 21
160 5 7 9 11 12 0 7 11 14 16 17
140 4 6 7 9 10 0 5 9 11 13 14
120 3 5 6 7 8 0 4 7 9 10 11
100 2 4 5 6 6 0 3 6 7 8 9
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Highest deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 38 54 62 69 72 51 69 77 83 85
160 31 46 54 60 63 43 60 68 75 78
140 26 38 45 52 55 36 51 60 66 69
120 21 32 38 44 46 29 43 51 58 61
100 17 26 31 36 39 24 36 43 49 52
Age 60 years Age 60 years
180 23 36 42 48 51 33 48 56 63 66
160 19 29 35 41 43 27 40 48 54 57
140 15 24 29 34 36 22 34 40 46 49
120 12 19 24 28 30 18 28 33 38 41
100 10 16 19 23 24 14 22 27 32 34
Age 50 years Age 50 years
180 14 22 27 31 33 20 31 37 43 45
160 11 18 22 26 27 16 25 31 36 38
140 9 14 18 21 22 13 21 25 29 31
120 7 11 14 17 18 11 17 20 24 26
100 6 9 11 13 15 8 13 17 19 21
Age 40 years Age 40 years
180 8 13 16 19 21 12 19 23 27 29
160 7 10 13 15 17 10 15 19 22 24
140 5 8 10 12 13 8 12 15 18 19
120 4 7 8 10 11 6 10 12 14 16
100 3 5 7 8 9 5 8 10 12 12
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Figure 7-2 ASSIGN 10-year risk charts - women 
Lowest deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 25 33 39 43 45 0 38 50 57 63 65
160 20 28 33 37 39 0 32 43 50 55 57
140 17 23 28 31 33 0 27 36 43 47 49
120 14 19 23 26 27 0 23 31 36 40 42
100 11 16 19 22 23 0 19 26 31 34 36
Age 60 years Age 60 years
180 13 18 21 24 25 0 21 29 34 38 40
160 10 15 18 20 21 0 17 24 28 32 34
140 9 12 15 17 17 0 14 20 24 27 28
120 7 10 12 14 14 0 12 16 20 22 23
100 6 8 10 11 12 0 10 13 16 18 19
Age 50 years Age 50 years
180 6 9 11 13 13 0 11 15 18 21 22
160 5 7 9 10 11 0 9 12 15 17 18
140 4 6 7 8 9 0 7 10 12 14 15
120 3 5 6 7 7 0 6 8 10 12 12
100 3 4 5 6 6 0 5 7 8 9 10
Age 40 years Age 40 years
180 3 5 6 6 7 0 5 8 9 11 11
160 3 4 5 5 5 0 4 6 8 9 9
140 2 3 4 4 4 0 4 5 6 7 8
120 2 2 3 3 4 0 3 4 5 6 6
100 1 2 2 3 3 0 2 3 4 5 5
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Highest deprived fifth 
Non-Smoker Smoker
Age 70 years Age 70 years
180 38 50 57 62 64 56 69 77 81 83
160 32 43 49 54 56 49 62 69 74 76
140 27 36 42 47 49 42 54 61 66 69
120 22 30 36 40 42 35 46 54 59 61
100 18 25 30 34 36 30 40 46 51 53
Age 60 years Age 60 years
180 21 28 34 38 39 33 44 51 56 58
160 17 24 28 32 33 28 37 44 48 50
140 14 20 23 27 28 23 31 37 41 43
120 12 16 19 22 23 19 26 31 35 37
100 9 13 16 18 19 16 22 26 29 31
Age 50 years Age 50 years
180 11 15 18 21 22 18 24 29 33 34
160 9 12 15 17 18 15 20 24 27 29
140 7 10 12 14 15 12 17 20 23 24
120 6 8 10 11 12 10 14 17 19 20
100 5 7 8 9 10 8 11 14 16 16
Age 40 years Age 40 years
180 5 8 9 11 11 9 13 15 18 18
160 4 6 8 9 9 7 10 13 14 15
140 4 5 6 7 7 6 9 10 12 13
120 3 4 5 6 6 5 7 8 10 10
100 2 3 4 5 5 4 6 7 8 8
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Figure 7-3: Life expectancies - men 
Lowest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 83.9 83.7 83.7 83.6 83.6 80.8 80.9 81.1 81.2 81.3
160 84.7 84.5 84.5 84.4 84.4 81.4 81.6 81.8 81.9 81.9
140 85.3 85.3 85.3 85.2 85.2 81.9 82.2 82.4 82.5 82.5
120 85.9 86.0 86.1 86.0 85.9 82.3 82.7 83.0 83.1 83.1
100 86.4 86.6 86.7 86.7 86.6 82.6 83.1 83.4 83.6 83.6
Age 60 years Age 60 years
180 81.4 81.1 81.2 81.2 81.1 77.6 77.9 78.3 78.5 78.5
160 82.2 82.1 82.1 82.0 82.0 78.3 78.7 79.0 79.2 79.2
140 83.0 82.9 83.0 82.9 82.8 78.9 79.4 79.7 79.9 79.9
120 83.7 83.7 83.8 83.7 83.6 79.4 80.0 80.3 80.5 80.5
100 84.2 84.4 84.5 84.4 84.4 79.8 80.4 80.8 81.1 81.1
Age 50 years Age 50 years
180 80.0 80.0 80.2 80.2 80.2 76.2 76.7 77.3 77.6 77.7
160 81.1 80.9 81.1 81.1 81.0 76.9 77.5 78.0 78.3 78.4
140 81.9 81.8 81.9 81.9 81.8 77.6 78.2 78.6 78.9 79.0
120 82.6 82.6 82.7 82.6 82.5 78.0 78.8 79.3 79.5 79.6
100 83.2 83.4 83.4 83.4 83.3 78.5 79.2 79.8 80.0 80.1
Age 40 years Age 40 years
180 79.9 79.9 80.2 80.4 80.4 76.1 76.9 77.6 78.1 78.3
160 80.8 80.8 81.0 81.0 81.0 76.8 77.5 78.2 78.6 78.8
140 81.6 81.6 81.7 81.8 81.8 77.3 78.1 78.8 79.1 79.3
120 82.3 82.3 82.4 82.4 82.4 77.8 78.7 79.3 79.6 79.8
100 82.9 83.0 83.1 83.1 83.0 78.2 79.1 79.7 80.1 80.2
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Highest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 80.5 80.2 80.1 79.9 79.8 77.8 77.7 77.8 77.8 77.8
160 81.1 80.9 80.8 80.6 80.5 78.3 78.3 78.4 78.3 78.3
140 81.7 81.5 81.5 81.3 81.2 78.6 78.8 78.9 78.9 78.9
120 82.1 82.1 82.1 82.0 81.9 79.0 79.2 79.4 79.4 79.3
100 82.5 82.7 82.7 82.6 82.5 79.2 79.6 79.8 79.8 79.8
Age 60 years Age 60 years
180 76.8 76.4 76.2 76.0 75.9 73.3 73.3 73.4 73.4 73.4
160 77.6 77.2 77.1 76.8 76.7 74.0 74.0 74.1 74.1 74.1
140 78.3 78.0 77.9 77.7 77.6 74.5 74.6 74.8 74.8 74.8
120 78.9 78.8 78.7 78.5 78.4 74.9 75.2 75.4 75.4 75.4
100 79.4 79.4 79.4 79.2 79.1 75.2 75.7 75.9 76.0 75.9
Age 50 years Age 50 years
180 74.6 74.1 73.9 73.7 73.6 70.7 70.8 71.0 71.0 71.0
160 75.6 75.0 74.9 74.6 74.5 71.5 71.6 71.7 71.7 71.7
140 76.3 75.9 75.8 75.5 75.4 72.1 72.3 72.4 72.4 72.4
120 77.1 76.8 76.6 76.4 76.3 72.6 72.9 73.1 73.1 73.1
100 77.6 77.5 77.4 77.2 77.0 73.0 73.4 73.7 73.7 73.7
Age 40 years Age 40 years
180 73.6 73.1 73.0 72.8 72.7 69.7 69.8 70.1 70.2 70.3
160 74.6 74.0 73.9 73.6 73.5 70.4 70.6 70.8 70.9 70.9
140 75.3 74.9 74.7 74.5 74.3 71.0 71.2 71.5 71.6 71.6
120 76.1 75.7 75.6 75.3 75.1 71.6 71.9 72.1 72.2 72.2
100 76.7 76.5 76.4 76.1 75.9 72.0 72.4 72.7 72.8 72.7
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Figure 7-4 Life expectancies - Women 
Lowest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 85.5 85.3 85.1 85.1 85.0 81.1 81.2 81.2 81.3 81.3
160 86.6 86.4 86.1 86.1 86.0 82.0 82.1 82.2 82.2 82.2
140 87.6 87.4 87.2 87.1 87.0 82.9 83.0 83.0 83.1 83.1
120 88.6 88.5 88.2 88.0 88.0 83.8 83.9 83.9 83.9 83.9
100 89.6 89.4 89.1 88.9 88.9 84.5 84.8 84.7 84.7 84.7
Age 60 years Age 60 years
180 82.8 82.7 82.5 82.4 82.4 77.7 77.9 78.0 78.1 78.2
160 84.0 83.9 83.7 83.5 83.5 78.8 79.0 79.1 79.1 79.2
140 85.2 85.1 84.8 84.6 84.5 79.8 80.1 80.1 80.2 80.2
120 86.3 86.2 85.7 85.6 85.5 80.8 81.1 81.1 81.1 81.2
100 87.3 87.1 86.8 86.5 86.5 81.7 82.0 81.9 82.0 82.0
Age 50 years Age 50 years
180 81.2 81.2 81.0 81.0 81.0 75.8 76.1 76.3 76.5 76.6
160 82.5 82.4 82.2 82.1 82.1 76.9 77.4 77.4 77.6 77.7
140 83.7 83.5 83.3 83.1 83.1 78.1 78.4 78.5 78.6 78.7
120 84.8 84.6 84.3 84.1 84.0 79.1 79.4 79.5 79.5 79.6
100 85.8 85.7 85.2 85.0 85.0 80.0 80.4 80.4 80.5 80.5
Age 40 years Age 40 years
180 80.4 80.4 80.3 80.3 80.4 74.9 75.4 75.7 76.0 76.1
160 81.6 81.6 81.4 81.3 81.4 76.1 76.6 76.8 77.1 77.2
140 82.8 82.7 82.4 82.3 82.3 77.2 77.7 77.8 78.1 78.1
120 83.8 83.7 83.4 83.2 83.1 78.1 78.7 78.7 78.9 79.0
100 84.9 84.6 84.3 84.1 84.0 79.1 79.6 79.6 79.7 79.8
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Highest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 83.0 82.9 82.7 82.6 82.6 79.4 79.5 79.5 79.5 79.6
160 83.9 83.8 83.5 83.4 83.3 80.1 80.2 80.2 80.2 80.2
140 84.8 84.6 84.3 84.2 84.1 80.8 80.9 80.8 80.9 80.9
120 85.6 85.4 85.1 85.0 84.9 81.5 81.6 81.5 81.5 81.5
100 86.4 86.2 85.9 85.7 85.6 82.1 82.2 82.1 82.1 82.1
Age 60 years Age 60 years
180 79.9 79.7 79.5 79.4 79.3 75.5 75.7 75.7 75.8 75.8
160 80.9 80.7 80.4 80.2 80.2 76.4 76.5 76.5 76.6 76.6
140 81.8 81.6 81.3 81.1 81.0 77.1 77.3 77.3 77.3 77.3
120 82.7 82.5 82.2 82.0 81.8 77.9 78.1 78.0 78.0 78.1
100 83.7 83.4 83.0 82.7 82.7 78.7 78.9 78.8 78.7 78.8
Age 50 years Age 50 years
180 77.9 77.8 77.6 77.5 77.5 73.1 73.4 73.6 73.7 73.7
160 79.0 78.7 78.5 78.3 78.3 74.0 74.4 74.4 74.5 74.5
140 80.0 79.7 79.4 79.2 79.1 74.9 75.2 75.2 75.3 75.3
120 80.9 80.6 80.3 80.0 79.9 75.8 76.0 76.0 76.0 76.0
100 81.8 81.5 81.0 80.8 80.7 76.5 76.8 76.7 76.7 76.8
Age 40 years Age 40 years
180 76.9 76.8 76.6 76.5 76.5 72.0 72.4 72.6 72.9 72.9
160 77.9 77.7 77.4 77.3 77.2 72.9 73.3 73.5 73.6 73.7
140 78.8 78.6 78.3 78.1 78.0 73.8 74.1 74.2 74.4 74.4
120 79.7 79.4 79.1 78.8 78.8 74.5 74.9 74.9 75.0 75.1
100 80.6 80.3 79.8 79.6 79.5 75.3 75.7 75.6 75.7 75.8
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Discounted maximum potential benefit: Figures 7-5 and 7-6 illustrates the maximum potential 
benefit from changes to modifiable risk factors. To reiterate, the assumption is to take 
modifiable risk profiles for individuals (stratified by age) to the bottom left hand corner of the 
non-smoking tables.  Individuals are then assumed to acquire to the life expectancy of that 
profile. Almost everyone can benefit from primary prevention. Discounting results in benefits 
to older age groups being valued more highly than otherwise equivalent risk factor profiles in 
younger groups. Females typically gain the most across all risk factor profiles. 
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Figure 7-5 Discounted maximum potential benefit - males 
Lowest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 1.3 1.5 1.6 1.7 1.7 3.4 3.4 3.4 3.4 3.4
160 0.9 1.1 1.1 1.1 1.2 3.0 3.1 2.9 2.9 2.9
140 0.5 0.6 0.6 0.7 0.8 2.7 2.7 2.5 2.5 2.5
120 0.2 0.3 0.2 0.3 0.3 2.5 2.4 2.2 2.2 2.2
100 0.0 0.0 0.0 0.0 0.0 2.3 2.1 1.9 1.9 1.9
Age 60 years Age 60 years
180 1.2 1.5 1.5 1.6 1.6 3.2 3.3 3.2 3.2 3.2
160 0.8 1.0 1.0 1.1 1.2 2.9 2.9 2.8 2.7 2.8
140 0.5 0.6 0.6 0.7 0.7 2.6 2.5 2.4 2.4 2.4
120 0.2 0.3 0.3 0.3 0.4 2.3 2.3 2.1 2.0 2.0
100 0.0 0.1 0.0 0.0 0.1 2.2 2.0 1.8 1.8 1.8
Age 50 years Age 50 years
180 1.0 1.2 1.2 1.3 1.3 2.7 2.8 2.6 2.6 2.6
160 0.7 0.8 0.8 0.9 0.9 2.4 2.4 2.3 2.2 2.2
140 0.4 0.5 0.5 0.6 0.6 2.2 2.1 2.0 1.9 1.9
120 0.2 0.3 0.2 0.3 0.3 1.9 1.8 1.7 1.6 1.6
100 0.0 0.1 0.0 0.0 0.1 1.8 1.6 1.5 1.4 1.4
Age 40 years Age 40 years
180 0.8 0.9 0.9 0.9 1.0 2.1 2.1 1.9 1.9 1.9
160 0.5 0.7 0.6 0.7 0.7 1.9 1.8 1.7 1.6 1.6
140 0.3 0.4 0.4 0.4 0.5 1.6 1.6 1.4 1.4 1.4
120 0.2 0.2 0.2 0.2 0.3 1.5 1.4 1.2 1.2 1.2
100 0.0 0.1 0.0 0.1 0.1 1.4 1.3 1.1 1.1 1.0
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Highest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 1.2 1.5 1.6 1.7 1.8 3.2 3.3 3.3 3.4 3.4
160 0.8 1.0 1.1 1.2 1.3 2.8 2.9 2.9 2.9 3.0
140 0.5 0.6 0.6 0.8 0.8 2.6 2.6 2.5 2.6 2.6
120 0.2 0.3 0.3 0.4 0.5 2.4 2.3 2.2 2.3 2.3
100 0.0 0.0 0.0 0.0 0.1 2.2 2.1 2.0 2.0 2.0
Age 60 years Age 60 years
180 1.2 1.6 1.7 1.8 1.9 3.3 3.5 3.5 3.5 3.6
160 0.8 1.1 1.2 1.3 1.4 3.0 3.1 3.0 3.1 3.1
140 0.5 0.7 0.8 0.9 1.0 2.6 2.7 2.6 2.7 2.7
120 0.2 0.3 0.4 0.5 0.6 2.4 2.4 2.3 2.3 2.4
100 0.0 0.1 0.1 0.1 0.2 2.3 2.2 2.0 2.0 2.1
Age 50 years Age 50 years
180 1.1 1.4 1.6 1.7 1.8 3.0 3.2 3.1 3.2 3.2
160 0.7 1.0 1.1 1.3 1.3 2.7 2.8 2.7 2.8 2.8
140 0.5 0.7 0.7 0.8 0.9 2.4 2.4 2.4 2.4 2.4
120 0.2 0.4 0.4 0.5 0.6 2.2 2.2 2.1 2.1 2.1
100 0.0 0.1 0.1 0.2 0.3 2.0 1.9 1.8 1.8 1.9
Age 40 years Age 40 years
180 0.9 1.2 1.3 1.4 1.4 2.4 2.5 2.5 2.5 2.5
160 0.6 0.9 0.9 1.0 1.1 2.2 2.2 2.2 2.2 2.2
140 0.4 0.6 0.6 0.7 0.8 1.9 1.9 1.9 1.9 1.9
120 0.2 0.3 0.4 0.5 0.5 1.7 1.7 1.7 1.7 1.7
100 0.0 0.1 0.1 0.2 0.3 1.6 1.5 1.5 1.5 1.5
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Figure 7-6 Discounted maximum potential benefit - females 
Lowest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 2.2 2.6 2.8 2.9 3.0 5.0 5.3 5.4 5.4 5.5
160 1.6 1.9 2.1 2.3 2.4 4.4 4.6 4.7 4.8 4.8
140 1.0 1.3 1.5 1.7 1.8 3.8 4.0 4.1 4.2 4.2
120 0.5 0.8 1.0 1.2 1.3 3.3 3.5 3.6 3.6 3.7
100 0.0 0.3 0.5 0.7 0.8 2.8 2.9 3.1 3.1 3.2
Age 60 years Age 60 years
180 1.9 2.2 2.4 2.5 2.5 4.6 4.7 4.8 4.9 4.9
160 1.3 1.6 1.8 2.0 2.0 3.9 4.1 4.2 4.2 4.2
140 0.8 1.1 1.3 1.5 1.5 3.4 3.5 3.6 3.7 3.7
120 0.4 0.7 0.9 1.0 1.1 2.9 3.0 3.1 3.2 3.2
100 0.0 0.3 0.5 0.6 0.7 2.4 2.5 2.6 2.7 2.7
Age 50 years Age 50 years
180 1.5 1.7 1.8 1.9 2.0 3.8 3.8 3.8 3.9 3.9
160 1.1 1.3 1.4 1.5 1.6 3.2 3.3 3.3 3.4 3.4
140 0.7 0.9 1.0 1.1 1.2 2.7 2.8 2.9 2.9 2.9
120 0.3 0.6 0.7 0.8 0.9 2.3 2.4 2.5 2.5 2.5
100 0.0 0.2 0.4 0.5 0.6 2.0 2.0 2.1 2.1 2.2
Age 40 years Age 40 years
180 1.1 1.3 1.3 1.4 1.5 2.8 2.9 2.8 2.8 2.9
160 0.8 1.0 1.0 1.1 1.2 2.4 2.5 2.5 2.5 2.5
140 0.5 0.7 0.7 0.8 0.9 2.1 2.1 2.1 2.1 2.2
120 0.2 0.4 0.5 0.6 0.7 1.7 1.8 1.8 1.8 1.9
100 0.0 0.2 0.3 0.4 0.5 1.5 1.5 1.6 1.6 1.6
3 5 7 9 10 3 5 7 9 10
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Highest deprived fifth  
Non-Smoker Smoker
Age 70 years Age 70 years
180 2.0 2.4 2.6 2.8 2.8 4.5 4.8 4.9 5.0 5.0
160 1.5 1.8 2.0 2.2 2.3 4.0 4.3 4.4 4.5 4.5
140 0.9 1.3 1.5 1.7 1.8 3.5 3.8 3.9 4.0 4.0
120 0.4 0.8 1.1 1.2 1.3 3.1 3.3 3.4 3.5 3.5
100 0.0 0.4 0.6 0.8 0.9 2.7 2.9 3.0 3.1 3.1
Age 60 years Age 60 years
180 1.8 2.1 2.4 2.5 2.5 4.3 4.5 4.6 4.6 4.7
160 1.3 1.6 1.9 2.0 2.1 3.8 4.0 4.1 4.1 4.2
140 0.8 1.2 1.4 1.6 1.6 3.3 3.5 3.6 3.6 3.7
120 0.4 0.7 1.0 1.1 1.2 2.9 3.0 3.1 3.2 3.2
100 0.0 0.3 0.6 0.7 0.8 2.4 2.6 2.7 2.8 2.8
Age 50 years Age 50 years
180 1.4 1.8 1.9 2.0 2.1 3.6 3.8 3.8 3.9 3.9
160 1.0 1.3 1.5 1.6 1.7 3.2 3.3 3.4 3.4 3.4
140 0.6 1.0 1.1 1.2 1.3 2.7 2.9 3.0 3.0 3.0
120 0.3 0.6 0.8 0.9 1.0 2.4 2.5 2.6 2.6 2.7
100 0.0 0.3 0.5 0.6 0.7 2.0 2.1 2.3 2.3 2.3
Age 40 years Age 40 years
180 1.1 1.3 1.4 1.5 1.6 2.8 2.9 2.9 2.9 2.9
160 0.8 1.0 1.1 1.2 1.3 2.4 2.5 2.5 2.6 2.6
140 0.5 0.7 0.9 1.0 1.0 2.1 2.2 2.3 2.3 2.3
120 0.2 0.5 0.6 0.7 0.8 1.8 1.9 2.0 2.0 2.0
100 0.0 0.3 0.4 0.5 0.5 1.6 1.6 1.7 1.8 1.7
3 5 7 9 10 3 5 7 9 10
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Implications for patient reprioritisation using a maximum potential benefit approach: Table 7-1 
compares which individuals would be given priority for primary prevention by moving from the 
ASSIGN 10-year risk score to a maximum potential benefit approach. This is dependent on 
the distribution of risk in the population. Following reprioritisation there would be a focus on 
females, younger individuals, more deprived groups and smokers.   
 
The key determinant in prioritising individuals was smoking behaviour. Prevalence is higher in 
these groups. For instance, the prevalence of smokers in the SHeS 2003 was 31% in 40-49 
year olds, compared to 17% in the over 70 year olds; and 14% in the lowest deprivation fifth 
compared to 45% in the higher deprivation fifth.    
 
Table 7-1 Patient prioritisation: comparing the ASSIGN 10-year risk score with a maximum 
potential benefit approach 
ASSIGN score Maximum benefit
Males 58.7 39.2
Females 41.3 60.8
40-49 1.2 29.5
50-59 17.0 34.0
60-69 49.0 26.8
70-74 31.9 9.6
Fifths of population Least deprived  1 14.0 11.6
(SHeS 2003) Least deprived  2 17.2 16.3
Least deprived  3 20.2 19.4
Least deprived  4 22.2 24.3
Most deprived   5 26.4 28.4
Smokers 36.3 90.5
Non-smokers 63.7 9.5
Gender
Age group
Smoking status
 
 
Population impact from re-prioritisation: Table 7-2 illustrates the maximum potential gains and 
losses in life years resulting from the switch in prioritisation method – from holding the 
number to be treated constant. Under a maximum potential benefit approach, it is estimated 
that a net gain of 1.5 million additional life years could have been achieved across the lifetime 
of the 2009 Scottish population. However, since different groups are reprioritised the gains 
and losses vary between subgroups. The magnitude of the potential gain in life years 
increases with deprivation quintile and age. Notably, the potential gains for the 40-59 year 
olds is 1.7 million years, in contrast to the 60-74 year olds which lose a total of 110,000 years. 
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Table 7-2 Expected additional life years from a switch to a potential to benefit approach 
in the Scottish general population 
 
ASSIGN Potential to benefit Change
65,746 67,296 1,551
Males 29,926 30,489 562
Females 35,819 36,808 988
40-49 30,337 31,455 1,118
50-59 19,792 20,335 543
60-69 12,152 12,127 -26
70-74 3,464 3,380 -84
1 (least) 12,078 12,213 135
2 12,840 13,038 198
3 13,524 13,837 313
4 14,359 14,740 381
5 (most) 12,945 13,468 523
Smokers 18,014 19,736 1,722
Non-smokers 47,731 47,560 -171
Expected additional life years (000s)
Total Population
Gender
Age Group
SIMD 2004 
quintile
Smoking 
status  
 
7.4 Discussion 
A potential benefit approach: The avoidance of premature mortality and the reduction of 
health inequalities are key aims of primary prevention. Conventional approaches of 
prioritising individuals solely on the basis of CVD risk scores, which is composed of 
modifiable and non-modifiable factors, is unlikely to elicit the greatest gains from prevention 
activities. Rather, prioritisation according to the potential benefit in terms of extended life 
expectancy may be more aligned with the ultimate aims of prevention. 
 
The policy model was used to describe a modelling approach which can transparently 
estimate the potential benefits from changes to modifiable risk factors in terms of additional 
life expectancy.  Currently, the evidence base is incomplete regarding the reversibility of risk 
factors and how this may differ by age, gender and deprivation status. Consequently, a 
potential benefit approach was illustrated by assuming modifiable risk to be completely 
reversible, and consequently termed a maximum potential benefit approach. 
 
For equivalent risk profiles, older age groups have potentially the most to gain in discounted 
life years than younger individuals with equivalent risk factor profiles. This is a similar finding 
as 10-year risk tables. However, 10-year risk is driven by age, whereas a potential benefit 
approach is driven by modifiable risk factors. Therefore, the actual population impact if there 
was a switch from prioritisation based upon 10-year risk to a maximum potential benefit 
approach would dependent on the distribution of modifiable risk factors across the population. 
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In the simulated within the SHeS, a switch to a potential benefit approach would result in a 
focus on younger individuals, females, smokers and deprived groups.   
 
Strengths and weakness: A key strength of the modelling framework is that it makes explicit 
weaknesses in the evidence base regarding the reversibility of risk and how this may differ 
between individuals. These potential benefit estimates can be adjusted based upon evidence 
of intervention efficacy and effectiveness, including intervention engagement and compliance 
estimates. Further, the model can formalise and make explicit equity judgements by 
weighting an extra year of life in particular groups, if appropriate.  
 
These results are largely consistent with current health policy aims. In terms of population-
wide interventions, for instance, there is a drive towards reducing smoking prevalence (e.g. 
legislation banning indoor smoking in enclosed public spaces) and general lifestyle advice is 
increasingly extended to younger age groups14-16). The model predictions have only been 
validated on individuals 40 year and above. However, the direction of using the model to 
make the case for prevention in younger age groups is fairly clear.  
 
Further, prevention programmes often have the reduction of health inequalities as a key aim. 
The value added of formalising a potential benefit approach is the ability to make explicit the 
additional life expectancy from interventions, permitting more focussed targeting, if required.   
 
Within the analysis socioeconomic deprivation status was defined as a non-modifiable risk 
factor.  This was for exposition purposes, and there is a vibrant policy and research 
movement regarding the wider determinants of health, such as changing the key variables 
that defined socioeconomic deprivation status such as income and employment(85). 
However, at present there is no direct evidence linking such interventions and consequent 
changes in risk factors. In principle, the model can incorporate such evidence if available. 
 
Further research: If an approach to prevention was to be based upon potential benefit rather 
than 10-year risk scores then several research areas are required to be addressed. Key 
among these is the reversibility of risk factors and equity implications regarding whether the 
additions to life expectancy should be valued more highly for certain groups than others. 
Indeed these areas are important to address regardless of which approach to primary 
prevention is adopted. The model makes such research gaps more explicit. 
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It is important to test whether the associations between risk factors and life expectancies are 
causal (Chapter 4). Total cholesterol was found to be protective of non-CVD mortality, 
consistent with findings elsewhere(322-323). However, it was decided to hold constant the 
impact of changes of total cholesterol constant when estimating non-CVD death, on the 
assumption that there is no causal relationship. Further research could usefully unpack the 
non-CVD event category within the model to investigate the impact of risk factor changes on 
specific conditions.  
 
A multi-factorial approach to treatment is currently recommended by clinical guidelines. If this 
approach continued under a potential benefit approach then smokers would receive priority, 
including non-smoking interventions.  This may be an emotive issue and is a decision for 
clinical guidelines. That said, it may be no more controversial that current skew in 
prioritisation towards the elderly using 10-year scores. Further, the policy model is very 
flexible and, for instance, can easily remove smoking as a covariate in the prioritisation of 
non-smoking interventions.  
 
Finally, reimbursement agencies such as NICE, recommend that cost effectiveness evidence 
is used to evaluate new interventions and to make reimbursement decisions. For primary 
prevention to be consistent with such policy guidelines, it has been argued that clinical 
guidelines should recommend that individuals also be prioritised on the basis of cost 
effectiveness evidence, and not risk thresholds(25).  
 
As was shown in Chapter 5, it is straightforward to extend quality adjusting life expectancy 
estimates and estimating the impact on lifetime health service costs, net of intervention costs. 
Therefore, there is a direct link between the flexible model structure presented here and the 
sort of cost-effectiveness models used by policymakers. 
 
It is important to reiterate that the starting point for the application of the model was the 
current practice of focussing targeted prevention on those aged 40-74 years. The chapter did 
not challenge the age at which individuals were to be screened or treated; but rather the 
basis upon which individuals are subsequently prioritised for intervention. The rationale was 
to build upon current practice, rather than necessary suggest a full scale ‘paradigm shift’.  
 
However, as discussed in Chapter 2 the onset of risk begins at a far earlier age in Scotland; 
and in the West of Scotland in particular. It was shown that risk behaviours and elevated risk 
factors cluster from 16 years or younger(86). This suggests that prevention should be 
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increasingly widening its focus to primordial prevention, to prevent the onset of risk 
behaviours. Taking a lifecourse perspective to prevention(324), would necessarily entail 
focussing on the social drivers of health behaviours, and brining the importance of upstream 
public health and social interventions into focus(325). To date, the effectiveness and 
economic evidence of such interventions to prevent early onset of risk behaviours is relatively 
limited(86, 325-326). Nonetheless, the Scottish government is investing heavily in early years 
prevention(18) and in an attempt to close health and social inequalities in general(326-327). 
The implication for the Scottish CVD Policy Model would be to extend the focus to younger 
individuals. The challenge is that data on the ASSIGN risk factors in young adults is not 
routinely available to model the relationship between risk factors and event in this group. The 
SHHEC-SMR dataset used to estimate model equations was a cohort aged 30-74 years. 
However, assumptions could be made to extend the model to these age groups, although 
appropriate validation checks would need to be undertaken in bespoke surveys and 
recalibration undertaken if required. An exercise of this kind has been attempted 
elsewhere(108). 
 
Summary: Overall, the Chapter has attempted to illustrate that the policy model could be 
used to develop a new clinical tool to replace 10-year risk scores in screening and prioritising 
individuals for intervention on the basis of potential gains in life expectancy. The model 
framework can be updated conditional on evidence of reversibility of risk, effectiveness of 
treatment (including compliance) and equity judgements. Overall, prioritising individuals on 
the basis of potential benefit, rather than risk, appear to provide greater congruence with the 
ultimate aims of primary prevention which is the avoidance of premature mortality, morbidity 
and the reduction of health inequalities.  
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Chapter 8 Economic evaluation of Scotland’s 
primary prevention programme 
8.1 Background  
Keep Well is a CVD primary prevention initiative funded by NHS Scotland(12). The 
programme is intended to identify asymptomatic individuals at high risk of premature CVD to 
be prioritised for subsequent intervention. The programme targets 45-64 year olds living in 
the 15% most deprived communities in Scotland, identified by the Scottish Index of Multiple 
Deprivation (SIMD) – an area based measure of socioeconomic deprivation.  
 
The programme was launched in 2007 within the Health Board areas of Greater Glasgow and 
Clyde (GGC) as a pilot. It has been subsequently rolled out nationally, in the absence of 
evaluative evidence, and its coverage now extends to all eligible areas within Scotland.  
 
The Keep Well programme is comprised of a sequence of stages, including the initial 
engagement individuals, clinical screening using the ASSIGN risk tool to identify those at high 
risk of an event over the next 10 years, and the offering of medication and behavioural 
interventions for those at high risk.   
 
GCC and Scottish Government intend to undertake an economic evaluation of the 
programme for Glasgow North and East, the first two administrative areas within GGC to 
begin Keep Well. In principle, this provides an opportunity to use the Scottish CVD Policy 
Model to estimate the long term cost effectiveness of the programme.  
 
However, there are major constraints. The programme pilot in 2007 was not set up in an 
experimental manner to test effectiveness or cost effectiveness. In particular, re-screening 
data for individuals who have completed the programme of intervention have not been made 
available. Further, there is no control group. This limited the ability to undertake a 
comprehensive economic evaluation. Rather, the baseline data of individual ASSIGN risk 
factors is used, and the literature is drawn upon to develop estimates of effectiveness and 
project the potential cost effectiveness of Keep Well.   
 
Given the severe limitations of the data currently available, key aims of the analysis were to: 
(i) make clear to policymakers the considerable uncertainty regarding the impact of Keep Well 
and need to conduct a rigorous evaluation, including following up patients regarding 
 340 
rescreening and intervention compliance; and (ii) demonstrating the ease at which the policy 
model can be used to project trial findings if an evaluation was conducted.    
 
The communication of how the policy model works and outputs generated is important. The 
policy audience that was recipient of the following work was not familiar with methods of 
health economic evaluation or models of this type. Therefore, a key aim was to communicate 
the methods used and findings as transparently and simply as possible. This influenced the 
methods used, especially the sensitivity analysis undertaken. Nonetheless, the analysis is 
intended to be as rigorous as the data allows. 
 
8.2 Methods 
Source data  
GGC provided a dataset for the Keep Well programme which was called the Tracking Tool. 
This covered Glasgow North and Glasgow East.  The dataset spanned an 18 month period, 
beginning in December 2006 and ending in August 2008. The dataset included the eligible 
asymptomatic population for Keep Well, baseline screening data for individuals who had been 
successfully contacted, the ASSIGN variables and 10 year risk scores for each individual, 
and tracked the medications prescribe and referrals to service interventions that were made.    
 
Engagement and screening:  
The tracking tool recorded the engagement success of the programme in attracting the 
eligible population for screening. Engagement was conducted mainly through GP practices 
contacting individuals between 45 and 64 years through a combination of telephone and 
letters.  
 
Keep Well programme interventions:   
Once high risk individuals are identified they are offered a range of medications and 
behavioural change interventions. Table 1 lists the interventions that could be offered. 
Medications included statins and anti-hypertensives. The behavioural interventions were very 
wide ranging; amongst the most prominent were (i) a health counsellor offering quarterly 
advice over the period of a year on exercise and diet; (ii) a 12 week group intervention to stop 
smoking; (iii) a three-month individualised alcohol counselling for heavy drinkers; and (iv), 
various mental health interventions (including massage), (v) social welfare intervention, such 
as advice regarding benefit entitlements; and (vi) an intervention to improve literacy levels.   
Individuals were also tracked to assess whether they completed the behavioural 
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interventions. It was not known whether individuals collected and/or took medications 
prescribed. 
 
Absence of follow-up data or a control group:  
There was a substantial amount of missing information that inhibited the conduct of a rigorous 
economic evaluation. This extended to missing data regarding whether individuals completed 
their referrals to behavioural interventions; the compliance behaviour with medication and re-
screening data to detect changes in risk factors.  
 
Further, no control group was to infer a counterfactual (risk factor changes under usual 
routine care) in order to attribute observed changes in CVD risk to the Keep Well programme. 
These are serious omissions. Therefore, there was no formal trial or rigorous evaluation. 
Consequently, it was unknown to what extent ASSIGN risk factors had changed and what 
could be attributed to the intervention group. 
 
Assumptions of impact: 
The impact of Keep Well was estimated by projecting the likely change in ASSIGN CVD risk 
factors from an individual who received the interventions. First, individuals referred to 
interventions were identified. For pharmaceuticals there was information regarding 
prescriptions received over the entire 18 month period. For individuals referred to behavioural 
interventions, the impact of these referrals was only estimate if individuals completed the 
entire intervention course (e.g. competed a full counselling programme regarding diet and 
physical activity). Once individuals were identified, the estimation of impact was developed in 
three stages:  
 
(i) Efficacy evidence:  Efficacy evidence was taken from the national SIGN Guidelines (on 
CVD), which was the result of various systematic reviews and expert clinical opinion. This 
evidence was summarised in Chapter 2.  
 
Keep Well interventions were only included in the modelling if there was sufficient evidence of 
similar interventions as judged by SIGN Guidelines(9). There was strong evidence for 
pharmaceuticals and to a lesser extent (given absence of RCTs) for lifestyle advice. There 
was no evidence for the other interventions impact on CVD outcomes, and were 
consequently excluded.  
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The impact of alcohol was excluded. While there is evidence of the impact of alcohol 
consumption on systolic blood pressure, there wasn’t adequate information on alcohol 
consumption in the Keep Well dataset. In any case, the number of individuals referred to this 
intervention to reduce alcohol consumption was very small (less than 40).  
 
Finally, to adjust for the possible side effects of medications, such as intolerance, quality of 
life from individuals taking medication by weight survival by 0.9875 is taken, as used in a 
Dutch economic model(248).  
 
(ii) Adjusted for compliance - effectiveness: To generate estimates of effectiveness, efficacy 
evidence was weighted by the long term compliance behaviour of individuals. The evidence 
base regarding compliance is poor, especially regarding the compliance behaviour of 
individuals from deprived backgrounds. Rather, an assumption of compliance was generated. 
Access to research conducted by GCC on compliance behaviour by secondary prevention 
patients was provided. This was a 2-year study that tracked the percentage of patients who 
regularly collected the prescriptions made by GPs. It was assumed that if prescriptions were 
pick-up then they were also taken correctly, which is optimistic. To then generate compliance 
estimates for primary patients, a study which measured the average compliance rates 
between secondary and primary patients who were prescribed statins was used. This 
provided a ratio that was applied to the Glasgow study of secondary individuals. All 
individuals in the Keep Well dataset were assumed to have the same compliance behaviour. 
With agreement from Keep Well programme management the same compliance estimates 
were applied to all interventions including behavioural, but with the exception of smoking. To 
estimate compliance regarding smoking quit rates, a previous study conducted in Glasgow 
was drawn upon, where the long term rate was estimated to 5.5%(169). 
 
(iii) Multiplicative interactions: It is largely unknown how risk factor interventions combine. The 
strongest evidence is regards single interventions. It was assumed that interventions 
combined multiplicatively.  
 
(iv) Adjusting for usual care: Finally, it is vital to estimate a counterfactual so that any 
changes in risk factors observed in Keep Well patient can be attributed to the programme.  
However, to reiterate there was no control group. As a consequence, it was estimated what 
proportion of the Keep Well patients would have received in routine care, in the absence of 
the programme. Estimates made by England’s Department for Health (DoH) Vascular 
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Screening Checks initiative was used(180). To reiterate, was a document that underpinned 
the roll-out of a population CVD screening initiative that began in 2009.  
 
Overall, the model was used to estimate the effectiveness of medications, the health 
counsellor and smoking group therapy on the Keep Well population.  
 
Costs: Unit costs were not available, but rather GGC provided annual budgets that were 
allocated to each of the key stages of the programme, including engagement, screening, and 
the interventions. Further, budgets for the management and administration of the programme, 
and the costs of the IT system used to track individuals through the programme.  
 
Budgets were provided for two years. Given, the evaluation period was over 18 months, 
monthly costs were estimated on a pro-rata basis provides estimates for the 18 month period.  
It was assumed that all budgets had been spent. 
 
Finally, a cost per patient was estimated by dividing the total number of patient screened by 
the total costs of the Keep Programme.  
  
Cost effectiveness: Individual risk profiles were run through the CVD Policy Model to estimate 
baseline hospital costs and QALYs in the absence of the Keep Well intervention.  Using the 
Tracking Tool (which tracked which interventions were received) the effectiveness estimates 
were applied to relevant individual and the model re-estimated hospital costs and QALYs. 
The impact on health service costs is net of the cost of Keep Well.  All estimates were 
discounted at 3.5%. Finally, an incremental cost effectiveness ratio (ICER) was calculated by 
estimating the differences in costs and dividing this by the differences is QALYs.   
 
Sensitivity analysis: There is clearly considerable uncertainty. The sensitivity analysis 
adopted an analysis of extremes, where the expected, worst case and best case scenarios 
were estimated. This approach takes the mean, and upper and lower confidence intervals of 
the intervention effect and divides each by the costs of the programme.  
 
8.3 Results 
 
Source data: Table 8-1 outlines the screened population for Glasgow North and East. There 
were 15,258 individuals eligible for the programme, and 8,495 patients screened in the period 
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between November 2007 and August 2009. This represents engagement success of 56%. 
The average age was 54 years and there was a higher proportion of woman (55%). Notably, 
smoking prevalence was very high, and average total cholesterol was in excess of 6 mmHg 
across both genders. 
 
Table 8-1 Keep Well population 
Men Women
Cohort size (total / %) 3,835 (45.1%) 4,660 (54.9%)
                              
                  
Age 54.4 (6.0) 54.5 (5.8)
Systolic blood pressure 134.9 (18.1) 130.1 (18.4)
Total cholesterol 6.0 (1.5) 6.1(1.5)
HDL cholesterol 1.3 (0.3) 1.5 (0.6)
Smokers (%)  42.2 40.9
Cigarettes per day 23.2 (9.2) 17.5 (8.7)
Family history (%) 29.5 34.6
 
 
Evidence of efficacy:  Table 8-2 details the efficacy evidence used and refers to the impact 
that interventions have on reducing modifiable risk factors if individuals were fully compliant. 
Obviously, for the smoking intervention the impact was be a 100% quit rate. The mean, 
minimum and maximum impacts are shown - where taken from the confidence intervals of 
relevant studies. For statins, SIGN Guidelines reported the percentage change in cholesterol 
readings; whereas evidence of the impact of other interventions was based on absolute 
reductions in risk factor levels.  
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Table 8-2 Intervention efficacy estimates 
Statins Anti-hypertensives Health counsellor
Systolic blood pressure
min  - -8.3 -2.7
expected  - -8.8 -3.8
max  - -9.4 -5
Total cholesterol
min -16%  - -0.49
expected -20%  - -0.79
max -24%  - -1.09
HDL Cholesterol
min 4%  - 0.16
expected 5%  - 0.21
max 6%  - 0.25  
 
Evidence of effectiveness: The Glasgow study of secondary prevention patients found that 
compliance after two years was 30% on average, with a lower estimate of 18% and an upper 
estimate of 37%. The efficacy estimates were then rescaled by using the ratio of compliance 
behaviour between primary and secondary patients, which was found to be 0.76. This gave a 
mean estimate of compliance in primary patients of 18%, with a lower limit of 8% and an 
upper limit of 37%. Finally, a study in Glasgow estimated that the long term quit rates for 
those engaging with the smoking intervention was 5.5%(169). An arbitrary lower and upper 
bound was then given of 4.5 and 6.5% respectively. These estimates were applied the 
efficacy evidence (Table 8-3). 
 
Table 8-3 Effectiveness estimates - adjusted for compliance  
Statins Anti-hypertensives Health counsellor
Systolic blood pressure
min  - -0.681 -0.222
expected  - -1.605 -0.693
max  - -3.459 -0.912
Total cholesterol
min -0.013  - -0.040
expected -0.036  - -0.144
max -0.088  - -0.401
HDL Cholesterol
min 0.003  - 0.013
expected 0.009  - 0.038
max 0.022  - 0.092  
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Attribution: The effectiveness estimates were adjusted to take into account what was likely to 
have taken place anyway under routine care (Table 8-4). The DoH estimated that 80% of 
anti-hypertensives and 50% of statins would have been prescribed in the absence of Keep 
Well. Further, of those referred to diet and exercise advice, and group smoking therapy for 
smoking 45% and 50% would have received this under usual care. There was no account 
made whether individuals would have received these interventions quicker under a screening 
programme.  
 
Table 8-4 Effectiveness estimates – adjusted for compliance and attribution 
 
Statins Anti-hypertensives Health counsellor
Systolic blood pressure
min  - -0.34 -0.11
expected  - -0.80 -0.35
max  - -1.73 -0.46
Total cholesterol
min -0.01  - -0.02
expected -0.04  - -0.07
max -0.09  - -0.20
HDL Cholesterol
min 0.003  - 0.001
expected 0.01  - 0.02
max 0.02  - 0.05  
 
Costs: Table 8-5 outlines the main costs of Keep Well, which included coordination, 
screening for CVD risk, lifestyle interventions (e.g. diet and exercise) and IT support. Cost per 
individuals was estimated by dividing global totals by patient numbers.  For instance, the 
average cost of the intervention, excluding pharmaceutical (considered next) was £349 per 
person. 
 
   Table 8-5 Total intervention costs 
Activity Total costs (21 months)
Management/coordination £868,125
Screening £967,500
Practice costs (GP, management,admin) £1,272,387
Referrals/Signposts £103,125
Interventions £1,863,990
Tracking tool £46,875
Total £5,122,002
Source: John Clyde North Glasgow CHCP   
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Table 8-6 provides annual medication costs used in the primary prevention of CVD. The 
recommended prescription dose was given by the SIGN Guidelines and the costs of drugs 
were taken from the Scottish Drug Tariff. The methods just described and consequent 
estimates were then validated by the Lead Pharmacist in Glasgow, Richard Lowrie.  For 
consistency with the effectiveness estimates, individual medication costs were weighted by 
compliance estimates.  
 
Table 8-6 Medication costs 
Medication Annual costs
Aspirin £13
Simvastatin £35
Amlodipine £15
Perindopril £29
Total £92
Source: Richard Lowrie/Scottish Drug Tariff   
 
Cost effectiveness: Using the analysis of extremes approach, the base case analysis of Keep 
Well had a cost effectiveness ratio of £58,948. Under a worst scenario, the cost per QALY is 
estimated to be £120,558. Under a “best case scenario”, Keep Well becomes cost effective 
with a cost per QALY of £12,762. In other words, there is huge uncertainty, and a necessity to 
conduct a robust evaluation and estimate the cost effectiveness results. 
 
8.4 Discussion  
Cost effectiveness of Keep Well: This analysis was illustrative of the Scottish CVD Policy 
Model’s ability to undertake cost effectiveness analysis of a CVD primary prevention 
programme.  
 
Strengths and limitations: Despite only having baseline information on risk factors and 
interventions referrals, this provided an opportunity to show how the Scottish CVD Policy 
Model can be used in the evaluation of Scotland multi-factorial programme.  
 
The fundamental limitation of the analysis is the lack of follow-up data (rescreening) and 
absence of a control groups. Consequently, a rigorous economic evaluation was not possible. 
Rather, a modelling exercise was conducted which gave an opportunity to illustrate the 
functioning of the policy model.  
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Consequently, there was considerable uncertainty. The decision was made to represent 
uncertainty as simply as possible given the audience for the outputs was a policymakers who 
were unfamiliar with such modelling and sensitivity analysis. Nonetheless, this was also an 
opportunity to demonstrate whether the process of generating outputs was transparent and 
comprehensible to policymakers, who are intended to be the ultimate end-users. 
 
Regarding sensitivity analysis, an analysis of extremes was felt to be the most effective 
method. This was a simple approach to communicate to policymakers the wide bounds of the 
uncertainty concerning the Keep Well programme, the origin of this uncertainty, and the need 
to undertake a rigorous study before assuming this national multi-factorial programme is a 
good use of scarce public resources. While a more sophisticated sensitivity analysis would 
have been probability sensitivity analysis, this requires knowledge of how interventions 
interact (and the associated statistical covariance); however there is a lack of trial evidence to 
inform this, as discussed in chapter 2 and chapter 3.  
 
The data constraints are symptomatic of the lack of (rigorous) evaluation culture in local 
policy circles. A key aim of the analysis was to make clear to policy that appropriate 
information needs to be collected before a rigorous evaluation can be conducted. Otherwise, 
there would remain considerable uncertainty regarding the programme effectiveness and cost 
effectiveness.  
 
The model functioning and outputs can be presented quite clearly. The results of the analysis 
were presented to Glasgow and the Scottish Government, where the latter has expressed a 
wish to undertake a national economic evaluation of the Keep well programme in the future. 
 
The Department of Health (DoH) for England conducted a modelling exercise prior to rolling-
out the National Vascular Screening Checks interventions in 2009. This is a similar 
programme to Scotland’s Keep Well intervention. They found that the mean cost per QALY 
was £7,000. This is in stark contrast to the estimates made here. The reasons for such a 
difference in estimates have been investigated as far as possible. However, the economic 
model used by the DoH to generate estimates has not been published or made publically 
available. A report has been published that details the screening approach that the DoH is 
advocating, and key assumptions used in the modelling have been published(180).  Perhaps 
a key reason why the DoH exercise found the programme will be cost effective result may be 
due to the compliance assumptions used; which may be considered to be optimistic. For 
instance, it was assumed that compliance with statins would be 75% and this estimate was 
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not sensitised. These compliance assumptions are in stark contrast to a 2-year study in 
Glasgow that found patient compliance in secondary patients was just 30% on average.  A 
threshold sensitivity analysis using the Keep Well data found that compliance levels were the 
key area of uncertainty. The intervention can become cost effective if average compliance 
rates are 62% across all individuals (holding efficacy and usual care assumptions constant). 
 
Summary: Overall, this exercise demonstrated how the Scottish CVD Policy Model can be 
used to evaluate the lifetime impacts of multi-factorial interventions, using the same risk 
variables as the ASSIGN score which is used to screen and prioritise individuals for 
interventions. This is the only model of its kind that can do this. The results of the exercise 
are speculative given the absence of outcome evaluation to date. In a sense the model has 
been used ‘pre-trial’ and intended to demonstrate the huge uncertainty regarding the 
programme. The practical implications for policymakers that while there are good intentions in 
rolling out primary prevention programmes, it is very important to properly evaluate impacts to 
ensure that scarce resources are being used cost effectively.  
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Chapter 9 Estimating the impact of population 
interventions  
9.1 Background  
The previous chapter showed how the model can be used to estimate the lifetime impact of 
targeted interventions. This chapter now demonstrates how the policy model can be used to 
assess the impact of population interventions.  
 
It has been argued that population interventions may have the potential to elicit the greatest 
gains in health, due to the intention to impact upon the whole population rather than the high 
risk, which is the extreme of the population(99-100). Existing policy models such as CHD 
Policy Model, IMPACT and NICE’s Programme Development Group (PDG) have produced 
convincing modelling exercises which corroborate these claims. However, existing estimates 
are limited in that the impacts of cumulative health service costs are not estimated, and the 
impact of extending life expectancy. These models also do not estimate the quality adjusted 
life years, and the NICE PDG model only estimates impacts over 10 years. Further, the 
impacts population health interventions on health inequalities have not been estimated by 
existing models. That is, while the population approach may deliver the greatest gain, the 
incidence of premature CVD tends to be concentrated in specific groups and Scotland suffers 
from a pronounced gradient in CVD by socioeconomic deprivation. 
 
There are two main determinants as to whether population interventions will reduce health 
inequalities. First, to reduce health inequalities a primary prevention intervention would need 
to impact upon the CVD risk of a higher percentage of asymptomatic individuals in deprived 
groups.  The potential problem for population health approaches to primary prevention is that 
the more deprived the group the higher percentage who already have CVD. Such individuals 
will likely be the recipients of intensive secondary prevention interventions.    
 
Secondly, the impact of an intervention on inequalities will likely depend on whether the 
intervention requires individual engagement with statutory health services and an individual’s 
long term compliance behaviour. Mass campaigns (e.g. screening and public health 
information) will tend to elicit greatest benefits in more affluent areas, given the greater 
tendency to engage with statutory services, undertake behaviour change, and affluent area 
tend to be better resourced than more deprived areas, exhibiting the Inverse Care Law(24). 
Population wide interventions that rely on patient engagement and/or the ability to local health 
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systems to respond may actually increase health inequalities(23). Therefore, there may be a 
trade-off equality of access and equality of outcome. The distinction is important given an 
explicit policy aim is to reduce health inequalities 
  
This Chapter provides an illustration that the Scottish CVD Policy can be used to generate 
estimates of the impact of population interventions, and also to assess the impact on health 
inequalities. For the sake of exposition the approach of cost utility analysis is used, and the 
discount rate of 3.5% is selected. This is intended to help facilitate comparison of the impact 
of these public health interventions with interventions that fall under health technology 
assessment. This approach is also consistent with a similar modelling exercise recently 
undertaken in the UK(35). 
 
The purpose of this chapter is to use the Scottish CVD Policy Model to run three intervention 
scenarios, and estimate the impact on population health, health service costs and 
inequalities. First, screening strategies are revisited and there is an illustration that a mass 
screening approach could increase health inequalities. Second, the impact of three 
legal/regulatory changes are simulated, where unlike screening these interventions are 
essentially paternal; there is no need to model individual engagement or compliance 
behaviour. Third, an illustration is provided to show how the model can be used strategically 
to develop optimal combinations of population and targeted approaches, whereas there both 
approaches can still often be treated as competing in the literature.  
 
9.2 Methods 
Mass screening and inequalities: 
This simulation extends the analysis in Chapter 7 and is intended to inform whether Scotland 
should move to population wide screening programme like England. The purpose of this 
illustration was to illustrate at which point a population wide screening strategy may increase 
health inequalities. The analysis determines to what extent engagement with screening would 
need to vary in the population for life expectancy to widen in the population, defined by fifths 
of socioeconomic deprivation. It is then discussed whether this difference between groups is 
plausible in reality. 
 
Defining the asymptomatic population: For the purpose of consistency to compare targeted 
and population approaches the impacts of intervention on 40-74 year olds. This may 
significantly underestimate the impact of population interventions that impact on all age 
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groups, and may have intergenerational impacts. Nonetheless, this comparison is still 
intended to be instructive of the potential for population interventions. Further, the NICE PDG 
also estimated impacts on the same age groups in England but over 10 years(35).  
 
Legal and regulatory interventions:  
Using the SHeS 2003 (the largest and most comprehensive of the surveys) the cost 
effectiveness of three interventions are estimated. The analysis as limited to primary 
prevention, and so first the proportion of the Scottish population that were asymptomatic was 
estimated, including how this varied by fifth of socioeconomic deprivation (SIMD).  
 
First, the impact of a reduction in salt within processed food is estimated, assuming that this 
will lead to a fall in systolic blood pressure (SBP) of 5% across all individuals.   
 
Secondly, a 5% reduction in total cholesterol was simulated which could be expected from a 
0.5% reduction in trans-fats. These reductions in SBP and total cholesterol are consistent 
with recent findings from prevention programmes administered elsewhere outside 
Scotland(35).    
 
Third, for exposition, a smoking intervention was simulated to demonstrate the importance of 
reducing smoking in the population.  For exposition, it was speculatively assumed that there 
was agreement from government and industry to reduce nicotine content of cigarettes leading 
to reductions of 25%, on average, across all brands. To be clear, nicotine is not itself harmful 
to health. Rather nicotine is the addictive substance leading to the inhalation of associated 
carcinogens which driven the harmful biochemical process leading to the associated CVD 
and non-CVD events(328). 
 
To simulate the impact of reducing nicotine content, and so the addictive nature of cigarettes, 
this was converted into an equivalent drop in average cigarettes smoked per day.  It has been 
estimated that on cigarettes contain between 1 to 3 grams of nicotine (329). Conservatively, it 
was assumed that on average the nicotine inhaled by smokers was 1 gram, in a crude 
attempt to account for differences in filters, length of draws, and so forth. Overall it was 
assumed that a 25% reduction in nicotine content for cigarettes is equivalent to a 25% 
reduction in cigarettes smoked per day. So for example, for a smoker of 20 per day this 
equates to 5 cigarettes per day.  
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Any knock-on effect as consequence of reducing nicotine is held constant. For instance, 
individuals may decide to buy more cigarettes or increase the yield from greater inhalation. 
On the other hand, future smokers may becoming less addicted, and/or enhance quit rates of 
other interventions (e.g. group therapy NRT treatments).  
 
Combing targeted and population approaches: 
The model is also used to illustrate that a combination of targeted and population 
interventions may an efficient and effective approach to improve population and also reduce 
health inequalities. This is done by revisiting the finding from Chapter 7 that targeted 
screening on deprived groups and those with family history could detect the majority of 
individuals are premature risk and free up resources for population wide interventions.  
 
9.3 Results 
Mass screening and inequalities: When investigating efficient screening strategies, we saw 
16% of the deprived population is at risk of premature CVD compared to just under 4% in the 
general population - a ratio of 4:1. Therefore, a mass screening approach may increase 
health inequalities if engagement and compliance in the deprived was less than a quarter that 
the rest of the population.  This is a realistic scenario, especially if the deprived are further 
categorised into hard to reach groups(23), and we further consider the inverse care law 
where there is generally less support for deprived groups(24). Therefore, a population wide 
intervention that requires GP surgeries to contact everyone is unlikely to engage with such 
groups.  
 
Asymptomatic population: Table 9-1 estimates the percentage of the Scottish population 
between the ages of 40 and 74 years who were free of CVD.  Just over 36% of the total 
population is free of CVD. There is a clear SIMD gradient where least deprived (SIMD) have 
43% who are asymptomatic falling to 30% in the most deprived (SIMD 5). This is consistent 
with the findings in Chapter 2 that the prevalence of CVD is higher in more deprived 
communities.  
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Table 9-1 Numbers asymptomatic in Scottish population 
Total      SIMD 1      SIMD 2     SIMD 3     SIMD 4     SIMD 5
Population 5,194,000   993,668         1,015,852      1,037,679      1,080,118      1,066,683      
Asymptomatic 1,891,571   422,867         403,892         389,468         359,468         315,876         
Percentage 36% 43% 40% 38% 33% 30%  
 
The impact of such interventions on QALY, costs and health inequalities will depend on the 
level and distribution of risk factors in the population. Table 9-2 illustrates that more deprived 
communities have on average high systolic blood pressure and in particular smoking 
prevalence, where over twice as many people in SIMD 5 smoked (45%) compared to 22% in 
SIMD 1. The distribution of cholesterol readings are fairly even across quintiles.  
 
Table 9-2 Average modifiable risk factors by fifths of socioeconomic deprivation (SIMD) 
Average SIMD 1 SIMD 2 SIMD 3 SIMD 4 SIMD 5
Systolic blood pressure 133.4 131.2 133.4 133.8 134.4 134.5
Smoking % 21.8 14 20 2 34 45
Total cholesterol 6.0 6 5.9 6 6 5.9
HDL Cholesterol 1.5 1.6 1.6 1.5 1.5 1.5  
 
Legal and regulatory interventions: Table 9-3 then illustrates the gains in discounted QALEs 
at the national level and across fifths of SIMD, which is a function of the numbers of people in 
each fifth and the risk factors levels. Overall, the potential gains are enormous and especially 
for the smoking intervention. Further, the impact on inequalities is generally favourable, and 
again this is especially the case for smoking. A reduction in salt intake would increase 
inequalities slightly due to the greater numbers of asymptomatic individuals more affluent 
quintiles. However, this is only with respects to the total (incremental) QALEs each 
deprivation fifth can achieve. At the level of individual, more deprived people are still 
expected to benefit more given higher (on average) systolic blood pressure readings. 
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Table 9-3 Gains in discounted quality adjusted life expectancy (QALE) 
Salt reduction
Quality adjusted life years ('000) 369  (341, 402) 69 (61, 74) 65 (59, 73) 87 (83, 94) 80 (76, 86) 68 (63, 76)
Cost reduction (£m) 467  (443, 508) 91 (84, 95) 88 (82, 95) 105 (95, 118) 96 (91, 101) 87 (77, 93)
Trans-fat reduction
Quality adjusted life years ('000) 140  (116, 156) 20 (14, 23) 32 (26, 37) 32 (27, 37) 29 (26, 34) 27 (23, 34)
Cost reduction (£m) 207  (194, 219) 34 (29, 41) 45 (39, 53) 48 (41, 54) 42 (37, 46) 38 (35, 43)
Nicotine reduction
Quality adjusted life years ('000) 471  (454, 496) 53 (44, 57) 71 (65, 78) 83 (76, 89) 125 (115, 131) 139 (126, 145)
Cost reduction (£m) 569 -546,581 74 (67, 79) 92 (86, 99) 95 (89, 102) 141 (131, 153) 167 (152, 176)
SIMD 1
Least deprived fifth
Total SIMD 5
Most deprived fifth
SIMD 2 SIMD 3 SIMD 4
 
 
Further, these interventions are cost saving, in discounted terms. In undiscounted terms, 
costs actually increase due to greater life expectancies, and the onset of co-morbidities in 
older age groups.  
 
Combining targeted and population approaches: Chapter 7 showed that a targeted screening 
approach that focussed on the most deprived fifth and those with family history could detect 
84% of the high risk by screening just 41% of the population. At a screening cost of £28 per 
person, a targeted rather than a mass population wide approach would save £18 million. 
Further, given clinical guidelines recommend screening every 5 years, this potential saving 
would be in perpetuity. 
 
The remaining 16% of the population at high risk of premature events over 10 years could be 
picked up by legal and regulatory changes. This freed resource could either be saved; 
redirected into better engagement strategies for the deprived or additional interventions, such 
as to improve adherence levels; or/and used to fund public health interventions such as mass 
media campaigns. Such population wide interventions would also reinforce the impacts of 
targeted initiatives. 
 
9.4 Discussion 
The impacts of population interventions: Population health interventions can have an 
enormous impact, and the legal and regulatory interventions would be relatively inexpensive 
to achieve. While heath service costs will increase (reversing what other research has 
 356 
concluded); once discounted the intervention are cost effective, given that the immediate cost 
of CVD events are averted and the costs of living longer lives are deferred to the future. 
  
Strengths and limitations: The policy model can be used to quickly undertake such modelling 
exercises. It is the only model to use socioeconomic deprivation as a risk factor to assess the 
impact of interventions on health inequalities. A key strength is the same model can be used 
to assess the impact of both population and targeted interventions. This consistency then 
allows all forms of interventions to be assessed and compared using the same model which 
can produce the outcomes of interest to individuals, clinician and policymakers.  
 
It is difficult to directly compare these results to other authors. For instance, the NICE PDG 
estimated the impacts on QALYs only over a 10-year period, there was no account taken of 
the quality of life impacts, and the cost impact was limited to avoidance or postponement of 
CVD events. Nonetheless, the fundamental issue is that such population health interventions 
can results in considerable improvements is consistent.   
 
The model can be used in a similar fashion to simulate any population interventions (e.g. 
mass media campaigns) if consequent changes in risk factors are estimated. The model can 
be used to convert changes into risk into QALE and costs. 
 
Summary: This Chapter concludes Part 3 of the thesis and demonstrates that the Scottish 
CVD Policy Model can be used to assess the impact of population interventions and on 
health inequalities, which can have considerable impacts and be cost saving (in discounted 
terms).  
 
Overall, the previous four chapters has attempted to address the research questions, and 
demonstrate that the model can be used flexibly as both a clinical tool to identify individuals at 
high risk and those who can benefit the most from intervention; and also as an evaluation tool 
and can inform the development and evaluation of both targeted and population interventions. 
This range of comprehensive outputs is an advance on existing policy models, and in 
application could help bring more coherence to the approach of primary prevention in Scottish 
policy making circles. 
 357 
Chapter 10: Conclusions and further research 
10.1 Introduction 
To complete the thesis this final chapter assesses the extent to which the objectives were 
met. The chapter is structured in three main parts. First a summary of the rationale, function 
and application of the Scottish CVD Policy Model is provided. This draws upon and 
summarises each of three parts of the thesis. Second, a discussion of the key strengths and 
weakness of the research is provided; and third, the chapter ends by describing certain areas 
for future research.  
 
10.2 Summary of the thesis  
The overall purpose of the thesis was to develop a Scottish CVD Policy Model that can be 
used to assist decision makers develop and evaluate primary prevention interventions.  Part 1 
of the thesis developed the rationale behind why a Scottish CVD Policy Model is needed, by 
describing the aims of primary prevention, the need for economic models to help generate the 
information required by decision makers to inform approaches to primary prevention; but then 
highlighting the weakness of current models regarding their potential use in Scotland. Part 2 
then described in detail how the Scottish CVD Policy Model was developed, and how it 
functions to generate the information required by both clinicians and policy makers. Part 3 
demonstrated how the model can be used to address key research questions to help improve 
the approach to primary prevention. Each of the three parts of the thesis is summarised in 
more detail below. 
 
Part 1 – Review of primary prevention 
Part one consisted of Chapters 2 and 3. Chapter 2 described how the primary prevention of 
CVD is a policy priority across the developed world. The general goals of prevention are to 
avoid premature mortality, morbidity and the consequent health service and wider economic 
costs. The prevalence of CVD has been falling consistently in recent decades, but the 
incidence and costs of CVD remain substantial. It is estimated that in 2011, CVD accounted 
for 30% of all deaths and resulted costs of over to the health sector and £3.4 billion to the 
health service and wider economy. 
 
The primary prevention of CVD is an increasing policy priority in Scotland. The goals are to 
avoid premature mortality, morbidity and the associated economic costs. Further, a key policy 
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aim is to reduce health inequalities. In all countries, the prevalence of premature CVD is 
generally skewed towards areas of lower socio-economic position. However, this social 
gradient is particularly apparent in Scotland.  Scotland has among the highest concentration 
of deprived areas in Western Europe, and the incidence of premature CVD is especially high.  
 
There are two main approaches to primary prevention: a targeted approach on individuals 
screened and identified as being at high risk of CVD events and a population approach 
intended to impact on everyone in a defined population (e.g. legal and regulatory changes) 
where interventions do not require the engagement of specific individuals.  
 
The current policy emphasis is on a targeted approach. Following clinical guidelines, 
individuals are screened using CVD risk scores and those at high risk of an event (estimated 
to be ≥ 20% over 10 years) are offered a tailored set of pharmaceutical and behavioural 
interventions. The SIGN 97 clinical guidelines adopted the ASSIGN 10-year risk score as the 
most appropriate risk tool, which was developed in Scotland and includes a measure of 
socioeconomic deprivation (the Scottish Index of Multiple Deprivation), as an independent 
risk factor. 
 
While there is a significant policy effort to reduce CVD and inequalities, the evidence base 
underpinning current approaches is relatively limited. There is robust cost effectiveness 
evidence of single drug interventions, and convincing modelling exercises of particular 
population-wide interventions. However, in particular, there is lack of efficacy, effectiveness 
and cost effectiveness evidence regarding multi-factorial interventions of the sort being rolled 
out in Scotland, and elsewhere.  
 
Overall, there are three main strategic weaknesses with current approaches to primary 
prevention. First, it is unknown what the optimal screening approach is to identify the high 
risk. Clinical guidelines recommend screening the entire population from 40-74 year old. 
However, more focussed approaches may be more efficient. Second, it is increasingly 
questioned whether 10-year risk scores are the most appropriate mechanism to prioritise 
individuals for intervention. The aims of prevention are to avoid premature CVD; yet 10-year 
scores are driven by age resulting in the prioritisation of older patients at the expense of 
younger individuals who may have most to benefit from early prevention. Third, the targeted 
and population approaches to prevention are still often treated as competing approaches 
whereas perhaps the key issue is how they might best combine. 
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An important part of the continued uncertainties is the lack of consistency in the evidence 
base. The efficacy and effectiveness evidence base consists of studies with different time 
frames, different end points (e.g. risk factors, CVD events, all cause mortality), and different 
populations, and often not fully exploring heterogeneity within a population. This is a problem 
for policy makers who are interested in the extent to which interventions prevent premature 
mortality, and when cost constrained how to prioritise resources.  
 
The approach of cost effectiveness analysis may provide a consistent framework to enable 
interventions to be directly compared in terms of quality adjusted life expectancy and health 
service costs. From an economic perspective these outcomes are necessary given scarce 
resources, and congruent with how reimbursement agencies, such as health technology 
agencies, make funding decisions.  
 
Chapter 3 outlined the importance of economic modelling to help generate cost effectiveness 
evidence. Among the key potential benefits of models are: the ability to project trial results to 
longer term outcomes, such as changes in risk factors to events rates and life expectancy; 
the syntheses of evidence from different sources; to enable comparison of interventions that 
may not have been trialled together; undertake sensitivity analysis; and ultimately to make the 
best decisions based on the information available. In this sense, economic models can be a 
useful aid to both develop evidence and also inform decision making. 
 
The chapter described existing models and made the case why building the Scottish CVD 
Policy Model is necessary.  Health economists have tended to concentrate on building 
bespoke economic models to evaluate the cost effectiveness of single interventions, such as 
statins. This practice has been entirely appropriate given the trials have focussed on single 
interventions. However, these models are not best placed to assess the impact of multi-
factorial intervention which is now the focus of policymakers. There is a class of models 
called Policy Models that seek to take a more generic modelling approach. There are two 
elements to the term generic. First, this is where a model includes multiple risk factors 
relevant to the disease area of focus. Secondly, that the long term impact of risk factors on a 
range of conditions, beyond that of principal interest, is included. In this sense, generic 
models seek to be comprehensive, in both the inputs used and outputs produced. The 
advantage is to provide a consistent modelling approach to estimate the impact of relevant 
interventions, as opposed to building multiple bespoke models. 
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A systematic review illustrated that there are a variety of generic policy models in existence. 
Modelling experts have developed best practice guidance regarding how to develop, test and 
disseminate economic models. These guidelines were used to appraise current models. It 
was shown that all models have considerable merits. Most models are built from synthesising 
numerous cross-sectional sources which estimate how the change in population prevalence 
of risk factors is associated with the change in incidence of CVD events over time. These 
models tend to produce convincing simulations of how falling risk factors levels have 
contributed to the observed reductions in CVD events in the population historically. These 
simulations appear to have informed the discourse regarding the role primary prevention 
appears to have had regarding the observed declines in CVD in the population.  
 
However, there are also common limitations to current policy models. No existing models 
estimate impacts of risk factor changes on non-CVD events which may be important when 
generating life expectancy estimates. Further, the increase in health service costs from 
extending life expectancy (given the accumulation of co-morbidities) is also not considered. 
Few models account for background morbidity of the population of interest and the impacts of 
non-fatal events. This may then lead to inaccurate estimates regarding the process of quality 
adjusted to generate quality adjusted life expectancy (QALE). Of crucial importance is that 
there has been a lack of consistency in the epidemiological models used to estimate the risk 
of events and the economic models used to estimate lifetime impacts from changes to risk 
factors to generate cost effectiveness evidence. Three models use the same set of risk 
factors as used in 10-year risk scores.  However, these models used the Framingham risk 
score which is inappropriate for use in Scotland, as it does not adjust for social deprivation 
and may lead to worsening health inequalities if the score is used as a basis for prioritising 
individuals. Further, the model estimates impacts only over 10 years and only on CVD 
mortality. Finally, it is rare for policy models to be tested in terms of external validity or the 
success in predicting outcomes in contemporary populations. The exception to these 
weaknesses may be the Archimedes model, which was developed in the United States and is 
extremely comprehensive. Nonetheless, this model is not ideally placed for use in Scotland, 
as there is a need for a model to use the ASSIGN risk factors, and bring consistency between 
clinical practice and policy decision making.  
 
The consequence of these weaknesses is that even if trial evidence existed regarding the 
impact of multi-factorial interventions, there is lack an economic model to project (short term) 
evaluation findings to lifetime impacts and to discriminate between individuals, in terms of 
quality adjusted life expectancy and lifetime health service costs.  
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Overall, the intention was to develop a new and comprehensive Scottish CVD Policy Model to 
help inform primary prevention and address the key uncertainties as discussed, which were 
formulated into the following specific research questions:  
 
(i) If the current approach to prioritising individuals for intervention is to use 10-year risk 
scores, can the model be used to identify optimal screening approaches to identify high-risk 
individuals? 
 
(ii) Given the weaknesses in 10-year risk scores, can a new approach to prioritising 
individuals be developed based upon individuals’ potential to benefit rather than risk?  
 
(iii) Can the model be used consistently to assess the cost effectiveness of both targeted and 
population interventions?   
 
Part 2 – Development of the Scottish CVD Policy Model 
The overall purpose of Part 2 of the thesis was to develop a new and a comprehensive policy 
model that could be used to help address the research questions. There was an opportunity 
to start from first principles and develop a single model, that could be used as both a clinical 
tool and as an economic tool to produce outcomes congruent with the ultimate aims of 
primary prevention. 
 
The key to the development of the model was access to the longitudinal dataset used to 
create the ASSIGN score. This linked the Scottish Heart Health Extended Cohort (SHHEC) to 
Scottish Morbidity Records (SMR) which audits all hospital events (CVD and non-CVD) and 
all deaths. The dataset consisted of over 16,000 individuals defined by the ASSIGN variables. 
These were divided into non-modifiable and modifiable factors. The former included age, sex, 
family history, diabetes and socio-economic deprivation as defined by the Scottish Index of 
Multiple Deprivation (SIMD). The latter included systolic blood pressure, total cholesterol, 
HDL-cholesterol and smoking (cigarettes smoked per day).This dataset was central to 
developing a simple model structure but which could produce a wide range of outputs. 
 
Chapter 4 detailed the model structure and statistical approaches to estimating life 
expectancy from individual risk factor profiles, as defined by the same variables as used in 
the ASSIGN 10-year risk score. A simple model structure was developed (see Figure 10-1) 
where from a CVD  
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Figure 10-1 The Scottish CVD Policy Model 
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Equation 1: Function (age at survey, SBP, TC, HDL, CPD, family history, SIMD) 
Equation 2: Function (age at event, family history, SIMD) 
Equation 3: Background morbidity = Function (age, deprivation) 
Equation 4: Morbidity impact of non-fatal CVD events = Function (age, CVD events, SIMD) 
Equation 5: Risk of subsequent CVD events = Function (age, family history, SIMD) 
Equation 6: Costs prior to 1
st
 event = Function (age, family history, SIMD) 
Equation 7: Costs post 1
st
 event = Function (age, family history, SIMD) 
 
free state an individual can incur one of four first events: non-fatal CHD, non-fatal CBVD, 
CVD death and non-CVD death. If the first event was non-fatal then individuals transit directly 
to a final death state. This structure is congruent with a primary prevention model to assess 
the impact of changes to risk factors in asymptomatic individuals on the lifetime risk of a first 
event and consequent life expectancy (including competing events). 
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To estimate the transitional probabilities from a CVD free state to the four first events a 
competing risk analysis was undertaken. The cause specific hazards were estimated in a 
parametric analysis using all the ASSIGN variables as covariates (linear predictor), and using 
a Gompertz ancillary parameter (Equation 1). This approach generates cumulative incidence 
estimates, where for any given cycle the sum across the probabilities of the five model states 
always sums to 1. Importantly, over a lifetime all individuals leave the CVD free-state and 
incur one of the first four events within a particular annual model cycle. Therefore, once the 
model has exhausted all 100 annual cycles the sum of probabilities across the four events 
must sum to 1 (i.e. an individual must incur one of the first four events over a lifetime).  
 
If the first event was non-fatal then a survival analysis was conducted where the risk of death 
was estimated conditional upon the type of first non-fatal event (CHD or CBVD), and using 
the covariates of: year of the event since screening and the non-modifiable risk factors 
(Equation 2). Separate risk equations were estimated for men and women.  
 
The model estimates overall life expectancy directly from a CVD-free state in four stages. 
First, the model conducts a “what-if” analysis and estimates the remaining life years from 
incurring each one of the first four events. This is calculated by summing the years before a 
first event and the survival time post non-fatal event. Given the model runs for 100 annual 
model cycles, and within each cycle any one of the four events could be experienced, this 
generates 400 different scenarios that an individual could face upon entering the model (i.e. 
type and timing of the first event). Each scenario is then associated with a particular life 
expectancy estimate. 
 
Second, the probability of incurring each one of these 400 scenarios is weighted by the 
probability of incurring a specific event in a particular year by using the annual addition to the 
cumulative incidence estimates. This weighting generates average remaining life expectancy. 
Third, the age of the individual upon entering the model is added which then gives an overall 
life expectancy estimate.  
 
The purpose of Chapter 5 was to quality adjust survival in the model and to estimate average 
annual health service costs as an individual ages in the model, and accumulates expected 
comorbidities. Summing over a lifetime would then provide quality adjusted life expectancy 
and cumulative lifetime health service costs.  
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Quality adjustment took into account background morbidity and non-fatal CVD events. 
Background morbidity was estimated specific to age group, sex and fifths (quintiles) of a 
SIMD score (Equation 3). The impact of experiencing a non-fatal CHD and CBVD was also 
estimated (Equation 4). Further, survival from first event was quality adjusted by estimating 
the probability of incurring further five non-fatal events (Equation 5) weighted by quality of life 
impact of incurring further non-fatal CVD events (Equation 4).  
 
All hospital events were recorded in the SMR and then costed taking into account the primary 
cause of admission, additional events within stay, and hotelier costs incurred as a function of 
length of stay.  Costs prior to a first event were estimated (Equation 6), and also after a first 
event and prior to death (Equation 7). 
 
Extensive validation tests were undertaken. Face validity was checked via an expert group of 
clinicians, an epidemiologist, a medical statistician and a health economist. This group met 
four times to discuss the model rationale, structure, function and capacity to generate credible 
outputs. The group was content that the model was fit-for-purpose. Internal validity was 
tested to see how well the model could predict observed first events within the SHHEC-SMR 
population. The model performed well. A more difficult test is external validity to test how well 
the model could predict first event outcomes in a dataset not used in its construction. The 
West of Scotland Coronary Prevention Study (WOSCOPS) was used, which was a trial of 
pravastatin affects in reducing CVD outcomes in asymptomatic men aged between 45 and 64 
years. The model also performed well, predicting outcomes for both the placebo and 
intervention group. An additional test of the model is how well it could predict life expectancy 
in a contemporary Scottish population in 2009. The model did not perform particularly well, 
which is unsurprising given life expectancy increases over time. Therefore, the model was 
consequently recalibrated. This was done by adjusting the risk of first events, by adding a 
multiplicative factor to the linear predictor. Life expectancy predictions now match 
observations to within 1 year or less across sex and age categories. 
 
The chapter ended by briefly illustrating that the policy model was ready to be used in 
evaluation. The model can simulate the impact of changes to risk factors on (undiscounted 
and discounted) life expectancy, quality adjusted life expectancy and lifetime health service 
costs. Importantly, the model is also able to assess the impact on health inequalities.  
 
Overall, part 2 built the model with the intention that it could be used to either conduct ‘what-if’ 
modelling exercises or to project forward actual trial evidence. The modelling approach is 
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flexible is that it can include any intervention that impacts on the ASSIGN variables; including 
single or multiple interventions and estimates can adjusted for compliance estimates.  
Further, the model can conduct extensive sensitivity analysis, either one-way, analysis of 
extremes or probability sensitivity analysis; and adjust key structural parameters, such as the 
discount rate. The key focus of the thesis was to demonstrate the model’s ability to 
discriminate between individuals in terms of QALE and costs, in a similar manner as 10-year 
risk scores.  
 
Part 3 – Demonstrating the Scottish CVD Policy Model 
Part 3 of the thesis was designed to demonstrate how the policy model may be used to help 
address the research questions. This was attempted in four short chapters, each focussing 
on a specific issue. Chapter 6 showed how the model can identify optimal screening 
strategies. It is likely that the current practice of using 10-year scores will continue to be used 
for the foreseeable future; however, the analysis showed that the impetus to screen the entire 
population is not efficient. The most cost effective approach is to screen the most deprived 
fifth in the population and those with family history. This could then identify 84% of all 
individuals in the general population that are at premature risk of CVD – the key target group 
when it comes to primary prevention.  
 
Chapter 7 then illustrated how the model could be used as a clinical tool to replace the use of 
ASSIGN 10-year scores, which are driven by age and where the use of a 20% threshold 
results in prioritisation of older patients.  There is a lack of trial evidence, especially regarding 
the impact of multi-factorial interventions. It is important to have a clinical tool which can 
estimate the potential benefits from risk factor modification. The policy model was used to 
estimate maximum potential benefits in terms of additional life expectancy. For exposition, the 
estimates generated were a theoretical maximum, assuming 100% compliance and 
immediate and full reversibility of risk. In practice, these assumptions are unlikely to hold; 
however, the benefit of using the model in this way was also to articulate the need for such 
research. Using this measure of potential benefit, rather than 10 year risk, would likely result 
in a switch in which individuals receive prioritisation, including younger patients, females, 
smokers and a greater focus on deprived individuals.  Nonetheless, the model is flexible in 
that these assumptions can be easily updated as and when new evidence becomes 
available. 
 
The models ability to be used as an economic evaluation tool was then illustrated. Chapter 8 
illustrated how the model could be used to evaluate Keep Well, Scotland flagship primary 
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prevention programme. Keep Well consists of screening deprived individuals using the 
ASSIGN risk tool and then prioritising high risk individuals for a mix of tailored pharmaceutical 
and lifestyle interventions. At present, there has not been a rigorous evaluation of impacts on 
risk factors or events. The policy model was used to demonstrate the considerable 
uncertainty of Keep Well through an analysis of extremes approach, as this could most easily 
illustrate the origins of the uncertainty, and consequent assumptions that policymakers 
themselves are making by rolling out the model without evidence.  Baseline screening data 
were run into the model, and both the academic literature and expert opinion was sought to 
generate appropriate assumptions regarding the probable impact of the Keep Well 
interventions, over and above usual care. The central expectation is that the programme is 
unlikely to be cost effective. However, under an extreme best case scenario, (e.g. using the 
most optimistic expectations of intervention efficacy and compliance estimates) Keep Well 
may be cost effective.  
 
The only other comparable analysis to date was by the Department of Health which 
developed an economic model to inform the roll-out of England’s national screening 
programme. The model however is not available for peer review. In reviewing the associated 
literature, it was particularly notable that the compliance assumptions were extremely 
optimistic. For instance, it was assumed that compliance with statins would be 70%; whereas 
the literature finds 50% is the upper limit, and in Glasgow it was estimated to be less than 
30%. 
 
Finally, Chapter 9 demonstrated that the model can be used to estimate the impact of 
population wide interventions, which could have enormous impacts in increasing (discounted) 
QALYs and reducing (discounted) hospital costs. The act of discounting is very important 
here, especially for cost estimates. Interventions tend to increase life expectancy, postpone 
events and individuals accumulative additional co-morbidities before death. This actually 
results in higher undiscounted health service costs. However, discounting, by weighting the 
future less than the present, results in the cumulative sum of lifetime costs being lower in 
individuals who have successfully lowered risk factor levels (as events are avoided or 
postponed).  
 
It is notable that legal and regulatory changes could also improve health inequalities, given 
the distribution of inflated risk factors is greater in more deprived communities and such 
interventions do not require the engagement of individuals, which is normally lower in 
deprived areas. An analysis also found that national screening could plausibility increase 
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health inequalities, conditional upon differential engagement rates across groups. Further, an 
approach to primary prevention that combined targeted screening with population wide 
interventions may have a better opportunity to be effective, cost effective and reduce health 
inequalities.  
 
Overall, the intention of Part 3 was that decision makers (clinicians and policy makers) could 
use the model flexibly to produce outcomes of interest. Further, given the model can be used 
to simulate the impact of a wide range of interventions, there may be an opportunity to use 
the model to develop more strategic approaches to primary prevention, regarding the optimal 
combination of interventions; rather than viewing targeted and population wide approaches as 
competing approaches.  
 
10.3 Strengths and limitations 
Strengths 
(i) Data sources: 
 In general, Scotland has excellent data sources. A key strength of the thesis was the 
robustness of the particular data sources used to construct, populate and validate the model. 
To build the Scottish CVD Policy Model access to the Scottish Heart Heath Extended Cohort 
(SHHEC) was granted, which consisted of five baseline surveys from the mid-1980s to the 
early 1990s. SHHEC was then linked to the Scottish Morbidity Records (SMR) until 2009. 
SMR records all hospitalisations and death, with up to 6 diagnostic codes, and recording 
length of stay. SHHEC was also linked to the General Registrars Office for Scotland (GROS) 
to record all deaths. Overall, the longitudinal dataset consisting of over 16,000 individuals, 
with a maximum follow-up of 25 years and an average follow-up of 21 years (given SHHEC 
consists of multiple surveys in different years).  
 
To populate the model to quality adjust survival estimates, the Scottish Health Survey was 
used to estimate background morbidity and the morbidity impact of experiencing non-fatal 
CVD events, as discussed further below. Further, to test the model’s external validity, the 
West of Scotland Coronary Prevention Study (WOSCOPS) was used. Using Scottish data 
sources enhances the internal validity of the model for use in Scotland. 
 
(ii) Consistency with ASSIGN Score:  
This was a similar dataset to the one used to create the ASSIGN 10-year score. The 
difference was that the dataset used in this thesis has an additional 3 years of liked SMR 
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data. Given the analysis is using the same variables as the ASSIGN score this may enhance 
the acceptability of the policy model as a natural extension to the 10-year risk score. On the 
one hand, the model can now be used to evaluate interventions using the same variables that 
were used to prioritise individuals. On the other hand, using the data to create a new clinical 
tool (based on potential benefit) may enhance its acceptability also.   
 
(iii) Modelling approach:  
There are a range of policy models in existence and all have considerable merits. However, 
other models can either be very complicated, both in the structure and statistical estimation 
(e.g. CHD policy Model, IMPACT model); or overly simple in the sense that the scope is 
limited (e.g. NICE’s PDG which projected benefits of population interventions only on CVD 
death avoided and only over 10 years). 
 
The Scottish CVD Policy Model may offer several innovative model features relative to 
standard cohort state transition models. This opportunity to develop the modelling approach 
was mainly the result of having developed a comprehensive longitudinal dataset.  
 
First, estimates between risk variables and events were made continuously where possible. 
This enhances the discriminatory ability of the model so that no averaging across groups is 
required, which is common in cohort state transition models.  
 
Second, in estimating first events risks the annual addition to the cumulative incidence 
estimates are read directly into the model. This is more elegant approach than the manual fix 
normally applied in state-transition models, where event risks in each cycle of model are 
calculated by multiplying hazards by the (decreasing) proportion still at risk. The cumulative 
incidence approach automates this process, and given cumulative risk must sum to 1, this 
approach provides an automatic model verification check. 
 
Third, by concentrating on primary prevention the total downstream consequences from 
experiencing a first event were directly estimated. This avoids the need for recurrent states 
and individuals moving between model states, both of which can complicate the model 
structure. Further, using a single dataset to estimate transition risks may enhance the 
transparency of the model estimates; as opposed to combining multiple sources from 
different time periods and contexts, which most other policy models have to do. This is not a 
criticism of models that have had to do this, given data limitations.   
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Fourth, the simple model structure (a maximum of three states) means that the model can 
track patient history. Age at screening determines the risk of a first event, and the age (time) 
at which an event occurs determines survival. This avoided the “memoryless” feature 
common in cohort state transition models.  Normally, time to event and individual history is 
associated with discrete event simulation.  
 
Fifth, to predict average (quality adjusted) life expectancy and lifetime costs a method most 
commonly associated with decision trees was used. That is, all possible scenarios in the 
model were given a life expectancy estimated, which were then weighted by the associated 
probability. To be clear, for each specific covariate profile, there are 400 possible scenario 
defined by the type of the first event experienced and the timing of that event (4 first events x 
100 model cycles). As an individual must incur one of these four first events, the sum of 
probabilities across all 400 scenarios must sum to 1. 
 
All of these model features enhance the simplicity and transparency of the model, reducing 
the risk that the model may be perceived to be a “black box”, which can be a general criticism 
of models. Overall, the model doesn’t easily fall into conventional categories as it shares 
features common to different models. The model is described as an individual state transition 
model, but could also be described as a ‘hybrid model’, as discussed in the ISPOR 2012 best 
practice guidelines.   
 
(iv )Focus on primary prevention:  
Given policymakers are currently focused on primary prevention, the modelling problem did 
not consider secondary prevention. This approach simplified the modelling problem, and 
facilitated a simple model to be develop, which contributes to the transparency of the 
modelling.  
 
(v) Estimating the impact of risk factor changes in non-CVD death: 
The SHHEC-SMR dataset permitted a competing risk analysis to be undertaken (using the 
competing cause of non-CVD death). As such, the impact of changes to risk factors on life 
expectancy takes account not only of CVD event, but also non-CVD death events, such as 
cancers and respiratory diseases. This is particularly important when considering the impact 
of changes to certain variables such as smoking. Other economic models either estimate the 
life expectancy through the avoidance of CVD events, or use general population lifetables. 
The latter is perfectly legitimate, though less elegant than the competing risk approach. 
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(vi)Quality adjustment:  
An analysis of the Scottish Health Survey allowed morbidity (background morbidity and event 
utility decrements) to be estimated enabling life expectancy to be quality-adjusted. 
Background morbidity estimates were made specific to sex and age categories, and most 
notably conditional upon deprivation status. This allows the model to more accurately 
estimate background morbidity and account for the underlying social gradient, that exists in 
terms of health related quality of life (in addition to life expectancy). The impact of 
experiencing non-fatal events was also made for five event categories, which is a wider set of 
CVD conditions that other comparable studies.  
 
Further, the SHHEC-SMR dataset permitted estimation of the lifetime risk of further non-fatal 
CVD events to be estimated following a first event. Consequently, quality adjustment was 
made throughout an individual’s lifetime. Most models do not make quality adjustments, and 
where it is done, it is not as comprehensive. 
 
(vii) Lifetime costs:  
The SHHEC-SMR dataset was also used to model and cost all events. This enabled 
estimation of expected lifetime hospital costs directly from a risk factor profile. From reviewing 
the literature, it appears that no other policy model estimates the impact of prevention and 
extending life expectancy on cumulative lifetime costs. It is important that this is done to more 
fully take into account the impact of prevention. Prevention essentially postpones fatal events, 
and it is important to account for the impact of longer life expectancies on health service 
costs. 
 
(viii) Possibility of greater congruence between clinical and economic approaches:  
The policy model was developed using the same ASSIGN variables currently used in clinical 
practice. This means that the variables used to prioritise individuals can now be used to 
model the lifetime impacts of changes to modifiable risk factor. Further, by using the same 
variables to develop a new clinical tool (based on potential benefit) this may enhance the 
possibilities of implementation in primary care. 
 
(viiii) Wide range of applications:  
As discussed, the model can be used to inform the entire approach to primary prevention, 
from identifying optimal screening strategies, prioritising individuals for intervention, and 
evaluating interventions, including single and multiple risk factor interventions at both the 
individual and population level. 
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(x) Validation:  
The validation exercises were more comprehensive than current policy models. In particular, 
external validation and recalibration to contemporary populations has not been done by other 
models.  Overall, the policy model has high internal validity using Scottish data sources and 
calibrating to contemporary populations. 
 
Limitations  
(i) Data sources: 
Within the SHHEC-SMR dataset there is much greater proportion of those in the most socio- 
economic deprived quintile than would be expected in a truly representative sample. 
However, when modelling event risk adjustment was made for deprivation status when 
estimating event risks (the cause specific hazards of Chapter 3), the model itself is 
representative of Scotland. 
 
Within the SHHEC-SMR dataset there remained a substantial amount of people alive and/or 
event free: 57% of men and 69% of women in SHHEC. However, of particular note is that 
there were just 9% of men and 5% of women who had died following a non-fatal event. This 
may be an important limitation. While there was sufficient power to undertake the analysis, 
this provides an opportunity to re-estimate the model equations in the future.  
 
The baseline screening population (SHHEC) dated from the 1980s, and it is likely that 
survival rates post-event would now be higher. Conditional upon appropriate evidence, the 
model can be re-calibrated to account for such changes.  This issue is revisited in the next 
section when discussing further research. 
 
(ii) Costing analysis:  
A limitation of the costing analysis is that only hospital costs are included. The implications for 
primary care costs are not considered as such information is not routinely available. This may 
be a particularly important limitation when estimating health service costs post–stroke, where 
stroke patients are increasing treated at the community level, rather than within secondary 
care. Further, in estimating the consequences of extending life expectancy the analysis found 
that costs increase, as expected, due the onset of more co-morbidity. It would be expected 
that this would impact upon primary care also.   
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(iii) Socioeconomic deprivation modelled as a non-modifiable risk factor:  
Socioeconomic deprivation is measured by the Scottish Index of Multiple Deprivation (SIMD). 
This was classed as a non-modifiable risk factor.  This is an important limitation given an 
increasing policy discussion on the social determinants of health. The decision to treat SIMD 
as a non-modifiable risk factor was taken for two reasons. First, there is no direct evidence 
linking area–level interventions (aimed at changing relative deprivation status) and 
consequent changes in CVD risk. Second, the perspective of the model is from the Health 
Service. The interventions that would change relative deprivation status (driven by income, 
education, area etc) do not reside with the NHS. Nonetheless, the model can incorporate 
such evidence if available. This would mean that the potential benefit calculation made in 
Chapter 6 would be revised. 
 
(iv) Socioeconomic deprivation status measured as an area-based variable 
SIMD is an area based measure, where households are grouped into small datazones of 740 
households, and a (continuous) score is given to represent socioeconomic status. The 
downside of this measure is the ecological fallacy, treating all individuals with a similar 
postcode the same. A better measure may be more specific to the individual household. 
Possible options being explored in Scotland is council tax band. However, at present no 
measure is perfect.  To reiterate, the modelling used is essentially as extension of the same 
variables used in clinical screening. 
 
(v) Constraints regarding generalisability:  
While the model has high internal validity, this may also be considered a weakness. In 
particular, the use of socioeconomic deprivation may limit its generalisability. SIMD is specific 
to Scotland. The variable is not equivalent to England’s Index of Multiple Deprivation (IMD), 
and other countries do have similar measure of socioeconomic deprivation.  
 
Overall, there are important strengths and limitations of this research. In reflecting upon 
these, there may be the opportunity for further research. The chapter now turns to a 
discussion of key areas that may be particularly fruitful. 
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10.5 Further research 
 
10.5.1 Improvements to the current model 
The following is divided into two sections. First, consideration is given to how the present 
model could be improved in terms of its estimation and validation. Second, discussion then 
turns to how the model itself can evolve and expand its scope and application.  
 
(i) Widen the range of CVD risk factors:  
It was important to build the Policy Model using the nine CVD risk factors that are used in the 
ASSIGN risk score. The intention was that clinicians and policy makers could view the Policy 
Model as a natural extension of the ASSIGN 10-year risk score. Nonetheless, there is the 
possibility to explore further increasing the number and/or changing the risk factors. 
Candidates may include (a) biomarkers, such as c-reactive protein (CRP), (b) particular 
conditions (e.g. hypertension, atrial fibrillation); (c) behavioural (e.g. alcohol, physical activity); 
and genetic factors. 
 
However, there is the possibility of diminishing marginal returns with respect to adding risk 
factors. From an epidemiological perspective, if the addition of risk factors improves 
predictions in CVD events and life expectancy predictions then the research is worth 
pursuing.  Regarding a dataset, a good candidate would be the Scottish Health Survey, a 
cross-sectional survey of the Scottish population that dates from 1995. At present, record 
linkage would extend to 2010, giving 15 years of follow-up. 
 
However, from an economics perspective, the key issue is whether the risk is modifiable and 
how will this help to improve the models ability to discriminate between individuals to inform 
the targeted approach to prevention. That is, it is important to assess whether the addition of 
risk factors are also cost effective. Research in this area is lacking. 
 
(ii) Accuracy of self-reported events:  
 It would be important to respond to the limitations that we outlined previously. The accuracy 
of self-reported CVD events within the SHeS 2003 by linking the survey to historical hospital 
data via patient ID. This type of linkage is readily available in Scotland for the purposes of 
research, subject to Government permission. 
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(iii) Primary costs:  
To improve the cost analysis, it would be worthwhile to access primary care records in 
Scotland to expand the analysis. It is estimated that primary care accounts for 7% of total 
CVD costs, with 80% hospital care and medications, which the model should includes. At 
present, access to primary care records is not routinely available. 
 
(iv) Improving a potential benefit approach:  
A potential benefit approach was illustrated by estimating the theoretical maximum gain in life 
expectancy from changes to modifiable risk factors. These estimates are overly optimistic. In 
practice, there is lack of evidence regarding the reversibility of risk factors and how this may 
differ by age, gender and deprivation status. A benefit of the model is to make these issues 
explicit and illustrate the importance of applied research in this area. The model has been 
programmed with the ability to adjust potential benefit estimates based upon evidence of 
intervention efficacy and effectiveness, including intervention engagement and compliance 
estimates.  
 
(v) Moving from a potential benefit approach based on cost effectiveness:  
From a health economics perspective, patient discrimination and prioritisation for intervention 
should be on the basis of potential cost effectiveness using QALE. At present, economic 
evidence is limited regarding the cost effectiveness of multi-factorial and lifestyle 
interventions. The model can be used to help generate this evidence. However, this is 
conditional upon policymakers developing a more rigorous evaluation agenda. 
  
(vi)The impact of interventions on improving background health utility:  
At present, the model estimates the health related quality of life impact of interventions on 
avoiding non-fatal events. However, it may also be the case that by reducing risk factor levels 
may result in improvements to background mortality irrespective of changes to event rates.  
 
As a proof of concept analysis, the cross-sectional SHeS 2003 was used to re-estimate 
population background morbidity conditional upon smoking status, finding striking differences. 
Smoking is associated with considerably lower health utility in both males and females, 
including the youngest age groups (Figure 1).  Average health utility in men who smoke was 
0.779 (0.804-0.753) compared to 0.816 (0.802-0.83) in non-smokers – an average reduction 
of 0.037 (4.5%). For women the average health utility in smokers was 0.762 (0.74-0.784) 
compared to 0.796 (0.783-0.808) – an average reduction of 0.034 (4.3%). For comparative 
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purposes, the size of these reductions is (approximately) equivalent to experiencing a 
myocardial infarction (see Table 5-8).   
 
Figure 1 Absolute differences in background morbidity (health utility): smokers versus non-
smoking  
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A similar analysis could be undertaken for other risk factors. For those measured on a 
continuous scale (e.g. systolic blood pressure, total cholesterol and HDL cholesterol) these 
could be dichotomised into high and low according to clinical guidelines (e.g. hypertensive 
versus non-hypertensive patients).  
 
However, given the cross-sectional nature of this dataset these estimates infer associations, 
not causation. That is, it does infer that the act of quitting smoking would result in smokers 
acquiring the utilities of non-smokers (at least not in the early stages of quitting). To test 
causal relationships, this analysis would need to be repeated using a longitudinal dataset. If 
evaluations take into account the impacts of interventions on background morbidity (in 
addition to mortality impacts and the impact of experiencing a non-fatal event) this would 
likely result in more favourable cost effectiveness results for primary prevention interventions. 
 
(vii) Make explicit equity judgements:  
In demonstrating the policy model, equal weight is given to an additional life year gained 
irrespective of deprivation status. This is consistent, with the assumption of reimbursement 
agencies such as the Scottish Medicine Consortium (SMC) or the National Institute for Health 
and Care Excellence(NICE).  
 
However, this assumption of equal value appears to be odds with government initiatives that 
have an explicit aim to close health inequalities. This signals that an extra year of life within 
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deprived communities is (all things remaining equal) valued more highly than an extra of year 
of life in the general population. However, it is important to formalise such value judgements 
explicitly into a set of equity weights which can then be used to adjust potential benefit 
calculations across the population. This process could then result in a more pronounced 
deprivation gradient in terms of the potential benefit across deprivation groups. The Policy 
Model provides a transparent conceptual framework upon which the impact of different equity 
judgement can be made. 
 
 (viii) Event and life expectancy predictions:  
In the future there will be an opportunity to acquire a further SHHEC-SMR linkage where 
more first CVD events and deaths will have been observed.  This provides an opportunity to 
re-estimate the model equations. 
 
(viiii) More accurate estimation of life expectancy: 
To estimate this area under the survival curve, the standard practice in state transition 
models as recommended for instance by the National Institute of Clinical Excellence, is to use 
the trapezoid method; by dividing the area under the curve into a series of segments into 
rectangles and triangles, defined by cycles of the model, and summing across the area. 
However, this is approach is an approximation and introduces avoidable error. That is, the 
area between the hypotenuse of the triangle and the survival curve is omitted. This problem 
can be reduced by smaller cycles of the model, and so more refined segments. However, a 
more elegant method, given survival is estimated in continuous time is to calculate the area 
under the curve by using integrals. However, in a practical sense the model will continue to 
be in error given the historical dataset. Recalibration of model outputs as illustrated in 
Chapter 5 will likely be a continual requirement over time.  
 
(viiii) Validation in more up-to-date population(s):  
The model was developed and validated on populations that date from the 1980s. It is 
important to assess how the model predictions perform on a more contemporary population, 
especially in terms of a population exposed to an intervention(s).  
 
(x) Developing optimal intervention strategies: combining the 10-year risk and potential 
benefit approach:  
The greatest benefits from interventions are potentially in younger individuals. However, it is 
the older individuals that are at most immediate risk. A switch to a potential benefit approach 
for prioritisation does not imply similar interventions offered. The concern expressed by 
 377 
advocates of a population wide approach that a targeted approach necessarily leads to 
medicalising the population is premature. That is, using 10 year risk scores can be used to 
define caseness where pharmaceutical interventions could be offered given the urgency of 
the problem. On the other hand, younger individuals could be expected to have a greater 
opportunity to live a healthier lifestyle, and have more chance for reversibility of risks.  As 
such, younger individuals could be offered lifestyle interventions. Indeed, this is aligned with 
how policymakers and clinicians tends to behave. The benefit of the model is to estimate the 
cost effectiveness of different approaches, and be used to further discriminate between 
individuals in terms of interventions offered, if necessary. 
 
(xii) Further re-calibration of life expectancy predictions 
The model is currently calibrated to a 2009 population. This can be redone for more 
contemporary populations, as lifetables are made available. 
 
 
(xiii) Generalisability outside of Scotland:  
As discussed earlier, the immediate application of the Policy Model is within Scotland. If the 
model were to be used in England then a mapping exercise between SIMD and England’s 
Index of Multiple Deprivation (IMD) would need to be undertaken. An alternative option, when 
considering using the model in England or elsewhere would be to drop SIMD from the model 
and simply recalibrate to the population. A precedent is that the Framingham risk score was 
developed in the US and originally in a 1970s population; but is still recommended (JBS2 
Guidelines) for use in England with the additional of intercepts intended to calibrate to the 
population. 
  
10.5.2 Widening the model scope  
There are a variety of ways in which the model can be developed further. We now outline the 
main areas. 
 
(i) Expand scope to consider younger age groups: 
The derivation and validation of the model was conducted using adults aged between 30 and 
74 years. This age range is commensurate with traditional focus of policymakers. In addition, 
of increasing focus are concern regarding a possible obesity epidemic and, in particular, the 
observations of increasing BMI in children and associated unhealthy lifestyle such as 
sedentary behaviour and diet. There is also concern regarding the associated costs and need 
for interventions. 
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There are few economic evaluations of such interventions, or indeed economic models, which 
can project short term study findings into longer term outcomes. A model under development 
is an agent-based model based at the Brookings Institute(106-107). This appears to be an 
extremely complex model structure with the intention to simulate individuals as agents, and 
the interactions between one another and with relevant contextual variables, such as school 
food policies.  
 
An example of an actual economic evaluation of a school based intervention, which was 
accompanied by an economic model to project longer term outcomes was conducted in 
England(108, 330). This is summarised below in relatively detail, as it provides an interesting 
approach to the modelling that informs how the Scottish CVD Policy Model might be adapted 
to be used in younger age groups. 
 
The intervention was nationwide to introduce diet and nutritional requirements for school 
meals.  The study conducted an evaluation within the North East between 2005 and 2010, 
and conducted a cost consequence analysis. Small, but significant reductions in the saturated 
fat content of school lunches were detected. To project the potential impacts on CVD, short 
term findings were extrapolated to estimate future CVD events, and consequent impacts on 
QALE.  
 
A discrete event simulation was developed with multiple states, with transitions between 
states driven by QRISK (discussed in Chapter 2). The model is described as proof-of-
concept, and the analysis exploratory. The reporting of the model is very transparent. The 
QRISK 10-year risk score were interpolated to estimate annual risk, allowing lifetime risk to 
be estimated. There was no significant change in discounted QALE and, taken, at face value 
the intervention wasn’t cost effective. However, the report states the potential wider impact of 
the intervention on non-CVD events, and potential wider non-health impacts were not valued 
in a cost effectiveness approach.  
 
In the context of this thesis the most relevant aspect is to learn from the modelling approach 
taken. While the model structure of the Scottish CVD policy model is different, the ASSIGN 
variables could be used in a similar way to how the model interpolated the QRISK variables.  
The Scottish CVD policy model has estimated the relationship between risk variables in 
continuous time (including age), and estimates lifetime risk, life expectancy, and cumulative 
lifetime health service costs. This process takes into account both CVD and non-CVD death 
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outcomes. Therefore, in taking a lead from this study, the policy model could be used in a 
similarly exploratory way. Nonetheless, the policy model isn’t validated for such groups. 
Further, the policy model also ignores the potentially wider impacts beyond the health 
service. 
 
(ii) Expand the model to consider secondary prevention:  
It was appropriate that the model focussed upon primary prevention, as this is the 
policymakers’ focus. The model already predicts the (time dependent) probability of 
secondary events conditional upon age at event.  The application was to quality adjust 
survival curves post-event. With further updates to the linkage over time, and greater 
numbers of secondary and recurrent events there may be the opportunity to expand the 
model to also inform secondary prevention. This would entail developing further model states 
representing secondary events with conditional life expectancies.   
  
(iii) Widen focus from CVD to become a chronic disease model:  
Perhaps, the most interesting research going forward is to expand the scope of the model 
and develop a chronic disease model. At present the model predicts non-CVD death, in 
addition to CVD events.  To develop a wider chronic disease model this category could be 
disaggregated into main constituent parts, such as cancers and respiratory diseases, for 
instance. Given the SMR links to all hospitalisations, there would be feasible to implement. 
Essentially, the approach of cause specific hazards would include other diseases. However, 
the simple structure could remain; unless secondary prevention was also included.  
 
(iv) Widen the perspective to estimate the broader economic impacts of prevention: 
A health perspective was adopted where the model is concerned with impacts of 
interventions on (quality adjusted) life expectancy and health service costs. This is the 
standard approach for health economic evaluation. However, a more ambitious analysis 
would be to adopt a societal perspective, which is more in keeping with the overall aims of 
economics to assess the overall social value of policy. A societal approach would estimate 
the impacts of interventions on the carers of individuals, and the knock-on financial impacts 
on the wider economy through changes in productivity from reductions in premature mortality 
and morbidity.  The approach of cost benefit analysis (CBA) is congruent with the societal 
perspective, where all (major) impacts are valued, and the perspective of the funding sector is 
a secondary consideration, rather than the prime concern of the cost effectiveness analysis 
approach. 
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A simple approach would be to estimate the productivity impacts by estimating working years 
lost from premature mortality and mortality, and value this using average wage levels, or 
imputed shadow wage prices. Estimates could be made as a function of age, sex and an 
individual’s social deprivation status. The latter may allow more refined estimates of the value 
of lost productivity which is dependent on the nature of work an individual undertakes. This 
essentially a static analysis, conditional upon the timing of an event the model could in 
principle, instantly computes a productivity cost estimate. The assumptions implicit in this 
approach are a constant employment ratio, wage rates and costs. 
 
A more sophisticated approach would be to build a dynamic model where the population and 
health sector is embedded with a larger macroeconomic model. This approach would need to 
follow an approach common in macroeconomic forecasting, such as computational general 
equilibrium models.  Indeed NATSEM-CHE-CoPS Micro-Macro Chronic Disease Prevention 
Model has attempted to take this approach, and where CVD is just one of many disease 
areas under consideration. The model was developed by the National Centre for Social and 
Economic Modelling (NATSEM) at the University of Canberra, and the Centre for Health 
Economics (CHE) and Centre of Policy Studies (CoPS) at Monash University, and can be 
used to model a wide variety of population health initiatives.  
 
Essentially, the model simulates the labour market, health sector and population health 
simultaneously. It is not clear how equations are estimates or the extent of the data sources 
used, however in principle this is an interesting approach. There are no examples for the 
primary prevention of CVD, however in principle this may be possible. 
 
In developing a research agenda to the guiding principle will be that a model should be as 
simple as possible, and not more so.  The key issue returns to what the modelling problem is, 
as outlined in Chapter 3 under modelling best practice guidelines. It may be that the simple 
approach as outlined, coupled with scenario analysis (e.g. future employment and wage 
rates) may be sufficient.  
 
(v) Modelling a wider set of interventions 
The demonstration of the model focussed on interventions that are intended to impact on risk 
factors directly. Further, the interventions were either traditional health sector interventions 
being rolled-out as part of multi-factorial interventions (drugs, lifestyle advice) or changes in 
legislation that do not require engagement of individuals, such as reduction in salt content of 
food. This was appropriate given the focus of the thesis.  However, the model could in 
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principle consider the social determinants, conditional upon evaluation evidence that links 
changes in upstream interventions (e.g. employment) on CVD events directly, or through 
mediating health behaviours. At present, socioeconomic deprivation, as measured by the 
Scottish Index of Multiple Deprivation (SIMD) is considered as a non-modifiable variable. In 
principle, this could be treated as modifiable conditional upon evidence, or could be used in a 
‘what-if’ modelling exercise to make the case for investment in the wider determinants.  
 
 
10.6 Conclusion 
To conclude, the thesis set out to build a Scottish CVD Policy Model that could be used to 
help inform the approach to primary prevention. The aims of primary prevention are to avoid 
premature mortality and morbidity, associated health service costs and to reduce health 
inequalities. However, it is unclear whether current approaches are best able to meet these 
objectives, given scarce resources. Key uncertainties concern optimal screening approaches, 
how best to prioritise individuals for interventions, and how to combine individually targeted 
and population wide interventions. The Scottish CVD Policy Model is intended to help 
address these uncertainties. “All models are wrong, but some are useful”(39). The model is 
intended to be rigorous, comprehensive and easy to understand. It appears to add value to 
the existing economic models regarding the model approach, validation of outputs and the 
wide range of applications. Nonetheless, no model should ever be considered complete(331). 
It is hoped that an exciting research agenda had been identified, and to be fulfilled in the 
future.  
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